### Plenary Session

**AZ Biltmore Ballroom**  
**9:00 - 11:15 AM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 9:00  | Welcome  
CPDD President Eric C. Strain                                       |
| 9:10  | Presentation of the Stephen G. Holtzman Travel Award for Preclinical Investigation to  
Chloe J. Jordan  
Introduction by Yung-Fong Sung                                       |
| 9:25  | Presentation of the CPDD/NIDA Media Award to Jeff Foote, Nicole Kosanke and Carrie Williams  
Introduction by Bertha Madras                                          |
| 9:40  | Presentation of the Martin and Toby Adler Distinguished Service Award to Cora Lee Wetherington  
Introduction by Loretta Finnegan                                        |
| 9:50  | Presentation of the Joseph Cochin Young Investigator Award to Adam Leventhal  
Introduction by Jennifer Tidey                                          |
| 10:00 | Presentation of the Mentorship Award to Michael Nader  
Introduction by Joshua Lile                                              |
| 10:10 | Presentation of the Nathan B. Eddy Award to Roland Griffiths  
Introduction by Eric C. Strain                                           |
| 10:25 | Nathan B. Eddy Award Lecture: My fascination with mood-altering drugs:  
*Hypnotics, caffeine and psilocybin*  
Roland Griffiths, Johns Hopkins University, Baltimore, MD               |

### CPDD Early Career Travel Awards Luncheon

**Aztec**  
**11:30 - 1:00 PM**

### President’s Lecture

**AZ Biltmore Ballroom**  
**1:30 - 2:30 PM**

*A Tale of Two C’s*  
Dr. Martin W. Adler, Temple University School of Medicine

### Symposium I

**AZ Biltmore Ballroom**  
**3:00 - 5:00 PM**

**FEMALES AND FLOWERS: SEX DIFFERENCES IN THE DEPENDENCE-RELATED EFFECTS OF Δ9-THC**

Chairs: Jenny Wiley and Cora Lee Wetherington

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 3:00  | Sex differences in antinociceptive tolerance to THC  
Rebecca Craft, Washington State University, Pullman, WA               |
| 3:25  | Sex-dependent effects of cannabis in the human laboratory  
Ziva D. Cooper, Columbia University and NYSPI, New York, NY           |
| 3:50  | Evaluation of sex differences in a rodent model of cannabinoid dependence  
Julie A. Marusich, RTI International, Research Triangle Park, NC      |
Symposium II
McArthur Ballroom 1/2
3:00 - 5:00 PM

NALOXONE FOR OVERDOSE PREVENTION: EXPANSION TO MULTIPLE SETTINGS AND POPULATIONS

Chairs: Caleb J. Banta-Green and Phillip O. Coffin

3:00 Naloxone provision to pain patients in primary care practice: Results from the naloxone for opioid safety evaluation
Phillip O. Coffin, University of California San Francisco, San Francisco, CA

3:25 Overdose risk characteristics of opiate users enrolled in an overdose prevention trial in an emergency department
Caleb J. Banta-Green, Boston University School of Medicine, Boston, MA

3:50 Implementation of naloxone rescue kit distribution in addiction treatment settings in Massachusetts
Alexander Y. Walley, Boston University School of Medicine, Boston, MA

4:15 Two paths forward for overdose prevention: Implementing pharmacy-based naloxone and naloxone at release from prison in Rhode Island
Traci C. Green, Warrant Alpert Medical School at Brown University, Providence, RI

4:40 DISCUSSANT: The importance of integrating naloxone distribution in diverse clinical and non-clinical settings
Redonna K. Chandler, National Institute on Drug Abuse, Bethesda, MD

Oral Communications I
McArthur Ballroom 4
3:00 - 5:00 PM

MIXING ADDICTIONS: POLYDRUG ABUSE

Chairs: Roger D. Spealman and Michelle R. Lofwall

3:00 Modulation of reinstated polydrug (cocaine/heroin) seeking by noradrenergic α2 agonists
R. D. Spealman1, J. Bergman2, 1New England Primate Research Center, Harvard Medical School, Southborough, MA, 2McLean Hospital, Harvard Medical School, Belmont, MA

3:15 Modeling the opioid system’s effects on cocaine reinforcement in environmentally enriched and impoverished rats using an economic demand function
R. S. Hofford1, J. S. Beckmann1, M. T. Bardo2, 1Psychology, University of Kentucky, Lexington, KY, 2Psychology, University of Kentucky, Lexington, KY

3:30 Identifying predictive profiles of amphetamine, heroin, and polysubstance dependence using machine learning approaches
W. Ahn1, G. Vasilev2, F. Moeller1, J. Vassileva1, 1Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, 2Bulgarian Addictions Institute, Sofia, Bulgaria
3:45 Alcohol and tobacco use in cocaine-dependent participants provided treatment with buprenorphine/naloxone and naltrexone
   A. Hasson, M. Hillhouse, C. Thomas, L. Mooney, W. Ling, UCLA, Los Angeles, CA

4:00 A pilot trial of vigabatrin for the treatment of cocaine and alcohol dependence

4:15 Can dronabinol, a CB1 agonist, suppress opioid withdrawal in humans?
   M. R. Lofwall1, S. Babaloni1, C. Elayi2, P. A. Nuzzo1, K. E. Gill1, S. L. Walsh1, 1Behavioral Science, Center on Drug and Alcohol Abuse, University of Kentucky, Lexington, KY, 2Internal Medicine, University of Kentucky, Lexington, KY

4:30 Effects of cannabis use on opioid injection frequency
   K. F. Corsi2, J. M. Davis2, A. Kral1, R. Bluthenthal3, R. E. Booth2, 1RTI International, San Francisco, CA, 2Psychiatry, University of Colorado Denver, Denver, CO, 3Preventive Medicine, University of Southern California, Los Angeles, CA

4:45 Symmetrical discounting of the future and the past in heavy smokers and alcohol drinkers
   L. Moody2,1, W. K. Bickel2, 1Virginia Tech, Roanoke, VA, 2Addiction Recovery and Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA

Oral Communications 2

McArthur Ballroom 5/6
3:00 - 5:00 PM

Measuring Anguish: Trauma & Stress

Chairs: Philip H. Smith and David V. Flores

3:00 Trauma exacerbates the effect of genetic variants in the dopamine system on cannabis use
   J. L. Meyers1, M. Uddin2, S. Galea1, A. Aiello3, D. Wildman2, K. C. Koenen1, 1Epidemiology, Columbia University, New York, NY, 2University of Champagne-Urbana, Urbana, IL, 3University of North Carolina Chapel Hill, Chapel Hill, NC

3:15 Distress tolerance moderates the relationship between trauma symptoms and depression in substance users
   A. M. Heads1, J. Schmitz2, C. Amador1, A. Vujanovic1, J. Hamilton1, J. Vincent1, 1Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, 2University of Texas Houston, Houston, TX

3:30 Field evidence for stress-induced drug use

3:45 Childhood trauma and initiation of drug use in adolescence
   H. Carliner1, E. Dunn2, K. Keyes1, S. S. Martins1, 1Epidemiology, Columbia University, New York City, NY, 2Psychiatry, Massachusetts General Hospital, Boston, MA

4:00 History of trauma associated with post-deployment relationship dysfunction in military veterans with concurrent PTSD and substance use disorders
   K. L. Ayers1, S. E. Back1,3, F. Beylotte2, K. Koon1, 1Psychiatry, Medical University of South Carolina, Charleston, SC, 2Psychiatry, Medical University of South Carolina, Charleston, SC, 3Psychiatry, Ralph H. Johnson VA Medical Center, Charleston, SC
4:15 Perpetrator vs. victim substance use associated elder abuse
D. V. Flores¹, J. Burnett², J. Booker³, ¹Graduate College of Social Work, University of Houston, Houston, TX, ²Internal Medicine, Geriatric and Palliative Care, University of Texas Medical School at Houston, Houston, TX, ³Adult Protective Services, Department of Family and Protective Services, Houston, TX

4:30 Childhood adversity, stress-sensitization, and lower likelihood of cigarette smoking cessation in a U.S. nationally representative sample: A study of sex differences
P. H. Smith², L. Oberleitner¹, K. Z. Smith², S. Mckee², ¹School of Medicine, DSA, Yale University, New Haven, CT, ²Psychiatry, Yale University School of Medicine, New Haven, CT

4:45 Childhood maltreatment and alcohol use in young adulthood: The role of self-regulation
S. Shin¹, L. Peasley¹, T. Wills², ¹Virginia Commonwealth University, Richmond, VA, ²Cancer Center, University of Hawaii, Honolulu, HI

Primm-Singleton Awardees Reception
AZ Biltmore History Room
5:00 - 6:00 PM

Members-In-Training Committee Meeting
AZ Biltmore Ballroom
6:00 - 7:00 PM

Workshop I
McArthur Ballroom 1/2
7:00 - 9:00 PM

Epidemiology and Public Health Research Methods
(Co-sponsored by CPDD International Programs Committee)

Chairs: James C. Anthony and Jan Copeland

Dr. James Anthony will introduce speakers and will moderate and encourage discussions, Q&A from the floor
James C. Anthony, Michigan State University, East Lansing, MI

Dr. Jan Copeland will moderate and encourage discussions and Q&A from the floor
Jan Copeland, University of New South Wales, Sydney, NSW, Australia

“Queremos aprender” – Issues of clinical intervention research with Mexican heritage families
Ruben Parra-Cardona, Michigan State University, East Lansing, MI

myEpi: Applications in e-technology-enhanced life history research
Georgiy Bobashev, Center for Data Science RTI International, Research Triangle Park, NC

Workshop II
McArthur Ballroom 4
7:00 - 9:00 PM

Turning Electronic Health Records into Actionable Knowledge in Addiction Research

Chairs: Yih-Ing Hser and Steven Sparenborg

Prescription opioid use in an integrated health system
Cynthia Campbell, Kaiser Permanente, Oakland, CA
What can electronic health records tell us about the clinical course of patients with cannabis-use disorders treated in primary care settings
   Elizabeth Evans, Integrated Substance Abuse Program, UCLA, Los Angeles, CA

Substance use disorders and hepatitis screening in the safety net population: A practice-based research network study
   Traci R. Rieckmann, OHSU and UCLA ISAP, Portland, OR

Schizophrenia and affective psychosis in patients with addiction
   Fung-Chang Sung, China Medical University, Taichung, Taiwan

Electronic health records and addiction research: Opportunities and challenges
   Yih-Ing Hser, Integrated Substance Abuse Program, UCLA, Los Angeles, CA

Workshop III McArthur Ballroom 5/6
7:00 - 9:00 PM

CLINICAL OUTCOMES AND COST EVALUATION IN CLINICAL TRIALS: FROM ABSTINENCE TO DOLLARS AND CENTS

Chairs: Sterling McPherson and Susan K. Mikulich-Gilbertson

What should I do when my substance use outcome is not normal?
   Susan K. Mikulich-Gilbertson, University of Colorado Anschutz Medical Center, Aurora, CO

Much ado about ‘Missing’?: The importance of missing data sensitivity analyses to evaluate treatment effects
   Sterling McPherson, Washington State University, Spokane, WA

Economic evaluation methods for randomized clinical trials
   Sean M. Murphy, Washington State University, Spokane, WA

Examining measurement invariance across treatment groups, gender, and time in clinical trials
   Celestina Barbosa-Leiker, Washington State University, College of Nursing, Spokane, WA

Workshop IV AZ Biltmore Ballroom
7:00 - 9:00 PM

NAVIGATING KEY STAGES OF A CAREER IN ADDICTION SCIENCE

Chairs: Denise C. Vidot and Cristina B. Bares

Navigating the pre-doctoral stage
   Denise C. Vidot, University of Miami Miller School of Medicine, Miami, FL

Navigating the post-doctoral stage
   Thomas J. White, University of Vermont College of Medicine, Burlington, VT

Navigating the early career stage and NIH funding
   Cristina B. Bares, Virginia Commonwealth University School of Social Work, Richmond, VA
Media Forum

WHAT’S HOT: 2015 ORAL ABSTRACT NOMINATIONS

Chairs: Bertha K. Madras and Anna Rose Childress

*Introduction to each speaker*
Anna Rose Childress, University of Pennsylvania, Philadelphia, PA

*Introduction to media and format*
Bertha K. Madras, Harvard Medical School, Southborough, MA

**MARIJUANA: CHILDREN AT RISK**

Richard Miech, University of Michigan, Ann Arbor, MI

*Surveying lactation professionals regarding breastfeeding and marijuana use*
Sarah H. Heil, University of Vermont, Burlington, VT

*Maternal age and trajectories of marijuana use over 17 years.* Authors: L. Goldschmidt, N. Day, M. Cornelius
Natacha De Genna, University of Pittsburgh School of Medicine, Pittsburgh, PA

*California Federal Judge rules that marijuana should not be rescheduled from Schedule I (no current medical use) to Schedule II (medical use)*
Bertha K. Madras, McLean Hospital, Belmont, MD

**OPIOIDS: PRESCRIBING, DEATH AND RESCUE**

J. R. Gaither, Yale, New Haven, CT

*Prescription opioid death rates are greater for females than males.* Authors: M.C. LeLait, S.G. Severtson, B. Bucher-Bartelson and R.C. Dart
J. Iwanicki, Rocky Mountain Poison and Drug Center, Denver, CO

*Implementing routine emergency department naloxone rescue kits for patients at risk of opioid overdose.* Authors: J. Ellison, E. Koppelman, P. Mitchell, J. Feldman, E. Bernstein and A. Walley
Mari-Lynn Drainoni, Boston University, Boston, MA

**E-CIGARETTES: USE PATTERNS**

*Use patterns, perceptions of relative harm, and gender effects in dual users of electronic and tobacco cigarettes* Authors: O. Rass, L.R. Pacek, P.S. Johnson and M.W. Johnson
Matthew W. Johnson, Johns Hopkins University, Baltimore, MD

*Use of electronic cigarettes among smokers in addiction treatment.* Authors: T. Le, B. Tajima, B. Andrews, E. Passalacqua and J. Guydish
Noah Gubner, USCF, San Francisco, CA
**Monday, June 15, 2015**

**ALCOHOL: TELEHEALTH IN TREATMENT**

*Impact of telehealth in-home-messaging devices on alcohol use in dually diagnosed veterans*

Authors: S. Martino and M. Gebregziabher  
Elizabeth J. Santa Ana, Charleston VA Medical Center, Charleston, SC

**FAMILIES AT RISK**

*Effects of parental alcohol vs. tobacco and marijuana use on early adolescent onset of alcohol use*

Authors: S.S. Tobero and K.C. Pears  
Deborah Capaldi, Oregon Social Learning Center, Eugene, OR

---

**Symposium III**

**McArthur Ballroom 1/2**

**10:00 - 12:00 PM**

**POSTTRAUMATIC STRESS AND SUBSTANCE USE DISORDERS: TREATMENT INITIATIVES AND CHALLENGES**

Chairs: Anka Vujanovic and Joy Schmitz

- **10:00** *Combining treatments for PTSD and alcohol with antidepressants and CBT*  
  Denise Hien, University of NY & Columbia University College of Physicians and Surgeons, New York, NY

- **10:25** *Use of mobile technologies to enhance substance abuse outcomes among individuals with posttraumatic stress disorder*  
  Eric Dedert, Durham VA and Duke University Medical Centers, Durham, NC

- **10:50** *Treatment of PTSD and substance use disorders: An integrated model using prolonged exposure*  
  Sudie E. Back, Medical University of South Carolina, Charleston, SC

- **11:15** *A novel integrated cognitive-behavioral treatment for posttraumatic stress and substance use disorders: Overview and preliminary results*  
  Anka Vujanovic, University of Texas Health Science, Houston, TX

- **11:40** *DISCUSSANT: Treating addiction in the context of trauma*  
  Dace Svikis, Virginia Commonwealth University, Richmond, VA

---

**Symposium IV**

**McArthur Ballroom 4**

**10:00 - 12:00 PM**

**EMERGING EVIDENCE ON OPIOID-RELATED OVERDOSE RISK AND INTERVENTION**

Chairs: Howard Chilcoat and Nabarun Dasgupta

- **10:00** *Risk of opioid overdose death in North Carolina by type of opioid and other controlled substances prescribed*  
  Nabarun Dasgupta, University of North Carolina, Raleigh, NC

- **10:25** *Comparison of risk factors for opioid overdose in the United Kingdom and the United States: Role of opioid dosage strength, multiple opioids, and age*  
  Paul Coplan, Purdue Pharma, Stamford, CT

- **10:50** *Opioid overdoses: A mixed-methods analysis of intentional vs. unintentional events*  
  Carla Green, Center for Health Research, Kaiser Permanente Northwest, Portland, OR
Oral Communications 3

Chairs: Jennifer W. Tidey and Sarah A. Kromrey

10:00 Taurine effectively inhibits cocaine preference in male and female rats: Candidate for SUD treatment
K. Salas-Ramirez1, K. Uribe2, E. Friedman3, S. Banerjee1, 1Physiology, Pharmacology and Neuroscience, The City College of New York, New York, NY, 2Biology, The City College of New York, New York, NY, 3Physiology, Pharmacology and Neuroscience, The City College of New York, New York, NY

10:15 Cocaine self-administration in male and female monkeys, treatment with progesterone and enriched environment
M. E. Carroll, M. Collins, B. Dougen, Psychiatry, University of Minnesota, Minneapolis, MN

10:30 Influence of reproductive hormones on social rank and vulnerability to cocaine reinforcement in female cynomolgus monkeys
S. Kromrey, P. W. Czoty, M. A. Nader, Physiology & Pharmacology, Wake Forest Univ School of Medicine, Winston-Salem, NC

10:45 Gender differences in craving and internalizing symptoms in methamphetamine dependence
E. E. Hartwell1,2, L. A. Ray1, 1Psychology, University of California, Los Angeles, Los Angeles, CA, 2Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA

11:00 Smoking topography in men and women with and without current depression: Findings from a 10-site clinical trial
J. W. Tidey1, A. Strasser2, E. Donny3, D. Hatsukami4, 1Center for Alcohol & Addictions Studies, Brown University, Providence, RI, 2University of Pennsylvania, Philadelphia, PA, 3University of Pittsburgh, Pittsburgh, PA, 4University of Minnesota Medical School, Minneapolis, MN

11:15 Gender differences in cannabis withdrawal symptoms among treatment-seeking cannabis users
E. S. Herrmann1, E. Weerts1, R. Vandreys, 1Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD

11:30 Prescription opioid death rates are greater for females than males
J. L. Iwanicki, M. C. Le Lait, S. G. Severtson, B. Bucher-Bartelson, R. C. Dart, RADARS® System, RMPDC, DHHA, Denver, CO

11:45 Gender differences in history of sexual and physical abuse in relation to addiction severity
J. E. Korte1, T. Killeen1, S. Sonne1, L. Haynes1, A. Malek1, K. T. Brady1,2, 1Medical University of South Carolina, Charleston, SC, 2Ralph H. Johnson VA Medical Center, Charleston, SC
**Oral Communications 4**

**MODERN ALCHEMY: MEDICATIONS DEVELOPMENT**

**Chairs:** Bronwyn M. Kivell and Ryan K. Lanier

10:00 *Kappa opioid agonist Mesyl Sal B attenuates behavioral sensitization to cocaine with few side-effects*

B. M. Kivell¹,², A. Culverhouse¹,², A. Morani¹, T. E. Prisinzano³, ¹School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand, ²Centre for Biodiscovery, Wellington, New Zealand, ³Medicinal Chemistry, University of Kansas, Lawrence, KS

10:15 *In vivo evaluation of novel serotonin 5-HT₂c receptor positive allosteric modulator CYD-1-79*

C. E. McAllister¹, R. M. Hartley¹, G. Zhang¹, R. G. Fox¹, N. C. Anastasio¹,², C. Wild¹, J. Zhou¹,², K. A. Cunningham¹,², ¹Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, ²Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX

10:30 *Effects of the trace amine associated receptor 1 agonist RO5263397 on behavioral indices of methamphetamine in rats*

J. Li¹, L. Jing¹, Y. Zhang², ¹Pharmacology and Toxicology, University at Buffalo, Buffalo, NY, ²Research Triangle Institute, Research Triangle Park, NC

10:30 *Systemic and intraaccumbens mGluR2/3 agonism attenuate ethanol-reinforced appetitive responding*

K. A. Windisch²,¹, C. L. Czachowski², ¹Rockefeller University, Indianapolis, IN, ²Psychology, IUPUI, Indianapolis, IN

10:45 *Effects of varenicline and GZ-793A on methamphetamine and food self-administration under a multiple schedule of reinforcement in rats*

D. J. Stairs¹, M. Kangiser¹, M. N. Pfaff³, S. Ewin¹, L. P. Dwoskin², ¹Psychology, Creighton University, Omaha, NE, ²Pharmaceutical Sciences, University of Kentucky, Lexington, KY

11:00 *The angiotensin receptor blocker candesartan attenuates the subjective effects of methamphetamine in humans*

C. N. Haile³, C. D. Verrico¹, D. G. Thompson-Lake³, J. J. Mahoney², T. Kosten¹, R. De La Garza¹, T. F. Newton¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Pearland, TX, ³Psychiatry, Baylor College of Medicine, Houston, TX

11:15 *Varenicline versus nicotine patch plus brief advice for sober smokers in substance treatment*

D. Rohsenow¹, J. W. Tidey¹,², R. A. Martin¹, S. Colby¹, P. M. Monti¹, ¹Center for Alcohol & Addictions Studies, Brown University, Providence, RI, ²Providence Veterans Affairs Medical Center, Providence, RI

11:30 *Effects of an anatabine and yerba maté lozenge on craving in smokeless tobacco users and heavy smokers*

R. K. Lanier, A. Cohen, K. Gibson, M. Varga, C. Wright, Rock Creek Pharmaceuticals, Inc., Sarasota, FL, FL
Monday, June 15, 2015

**Poster Session I**

**Frank Lloyd Wright Ballroom**

12:00 - 2:00 PM

(10)

Odd-numbered posters manned first hour;
Even-numbered, second hour

Set-up time begins Sunday 3:00 PM
Must be removed at 2:00 PM Monday

**FOOD**

1. *The validity of DSM-5 criteria for substance-related and addictive disorders adapted for “Food Addiction”*
   L. R. Reis, M. C. Rosa, F. H. P. Kessler, E. Ferreira e Ferreira, F. P. Pechansky,
   1Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil,
   2Department of Social and Preventive Dentistry, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, Belo Horizonte, Brazil

2. *Overlap between food addiction and DSM-5 eating disorders in a treatment seeking sample*
   M. C. Rosa, J. Collombat, C. M. Denis, J. Alexandre, F. Serre, M. Auriacombe,
   1Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil,
   2Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France,
   3University of Pennsylvania, Philadelphia, PA

3. *Measuring “craving” in food addiction: Type, frequency, intensity*
   M. Fatseas, J. Collombat, M. C. Rosa, C. M. Denis, J. Alexandre, R. Debrabant,
   F. Serre, M. Auriacombe, 1Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France,
   2Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil,
   3University of Pennsylvania, Philadelphia, PA

4. *Validity of the eating section for the modified Addiction Severity Index*
   M. Auriacombe, C. M. Denis, M. C. Rosa, J. Collombat, F. Serre, J. Daulouede,
   M. Fatseas, 1BIZIA, Bayonne, France, 2Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil,
   3Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France,
   4University of Pennsylvania, Philadelphia, PA

5. *Topiramate effect on weight gain during methadone maintenance*
   A. Umbricht, J. R. Schroeder, D. G. Antoine, D. A. Tompkins, C. Barnhouser,
   E. C. Strain, G. Bigelow, 1Johns Hopkins University School of Medicine, Baltimore, MD,
   2Schroeder Statistical Consulting, Ellicott City, MD

6. *Associations between isomeric serum methdone levels, total sugar intake, and orexin-A*
   D. G. Antoine, E. C. Strain, A. Umbricht, 1Behavioral Pharmacology Research Unit,
   Johns Hopkins Bayview, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD

7. *Examining different choice procedures to study cocaine vs. food reward*
   J. J. Chow, J. S. Beckmann, 1Psychology, University of Kentucky, Lexington, KY,
   2Psychology, University of Kentucky, Lexington, KY

8. *The role of serotonin 2A (5-HT2A) and 2C (5-HT2C) receptors in the association between binge eating and impulsive action*
   S. J. Stutz, N. C. Anastasio, K. A. Cunningham, 1Center for Addiction Research,
   University of Texas Medical Branch, Galveston, TX, 2Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX
9 Aversive effects of drugs: A comparison of conditioned taste and place avoidance  

10 An assessment of MDPV-induced place preference in adult Sprague-Dawley rats  
H. E. King¹, B. B. Wetzell², K. Rice³, A. L. Riley¹, ¹Psychology, American University, Washington, DC, ²Psychopharmacology Laboratory, American University, Washington, DC, ³Chemical Biology Research Branch, NIDA, Bethesda, MD

STIMULANTS - ANIMALS

11 The effects of estrous cycling on cocaine self-administration in socially housed male-female dyads  
R. Lacy, M. Feinstein, J. C. Strickland, M. A. Smith, Department of Psychology, Davidson College, Davidson, NC

12 A computation opponent process model describes and predicts cocaine self-administration among naïve rats  
G. Bobashev¹, N. Seider², S. Ahmed³, ¹RTI International, Durham, NC, ²Psychology, UNC Chapel Hill, Chapel Hill, NC, ³University of Bordeaux, Bordeaux, France

13 Comparison of cocaine reinforcement in lean and obese Zucker rats: Dose-sensitivity and reinstatement of extinguished operant responding  
D. Townsend¹, K. Freeman², ¹Program in Neuroscience, University of Mississippi Medical Center, Jackson, MS, ²Dept. of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS

14 CaMKII inhibition affects cocaine-cue memory processes to attenuate reinstatement  
M. T. Rich¹, M. M. Torregrossa², ¹University of Pittsburgh, Pittsburgh, PA, ²Psychiatry, University of Pittsburgh, Pittsburgh, PA

15 CamKII and β-actin are activated both in striatum and hippocampus in opioid-induced conditioned place preference  
J. M. Andersen, F. Boix Escolan, Division of Forensic Sciences, Norwegian Institute of Public Health, Oslo, Norway

16 Serotonin (5-HT) 5-HT₁C receptor (5-HT₁C₉) agonist loracaserin suppresses cocaine or oxycodone cue reactivity  
R. G. Fox¹, S. J. Stutz¹, S. Comer², M. Haney², N. C. Anastasio¹³, F. G. Moeller⁴, K. A. Cunningham¹³, ¹Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, ²Div on Substance Abuse Dept of Psychiatry, Columbia University Medical Center, New York, NY, ³Dept Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, ⁴Dept of Psychiatry, Virginia Commonwealth University School of Medicine, Richmond, VA

17 Novel bivalent serotonin 5-HT₂₄ and 5-HT₂C receptor ligands demonstrate distinct activities in vitro and in vivo  
R. M. Hartley¹, S. Gilbertson¹², Y. Chen², N. C. Anastasio¹³, R. G. Fox¹, S. J. Stutz¹, C. Watson¹⁴, K. A. Cunningham¹³, ¹Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, ²Department of Chemistry, University of Houston, Houston, TX, ³Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, ⁴Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX
Disruption of serotonin 5-HT$_{2C}$ receptor (5-HT$_{2C}$R) interaction with protein phosphatase and tensin homologue (PTEN) results in distinct patterns of cortical phosphorylated extracellular-signal regulated kinase$_{1/2}$ (pERK$_{1/2}$)

C. Soto$^1$, N. C. Anastasio$^1$, S. E. Swinford-Jackson$^1$, R. G. Fox$^1$, H. C. Du$^2$, S. Gilbertson$^2$, K. A. Cunningham$^1$, $^1$Center Addiction Research, University of Texas Medical Branch, Galveston, TX, $^2$Dept. Chem, University of Houston, Houston, TX

Serotonin 5-HT$_{2C}$ receptors in the ventral subiculum regulate cocaine-evoked hyperactivity in rats

H. Neelakantan$^1$, S. J. Stutz$^1$, M. J. Bubar$^1$, R. M. Sears$^3$, R. J. DiLeone$^3$, K. A. Cunningham$^{1,2}$, $^1$Center Addiction Research, University of Texas Medical Branch, Galveston, TX, $^2$Dept. Pharm, University of Texas Medical Branch, Galveston, TX, $^3$Dept. Psychiatry, Yale University, New Haven, CT

Chemokines and CXCR4: Role in cocaine dependence and relapse

J. K. Kim$^1$, S. H. Ramirez$^2$, S. Rawls$^1$, $^1$Pharmacology, CSAR, and $^2$Pathology, Temple University, Philadelphia, PA

Effects of l-methamphetamine on the discriminative stimulus and reinforcing effects of cocaine

S. Kohut$^1$, B. Blough$^2$, J. Bergman$^1$, $^1$McLean Hospital/Harvard Medical School, Belmont, MA, $^2$Research Triangle Institute, Research Triangle Park, NC

Cocaine-cue extinction learning in rats: Impact of cocaine training dose and modulation by environmental enrichment

J. M. Gauthier$^1$, R. D. Spealman$^2$, K. M. Kantak$^1$, $^1$Boston University, Boston, MA, $^2$Harvard Medical School, Boston, MA

Attenuating effect of environmental enrichment and abstinence on cardiac and renal toxicity induced by ketamine and methamphetamine self-administration in rats

Y. Liu$^1$, P. Li$^2$, S. Li$^2$, W. Zhou$^{2,3}$, $^1$Ningbo University, Ningbo, China, $^2$School of Medicine, Ningbo University, Ningbo, China, $^3$Ningbo Addiction Research and Treatment Center, Ningbo, China

GSK3B silencing in the NAc produces addiction- and depression-like phenotypes opposite of environmental enrichment and alters neuronal excitability

E. J. Crofton, M. N. Nenov, Y. Zhang, X. Fan, D. Li, F. Laezza, T. A. Green, University of Texas Medical Branch, Galveston, TX

Modeling anhedonia in serine racemase knockout mice: Implications for co-morbid substance abuse and schizophrenia

M. Puhl, R. Donahue, S. Landino, W. Carlezen, J. Coyle, Psychiatry, Harvard Medical School/McLean Hospital, Belmont, MA

Simultaneous determination of the effects of methamphetamine on GABA, glutamate and monoamines by microdialysis in the prefrontal cortex and hippocampus of rats

H. L. Rowley, L. Pinder, R. Kulkarni, S. Cheetham, D. J. Heal, RenaSci Ltd, Nottingham, United Kingdom

Pramipexole alters GSK-3β signaling and AMPA receptor trafficking in limbic brain structures

S. Grasso$^{1,3}$, A. Persons$^{1,3}$, S. E. Tedford$^{1,3}$, A. Newman$^2$, C. Napier$^{1,4,3}$, $^1$Pharmacology, Rush University, Chicago, IL, $^2$NIDH, Baltimore, MD, $^3$Center for Compulsive Behavior and Addiction, Rush University, Chicago, IL, $^4$Psychiatry, Rush University, Chicago, IL

Retinoic acid signaling in the nucleus accumbens: A novel mechanism controlling addiction-related behavior

Y. Zhang, E. Crofton, D. Li, X. Fan, T. Green, University of Texas Medical Branch, Galveston, TX
29 Proteomics analyses: Peroxisome proliferator-activated receptor gamma agonist for chronic cocaine administration in rodents
N. S. Tannu1, J. Schmitz2, S. D. Lane1, C. Green4, K. A. Cunningham3, R. Suchting4, J. Herrera4, P. A. Narayana4, 1Department of Psychiatry and Behavioral Sciences, The University of Texas Medical School at Houston, Houston, TX, 2University of Texas Houston, Houston, TX, 3Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, 4The University of Texas Medical School at Houston, Houston, TX

30 The effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor
Y. Zhang1, D. A. Perrey1, N. A. German1, A. M. Decker1, D. Thorn2, J. Li2, B. P. Gilmour1, B. F. Thomas1, D. L. Harris1, S. P. Runyon1, 1Research Triangle Institute, Research Triangle Park, NC, 2Pharmacology and Toxicology, University at Buffalo, Buffalo, NY

31 Oral JPC-077 and JPC-141, vesicular monoamine transporter-2 inhibitors, reduce methamphetamine self-administration and methamphetamine-induced reinstatement in rats
A. Wilson1, J. Nickell1, J. P. Culver1, V. Janganati2, G. Zheng2, P. A. Crooks2, L. P. Dwoskin1, M. T. Bardo1, 1University of Kentucky, Lexington, KY, 2University of Arkansas for Medical Science, Little Rock, AR

32 Identification of novel allosteric dopamine transporter ligands with nanomolar potency
R. B. Rothman1, J. S. Partilla1, S. K. Saini2, O. Moukha-Chafiq2, V. Pathak2, M. H. Baumann1, S. Ananthan2, 1IRP, NIDA, NIH, Baltimore, MD, 2Southern Research Institute, Birmingham, AL

33 Drug scheduling of stimulants: Dopamine transporter effects, brain occupancy and abuse liability
B. K. Madras1,5, A. J. Fischman4, P. C. Meltzer2, A. A. Bonab3, 1Psychiatry, Harvard Medical School, Southborough, MA, 2Organix Inc, Woburn, MA, 3Radiology, Massachusetts General Hospital, Boston, MA, 4Nuclear Medicine, Shriners Hospital for Children, Boston, MA, 5Alcohol and Drug Abuse, McLean Hospital, Belmont, MA

34 The effect of chronic concurrent intake of alcohol and cocaine on neural stem cell survival and differentiation
E. McGrath1,3,4, P. Wu4, J. Gao4, T. Dunn4, J. Allende-labastida4, K. A. Cunningham3, K. Dineley2, B. Kaphalia3, L. Wang4, Y. Hao4, 1Institute of Translational Sciences, UTMB, Galveston, TX, 2Neurology, University of Texas Medical Branch, Galveston, TX, 3Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, 4Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX, 5Pathology, University of Texas Medical Branch, Galveston, TX

IMPULSIVITY

35 Strength from recovery: Former drug-dependent individuals discount the future less than current users and controls
A. Quisenberry1, M. N. Koffarnus2, C. Franck4, W. K. Bickel1, 1Virginia Tech Carilion Research Institute, Roanoke, VA, 2Addiction Recovery Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA, 3Addiction Recovery and Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA, 4Statistics, Virginia Tech, Roanoke, VA

36 Temporally rapid, pharmacological state-dependent heroin delay discounting modulated by drug-use impulsivity
J. J. Stoltman, E. A. Woodcock, J. J. Lister, L. H. Lundahl, M. K. Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI
Mediatonal pathways among attentional impulsivity, heroin use consequences, mood, and stress level
H. H. Reid, L. H. Lundahl, J. J. Lister, M. K. Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI

Impulsiveness and sex trading for drugs, money, both, or neither
S. Clingan, D. G. Fisher, G. L. Reynolds, Center for Behavioral Research and Services, California State University, Long Beach, Long Beach, CA

Effects of working memory training regimen on learning acquisition and score asymptote in alcohol dependents
S. E. Snider, C. Franck, M. N. Koffarnus, S. LaConte, W. K. Bickel, Addiction Recovery and Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA, Department of Statistics, Virginia Polytechnic Institute and State University, Blacksburg, VA, Virginia Tech Carilion Research Institute, Roanoke, VA

Age of cigarette smoking onset is associated with impulsive responding on a smoking Go/NoGo task
Y. Mashhoon, S. Farmer, J. Betts, S. Lukas, Behavioral Psychopharmacology Research Lab, McLean Hospital, Belmont, MA

Behavioral laboratory measures of impulsivity and decision-making in cigarette smokers
D. Rameshi, W. Ahn, L. A. Keyser-Marcus, F. Moeller, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA

Impulsivity and marijuana demand among frequent marijuana users
E. Aston, J. Metrik, C. W. Kahler, J. MacKillop, Center for Alcohol and Addiction Studies, Brown University, Providence, RI, Providence VA Medical Center, Providence, RI, Peter Boris Centre for Addictions Research, McMaster University, Hamilton, ON, Canada

Dopamine, time perception, and future time perspective

Dynamic causal modeling in humans offers a novel approach to delineate prefrontal-striatal serotonergic drivers of impulsivity in rats
A. E. Price, H. Neelakantan, L. Ma, J. L. Steinberg, S. D. Lane, J. M. Bjork, P. A. Narayana, T. Kosten, A. Bechara, N. C. Anastasio, F. Moeller, K. A. Cunningham, Center Addiction Research, University of Texas Medical Branch, Galveston, TX, Dept Radiology and Dept Psych, Virginia Commonwealth University, Richmond, VA, Dept Psych & Behav Sci and Dept Diag & Intervent IMG, University of Texas Health Science Center, Houston, TX, Dept Psych, Baylor College of Medicine, Houston, TX, Dept Psych, University of Southern California, Los Angeles, CA, Dept Pharm, University of Texas Medical Branch, Galveston, TX, Dept Pharm, Virginia Commonwealth University, Richmond, VA

Treating impulsivity for cocaine and food in female and male rats by repurposing therapeutics
J. R. Smethells, M. E. Carroll, University of Minnesota, St. Paul, MN

OPIOIDS

Are DSM-5 pharmaceutical opioid use disorder continua consistent across chronic pain and injecting drug use samples?
R. Bruno, A. Peacock, G. Campbell, B. Larance, N. Lintzeris, S. Nielsen, W. Hall, M. Cohen, L. Degenhardt, University of Tasmania, Hobart, TAS, Australia, National Drug and Alcohol Research Centre, Sydney, NSW, Australia
47 A novel oral oxycodone maintenance procedure for human laboratory studies
M. A. Coe, P. A. Nuzzo, M. R. Lofwall, S. L. Walsh, University of Kentucky College of Medicine, Lexington, KY

48 Inspection time as a general measure of cognitive impairment following acute opioid exposure
S. Kershaw1, M. Dry2, C. Della Vedova1, I. Majumder1,3, M. Ward1, P. Williamson4, J. White1, 1Pharmacy & Medical Sciences, University of South Australia, Adelaide, SA, Australia, 2Psychology, University of Adelaide, Adelaide, SA, Australia, 3Rural & Remote Mental Health Services, Country Health South Australia, Adelaide, SA, Australia, 4Drug & Alcohol Services South Australia, Adelaide, SA, Australia

49 Evidence for anhedonia in early recovery from prescription opiate addiction: Affect-modulated startle response suggests blunted hedonic responses to natural reward cues
A. S. Huhn, J. Harris, R. E. Meyer, E. Bixler, S. Bunce, Psychiatry, Penn State Hershey Medical Center, Hershey, PA

50 Chronic pain, craving and recent opioid use among patients treated for opioid use disorders
M. C. Lira2, D. M. Cheng3, M. R. Winter4, J. M. Liebschutz2, D. Alford2, R. R. Edwards1, J. Samec2, J. I. Tsui4, 1Brigham and Women’s Hospital, Chestnut Hill, MA, 2BU School of Medicine, Boston, MA, 3BU School of Public Health, Boston, MA, 4UW School of Medicine, Seattle, WA

51 Evaluation of remifentanil and morphine as reinforcing agents in a rat intravenous self-administration procedure
D. J. Heal2, S. Smith2, J. Gosden2, E. Johnson2, M. Hallam2, R. Dean1, M. S. Todtenkopf1, 1Life Sciences, Alkermes, Inc., Cambridge, MA, 2RenaSci Ltd, Nottingham, United Kingdom

52 Suppression of acute up-regulation of phosphorylated extracellular-regulated kinase by mu-opioid receptor agonist in ventral tegmental area related to resistance of rewarding effect under bone cancer model mice
A. Nakamura, SHIONOGI & CO., LTD., Toyonaka, Japan

53 Influence of stereochemistry in the macrocyclic tetrapeptide CJ-15,208 on antinociceptive efficacy and opioid receptor selectivity
S. O. Eans1, M. Ganno1, E. Mizrachi1, S. Senadheera2, J. Aldrich2,3, J. P. McLaughlin1, 1Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL, 2Medicinal Chemistry, University of Kansas, Lawrence, KS, 3Medicinal Chemistry, University of Florida, Gainesville, FL

54 Simultaneous PET/MRI of neurovascular coupling to the μ-opioid receptor occupancy
H. Wey1, J. M. Hooker1, M. S. Placzek1,2, B. R. Rosen1, J. B. Mandeville1, 1Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Brain Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA

HIV I

55 ASSIST in HIV/AIDS service settings: Comparison of self-screening and peer-support screening method
G. M. Le1, H. Nguyen1, H. Tran1, G. Bart2, T. R. Rieckmann3, H. Tran1, K. Darfler4, R. Rawson5, 1Hanoi Medical University, Hanoi, Viet Nam, 2Medicine, Hennepin County Medical Center, Minneapolis, MN, 3Public Health, OHSU, Portland, OR, 4UCLA ISAP, Los Angeles, CA
56 Alcohol and drug use among patients of HIV services in Hanoi, Vietnam
G. Bart2, G. M. Le1, H. Nguyen1, H. Tran1, T. R. Rieckmann3, S. Nguyen1, K. Darfler4, R. Rawson1, 1Hanoi Medical University, Hanoi, Viet Nam, 2Medicine, Hennepin County Medical Center, Minneapolis, MN, 3Public Health, OHSU, Portland, OR, 4UCLA ISAP, Los Angeles, CA

57 A 6-month follow-up of the integrated treatment for opiate addiction and HIV in Vietnam
C. M. Denis4, D. Metzger4, L. Huang6, V. Trias6, M. Auriacombe3, G. Raguin6, S. Mai Thi Hoai5, G. Le Truong5, J. Daulouede1, C. P. O'Brien2, 1BIZIA, Bayonne, France, 2U Penn, Phila, PA, 3Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, 4University of Pennsylvania, Philadelphia, PA, 5HCMC AIDS Committee, Ho Chi Minh City, Viet Nam, 6ESTHER, Paris, France

58 Verbal memory is impaired among HIV+ female, but not HIV+ male cocaine users
E. Martin1, R. Gonzalez2, J. Vassileva3, P. Maki4, 1Psychiatry, Rush University Medical Center, Chicago, IL, 2Psychology, Florida International University, Miami, FL, 3Psychiatry, Virginia Commonwealth University, Richmond, VA, 4Psychiatry, University of Illinois, Chicago, IL

59 Risky decision-making in HIV-infected and non-infected methamphetamine users
P. T. Korthuis2, D. Schwartz1, V. Wilson1, D. Ha1, B. Tremblay1, L. Dennis1, R. Lisowski1, S. Bielavitz1, W. Hoffman1, 1OHSU, Portland, OR, 2HIV Program, Oregon Health & Science University, Portland, OR

60 Overexpression of GRP78 confers protection against neurocognitive impairment in HIV-infected polydrug users
N. Boukli, M. Rodriguez, S. Lopez, M. Rivera, K. Narvaez, L. Cubano, E. Rios, Microbiology and Immunology, Universidad Central Del Caribe, Bayamon, PR

61 Do prescribed opioids impact CD4 count restoration among HIV+ patients initiating antiretroviral therapy?
E. J. Edelman1, J. Tate1, K. S. Gordon2, W. Becker2,1, K. Bryant3, K. Crothers6, J. R. Gaither1, C. Gibert7, A. J. Gordon3, B. D. Marshall4, M. Rodriguez-Barradas8, J. Samet6, M. Skanderson2, A. Justice1,2, D. A. Fiellin1, 1Yale, New Haven, CT, 2VA CT, West Haven, CT, 3Univ. of Pittsburgh, Pittsburgh, PA, 4Brown, Providence, RI, 5NIAAA, Bethesda, MD, 6Univ. of Washington, Seattle, WA, 7DC VAMC, Washington, DC, 8MED VAMC and Baylor, Houston, TX, 9Boston University, Boston, MA

62 Marijuana use, heavy drinking, and cognitive dysfunction in people with HIV infection and substance dependence
S. A. Lorkiewicz1, A. S. Ventura2, T. Heeren2, M. R. Winter2, A. Walley1,3, M. Sullivan1,3, J. Samet1,2,3, R. Saitz1,2,3, 1School of Medicine, Boston University, Boston, MA, 2School of Public Health, Boston University, Boston, MA, 3Boston Medical Center, Boston, MA

63 Behavioral economic analysis of marijuana consumption, diversion, and medical certification demand in HIV+ patients
M. K. Greenwald, L. H. Lundahl, Psychiatry, Wayne State University, Detroit, MI

64 Marijuana use and undetectable HIV viral load in persons living with HIV in Florida
65 Prize contingency management for smoking cessation among people living with HIV/AIDS: Preliminary analysis
D. M. Ledgerwood¹, L. H. Lundahl¹, M. Greenwald¹, C. L. Arfken¹, M. E. Tancer¹, J. A. Cohn², ¹Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, ²Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI

66 Low threshold methadone protects against HIV incidence in a Canadian setting
K. Ahamad¹,², K. Hayashi², P. Nguyen², S. Dobrer², T. Kerr²,³, J. Montaner², E. Wood²,¹, ¹University of British Columbia, Vancouver, BC, Canada, ²British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada

67 The relationship between African-American women’s health discussion networks & HIV risk behaviors
C. B. Oser¹, K. Eddens¹, E. Pullen¹, B. Perry², R. Crosby¹,¹Univ of Kentucky, Lexington, KY, ²Indiana University, Bloomington, IN

68 Psychosocial syndemic affecting women living with and at-risk for HIV
A. Batchelder¹, A. W. Carrico¹, A. Palma², E. Schoenbaum³, J. Gonzalez³, ¹University of California - San Francisco, San Francisco, CA, ²Columbia University, New York, NY, ³Yeshiva University, Bronx, NY

69 Comprehensive women-centered treatment for substance use in Georgia: Initial examination of drug use and HIV risk
I. Kirtadze², D. Otiashvili², K. O’Grady⁴, W. Zule³, E. Krupitksy⁴, W. Wechsberg⁶, H. E. Jones¹, ¹OB/GYN, UNC Chapel Hill, Chapel Hill, NC, ²Addiction Research Center, Union Alternative Georgia, Tbilisi, Georgia, ³RTI International, Research Triangle Park, NC, Durham, NC, ⁴Department of Addictions, Bekhterev Research Psychoneurological Institute, St. Petersburg, St. Petersburg, Russian Federation, ⁵Department of Psychology, University of Maryland, College Park, MD, Baltimore, MD, ⁶RTI International, Durham, NC

70 The evolution of illicit opioid use among HIV-infected opioid users in Russia (2004-2014)
E. Blokhina², E. Krupitsky²,³, D. M. Cheng¹, C. Bridden³, A. Walley¹, O. Toussova², T. Yaroslavtseva², N. Gnatienko³, L. Forman¹, J. Samet¹,³, ¹Boston University, Boston, MA, ²First Pavlov State Medical University, St. Petersburg, Russian Federation, ³Boston Medical Center, Boston, MA, ⁴St. Petersburg Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation

71 Factors associated with participation in HIV case management intervention among Russian drug users
O. Toussova⁴, D. M. Cheng³, E. Blokhina¹, C. Briddien¹, N. Gnatienko¹, E. Quinn³, A. Raj⁶, T. K. Kiriazova⁵, K. Lunze³, A. Y. Walley², E. Krupitksy⁷, J. Samet¹, ¹Boston Medical Center, Boston, MA, ²General Internal Medicine, Boston Univ, Boston, MA, ³Boston University, Boston, MA, ⁴First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation, ⁵NGO “Future Without AIDS”, Odessa, Ukraine, ⁶UCSD, San Diego, CA, ⁷Bechterev Research Psychoneurological Institute, St. Petersburg, Russian Federation

72 Implementation of case management to link HIV-infected Russian addiction patients to HIV service
K. Lunze¹, T. K. Kiriazova², E. Blokhina³, N. Gnatienko⁴, L. A. Wulach⁴, C. Curnyn⁴, N. Bushara¹, C. Bridden², E. Krupitsky³, A. Raj⁵, A. Gifford³, J. Samet¹, ¹Boston University, Boston, MA, ²NGO “Future Without AIDS”, Odessa, Ukraine, ³UCSD, San Diego, CA, ⁴First Pavlov State Medical University, St. Petersburg, Russian Federation, ⁵UCSD, San Diego, CA
73 Food insecurity and HIV drug and sex risk behaviors among Russians living with HIV
B. Idrisov1, K. Lunze3, D. M. Cheng3, E. Blokhina2, N. Gnatienko3, G. Patt3, A. Tyurina2,
C. Bidden3, C. Chaisson3, M. Larson4, E. Krupitsky2, J. H. Samet3, 1Bashkir State Medical
University, Ufa, Russian Federation, 2First Pavlov State Medical University, St. Petersburg,
Russian Federation, 3Boston University, Boston, MA, 4Brandeis University, Waltham, MA

74 HIV-related stigma and substance use in a Russian cohort of HIV+ risky drinkers
J. Samet1, K. Lunze1, D. M. Cheng1, D. Lioznov3, E. Quinn1, C. Bidden1, C. Chaisson1,
A. Y. Walley1, E. Krupitsky3, A. Raj4, E. J. Edelman2, 1Boston University, Boston, MA,
2Yale, New Haven, CT, 3First St. Petersburg Pavlov State Medical U, St. Petersburg, Russian
Federation, 4UCSD, San Diego, CA

TECHNOLOGY

75 Can persons with a history of multiple addiction treatment episodes and chronic relapse benefit from technology-delivered behavior therapy?
S. J. Kim, L. A. Marsch, Psychiatry, Dartmouth College, Lebanon, NH

76 Integrating text messaging in a safety-net office-based buprenorphine program: A feasibility study
B. Tofghii2, E. Grossman2, S. Bereket2, Y. Aphinyanaphongs2, J. D. Lee1, 1Population Health,
New York University, New York, NY, 2Population Health, New York University School of
Medicine, New York City, NY

77 Utilization of an electronic information system to evaluate and enhance practice at a medication-assisted opioid treatment program
M. Lin, L. S. Brown, S. Kritz, R. Zavala, B. Louie, START Treatment & Recovery Centers,
Brooklyn, NY

78 Ambulatory field measurement of heart rate in opioid/cocaine users
K. L. Preston1, A. Kennedy1, M. L. Jobes1, K. A. Phillips1, D. Agage1, M. Tyburski1,
S. Kumar2, D. Epstein1, 1NIDA IRP, Baltimore, MD, 2U Memphis, Memphis, TN

79 ALERRT™ visual analog scale: Assessing “work” requirements associated with tampering of abuse-deterrent opioid formulations
Bethesda, MD

80 Remotely monitoring smoking and relapse in adolescents and emerging adults
E. A. McClure1, M. J. Carpenter1, F. A. Treiber2, K. M. Gray1, 1Psychiatry and Behavioral
Sciences, Medical University of South Carolina, Charelston, SC, 2College of Nursing, Medical
University of South Carolina, Charleston, SC

81 Patient attitudes toward technology-assisted treatment during hospital-based dual-diagnosis treatment
A. S. Hammond1, E. C. Strain2, J. Hsu1, D. G. Antoine2, 1Psychiatry and Behavioral Sciences,
Johns Hopkins University School of Medicine, Baltimore, MD, 2Behavioral Pharmacology
Research Unit, Johns Hopkins University School of Medicine, Bayview Campus,
Baltimore, MD

82 Facebook as a locating and tracking strategy among rural drug-using women
M. F. Dickson1, M. Staton-Tindall2, C. Leukefeld3, M. Webster3, C. B. Oser4, 1Center on
Drug and Alcohol Research, University of Kentucky, Lexington, KY, 2College of Social
Work, University of Kentucky, Lexington, KY, 3Behavioral Science, University of Kentucky,
Lexington, KY, 4Sociology, University of Kentucky, Lexington, KY
Using Facebook ad sampling to efficiently survey cannabis vaporizer use
B. S. Crosier¹, D. C. Lee², A. J. Budney³, ¹Center for Technology and Behavioral Health, Dartmouth College, West Windsor, VT, ²Geisel School of Medicine, Dartmouth College, Lebanon, NH

“Time for dabs”: Analyzing Twitter data on butane hash oil use
R. Daniulaityte², R. Carlson², F. Golroo¹, S. Wijeratne¹, E. W. Boyer⁴, S. S. Martins¹, R. W. Nahhas², A. P. Sheth³, ¹Epidemiology, Columbia University, New York City, NY, ²Community Health, Wright State University, Dayton, OH, ³Kno.e.sis, Department of Computer Science, Wright State University, Dayton, OH, ⁴University of Massachusetts Medical School, Boston, MA

A smartphone application for managing cannabis use
S. Rooke, L. Webb, L. Albertella, J. Copeland, National Cannabis Prevention and Information Centre, UNSW Medicine, Sydney, NSW, Australia

Content analysis of cannabis smartphone applications
D. Ramo¹, L. Popova², S. Zhao¹, K. Chavez³, R. Grana Mayne³, ¹Psychiatry, UC San Francisco, San Francisco, CA, ²Center for Tobacco Control Research and Education, UC San Francisco, San Francisco, CA, ³Tobacco Control Research Branch, National Cancer Institute, Rockville, MD, ⁴Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, CA

6- and 9-month recovery trajectories among youth who participated in an aftercare pilot study
R. Gonzales-Castaneda¹,², A. Ang¹, S. B. Douglas², M. Hernandez², A. McKeown², S. Davidson², G. Kim², K. Abs², J. Welch², C. Nuzum², B. Bagwell², A. Guillen², ¹ISAP, UCLA, Los Angeles, CA, ²Psychology, APU, Alta Loma, CA

Theory-based text-messaging to reduce meth and sex risks among MSM
C. J. Reback¹,², J. B. Fletcher¹, ¹Friends Research Institute, Los Angeles, CA, ²ISAP, UCLA, Los Angeles, CA

Contrasting trajectories of intervention-related self-monitoring in HIV primary care patients
E. Delker¹, D. Cannizzaro¹, D. S. Hasin¹,², E. Aharonovich¹,², ¹New York State Psychiatric Institute, New York, NY, ²Columbia University, New York, NY

Feasibility of web-based treatment delivery for cocaine use disorder: Profile of Internet access by active cocaine users
F. P. Wagner¹, J. C. Strickland², W. W. Stoops¹,²,³, C. R. Rush¹,²,³, ¹Behavioral Science, University of Kentucky, Lexington, KY, ²Psychology, University of Kentucky, Lexington, KY, ³Psychiatry, University of Kentucky, Lexington, KY

BSAFER: A web intervention for women in the ED with drug use and IPV
E. Choo¹, C. Zlotnick², D. Strong³, M. Mello¹, ¹Department of Emergency Medicine, Brown University, Providence, RI, ²Psychiatry and Human Behavior, Brown University, Providence, RI, ³Department of Family and Preventive Medicine, UCSD, San Diego, CA

Scientific evaluation on substance abuse research through Web of Science over the 2008-2012 period
D. Melero-Fuentes¹, R. Aguilar-Moya², J. Valderrama-Zurián³, F. Bueno-Cañigral⁴, R. Aleixandre-Benavent⁵, J. Pérez-de-los-Cobos⁶, ¹INDOTEI, Universidad Católica de Valencia, Godella, Spain, ²Departamento de Ciencias de la Educación, Universidad Católica de Valencia, Godella, Spain, ³Universitat de València, Valencia, Spain, ⁴Plan Municipal de Drogodependencias, Ayuntamiento de Valencia, Valencia, Spain, ⁵INGENIO, Spanish Research Council-CSIC, Valencia, Spain, ⁶Servicio de Psiquiatría, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
93 Consumption of anabolic steroids in athletes: A bibliometric approach (2006-2012)
R. Aleixandre-Agulló1, F. Bueno-Cañigral2, J. Valderrama-Zurián3, D. Melero-Fuentes1,
R. Aleixandre-Benavent4, J. Pérez-de-los-Cobos5, 1INDOTEI, Universidad Católica de
Valencia, Godella, Spain, 2Plan Municipal de Drogodependencias, Ayuntamiento de Valencia,
Valencia, Spain, 3Universitat de València, Valencia, Spain, 4INGENIO, Spanish Research
Council-CSIC, Valencia, Spain, 5Servicio de Psiquiatría, Hospital de la Santa Creu i Santa
Pau, Barcelona, Spain

CRIMINAL JUSTICE

94 Substance use and offenses among juvenile offenders
C. G. Leukefeld1, M. Staton-Tindall3, M. F. Dickson3, M. Webster4, C. B. Oser2,
H. K. Knudsen1, E. Pullen1, J. R. Havens4, 1Behavioral Science, Univ of Kentucky,
Lexington, KY, 2Sociology, Univ of Kentucky, Lexington, KY, 3University of Florida, Gainesville, FL

95 Identifying and addressing unmet medical needs: A call to broaden the scope of drug courts
K. L. Dugosh, D. Festinger, Section on Law and Ethics, Treatment Research Institute,
Philadelphia, PA

96 Sex, drugs, and violence: An analysis of women in drug court
A. Acheampong2, C. W. Striley3, D. O. Fakunle1, L. Cottler1, 1Mental Health, Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD, 2University of Florida, Gainesville, FL

97 Predictors of HIV risk among ex-offenders entering Sober Living Recovery Residences for drug
problems
D. L. Polcin1, T. Nemoto2, R. Korcha1, A. Mericle1, E. Mahoney1, 1Alcohol Research Group,
Emeryville, CA, 2Public Health Institute, Oakland, CA

98 Moved to Thursday, Poster Session IV, Poster 137

99 Meeting the HIV and hepatitis C needs of female drug court participants in the context of their
trauma
D. Morse1, C. Cerulli1, P. Bedell1, J. L. Wilson1, H. Amaro2, 1Psychiatry, University of
Rochester School of Medicine, Rochester, NY, 2Social Work and Preventive Medicine,
University of Southern California, Los Angeles, CA

100 Healthcare utilization and insurance status of substance using ex-offenders in primary care
J. E. Chambers1, A. C. Brooks1, C. M. Carpenedo1, J. Lauby2, D. Metzger1,3, K. C. Kirby1,
1Treatment Research Institute, Philadelphia, PA, 2Public Health Management Corporation,
Philadelphia, PA, 3Department of Psychiatry, University of Pennsylvania, Philadelphia, PA

PREVENTION

101 Criminal arrests among drug-using assault-injured youth seeking ED care: A prospective
cohort study
R. M. Cunningham1, P. M. Carter1, M. Zimmerman1, F. Blow1, M. A. Walton1, 1Univ. of
Michigan, Ann Arbor, MI

102 Event-level analysis of antecedents to firearm violence among drug-using ED youth
P. M. Carter1, M. A. Walton1, Q. Epstein-Ngo1, E. A. Austic1, M. Zimmerman1, F. Blow1,
S. Chermack1, A. Buu2, R. M. Cunningham1, 1Univ. of Michigan, Ann Arbor, MI, 2Indiana
University, Bloomington, IN

103 Lifetime victimization and sexual relationship power among substance-abusing African-
American women
C. Ahuama-Jonas, K. Burlew, University of Cincinnati, Taylor Mill, KY
104 The risks of gang association among drug-using women in Cape Town, South Africa
T. Carney\textsuperscript{2}, B. Myers\textsuperscript{1,3}, F. Browne\textsuperscript{4}, P. Wechsberg\textsuperscript{4,5,6}, D. Kline\textsuperscript{4}, \textsuperscript{1}Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Tygerberg, South Africa, \textsuperscript{2}Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Cape Town, South Africa, \textsuperscript{3}Psychiatry and Mental Health, University of Cape Town, Rondebosch, South Africa, \textsuperscript{4}Research Triangle Institute International, Raleigh/Durham, NC, \textsuperscript{5}Psychology in the Public Interest, North Carolina State University, Raleigh, NC, \textsuperscript{6}Psychiatry and Behavioral Sciences, Duke University, Durham, NC

105 Testing differential implementation feasibility and initial efficacy in a culturally adapted parenting intervention for Latino/a immigrants
R. Parra-Cardona, D. Bybee, Michigan State University, East Lansing, MI

106 Parents as interventionists to address adolescent drug abuse
K. Winters, \textsuperscript{1}University of Minnesota Medical School, Minneapolis, MN, \textsuperscript{2}Treatment Research Institute, Philadelphia, PA

107 Prevalence and correlates of drug use in women patients of community health centers in Tijuana, Mexico and Los Angeles, USA
M. Arroyo\textsuperscript{1}, G. Natera\textsuperscript{1}, L. Gelberg\textsuperscript{2}, R. Andersen\textsuperscript{3}, M. Rico\textsuperscript{2}, \textsuperscript{1}National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico, \textsuperscript{2}Family Medicine; Public Health, UCLA, Los Angeles, CA, \textsuperscript{3}UCLA School of Public Health, Los Angeles, CA

108 Comparing attitudes toward addressing patient drug use among health professionals in training
J. A. Johnson\textsuperscript{6}, U. Kelly\textsuperscript{1}, A. Tindol\textsuperscript{3}, D. Macmillan\textsuperscript{2}, F. Payne\textsuperscript{3}, S. Chalmers\textsuperscript{4}, S. Shellenberger\textsuperscript{3}, K. Le\textsuperscript{5}, P. Seale\textsuperscript{1}, \textsuperscript{1}Emory Univ., Atlanta, GA, \textsuperscript{2}Georgia College & State Univ., Milledgeville, GA, \textsuperscript{3}Mercer Univ., Macon, GA, \textsuperscript{4}Univ. of North Georgia, Dahlonega, GA, \textsuperscript{5}Wake Forest Univ., Winston-Salem, NC, \textsuperscript{6}Georgia Regents Univ., Augusta, GA

109 Adolescent input on a web-based prescription opioid abuse prevention tool
S. K. Moore\textsuperscript{1}, L. A. Marsch\textsuperscript{2}, M. Grabinski\textsuperscript{3}, S. Semino\textsuperscript{4}, \textsuperscript{1}Capital Health Medical Center, Hopewell, NJ, \textsuperscript{2}Center for Technology and Behavioral Health, Dartmouth College, Hanover, NH, \textsuperscript{3}HealthSim, LLC, New York, NY, \textsuperscript{4}NY Public Library, New York, NY

110 Exploring the feasibility to quantify prescription drug misuse and abuse: Focus group findings
D. S. Varma\textsuperscript{1}, L. Hoffer\textsuperscript{2}, L. Cottler\textsuperscript{1}, \textsuperscript{1}Epidemiology, University of Florida, Gainesville, FL, \textsuperscript{2}Anthropology, Case Western Reserve University, Cleveland, OH

111 Perceptions among healthcare professionals of prescription drug misuse
A. Porath-Waller, S. Gereghty, P. Robeson, Canadian Centre on Substance Abuse, Ottawa, ON, Canada

112 Predictors of transition to opioid dependence among illicit pharmaceutical opioid users
R. Carlson\textsuperscript{2}, R. Nahhas\textsuperscript{2}, S. S. Martins\textsuperscript{1}, R. Daniulaityte\textsuperscript{2}, \textsuperscript{1}Epidemiology, Columbia University, New York City, NY, \textsuperscript{2}Community Health, Wright State University, Dayton, OH

113 Patterns of opioid use and co-morbidity in non-treatment-seeking individuals with opioid use disorder

114 A randomized clinical trial of a behavioral intervention to reduce opioid overdose risk behavior
A. S. Bohnert\textsuperscript{1,3}, F. Blow\textsuperscript{1,3}, R. Cunningham\textsuperscript{1}, L. Thomas\textsuperscript{1}, M. K. Greenwald\textsuperscript{2}, S. Chermack\textsuperscript{1,3}, E. E. Bonar\textsuperscript{1}, M. Walton\textsuperscript{1}, \textsuperscript{1}University of Michigan, Ann Arbor, MI, \textsuperscript{2}Psychiatry, Wayne State University, Detroit, MI, \textsuperscript{3}VA Center for Clinical Management Research, Ann Arbor, MI
115 Non-fatal overdose among recent veterans: Lessons learned from a mixed methods analysis
A. S. Bennett1, L. Elliott1, A. Golub2, E. R. Pouget2, A. Rosenblum3, P. Britton4, 1National Development and Research Institutes, New York City, NY, 2NDRI, Burlington, VT, 3Institute for Treatment and Services Research, National Development and Research Institutes, Inc., New York, NY, 4Center of Excellence for Suicide Prevention Canandaigua VAMC University of Rochester Medical Center, Rochester, NY

116 Overdose education and naloxone for patients prescribed opioids in primary care: A qualitative study
I. A. Binswanger1,3, S. Koester2, S. Mueller1, E. Gardner3, K. Goddard4, J. Glanz4, 1Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, CO, 2University of Colorado Denver, Denver, CO, 3Denver Health, Denver, CO, 4Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, 5Colorado School of Public Health, Aurora, CO

117 Screening and brief intervention for low risk drug use in primary care: A pilot randomized trial
S. Meli1, T. Palfai2, D. M. Cheng3, D. Alford4, J. Bernstein1, J. Samet4, R. Saitz1, 1Community Health Sciences, Boston University, Boston, MA, 2Psychological and Brain Sciences, Boston University, Boston, MA, 3Biostatistics, Boston University, Boston, MA, 4Medicine, Boston University, Boston, MA

118 Participation in the binational QUIT trial for reducing problem drug use among patients of community health centers in East Los Angeles and Tijuana: The role of cross-border migration
M. Vahidi1, G. Naterra1, M. Rico1, M. Arroyo3, R. Andersen4, J. Yacenda1, L. Gelberg2, 1Family Medicine, UCLA, Woodland Hills, CA, 2Family Medicine; Public Health, UCLA, Los Angeles, CA, 3National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico, 4UCLA School of Public Health, Los Angeles, CA

119 Cannabis, Lord Shiva and holy men: Cannabis use among sadhus in Nepal
J. Copeland2, S. Acharaya1, J. Howard2, 1Ministry of Health and Population, Kathmandu, Nepal, 2National Cannabis Prevention and Information Centre, University of NSW, Sydney, NSW, Australia

120 Moderators of electronic screening and brief intervention for marijuana among students in a health center: eCHECKUP TO GO bolsters efforts of those who are already trying to change
T. Palfai1, R. Saitz2, M. R. Winter3, 1Psychological and Brain Sciences, Boston University, Boston, MA, 2Community Health Sciences, Boston University and Boston Medical Center, Boston, MA, 3Data Coordinating Center, Boston University, Boston, MA

121 Evaluating the documentation of risky substance use in federally qualified health centers
A. Reddy1, M. Vahidi2, N. Cox1, H. Alden1, R. Andersen4, L. Gelberg3, 1Department of Family Medicine, UCLA, Los Angeles, CA, 2Family Medicine, UCLA, Woodland Hills, CA, 3Family Medicine; Public Health, UCLA, Los Angeles, CA, 4UCLA School of Public Health, Los Angeles, CA

122 Underreporting of risky drug use among prime care patients in federally qualified health centers
M. Vahidi1, C. Bone1, R. Andersen3, J. Yacenda1, L. Gelberg2, 1Family Medicine, UCLA, Woodland Hills, CA, 2Family Medicine; Public Health, UCLA, Los Angeles, CA, 3UCLA School of Public Health, Los Angeles, CA

123 Reporting errors on combined use of caffeine and alcohol questions in a qualitative questionnaire
K. M. Polak2, D. Svikis1, L. Hancock2, D. Pomm2, 1Virginia Commonwealth Univ., Richmond, VA, 2Psychology, Virginia Commonwealth University, Henrico, VA
Effects of cultural congruity on alcohol use severity among Hispanic emerging adults in college
M. Cano1, E. Vaughan3, M. de Dios4, Y. Castro2, A. Roncancio5, L. Ojeda6, 1Epidemiology, Florida International University, Miami, FL, 2School of Social Work, University of Texas at Austin, Austin, TX, 3Indiana University, Bloomington, IN, 4MD Anderson Cancer Center, Houston, TX, 5UT Health Science Center, Houston, TX, 6Texas A&M University, College Station, TX

Correlates of specific personality and alcohol use with nonmedical use of prescription stimulants in college students
S. Bierma1, S. J. Lookatch2, K. Ritter1, G. Kurdziel2, T. Moore1, E. C. Katz3, 1University of Tennessee, Knoxville, TN, 2Department of Psychology, University of Tennessee, Knoxville, TN, 3Towson University, Towson, MD

Impacts of drinking-age legislation on arrests for alcohol-impaired driving among young people in Canada, 2009-2012
R. C. Callaghan1, J. Gatley1, M. Sanches2, 1Northern Medical Program, University of Northern British Columbia, Prince George, BC, Canada, 2Biostatistical Consulting Unit, Centre for Addiction and Mental Health, Toronto, ON, Canada

How are private health plans providing drug and alcohol services in an age of parity and health reform?
C. M. Horgan, M. Stewart, S. Reif, D. W. Garnick, D. Hodgkin, E. L. Merrick, A. Quinn, Brandeis University, Waltham, MA

Hospital discharges for marijuana dependence over time in Colorado
J. M. Davis, K. Suleta, K. F. Corsi, R. Booth, University of Colorado Denver, Denver, CO

“How smoking pot helps me focus”: A qualitative analysis of Internet forum discussions of ADHD and cannabis use

Medical marijuana laws and annual opioid analgesic sales in the United States
J. H. Kim2, J. Santaella1, M. Cerda1, S. S. Martins1, 1Epidemiology, Columbia University, New York City, NY, 2Epidemiology, Mailman School of Public Health, New York, NY

The spatial-temporal relationship of policing in areas with high drug activity
T. Gaines1, D. Werb1, J. Arredondo1, V. M. Alaniz2, L. Beletskey2, 1Medicine, University of California San Diego, La Jolla, CA, 2School of Law, Northeastern University, Boston, MA, 3Tijuana Police Department, Tijuana, Mexico

Scaling up SBIRT: Statewide implementation in the Oregon Health Plan
D. McCarty1, T. R. Rieckmann1, S. Renfro2, J. McConnell2, 1Public Health, OHSU, Portland, OR, 2Center for Health Systems Effectiveness, Oregon Health & Science University, Portland, OR

A pre–post comparison in healthcare service utilization among heroin-using women in the methadone maintenance treatment in Taiwan
Y. Lien2, H. H. Yeh1, S. Fang2, C. Chen2, 1Epidemiology, Michigan State University, East Lansing, MI, 2Institute of Public Health, National Yang-Ming University, Taipei, Taiwan

Impact of prescription monitoring on care of opioid-dependent patients
135 Naloxone distribution to drug users in California and opioid-related overdose death rates  
P. J. Davidson¹, E. Wheeler², J. Proudfoot³, R. Xu³, K. D. Wagner¹, ¹Medicine, University of  
California San Diego, La Jolla, CA, ²Harm Reduction Coalition, Oakland, CA, ³Clinical &  
Translational Research Institute, University of California, San Diego, La Jolla, CA

136 Factors associated with illicit methadone injecting in a Canadian setting  
D. Tucker¹, M. Milloy¹,², K. Hayashi¹,², R. Lung³, P. Nguyen¹, T. Kerr¹,², E. Wood¹,², ¹BC  
Centre for Excellence in HIV/AIDS, St Paul’s Hospital, Vancouver, BC, Canada, ²Department  
of Medicine, University of British Columbia, Vancouver, BC, Canada

137 Limitations to participation in opioid maintenance treatment in Europe  
L. Brandt¹, A. Unger², L. Moser¹, G. Fischer²,¹, R. Jagsch³, ¹Center for Public Health and  
²Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria,  
³Faculty for Psychology, University of Vienna, Vienna, Austria

138 Access to buprenorphine treatment: Is the patient limit a barrier?  
H. K. Knudsen¹, M. R. Lofwall², ¹Behavioral Science, University of Kentucky,  
Lexington, KY, ²Behavioral Science & Center on Drug and Alcohol Research, University of  
Kentucky, Lexington, KY

139 U.S. federal cocaine essential ("precursor") chemical regulation impacts on U.S. cocaine  
availability: An intervention time series analysis with temporal replication  
J. K. Cunningham¹, R. C. Callaghan², L. Liu³, ¹Family and Community Medicine, University  
of Arizona, Tucson, AZ, ²Northern Medical Program, University of Northern British  
Columbia, Prince George, BC, Canada, ³Economics, National Taiwan University, Taipei,  
Taiwan

140 Crack users with conduct disorder have more association with violence, trauma and psychiatric  
comorbidities  
M. P. Pachado¹, D. S. Souza⁴, J. N. Scherer⁵, F. P. Pechansky⁶, F. Kessler³, S. Faller²,  
¹Psychiatric Dept, Center for Drug and Alcohol Research, Porto Alegre, Brazil, ²Center for  
Drug and Alcohol Research (CPAD) - Federal University of Rio Grande do Sul (UFRGS),  
Porto Alegre, Brazil, ³Psychiatry, Center for Drug and Alcohol Studies at HPCA/UFRGS,  
Porto Alegre, Brazil, ⁴Psychiatric Dept, Federal University of Rio Grande do Sul, Porto  
Alegre, Brazil, ⁵Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

141 Brazilian crack/cocaine inpatients show more legal and family social problems than outpatients  
F. Kessler, Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre,  
Brazil

142 The impacts of graphic warning labels in an addiction treatment population  
B. Tajima, D. Garina, T. Le, A. Batchelder, J. Guydish, University of California San  
Francisco, San Francisco, CA

143 Reactions to the FDA proposed graphic warning labels among smokers in addiction treatment  
centers  
T. Le, B. Tajima, E. Passalacqua, J. Guydish, Philip R. Lee Institute for Health Policy Studies,  
UCSF, San Francisco, CA

144 State-level tobacco-related norms and policies show differential effects on cigarette smoking in  
population subgroups  
D. Shmulewitz, M. Stohl, K. M. Keyes, Q. Brown, D. Hasin, Columbia University, New  
York, NY
Assessing the cost-effectiveness of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness

S. M. Murphy,1,2 M. G. McDonell,3 S. McPherson,2 D. Srebnik,4 J. M. Roll,2 R. Ries,3 1Health Policy & Administration, Washington State University, Spokane, WA, 2Program of Excellence in Addictions Research (PEAR), Washington State University, Spokane, WA, 3Medical School, University of Washington, Seattle, WA, 4King County Mental Health, Seattle, WA

Symposium V

McArthur Ballroom 1/2
2:00 - 4:00 PM

CANNABIDIOL AND DRUGS OF ABUSE: PRECLINICAL AND CLINICAL STUDIES OF CANNABIDIOL AND COCAINE, ETHANOL, OPIOIDS AND CANNABINOIDS

Chairs: Margaret Haney and Yasmin L. Hurd

2:00 Cannabidiol: Long-lasting amelioration of vulnerability states associated with relapse risk as determined in animal models of drug seeking, anxiety, and impulsivity
Friedbert Weiss, The Scripps Research Institute, La Jolla, CA

2:25 Study to test the safety and efficacy of cannabidiol as a treatment intervention for opioid relapse
Didier Jutras-Aswad, University of Montreal, Montreal, QC, Canada

2:50 The interactions of cannabidiol and delta-9-tetrahydrocannabinol in healthy humans
Mohini Ranganathan, Yale School of Medicine, New Haven, CT

3:15 Influence of oral cannabidiol on the subjective, reinforcing and cardiovascular effects of smoked marijuana
Margaret Haney, Columbia University Medical Center, New York, NY

3:40 DISCUSSANT: Preclinical and clinical experience testing cannabidiol for opioid dependence
Yasmin Hurd, Mount Sinai Hospital, New York, NY

Oral Communications 5

Grand Ballroom
2:00 - 4:00 PM

MAINTAINING ABSTINENCE: TREATMENTS FOR OPIOID DEPENDENCE

Chairs: Mark A. Smith and Andrew Rosenblum

2:00 The effects of strength training on heroin self-administration
M. A. Smith, G. Fronk, S. Bills, R. Lacy, Davidson College, Davidson, NC

2:15 Casein kinase-1 inhibitors as a novel treatment for substance use disorders
D. B. Horton,1 E. Dunn-Sims,1 T. T. Wager,1 C. Chang,2 A. Doran,3 A. Rosado,4 A. N. Mead,1
1Global Safety Pharmacology, DSRD, Pfizer, Inc, Groton, CT, 2PDM - NCE, Pfizer, Inc., Groton, CT, 3Neuroscience Research Unit, Pfizer, Inc., Cambridge, MA

2:30 Hapten selection for heroin vaccines
G. R. Matyas,1 J. Antoline,1 R. Jalalah,1 R. Torres,4 Z. Beck,4 A. Jacobson,1
1Drug Design and Synthesis Section, National Institute on Drug Abuse, NIH, Bethesda, MD, 2US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, 3National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD, 4US Military HIV Research Program, Hemy M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD
Effects of ibudilast on the reinforcing, subjective and analgesic effects of oxycodone – preliminary results


Reducing the cost of free time: Treatment success in a randomized trial of clonidine as adjunct to buprenorphine maintenance is associated with more leisure activities in the clonidine condition


Extended-release naltrexone for opioid relapse prevention among opioid-dependent, criminal justice-involved adults

J. D. Lee¹, P. D. Friedmann², T. W. Kinlock³, E. V. Nunes⁴, M. S. Gordon⁵, C. P. O’Brien⁶, ¹Population Health, New York University, New York, NY, ²Medicine, Rhode Island Hospital, Providence, RI, ³Friends Research Institute, Baltimore, MD, ⁴Columbia University, New York, NY, ⁵Psychiatry, University of Pennsylvania, Philadelphia, PA

Reduction in prescription opioid misuse among enrollees into opioid treatment programs

A. Rosenblum, C. Fong, H. Matusow, ITSR, National Development and Research Institutes, New York, NY

Implementing routine emergency department naloxone rescue kits for patients at risk of opioid overdose

M. Drainoni³,², J. Ellison³, E. Koppelman³, P. Mitchell²,¹, J. Feldman²,¹, E. Bernstein²,¹, A. Walley²,¹, ¹Boston Medical Center, Boston, MA, ²Medicine, Boston Univ, Boston, MA, ³Public Health, Boston Univ, Boston, MA

Oral Communications 6

ADLERcENTs: ADOLESCENT DRUG ABUSE

Chairs: Richard Miech and Chloe J. Jordan

Trends in use of and attitudes toward marijuana among youth before and after decriminalization: The case of California 2007-2013

R. Miech, L. A. Johnston, P. O’Malley, J. Bachman, J. Schulenberg, M. Patrick, University of Michigan, Ann Arbor, MI

Adolescent d-amphetamine treatment in a rodent model of ADHD: Pro-cognitive effects during adolescence and cocaine abuse risk during adulthood

C. J. Jordan¹, D. M. Taylor¹, S. Jeon¹, B. M. Baskin¹, L. P. Dwoskin², K. M. Kantak¹, ¹Psychological & Brain Sciences, Boston University, Boston, MA, ²Pharmaceutical Sciences, University of Kentucky, Lexington, KY

Amphetamine exposure during adolescence alters anxiety- and depression-like behaviors and prefrontal cortex dopamine receptor expression in adulthood

S. Kang², M. Wu¹, R. Galvez¹,², J. M. Gulley¹,², ¹Psychology Department, University of Illinois, Urbana-Champaign, Champaign, IL, ²Neuroscience program, University of Illinois, Urbana-Champaign, Champaign, IL
2:45  *Adaptive reward learning is intact in young adults with remitted substance use and depressive disorders*
S. A. Langenecker, N. A. Crane, S. DelDonno, L. Gabriel, J. Gowins, C. Nagel, B. Mickey, J. Zubieta, R. Mermelstein, E. Martin
Psychiatry, Rush University Medical Center, Chicago, IL; Psychiatry and Psychology, The University of Illinois at Chicago, Chicago, IL; Psychology, University of Illinois at Chicago, Chicago, IL; Psychiatry, The University of Michigan, Ann Arbor, MI

3:00  *Adolescent C57Bl/6J mice self-administer more oxycodone than adult mice in an extended-access paradigm (4hrs)*
S. P. Rahm, A. Ho, M. Kreek, Y. Zhang, The Laboratory of the Biology of the Addictive Diseases, The Rockefeller University, New York, NY

3:15  *Effects of environmental enrichment on microRNA-221 expression and ERK phosphorylation in the rat prefrontal cortex following nicotine-induced sensitization or nicotine self-administration*
J. Zhu, A. M. Gomez, W. Sun, D. Altmare, K. E. Creek, S. B. Harrod
Dept. of Drug Discovery and Biomedical Sciences, University of South Carolina, Columbia, SC; Psychology, University of South Carolina, Columbia, SC

3:30  *Effects of withdrawal from chronic nicotine on emotional and cognitive behaviors in adult and adolescent mice*
Psychology, Temple University, Philadelphia, PA; Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA

3:45  *Effects of parental alcohol vs. tobacco and marijuana use on early adolescent onset of alcohol use*
D. Capaldi, S. S. Tiberio, D. C. Kerr, K. C. Pears
School of Psychological Science, Oregon State University, Corvallis, OR; Oregon Social Learning Center, Eugene, OR

Oral Communications 7  McArthur Ballroom 5/6  2:00 - 4:00 PM

**MARTY'S AMINES: MONOAMINES**

Chairs: Ronald Cowan and Sarah E. Swinford-Jackson

2:00  *Combined enhancement of acetylcholine and monoamines causes persistent reductions in cocaine reward*
K. Grasing, F. Yang, H. Xu, Kansas City VA Medical Center, Kansas City, MO

2:15  *Drug-seeking following extinction of MDMA self-administration: Role of dopamine and serotonin*
S. Schenk, Psychology, Victoria University Wellington, Wellington, New Zealand

2:30  *Subjective responses to acute cocaine are moderated by variants of the serotonergic system*
Psychiatry, Baylor College of Medicine, Houston, TX; Statistical and Genetic Consulting LLC, Darien, CT

2:45  *Neuropharmacology of replacement analogs of the designer drug 3,4-methylenedioxymethcathinone*
M. H. Baumann, O. Dillon-Carter, M. O. Bukhari, R. B. Rothman, J. S. Partilla, IRP, NIDA, NIH, Baltimore, MD

3:00  *Effects of the 5-HT1B receptor agonist CP 94253 on methamphetamine self-administration*
R. Garcia, N. Pentkowski, J. Venault, K. Leslie, J. Bonadonna, A. Cotter, M. F. Olive, J. L. Neisewander, School of Life Sciences, Arizona State University, Tempe, AZ
Monday, June 15, 2015

3:15  Ceftriaxone attenuates acute cocaine evoked motor activity and dopaminergic neurotransmission in the dorsal and ventral striatum  
J. L. Barr¹, B. A. Rassmussen¹, C. S. Tallarida¹, J. L. Scholl², G. L. Forster², E. Unterwald¹, S. Rawls¹, ¹Pharmacology and Center for Substance Abuse Research, Temple University, Philadelphia, PA, ²Center for Brain and Behavior Research, The University of South Dakota, Vermillion, SD

3:30  Differential modulation of cocaine-related behaviors consequent to knockdown of serotonin 5-HT₂c receptor in the nucleus accumbens shell vs. ventral tegmental area  
S. É. Swinford-Jackson¹, N. C. Anastasio¹², S. J. Stutz¹, R. G. Fox¹, K. A. Cunningham¹², ¹Center Addiction Res, University of Texas Medical Branch, Galveston, TX, ²Dept. Pharmacology, University of Texas Medical Branch, Galveston, TX

3:45  Increased cortical excitability in human MDMA users  
R. Cowan¹, M. Dietrich¹, J. Kim², D. Zald², ¹Psychiatric Neuroimaging Program, Vanderbilt University, Nashville, TN, ²Psychology, Vanderbilt University, Nashville, TN

Marian W. Fischman Memorial Award Lecture
McArthur Ballroom 4
4:30 - 5:30 PM

Presentation of the Marian W. Fischman Award to Kathleen Brady

Introduction by Sudie Back

Stress and addictions
Kathleen T. Brady

Pre- and Post Doctoral Trainees Networking Event
Gold
5:30 - 7:00 PM

Workshop V
McArthur Ballroom 1/2
7:00 - 9:00 PM

THE CASE FOR RESCHEDULING PSYLOCYBIN AS A TREATMENT MEDICATION: REGULATORY RATIONALE, ABUSE LIABILITY, SAFETY, AND TREATMENT EFFICACY

Chairs: Roland R. Griffiths and Matthew W. Johnson

Psilocybin: Efficacy in treatment of psychological distress in cancer patients and eight-factor analysis of abuse liability under the Controlled Substances Act  
Roland R. Griffiths, Johns Hopkins University School of Medicine, Baltimore, MD

National household survey data on suicide-associated correlates of psilocybin use  
Peter S. Hendricks, University of Alabama at Birmingham, Birmingham, AL

Psilocybin treatment of tobacco and other addictions  
Matthew W. Johnson, Johns Hopkins University, Baltimore, MD

Can there be a role for psilocybin as a medical intervention?  
H. Westley Clark, Center for Substance Abuse Treatment, Santa Clara, CA
Workshop VI

USE OF SBIRT TO ADDRESS ADOLESCENT DRUG ABUSE

Chairs: Ken Winters and Michael L. Dennis

- Efficacy study of a SBIRT program in a school setting
  Ken Winters, University of Minnesota, Minneapolis, MN

- Adolescent SBIRT implementation in pediatric primary care: Patient outcomes in a randomized trial in an integrated health care delivery system
  Stacy Sterling, Kaiser Permanente Division of Research, Oakland, CA

- A small, randomized comparison of two SBIRT models for increasing treatment engagement among treatment-referred adolescents
  Douglas C. Smith, University of Illinois at Urbana-Champaign, Chicago, IL

- Brief alcohol interventions for adolescents and young adults: A systematic review and meta-analysis
  Emily Tanner-Smith, Vanderbilt University, Nashville, TN

- Implications of SBIRT in health service delivery
  Michael L. Dennis, Chestnut Health Systems, Normal, IL

Workshop VII

SUBSTANCE ABUSE TREATMENT CLINICAL TRIALS: DOES GENDER MATTER?

Chairs: Shelly F. Greenfield and Carmen Rosa

- Stimulant reduction intervention using dosed exercise: Gender differences and treatment acceptability
  Therese Killeen, Medical University of South Carolina, Charleston, SC

- Gender differences in response to a 12-step engagement intervention: Results of a national drug abuse treatment clinical trials network study
  Mary Hatch-Maillette, University of Washington, Seattle, WA

- Web-based psychosocial treatment for outpatient substance abuse treatment seekers: Gender differences in acceptability and treatment outcomes
  Aimee Campbell, Columbia University College Medical Center, New York, NY

- Gender differences in accessing substance abuse treatment following an emergency department SBIRT intervention
  Audrey Brooks, University of Arizona, Tucson, AZ

DISCUSSANT: Recent results in the NIDA clinical trials network: Does gender matter?
  Shelly F. Greenfield, Harvard Medical School, Boston, MA
Workshop VIII

INTERVENTION 2.0: USING SOCIAL DIGITAL TOOLS TO REACH DIFFICULT-TO-TREAT SUBSTANCE USERS

Chairs: Danielle Ramo and Suzette Glasner-Edwards

Mobile phone technology targeting relapse prevention and medication adherence among HIV+ substance users
Suzette Glasner-Edwards, University of California Los Angeles Integrated Substance Abuse Programs, Los Angeles, CA

Integrating online monitoring, treatment and social networking into managing binge drinking and depression in young Australians
Frances Kay-Lambkin, University of New South Wales National Drug, Randwick, NSW, Australia

Using social media to recruit parents to a family program to prevent teen drug use
Sabrina Oesterle, University of Washington, Seattle, WA

One-year outcomes from a smoking cessation intervention on Facebook
Danielle Ramo, University of California San Francisco, San Francisco, CA

DISCUSSANT:
Alan J. Budney, Geisel School of Medicine at Dartmouth, Lebanon, NH
2015 NIDA International Forum Abstracts
June 15, 2015–7:00 to 9:00 p.m.

Basic Science

100 Characterization of the lethality and biological safety profiles on rodents of a 10-valent opiate vaccine, the M-TT vaccine

101 Haloperidol and ketanserine prevent psychosis-like behaviors induced by toluene in rats
S. Cruz, M. Rivera-García, C. López-Rubalcava. Cinvestav, Mexico

102 Kappa opioid receptor agonist 16-bromosalvinorin A reduces cocaine-seeking in rats
A. Ewald1, J. Miller1, T. Prisinzano2, B. Kivell1. 1Centre for Biodiscovery, Victoria University of Wellington, New Zealand; 2Department of Medicinal Chemistry, The University of Kansas, United States

103 Abuse liability evaluation of mephedrone in humans
M. Farré1,2, C. Pérez-Mañá1,2, J. Mateus1,2, M. Pujadas1, F. Fonseca1, M. Torrens1,2, R. de la Torre1,3, E. Papaseit1,2. 1Hospital del Mar Medical Research Institute-IMIM and Drug Addiction Unit, Parc de Salut Mar, Spain; 2Universidad Autónoma de Barcelona, Spain; 3Universidad Pompeu Fabra, Spain

104 Evaluation of dried urine spot method for detection of cotinine among tobacco users
R. Jain, R. Quraishi, A. Verma. National Drug Dependence Treatment Center, All India Institute of Medical Sciences, India

105 Heterogeneity of heroin dependence and genetic polymorphism of dopamine system
A. O. Kibitov, V. M. Brodyansky, N. A. Chuprova. National Research Centre on Addictions, Russia

106 Kappa opioid receptor agonist Mesyl Sal B attenuates behavioral sensitization to cocaine with fewer aversive side effects
B. M. Kivell1, A. S. Morani1, A. Culverhouse1, T. E. Prisinzano2. 1School of Biological Science, Centre for Biodiscovery, Victoria University of Wellington, New Zealand; 2Department of Medicinal Chemistry, The University of Kansas, United States

107 Decreased thalamocortical connectivity in chronic ketamine users: Implications for schizophrenia
Y. Liao1, M. Song2, J. Tang1, J. Liu3, M. Yang1,4,5, M. Ma6, X. Wang1, Q. Deng1, H. Chen1, X. Xiang1, T. Liu1, X. Chen1, W. Hao1. 1Mental Health Institute, the Second Xiangya Hospital of Central South University, China; 2Brainnetome Center and National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, China; 3The People’s Hospital of Hunan Province, China; 4Department of Addiction Medicine, Hunan Brain Hospital, China; 5School of Public Health, Central South University, China; 6The Kangda Voluntary Drug Rehabilitation Centers in Hunan Province, China

108 The M-TT vaccine preserves its immunogenic efficacy to trigger humoral immune responses in compromised opiate-immunodepressed rodents
109 Development of a combination heroin-HIV vaccine
Institute of Research, United States; 2U.S. Military HIV Research Program, Henry M. Jackson
Foundation for the Advancement of Military Medicine, United States; 3National Institute on
Drug Abuse, National Institutes of Health (NIH), United States; 4National Institute on Alcohol
Abuse and Alcoholism, NIH, United States

110 Association between crack addiction and the intron 8 variable number of tandem repeats
polymorphism of the DAT1 gene
D. Müller1, A. R. Stolf2, G. C. Akutagava-Martins1, L. S. P. Guimaraes2, F. H. P. Kessler2,
F. Pechansky2, T. Roman1. 1Department of Genetics, Federal University of Rio Grande do Sul, Brazil;
2Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil

111 Reacquisition of cocaine-conditioned place preference and its inhibition by previous social
interaction preferentially affect D1-medium spiny neurons in the accumbens corridor
J. M. Prast1, A. Schardl1, C. Schwarzer1, G. Dechant1, A. Saria1, G. Zernig1,2. 1Innsbruck
Medical University, Austria; 2Leopold-Franzens University of Innsbruck, Austria

112 Effect of nalbuphine on plasma corticosterone levels and opiate withdrawals
Centre, All India Institute of Medical Sciences, India

113 Cannabis users show increased susceptibility to false memories
J. Riba1, F. Sampedro2, A. Rodríguez-Pujadas1, S. Martínez-Horta1, J. Kulisevsky1, J. Pérez
de los Cobos3, A. Rodríguez-Fornells2, M. Valle1. 1Human Neuropsychopharmacology
Group, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Spain; 2Universidad de
Barcelona, Spain; 3Hospital de la Santa Creu i Sant Pau, Spain

114 Overexpression of GRP78 confers protection against neurocognitive impairment in HIV-
infected polydrug users
M. Rodríguez, S. Lopez, M. Rivera, K. Narvaez, L. Cubano, E. Rios, N. Boukli. Universidad
Central del Caribe Medical School, United States

115 Role of DJ1 gene in cocaine addiction and HIV-associated cognitive impairment
U. Roy, V. Atluri, M. Agudelo, M. Nair. Herbert Wertheim College of Medicine, Florida
International University, United States

116 Khat synergizes gentamicin-induced nephrotoxicity in rats: Drug of abuse beyond addiction
Z. S. Sabe1, E. Engidawork2. 1College of Medicine and Health Sciences, University of Gondar,
Ethiopia; 2College of Medicine and Health Sciences, Addis Ababa University, Ethiopia

117 Immunopharmacological characterization of combination use of two structurally related tetanus
toxoid-based morphine vaccines
A. Salazar, J. Hernandez-Calderon, S. Barbosa, R. Hernandez-Miramontes, R. Acevedo,
E. Ramos-Ochoa, S. Jacinto, J. Calva, D. Meneses, I. Feregrino Marta, C. Martinez, M. Matus,
A. Flores, S. Martíñon, A. Benito. National Institute of Psychiatry, Ramón de la Fuente,
Mexico

118 Effects of khat (Catha edulis Forsk) on electrophysiologic properties of the heart and of lung
function indices
Y. M. Sewiye. Jimma University, Ethiopia
Clinical characteristics and genotype frequencies of the dopamine transporter gene (DAT1/SLC6A3) 3' UTR variable number of tandem repeats in crack cocaine users
A. R. Stolf, G. C. Akutagava-Martins, D. Müller, L. S. P. Guimarães, F. Pechansky, T. Roman, F. H. P. Kessler. 1Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil; 2Department of Genetics, Federal University of Rio Grande do Sul, Brazil

Effect of hapten density on the induction of antibodies to heroin hapten-protein conjugates

Assessment of Oxidative DNA damage biomarker 8-hydroxy-2'-deoxyguanosine among adolescent inhalant users
A. Verma, R. Jain, A. Dhawan, R. Lakshmy. 1National Drug Dependence Treatment Center, All India Institute of Medical Sciences, India; 2Department of Cardiac Biochemistry, All India Institute of Medical Sciences, India

VTA glutamate neurons that co-release GABA can be excitatory or inhibitory
V. Zell, J. H. Yoo, N. Gutierrez-Reed, K. Fife, T. S. Hnasko. University of California San Diego, United States

Screening substance use among college and faculty students in Bucharest
A. O. Abagiu, M. I. Maftei, A. Atomoaie, I. T. Niculescu. National Institute for Infectious Diseases Prof. Dr. Matei Bals, Romania

Differences in tobacco use, attitude, and knowledge among young Jordanians
M. Abdoh, R. M. Jones. 1Humphrey Fellowship Program, Virginia Commonwealth University, United States; 2School of Medicine and Massey Cancer Center, Virginia Commonwealth University, United States

Low threshold methadone protects against HIV incidence in a Canadian setting
K. Ahamad, K. Hayashi, P. Nguyen, S. Dobrer, T. Kerr, J. Montaner, E. Wood. 1University of British Columbia, Canada; 2British Columbia Centre for Excellence in HIV/AIDS, Canada

Effect of Gaza 2014 war on use of smoking, tramadol, and psychoactive drugs among university students
M. F. Afifi, M. Sakka, M. Shehada, R. Afifi. 1Substance Abuse Research Center, Palestinian Territories; 2Al-Azhar University, Palestinian Territories

Findings from the Inaugural Iraqi Community Epidemiological Workgroup on Substance Use
N. Al Hemiary, A. Abutiheen, E. Abdulrazzaq, M. Al-Hachami, R. Dabbagh, A. Hasson, V. Antonini, R. Rawson. 1College of Medicine, University of Baghdad, Iraq; 2College of Medicine, Karbala University, Iraq; 3Ministry of Health, Iraq; 4Integrated Substance Abuse Programs, University of California, Los Angeles, United States

Age of first use and drug dependence: Data from 617 consecutively ascertained subjects
S. Bacciardi, A. G. I. Maremmani, E. Butelman, B. Ray, E. Ducat, M. J. Kreek. 1“VP Dole” Dual Diagnosis Unit, Santa Chiara University Hospital of Pisa, Italy; 2Laboratory of the Biology of Addictive Diseases, The Rockefeller University, United States
Size estimation of injecting drug users in Sri Lanka
A. I. Bandara. National Dangerous Drugs Control Board (retired), Sri Lanka

Second online survey on drug use in college students at a private university in El Salvador
F. Bautista Pérez. Universidad Evangélica de El Salvador, El Salvador

The use of new psychoactive substances in Belgium: A worrying phenomenon
P. Blanckaert¹, T. Windelinckx², K. Maudens³. ¹Belgian Early Warning System Drugs, Belgium; ²Free Clinic Needle Exchange–Antwerp, Belgium; ³Toxicological Center, Antwerp University, Belgium

Pharmaceutical opioid use and dependence among people living with chronic pain: Associations observed within the Pain and Opioids IN Treatment (POINT) cohort
G. Campbell¹, S. Nielsen¹,², B. Larance¹, R. Bruno¹,³, R. Mattick¹, W. Hall⁴, N. Lintzeris²,⁵, M. Cohen⁶, K. Smith¹, L. Degenhardt¹,⁷,⁸,⁹. ¹National Drug and Alcohol Research Centre, University of New South Wales (UNSW), Australia; ²School of Medicine, University of Tasmania, Australia; ³The Langton Centre, South East Sydney Local Health District Drug and Alcohol Services, Australia; ⁴St. Vincent’s Clinical School, UNSW Medicine, Australia; ⁵Sydney Medical School, Sydney University, Australia; ⁶Black Dog Institute, UNSW, Australia; ⁷Centre for Youth Substance Abuse Research, University of Queensland, Australia; ⁸National Addiction Centre, King’s College London, England; ⁹School of Population and Global Health, University of Melbourne, Australia

Characteristics of pregnant women who smoke in Guadalajara, Mexico
O. Campollo¹,², F. Hernandez Mora², E. Angulo², A. Guzman², A. Munguía², M. García², J. K. Cunningham³. ¹Center of Studies on Alcohol and Addictions, CUCS, Universidad de Guadalajara, Mexico; ²Hospital Civil de Guadalajara, Mexico; ³Department of Family and Community Medicine, University of Arizona, United States

Dimensional and categorical phenotypes of opioid use disorder criteria among frequent nonmedical prescription opioid users: Investigating sociodemographic, psychiatric, and source correlates
J. M. Castaldelli-Maia¹,²,³, L. H. Andrade¹, K. M. Keyes⁴, M. Cerdá⁴, D. J. Pilowsky⁴,⁵, S. S. Martins⁶. ¹Section of Psychiatric Epidemiology, Department and Institute of Psychiatry, University of São Paulo Medical School, Brazil; ²Interdisciplinary Group of Studies on Alcohol and Drugs, Department and Institute of Psychiatry, University of São Paulo Medical School, Brazil; ³Department of Neuroscience, Medical School, Fundação do ABC, Brazil; ⁴Department of Epidemiology, Mailman School of Public Health, Columbia University, United States; ⁵New York State Psychiatric Institute, United States

Study of socio-demographic profile and correlates of injection drug use among children in India
B. Chatterjee, A. Dhawan, A. Chopra, R. Bhargawa, R. D. Pattanayak. National Drug Dependence Treatment Centre and Department of Psychiatry, All India Institute of Medical Sciences, India

New epidemiological evidence on coca leaf chewing and a dependence syndrome in 2008
V. Cruz¹,², J. C. Anthony¹,². ¹Department of Epidemiology, Michigan State University, United States; ²School of Public Health, Cayetano Heredia University, Peru; ³Peruvian National Institute of Mental Health, Peru
214 Substance use and adherence among HIV-infected persons receiving antiretroviral therapy in Latin America
R. B. De Boni¹, B. E. Shepherd², B. Grinsztejn¹, C. Cesar³, C. Cortés⁴, D. Padgett⁵, E. Gotuzzo⁶, F. Belaunzarán¹, S. Duda², C. McGowan², The Caribbean, Central and South America Network for HIV Research (CCASAnet)⁸. ¹Instituto de Pesquisa Clínica Evandro Chagas - Fundação Oswaldo Cruz, Brazil; ²Vanderbilt University, United States; ³Fundación Huésped, Argentina; ⁴Fundación Arriaran, Chile; ⁵Instituto Hondureño de Seguridad Social and Hospital Escuela, Tegucigalpa, Honduras; ⁶Universidad Peruana Cayetano Heredia, Lima; ⁷Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico; ⁸CCASAnet, Vanderbilt University, United States

215 Experience of adjunctive cannabis use for chronic noncancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study
L. Degenhardt¹, N. Lintzeris³⁴, G. Campbell¹, R. Bruno¹⁵, M. Cohen⁶, M. Farrell¹, W. Hall⁷. ¹National Drug and Alcohol Research Centre, University of New South Wales, Australia; ²School of Population and Global Health, University of Melbourne, Australia; ³Discipline of Addiction Medicine, University of Sydney (UNSW), Australia; ⁴The Langton Centre, South East Sydney Local Health District Drug and Alcohol Services, Australia; ⁵School of Medicine, University of Tasmania, Australia; ⁶St. Vincent’s Clinical School, UNSW Medicine, Australia; ⁷Centre for Youth Substance Abuse Research, University of Queensland, Australia; ⁸National Addiction Centre, King’s College London, England

216 Increase in prevalence of marijuana use among university students in Bolivia, Colombia, Ecuador, and Peru
M. Demarco¹, M. Hynes¹, J. C. Araneda², F. Cumsille¹. ¹Inter-American Observatory on Drugs, Inter-American Drug Abuse Control Commission, Organization of American States, United States; ²Global Synthetics Monitoring: Analyses, Reporting and Trends Programme (SMART)-Latin America, United Nations Office on Drugs and Crime, Switzerland

217 Study of socio-demographic profiles and correlates of inhalant use among children in India
A. Dhawan, B. Chatterjee, A. Chopra, R. Bhargawa, R. D. Pattanayak. National Drug Dependence Treatment Centre and Department of Psychiatry, All India Institute of Medical Sciences, India

218 Three rounds of integrated bio-behavioral surveillance confirm declining HIV prevalence among people who inject drugs (PWID) in Ukraine
K. Dumchev¹, T. Salyuk², Y. Sazonova². ¹Institute on Public Health Policy, Ukraine; ²International HIV/AIDS Alliance–Ukraine, Ukraine

219 Use patterns of tobacco and nicotine-containing products among college students in the United States
O. El-Shahawy¹, S. Cho², A. McGann³, K. Hill³. ¹School of Medicine, Virginia Commonwealth University, United States; ²Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, United States; ³Wellness Resource Center, Virginia Commonwealth University, United States

220 Aspects of substance abuse among adolescents detained in a juvenile delinquency institution in Upper Egypt
A. A. Elkoussi¹, T. S. Bakheet², S. H. Bakheet³. ¹Department of Pharmacology, College of Medicine, Assiut University, Egypt; ²Department of Sociology, College of Arts, Assiut University, Egypt
Mortality and cannabis detection in a cohort of patients with opiate, cocaine, and alcohol dependence
D. Fuster1,2, A. Sanvisens1,2, P. Zuluaga1,2, J. Tor1,2, I. Rivas3, R. Muga1,2. 1Internal Medicine Service. Hospital Germans Trias i Pujol, Spain; 2Universitat Autònoma de Barcelona, Spain; 3Municipal Centre for Substance Abuse Treatment, Centro Delta, IMSP, Spain

Mixed drug intake and its dosage as a predictor of mental health status, Bahir-Dar, North West Ethiopia
A. G. Gebresilus. College of Education and Behavioral Studies, Addis Ababa University, Ethiopia

ASSIST in HIV/AIDS service settings: Comparison of self-screening and peer-support screening method
L. M. Giang1, H. Nguyen1, H. Tran1, G. Bart2, T. Rieckmann3, H. Tran1, K. Darfler4, R. Rawson2. 1Hanoi Medical University, Viet Nam; 2Department of Medicine, Hennepin County Medical Center, United States; 3School of Public Health, Oregon Health & Science University, United States; 4Integrated Substance Abuse Programs, University of California, Los Angeles, United States

Occupational and demographic factors associated with drug use among female sex workers in Burma (Myanmar)
K. Hail-Jares1, S. Choi1, J. Huang1, L. Duo2, Z. Luo2. 1Department of International Health, School of Nursing and Health Studies, Georgetown University, United States; 2Yundi Harm Reduction Network, China

Naloxone in Egypt—availability and challenges
W. Hassan1,2, R. Naguib1. 1Institute of Psychiatry, Ain Shams University, Egypt; 2Hubert Humphrey Fellowship Program, Virginia Commonwealth University, United States

R. Isralowitz, A. Reznik. Regional Alcohol and Drug Abuse Research Center, Spitzer Department of Social Work, Ben Gurion University, Israel

Piloting of ASSIST screening tool for identification of alcohol, tobacco, and drug use in pregnancy in two cities of Ukraine
T. Kiriazova1, T. Tarasova2, O. Makarenko1, O. Zeziulin1, V. Martsinovskaya3, S. Dvoriak1. 1Ukrainian Institute on Public Health Policy, Ukraine; 2UNICEF, Ukraine; 3Ukrainian Center for Socially Dangerous Disease Control, Ministry of Health, Ukraine

Transition from heroin use to dependence and treatment seeking among an opioid-dependent sample
B. Larance1, E. Cama1, N. Gisev1, E. Nelson2, L. Degenhardt1. 1National Drug and Alcohol Research Centre, University of New South Wales, Australia; 2Washington University in St. Louis, United States

Diagnosis of hepatitis C virus infection after entry to opioid substitution therapy: A 15-year observational cohort study
S. Larney1, J. Grebely2, M. Falster1,4, A. Swart4, J. Amin2, L. Degenhardt1, L. Burns1, C. M. Vajdic4. 1National Drug and Alcohol Research Centre, University of New South Wales (UNSW), Australia; 2The Kirby Institute, UNSW, Australia; 3Centre for Health Research, University of Western Sydney, Australia; 4Prince of Wales Clinical School, UNSW, Australia

Risk of schizophrenia in marijuana users: Findings from a nationwide sample of drug users in Chile
N. Libuy, V. Angel, C. Ibáñez. Department of Psychiatry and Mental Health North, Clinical Hospital, University of Chile, Chile
<table>
<thead>
<tr>
<th>231</th>
<th>A pre–post comparison in health care service utilization among heroin-using women in methadone maintenance treatment in Taiwan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y-T. Lien¹,², H-H. Yeh³, S-Y. Fang¹,², C-Y. Chen¹,². ¹Institute of Public Health, National Yang-Ming University, Taiwan; ²Center for Neuropsychiatric Research, National Health Research Institutes, Taiwan; ³Department of Epidemiology and Biostatistics, Michigan State University, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>232</th>
<th>Performance of lay outreach workers in a needle exchange program in China</th>
</tr>
</thead>
<tbody>
<tr>
<td>W. Liu¹,², H. Li³, L. Duo⁴, Z. Luo², J. Yang³, H. Xue², L. Yang³, Z. K. Hail-Jares⁵, J. Huang⁵. ¹School of Public Health, Kunming Medical University, China; ²Kunming Yundi Behavior and Health Research Center, China; ³Yunnan Provincial Center for Disease Prevention and Control, China; ⁴Second People’s Hospital of Yunnan Province, China; ⁵Department of International Health, Georgetown University, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>233</th>
<th>Gender differences in methamphetamine use in a Mexico-U.S. border city</th>
</tr>
</thead>
<tbody>
<tr>
<td>O. Loza¹, J. Ferreira-Pinto¹, R. Ramos², M. E. Ramos Rodriguez³. ¹University of Texas-El Paso, United States; ²Alliance Border Collaboratives, United States; ³Instituto Nacional de Psiquiatría, Ramón de la Fuente Muñiz, México</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>234</th>
<th>Substance-related disorders among patients with human immunodeficiency virus: An analytical study</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. T. Mahmud. Bogra Anti-Drug Society, Bangladesh</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>235</th>
<th>Psychiatric diagnoses in a cohort of normal volunteers and drug-dependent subjects: Comparative data from 617 consecutive subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. G. I. Maremmani¹,², S. Bacciardi¹,², E. Butelman², B. Ray², E. Ducat², M. J. Kreek². ¹“VP Dole” Dual Diagnosis Unit, Santa Chiara University Hospital of Pisa, Italy; ²Laboratory of the Biology of Addictive Diseases, The Rockefeller University, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>236</th>
<th>Application of outreach strategies to international collaborative research</th>
</tr>
</thead>
<tbody>
<tr>
<td>H. V. McCoy¹, A. J. M. Bengoa², A. J. Mendez², J. M. Shultz², D. C. McBride³, R. Achi⁴, S. Lai⁵, M. Zhao⁶, J. Cordova¹. ¹Florida International University, United States; ²University of Miami, United States; ³Andrews University, United States; ⁴University of Costa Rica, Costa Rica; ⁵Johns Hopkins University, United States; ⁶Shanghai Mental Health Center, China</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>237</th>
<th>Pathways from Gini (index) and neighborhood characteristics to children’s drug use: Multinational study</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. Miyamoto¹,². ¹School of Medicine, University of Tokyo, Japan; ²School of Public Health, Drexel University, United States</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>238</th>
<th>Drug abuse in Afghanistan also includes problems with children under 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. S. Momand¹,². ¹Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; ²Drug Demand Reduction Consultant, Afghanistan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>239</th>
<th>Predictors of early relapse in adolescent crack users after hospital discharge</th>
</tr>
</thead>
<tbody>
<tr>
<td>H. Moura¹, R. Rosa¹, F. Kessler¹, T. G. Pianca¹, L. Guimarães¹, P. Ferronato¹, E. Pagnussat², F. Pechansky¹, L. von Diemen¹. ¹Center for Drug and Alcohol Research Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Brazil; ²Pontifical Catholic University of Rio Grande do Sul, Brazil</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>240</th>
<th>Sex-specific disease outcomes of HIV-positive patients in a methadone treatment program with access to cART</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. Muga¹,², I. Rivas³, E. Faure³, D. Fuster¹,², P. Zuluaga¹,², J. L. Garcia-Medina¹,², J. Tor¹,², A. Sanvisens¹. ¹Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Spain; ²Universitat Autònoma de Barcelona, Spain; ³Municipal Center for Substance Abuse Treatment, Centro Delta, IMSP, Spain; ⁴Escuela Superior de Medicina, Instituto Politécnico Nacional, México</td>
<td></td>
</tr>
</tbody>
</table>
241 Measuring stigma associated with opioid drug use
T. Mukherjee1, J. Wickersham2, V. Earnshaw2, F. L. Altice1,2,3, A. B. Kamarulzaman2,3.
1School of Public Health, Yale University, United States; 2School of Medicine, Section of
Infectious Diseases, AIDS Program, Yale University, United States; 3Universiti of Malaya,
Centre of Excellence for Research in AIDS, Malaysia

242 Effect of negative affect regulation and impulsivity on food addiction in a sample of Egyptian
females

243 Substance abuse prevalence in Karachi and services by Drug Free Pakistan Foundation
F. Naveed1,2, 1Drug Free Pakistan Foundation, Pakistan; 2Hubert H. Humphrey Fellowship
Program, Virginia Commonwealth University, United States

244 Internalizing and externalizing disorders as risk factors for the increase of cannabis use and
the onset and stability of cannabis use disorders: A systematic review of cohort studies from the
general population
M. Neumann1, S. Behrendt1, A. Perkonigg2, G. Bühringer1. 1Addiction Research Unit, Institute
for Clinical Psychology and Psychotherapy, Dresden University of Technology, Germany;
2Psychopathology and Clinical Intervention Unit, Department of Psychology, University of
Zurich, Switzerland

245 Substance dependence criteria, not substance use, associated with HIV virologic control
S. Nolan1, A. Y. Walley2, T. C. Heeren2, G. J. Patt2, A. S. Ventura2, M. Sullivan2,
J. H. Samet2, R. Saitz2. 1Department of Medicine, University of British Columbia, Canada;
2Boston University, United States

246 Use of substance “h” (heroin) among students in Ecuador: Findings from qualitative research
in five school systems in Guayaquil and two school systems in Santa Elena
D. Oceña1, J. Paspuel1, S. Almeida1, P. Jacobs2. 1National Observatory, Consejo Nacional de
Sustancias Estupefacientes y Psicotrópicas del Ecuador, Ecuador; 2The Catholic University de
Santiago in Guayaquil, Ecuador

247 Illicit drug use in Nigeria: Recent findings from the National Survey on Alcohol and Drug Use
A. Ogunwale, T. A. Adamson, A. O. Oggunlesi, A. O. Akinhanmi, P. O. Onifade,
E. B. Somoye. Neuropsychiatric Hospital, Nigeria

248 Use of marijuana and expression of antisocial behavior among young people in urban Nigeria
M. O. Onoja1; K. A. Raphael2; A. Okoh3; J. A. Ocheh4. 1National Primary Health Care
Development Agency, Nigeria; 2Dunamis Christian Academy, Nigeria; 3Paths Educational
Centre, Nigeria; 4Young People’s Home, Nigeria

249 Pattern of psychoactive substance use among long-distance commercial drivers in Calabar
metropolis, Cross River State
T. Onyuku. Federal Neuropsychiatric Hospital–Calabar Cross River State, Nigeria

250 Drug use and injection practices in Tajikistan: Qualitative study in Kulob and Khorog
D. Otiashvili1, A. Latypov2, U. Ibragimov3, I. Kirtadze1, W. Zule4. 1Addiction Research Center,
Alternative Georgia, Georgia; 2Management Sciences for Health, Leadership, Management
and Governance, Ukraine; 3Laney Graduate School, Emory University, United States; 4RTI
International, United States

251 Crack users with conduct disorder have greater association with violence, trauma, and
psychiatric comorbidities
Alcohol and Drugs Research, Federal University of Rio Grande do Sul, Brazil
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>252</td>
<td>Cocaine base paste use in South America: Review of epidemiological</td>
<td>A. Pascale¹, M. Hynes², F. Cumsille², C. B. Bares³. ¹Red Latinoamericana de Investigadores en Drogas (REDLA) Network, Uruguay; ²Inter-American Observatory on Drugs, Inter-American Drug Abuse Control Commission, Organization of American States, United States; ³School of Social Work, Virginia Commonwealth University, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and toxicological aspects.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>253</td>
<td>Comparison of DUI prevalences among fatal, nonfatal, and roadside</td>
<td>F. P. Pechansky, L. Von Diemen, A. O. Sordi. Center for Drug and Alcohol Studies, Federal University of Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Brazil; Secretariat for Drug and Alcohol Policies (SENAD) Collaborating Center on Alcohol and Drugs, Brazil</td>
<td></td>
</tr>
<tr>
<td></td>
<td>samples of Brazilian drivers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>254</td>
<td>Transition from first substance use to crack cocaine: Predictors of</td>
<td>T. G. Pianca¹, R. L. Rosa², A. P. de Assis Begnis³, P. B. Ferronato¹, M. C. Jensen¹, L. A. P. Rohde¹, F. Pechansky¹, C. M. Szobot¹. ¹Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil; ²Hospital Psiquiátrico São Pedro, Brazil; ³Universidade Luterana do Brasil, Brazil</td>
<td></td>
</tr>
<tr>
<td></td>
<td>faster addiction progression and clinical characteristics in crack</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>cocaine adolescent users</td>
<td></td>
<td></td>
</tr>
<tr>
<td>255</td>
<td>Methamphetamine use among Iranian patients in methadone maintenance</td>
<td>S. R. Radfar¹, U. S. Warda¹, R. Rawson¹. ¹Integrated Substance Abuse Programs, University of California, Los Angeles, United States; ²Thought, Culture and Health (ROOZBEH) Institute, Iran</td>
<td></td>
</tr>
<tr>
<td></td>
<td>treatment: Is this a threat?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>256</td>
<td>Association of alcohol use with alcohol and weapon carrying among</td>
<td>O. Saiphoklang¹, K. Wongboonsin¹, P. Wongboonsin¹, U. Pernparr¹, L. B. Cottler¹. ¹College of Population Studies, College of Public Health Sciences, Chulalongkorn University, Thailand; ²Substance Abuse Training Center in Public Health, University of Florida, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thai adolescents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>257</td>
<td>HIV-related stigma and substance use in a Russian cohort of HIV-</td>
<td>J. H. Samet¹, K. Lunze¹, D. M. Cheng¹, D. Lioznov², E. Quinn¹, C. Bridden¹, C. Chaisson¹, A. Y. Walley¹, E. Krupitsky², A. Raj¹, E. J. Edelman¹. ¹Boston University, United States; ²First St. Petersburg Pavlov State Medical University, Russia; ³University of California, San Diego, United States; ⁴Yale University, United States</td>
<td></td>
</tr>
<tr>
<td></td>
<td>infected risky drinkers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>258</td>
<td>Adolescent substance use and specificity of association with</td>
<td>E. Silins¹, L. J. Horwood², D. Fergusson², G. Patton³, C. Olsson⁴, D. Hutchinson¹, L. Degenhardt¹, R. Mattick¹. ¹National Drug and Alcohol Research Centre, University of New South Wales, Australia; ²Christchurch Health and Development Study, Department of Psychological Medicine, University of Otago, New Zealand; ³Centre for Adolescent Health, Murdoch Children’s Research Institute, University of Melbourne, Australia; ⁴Department of Paediatrics, and School of Psychological Sciences, University of Melbourne, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>educational outcomes in young adulthood</td>
<td></td>
<td></td>
</tr>
<tr>
<td>259</td>
<td>Users’ knowledge about risks of benzodiazepine dependence in Kosovo</td>
<td>Z. Tahiri¹, F. Berisha¹, I. Rrahmani³. ¹Medical University of Tirana, Mexico; ²Main Family Medicine Center, Mexico; ³Regional Hospital of Gjilan, Mexico</td>
<td></td>
</tr>
<tr>
<td>260</td>
<td>“We need more than condoms”: Community mobilization of substance-</td>
<td>L. A. Urada¹, E. Reed¹, T. Gaines¹, C. Magis-Rodriguez², K. Meckel-Parker¹, P. Gonzalez-Zuniga¹, K. C. Brouwer¹. ¹Department of Medicine, Division of Global Public Health, University of California, San Diego, ²Concorcio de Investigacion sobre HIV/AIDS and TB, Mexico</td>
<td></td>
</tr>
<tr>
<td></td>
<td>using female sex workers in Tijuana, Mexico</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
261 Cross-sectional and prospective relation of cannabis potency, dosing, and smoking behavior with cannabis dependence: An ecological study
P. Van der Pol, N. Liebregts, T. Brunt, J. van Amsterdam, R. de Graaf, D. J. Korf, W. van den Brink, M. van Laar. The Trimbos Institute, Netherlands Institute of Mental Health and Addiction, The Netherlands; Bonger Institute of Criminology, Academic Medical Centre, University of Amsterdam, The Netherlands

262 Adaptation of a risk and protective factor survey for substance use among 9th and 10th grade students in Burma (Myanmar)
N. Wan1, W. L. Kliewer2. 1Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; 2Department of Psychology, Virginia Commonwealth University, United States

263 Substance abuse in Iraq “psychiatrists’ experience”
R. I. Yasein, V. Hussein. Ministry of Health-Kurdistan, Iraq

H-H. Yeh1, J. C. Anthony2, R. B. Seedall2. 1Department of Epidemiology, Michigan State University, United States; 2Department of Family, Consumer, and Human Development, Utah State University, United States

265 A rapidly changing recreational drug market: Findings from the Canadian Community Epidemiology Network on Drug Use
M. M. Young1,2, T. Pirie1, S. Hosein3. 1Canadian Centre on Substance Abuse, Canada; 2Carleton University, Canada; 3University of Calgary, Canada

266 Substance use dynamics and emergence of new drugs in Ukraine
O. Zeziulin1, K. Dumchev1, O. Varetskaya2, T. Salyuk2. 1Ukrainian Institute on Public Health Policy, Ukraine; 2International HIV Alliance–Ukraine, Ukraine

Other

300 Consumption of anabolic steroids in athletes: A bibliometric approach (2006–2012)
R. Aleixandre-Agulló1, F. Bueno-Cañigral2, J. C. Valderrama-Zurián3, D. Melero-Fuentes4, R. Aleixandre-Benavent4, J. C. Pérez-de-los-Cobos5. 1Instituto de Documentación y Tecnologías de la Información, Universidad Católica de Valencia, Spain; 2Plan Municipal de Drogodependencias, Ayuntamiento de Valencia, Spain; 3Departamento de Historia de la Ciencia y Documentación, Universitat de València, Spain; 4Instituto de Gestión de la Innovación y del Conocimiento, Spanish Research Council-CSIC, Spain; 5Servicio de Psiquiatría, Hospital de la Santa Creu i Sant Pau, Spain

301 Review of narcotics law in the process of the national reform movement in Burma (Myanmar)
N. P. E. Kham1, E. Jensema2, R. L. Balster1. 1Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; 2Transnational Institute, The Netherlands

302 The Hubert H. Humphrey Fellowship Program at Virginia Commonwealth University
J. R. Koch, R. L. Balster, A. Breland, L. D. Hedges. Virginia Commonwealth University, United States

303 The VCU Hubert H. Humphrey Fellowship in Substance Abuse Prevention, Treatment, and Policy: A follow-up assessment
O. Leonchuk1, J. R. Koch2, R. L. Balster2, A. Breland2. 1North Carolina State University, United States; 2Virginia Commonwealth University, United States
Long-acting reversible contraception (LARC) use and implemental barriers in the Song District, Sarawak, Malaysia
J-L. Lim, C. Z. F. Chua. 1Ministry of Health, Malaysia; 2Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; 3Klinik Kesihatan Song, Malaysia

International collaboration improves the impact of addiction research articles: A bibliometric analysis
J. McCormally. International Programme in Addiction Studies, Virginia Commonwealth University, United States

Scientific evaluation on substance abuse research through Web of Science over the 2008–2012 period
D. Melero-Fuentes, R. Aguilar-Moya, J. C. Valderrama-Zurián, F. Bueno-Cañigral, R. Aleixandren-Beaven, J. C. Pérez-de-los-Cobos. 1Instituto de Documentación y Tecnologías de la Información, Universidad Católica de Valencia, Spain; 2Departamento de Ciencias de la Educación, Universidad Católica de Valencia, Spain; 3Departamento de Historia de la Ciencia y Documentación, Universitat de València, Spain; 4Plan Municipal de Drogodependencias, Ayuntamiento de Valencia, Spain; 5Instituto de Gestión de la Innovación y del Conocimiento, Spanish Research Council-CSIC, Spain; 6Servicio de Psiquiatría, Hospital de la Santa Creu i Santa Pau, Spain

The “War on Drugs” in West Africa: An appraisal by participants at a human rights and drug policy training–Ghana
O. O. Umoh. University of Uyo, Nigeria

Creating capacity across continents through distance education: A multimethod assessment of the International Programme in Addiction Studies, Master’s in Addiction Studies
A. Williams, L. Cathers, M. Loos, R. Balster, K. Dyer, J. Strang, F. Buisman-Pijlman, G. Kandler, A. Salem. 1King’s College London, United Kingdom; 2Virginia Commonwealth University, United States; 3University of Adelaide, Australia

Cannabis, Lord Shiva, and holy men: Cannabis use among sadhus in Nepal
S. L. Acharya, J. Howard, S. B. Pant, J. Copeland. 1Ministry of Health and Population, Nepal; 2National Cannabis Prevention and Information Centre, University of New South Wales Medicine, Australia; 3Saarathi OST Program, Tribuvan University, Nepal

Content analysis of evaluation of effectiveness in prevention programs on drug abuse
R. Aleixandre-Benavent, D. Ribeiro-Schneider, F. Bissoli-Neto, M. Bolaños-Pizarro, F. Bueno-Cañigral, J. C. Pérez-de-los-Cobos. 1Unidad de Información e Investigación Social y Sanitaria, IHMC López Piñero, CSIC-Universidad de Valencia, Spain; 2Núcleo de Pesquisas em Psicologia Clínica, Departamento de Psicología, Universidade Federal de Santa Catarina, Brazil; 3Plan Municipal de Drogodependencias, Concejalía de Sanidad y Consumo, Ayuntamiento de Valencia, Spain; 4Servicio de Psiquiatría, Hospital de la Santa Creu i Santa Pau, Spain

Adolescents’ and parents’ perceptions of substance use and factors influencing substance use: A qualitative study in Abu Dhabi, United Arab Emirates

Together, marginalized youths can make a difference in HIV response
Y. Aung. Hubert H. Humphrey Fellow, Virginia Commonwealth University, United States
Socio-demographic and drug use profiles of persons who inject drugs (PWID) across different HIV prevention service utilization patterns in Ukraine
I. Barska1, M. Samko1, Dumchev2. 1International HIV/AIDS Alliance–Ukraine, Ukraine; 2Ukrainian Institute on Public Health Policy, Ukraine

At risk and at home: Young women who have left school early
T. Carney1, B. Myers1,2, K. Johnson1, F. A. Browne3, T. Kline3, I. Doherty3, W. M. Wechsberg3,6. 1Alcohol, Tobacco and Other Drug Abuse Research Unit, South African Medical Research Council, South Africa; 2Department of Psychiatry and Mental Health, University of Cape Town, South Africa; 3RTI International, United States; 4Health, Policy and Administration, Gillings School of Global Public Health, The University of North Carolina, Chapel Hill, United States; Psychology in the Public Interest, North Carolina State University, United States; 6Psychiatry and Behavioral Sciences, School of Medicine, Duke University, United States

Peak versus off-peak effects of cannabis: Impacts on driving performance
G. Gaffney1,2, G. Milavetz1,3, T. Brown1, A. Spurgin1,3, R. J. Johnson4. 1National Advanced Driving Simulator, University of Iowa, United States; 2Carver College of Medicine, University of Iowa, United States; 3College of Pharmacy, University of Iowa, United States; 4Advanced Brain Monitoring–San Diego, United States

Can peers be more important than friends in predicting adolescents’ drug use?
A. Gardikiotis1, W. D. Crano2. 1Aristotle University of Thessaloniki, Greece; 2Claremont Graduate University, United States

Substance use disorders among adolescent girls in Paraguay and its potential consequences on their offspring
E. G. Gonzalez Willim. Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States

National Drug Facts Week campaign in Egypt in collaboration with NIDA
A. Hammad1, M. Elkhouly1, M. Hussein1, H. Hassan2, W. Ebrahim3,4, M. ElHamshary4,5. 1Abbasiya Mental Hospital, Egypt; 2National Research Center, Egypt; 3AinShams University, Egypt; 4Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; 5Psychological Medicine Hospital, Egypt

Food insecurity and HIV drug and sex risk behaviors among Russians living with HIV
B. Idrisov1, K. Lunze2, D. M. Cheng2, E. Blokhina3, N. Gnatienko2, G. Patts2, A. Tyurina3, C. Bridden2, C. Chaisson2, M. J. Larson3, E. Krupitsky3, J. H. Samet5. 1Bashkir State Medical University, Russia; 2Boston University, United States; 3First St. Petersburg Pavlov State Medical University, Russia; 5Brandeis University, United States

Ambiguous roles of police in harm minimization in Nepal
C. K. Jha, D. M. Donovan. Alcohol and Drug Abuse Institute, University of Washington, United States

Family and socio-cultural practices influencing the onset and continuation of alcohol and drug use among youth polytechnic students in Kirinyaga County, Kenya
T. K. Kinai. Kenyatta University, Kenya

Reduce substance use and road accidents among commercial drivers in Greater Accra Region, Ghana
S. Koomson. Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
Validation of self-reported risk practices among persons who inject drugs in Ukraine: Findings from the ethnographic study

Adapting keepin’ it REAL for Mexico: The effects on trajectories of substance use behaviors
F. Marsiglia1, S. Kulis1, B. Nuño-Gutierrez2, J. Booth3, S. Ayers1. 1Southwest Interdisciplinary Research Center, Arizona State University, United States; 2Mexican Social Security Institute, Mexico; 3School of Social Work, University of Pittsburgh, United States

Peer educator program among injecting drug users associated with lower incidence of HIV, HVC, and HVB infection
R. Myint1, L. A. Swe2. 1Myanmar Anti Narcotic Association, Burma (Myanmar); 2Community-Based Self-Help Group, Burma (Myanmar)

HIV testing uptake among methadone maintenance treatment patients and testing referrals for their sexual partners
L. Nguyen1, B. X. Tran2. 1School of Public Health, Harvard University, United States; 2Bloomberg School of Public Health, Johns Hopkins University, United States

Substance use among secondary school students in Calabar, Nigeria: A study in advance of establishing a school-based prevention program
U. C. Onukogu1, E. E. Ekpe1, B. Edet1, C. A. Anya2. 1Federal Neuro Psychiatric Hospital, Calabar, Nigeria; 2Federal University Zamfara, Nigeria

Introduction of a tamper-resistant formulation of controlled-release oxycodone: A prospective cohort study
A. Peacock1, L. Degenhardt2, B. Larance2, E. Cama2, N. Lintzeris3, R. Ali4, R. Bruno1. 1School of Medicine, University of Tasmania, Australia; 2National Drug and Alcohol Research Centre, University of New South Wales, Australia; 3Sydney Medical School, Sydney University, Australia; 4University of Adelaide, Australia

From zero to demand: Moving Guatemala City public schools toward substance abuse prevention for adolescents
M. Porta1, P. Dustman2, J. Booth3. 1Uyumcap Organization, Guatemala City, Guatemala; 2Southwest Interdisciplinary Research Center, Arizona State University, United States; 3School of Social Work, University of Pittsburgh, United States

HIV risks due to substance abuse—the case of Nepal
M. B. Poudyal-Chhetri. Nepal Center for Disaster Management, Nepal

Risk and protective factors for recreational and hard drug use among Malaysian adolescent and young adults
M. Razali1, W. Kliewer2. 1Sultan Idris Education University, Malaysia; 2Virginia Commonwealth University, United States

Evaluation of “Choice-8” effect a year after implementing the substance abuse prevention program
V. Ryabukha. Prevention Center, “Choice,” Ukraine

Risky injection practices among persons who inject drugs (PWID) in smaller Ukrainian cities: An overlooked at-risk population of PWID

Evaluation of impact of HIV prevention programs for persons who inject drugs on HIV seroconversion by using a cohort study design.
M. Samko1, J. Barska1, Dumchev2. 1ICF “International HIV/AIDS Alliance–Ukraine,” Ukraine; 2Ukrainian Institute on Public Health Policy, Ukraine
426  *A critical analysis of the falling age of initiation among injecting drug users and the programmatic response in Manipur, India*
   K. K. Shimray. Royal Tropical Institute, Vrije Universiteit, The Netherlands

427  *Factors associated with participation in HIV case management intervention among Russian drug users*
   O. Toussova¹, D. M. Cheng², E. Blokhina¹, C. Bridgen³, N. Gnatienko⁴, E. Quinn², A. Raj⁴, T. Kiriazova², K. Lunze², A. Y. Walley²,³, E. M. Krupitsky¹,⁶, J. H. Samet²,³. ¹First St. Petersburg Pavlov State Medical University, Russia; ²Boston University, United States; ³Boston Medical Center, United States; ⁴University of California, San Diego, United States; ⁵Future without AIDS–Odessa, Ukraine; ⁶St. Petersburg Bekhterev Research Psychoneurological Institute, Russia

428  *Familias unidas for high-risk adolescents: Cultural adaptation of a U.S. drug and HIV prevention intervention in Ecuador—preliminary results of phase 1 (pilot) testing*
   G. Valenzuela¹, A. Quevedo¹, C. Condo¹, M. Albán¹, G. Prado², Y. Estrada², M. Tapia², M. Velazquez², P. Jacobs¹. ¹The Catholic University de Santiago, Ecuador; ²University of Miami, United States

429  *Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia*
   A. Vijay¹, A. R. Bazazi¹,², A. Kamarulzaman¹,³, F. L. Altice¹,²,³. ¹AIDS Program, Section of Infectious Diseases, Department of Medicine, School of Medicine, Yale University, United States; ²School of Public Health, Yale University, United States; ³Centre of Excellence for Research in AIDS (CERiA), Universiti of Malaya, Malaysia

430  *Family functioning and self-esteem among substance abusers in two substance abuse treatment centres, Kuala Lumpur*
   S. Wahab¹, E. C. Lau², A. M. Zahidi², N. M. Ishak², A. Tsutsumi³, S. E. Haque³, N. A. Muhammad⁴, M. Mazlan⁵. ¹Department of Psychiatry, Universiti Kebangsaan Malaysia Medical Centre, Malaysia; ²PERMApintarTM, National Gifted Centre, Universiti Kebangsaan, Malaysia; ³International Institute for Global Health, United Nations University, Malaysia; ⁴Institute for Medical Research, Malaysia; ⁵Substance Abuse Research Centre, Malaysia

431  *Methamphetamine use and risk behavior in Cape Town adolescents*
   E. H. Weybright¹, L. Wegner², P. Bediako³, L. L. Caldwell⁴, E. A. Smith⁵. ¹Human Development, Washington State University, United States; ²Occupational Therapy, University of the Western Cape, South Africa; ³Health Policy and Administration, Pennsylvania State University, United States; ⁴Recreation, Park, and Tourism Management, Pennsylvania State University, United States; ⁵Prevention Research Center, Pennsylvania State University, United States

Treatment

500  *An alternative to incarceration of drug users: A comparative study of Ghana and the United States*
   D. Amankwaah. Narcotics Control Board, Ghana

501  *The evolution of illicit opioid use among HIV-infected opioid users in Russia (2004–2014)*
   E. Blokhina¹, E. M. Krupitsky¹,², D. M. Cheng³, C. Bridgen⁴, A. Y. Walley³, O. Toussova¹, T. Yaroslavtseva¹, N. Gnatienko⁴, L. Forman³, J. H. Samet³,⁴. ¹First St. Petersburg Pavlov State Medical University, Russia; ²St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; ³Boston University, United States; ⁴Boston Medical Center, United States
Limitations to participation in opioid maintenance treatment in Europe
L. Brandt¹, A. Unger², L. Moser¹, G. Fischer¹,², R. Jagsch³. ¹Center for Public Health, Medical University of Vienna, Austria; ²Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria; ³Faculty of Psychology, University of Vienna, Austria

Evaluation of cognitive functioning of co-occurring opiate and amphetamine-type stimulant use disorders in Malaysia
W-T. Chooi¹, N. M. Zaharim¹, A. Desrosiers², I. Ahmad¹, M. A. M. Yasin¹, S. Z. Syed-Jaapar¹, R. S. Schottenfeld², B. K. Vicknasingam¹, M. C. Chawarski². ¹Universiti Sains, Malaysia; ²School of Medicine, Yale University, United States

A comparison of outcomes and costs in three modalities of opioid dependence treatment in Ukraine
V. Chtenguelov¹, S. Dvoriak², G. Prib³. ¹Department of Social Work and Applied Psychology, Academy of Labor, Social Relations and Tourism, Ukraine; ²Ukrainian Institute on Public Health Policy, Ukraine; ³Department of Psychology, Institute of Professional Training for Public Employment Service, Ukraine

Illicit drug users age 60 and older in Western Rio de Janeiro, Brazil: Trajectory, added risks, and experiences
J. Da Silva, M. Rodrigues, J. Santos. Anna Nery School of Nursing, Federal University of Rio de Janeiro, Brazil

Screening, brief intervention, and referral to treatment (SBIRT) implementation in primary care centers in Brazil: Innovative technology-building relationships
F. De Conto, S. A. L. Saraiva, R. de Cerqueira Campos, J. Zepeda. Florianopolis Department of Mental Health and Primary Care, Brazil

A 6-month follow-up of an integrated treatment program for opiate addiction and HIV in Vietnam
C. Denis¹, D. Metzger¹, L. Huang², V. Trias², M. Auriacombe², G. Raguin², S. Mai Thi Hoai⁴, G. Le Truong⁴, J-P. Daulouède²,³,⁵, C. O’Brien¹. ¹Center for Studies of Addiction, University of Pennsylvania, United States; ²Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau—ESTHER, France; ³USR3413, CNRS, Someil-Attention-Neuropsychiatrie (SANPsy), University of Bordeaux, France; ⁴Ho Chi Minh City AIDS Committee, Vietnam; ⁵Bizia Addiction Clinic, France

HIV status, mental health, and quality of life among opiate-using adults in Russia
A. Desrosiers¹, E. Blokhina², E. Krupitsky², E. Zvartau², R. Schottenfeld¹, M. Chawarski¹. ¹Department of Psychiatry, School of Medicine, Yale University, United States; ²First Pavlov State Medical University, St. Petersburg, Russia

Development of treatment capacity of addicted women in the context of attachment-based therapy
P. Dolezalova. Clinic of Addictology, Charles University in Prague, National Institut of Menthal Health, Czech Republic

International addiction medicine: A certification exam and new textbook
N. El-Guebaly. University of Calgary, Canada

Psychometric properties of the Spanish-language version of the University of Rhode Island Change Assessment (URICA) scale
Providing treatment in the Social Security health care system in Peru from 2005 to 2014

F. Fiestas, V. Dongo, K. Hoffman, J. Ponce, D. McCarty. Seguro Social de Salud (ESSALUD), Peru; Universidad Antonio Ruiz de Montoya, Peru; International Center for Advanced Research and Applied Science, Peru; Oregon Health & Science University, United States

Retention in a methadone maintenance treatment program: Impact of comorbidity

F. Fonseca, C. Castillo, D. Martínez-Sanvisens, P. Rossi, A. Roquer, M. Farré, M. Torrens, Institut de Neuropsiquiatria I Addiccions–Parc de Salut Mar, Spain; Psychiatry and Pharmacology Departments, Autonomous University of Barcelona, Spain

International standards in the treatment of drug use disorders

G. Gilberto, I. Koutsenok, E. Saenz, A. Busse. Drug Prevention and Health Branch, United Nations Office on Drugs and Crime (UNODC), Austria; Prevention Treatment and Rehabilitation Section, UNODC, Austria

Implementation of the Matrix Model in Cape Town, South Africa: Evaluating treatment engagement and relapse outcomes

H. Gouse, J. Magidson, W. Burnhams, J. E. Remmert, J. Joska, A. W. Carrico. University of Cape Town, South Africa; Massachusetts General Hospital, United States; Harvard Medical School, United States; University of California, San Francisco, United States

Applicability of evidence-based treatment program for offenders under community corrections

A. Hetti-Arachchige. Department of Community Based Corrections, Ministry of Rehabilitation and Prison Reform, Sri Lanka

Ensuring continuity of opioid substitution treatment (OST), HIV, and TB treatment for OST patients from annexed Crimea and occupied territory (Donetsk, Luhansk) of Ukraine


Changes in P300 event-related potentials vary with changes in craving among methamphetamine-dependent patients followed at 3 and 6 months after cessation

H. Jiang, W. Zhuang, H. Cheng, C. Li, J. Du, H. Sun, Z. Chen, D. Xu, J. Wang, M. Zhao. Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, China; Shanghai Bureau of Drug Administration, China

Effectiveness of psycho-educational group therapy to motivate change among addicts in the early stages of change


Comprehensive women-centered treatment for substance use in Georgia: Initial examination of drug use and HIV risk

I. Kirtadze, D. Otiashvili, K. O’Grady, W. Zule, E. Krupitsky, W. Wechsberg, H. E. Jones. Addiction Research Center, Alternative Georgia, Georgia; Department of Psychology, University of Maryland, United States; RTI International, United States; Department of Addictions, Bekhterev Research Psychoneurological Institute, St. Petersburg, Russia; University of North Carolina (UNC) Horizons, Department of Obstetrics and Gynecology, UNC at Chapel Hill, United States
Alcohol screening among opioid agonist patients in a primary care and opioid treatment program

J. Klimas1,2, J. Muench3, K. Wiest4, R. Croff5, T. Rieckman6, D. McCarty5. 1School of Medicine and Medical Science, University College Dublin, Ireland; 2Addiction & Urban Health Research Initiative, BC Centre for Excellence in HIV/AIDS, Canada; 3Department of Family Medicine, Oregon Health & Science University (OHSU), United States; 4Comprehensive Options for Drug Abusers, Inc., United States; 5Department of Public Health and Preventive Medicine, OHSU, United States

Anhedonia, depression, anxiety, and craving for opiates in opiate addicts stabilized on oral naltrexone and long-acting naltrexone implant

E. Krupitsky1,2, E. Zvartau2, E. Blokhina2, E. Verbitskaya2, V. Palatkin2, A. Tyurina2, T. Yaroslavtseva1, N. Bushara3, A. Pecoraro3, G. Woody3. 1St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; 2St. Petersburg Pavlov State Medical University, Russia; 3University of Pennsylvania, Philadelphia, United States

Changes of CD4 cell counts in patients with antiretroviral treatment and associated factors, including drug use at outpatient clinics in Hanoi

L. La1, T. Le1, D. Nguyen1, H. Nguyen1, H. Tran1, D. Cao1, N. Vu2, T. Do2, H. Le2, X. Le2, S. Nguyen3, H. Vu4. 1Hanoi AIDS Center, Vietnam; 2Hanoi School of Public Health, Vietnam; 3Hanoi Medical School, Vietnam; 4Substance Abuse and Mental Health Services Administration, U. S. Department of Health and Human Services, Vietnam

Trends and gender differences in drug use patterns as reported by polydrug users seeking treatment in a therapeutic community in Israel (2011–2014)

M. Lawental1, E. Shahar2, A. Michael2, E. Lawental3. 1University of Haifa, Israel; 2Ha’Derech TC, Israel; 3Tel-Hai Academic College, Israel

Incremental cost-effectiveness of a voucher-based contingency management protocol added to cognitive behavioral treatment for smoking cessation

C. López-Núñez, F. Alonso-Pérez, S. Weidberg, I. Pericot-Valverde, R. Secades-Villa. Department of Psychology, University of Oviedo, Spain

Compulsory addiction treatment and subsequent hospitalizations: A Swedish registry-based study

L. Lundgren1,2, D. McCarty3, M. Padyab1. 1Umea University, Sweden; 2Boston University, United States; 3Oregon Health & Sciences University, United States

Implementation of case management to link HIV-infected Russian addiction patients to HIV services

K. Lunze1, T. Kiriazova2, E. Blokhina3, N. Gnatienko1, L. Wulach1, C. Curnyn1, N. Bushara3, C. Bridden1, E. Krupitsky1, A. Raj4, A. Gifford1, J. H. Samet1. 1Boston University, United States; 2Future without AIDS, Ukraine; 3First Pavlov State Medical University, Russia; 4University of California, San Diego, United States

Effects of cytidine 5’-diphosphocholine administration on gray matter volumes in methamphetamine dependents

I. K. Lyoo1,2,3, S. Yoon1, Y. H. Sung4, J. Hwang5, J. E. Kim1,3, E. Namgung1,3, S. Oh1,3, S. Moon1,2, S. Kim1,3, S. Yu1,3, P. F. Renshaw4. 1Ewha Brain Institute, Ewha W. University, South Korea; 2Graduate School of Pharmaceutical Sciences, Ewha W. University, South Korea; 3Brain and Cognitive Sciences, Ewha W. University, South Korea; 4The Brain Institute, University of Utah, United States; 5Department of Psychiatry, Soonchunhyang University, South Korea
529 **Vocalized truths: Participation of Iranian drug-using women in a qualitative study**  
E. Merghati-Khoiì¹, Kate Dolan², Threse Kileen³, Faribal Yaddolahi⁴. ¹Iranian National Center of Addiction Studies, Tehran University of Medical Sciences, Iran; ²National Drug and Alcohol Research Centre, University of New South Wales, Australia; ³Clinical Neuroscience Division, Medical University of South Carolina, United States; ⁴School of Public Health, Iran University of Medical Sciences, Iran

530 **Cognition and impulsiveness in adults with attention-deficit/hyperactivity disorder (ADHD) with and without cocaine and/or crack dependence**  
C. S. Miguel¹, P. A. Martins², M. Klein¹, N. A. Moleda³, P. J. Cunha⁴,⁵, M. A. Gobbo¹, T. Chaim⁴, T. M. Alves¹, M. A. Silva¹, M. R. Louzå¹,². ¹Adult ADHD Research Program (PRODATH), Institute of Psychiatry (ISP), Faculty of Medicine, University of São Paulo (USP), Brazil; ²Early Psychosis Evaluation and Intervention Program (ASAS), ISP, Faculty of Medicine, USP, Brazil; ³Universidade Presbiteriana Mackenzie, Brazil; ⁴Laboratory of Neuroimaging (LIM-21), Faculty of Medicine, USP, Brazil; ⁵Interdisciplinary Group of Studies on Alcohol and Drugs (GREA), Faculty of Medicine, USP, Brazil

531 **Considerations about psychotropic drugs and their repercussions in physicians’ prescription habits**  
F. J. Montero-Bancalero¹, E. Moreno-San-Pedro², J. Gómez-Bujedo². ¹University of Osuna, Spain; ²University of Huelva, Spain

532 **Addressing substance use within primary health care settings in South Africa: Opportunities and challenges**  
B. Myers¹, K. Sorsdahl². ¹Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, South Africa; ²Alan J. Flisher Centre for Public Mental Health, University of Cape Town, South Africa

533 **Adult antisocial behaviors in methadone patients with and without comorbid alcohol use disorder**  

534 **An Australian cohort of pharmaceutical opioid users in treatment**  
S. Nielsen¹,², B. Larance³, N. Lintzeris²,³, S. Holliday³, M. Vanderhaven⁴, G. Lattas¹, A. Hordern¹, A. Dunlop⁴,⁵, P. Haber³,⁶, B. Murnion³,⁶, C. Silsbury⁷, J. Johnson⁸, A. Demirkoł²,⁹, C. Sadler⁴,⁵,⁹, N. Phung⁷, L. Burns¹, R. Mattick¹, G. Campbell¹, M. Farrell¹, M. Cohen¹⁰,¹¹, R. Bruno¹², M. Hardy¹³, A. Brown⁴, J. Houseman¹³, L. Degenhardt¹. ¹National Drug and Alcohol Research Centre, University of New South Wales, Australia; ²The Langton Centre, South East Sydney Local Health District Drug and Alcohol Services, Australia; ³Discipline of Addiction Medicine, University of Sydney, Australia; ⁴Drug and Alcohol Clinical Services, Hunter New England Local Health District, Australia; ⁵University of Newcastle, Australia; ⁶Royal Prince Alfred Hospital, Australia; ⁷Drug Health Service, Western Sydney Local Health District, Australia; ⁸University Centre for Rural Health, Australia; ⁹Cavalry Mater Hospital, Australia; ¹⁰University of New South Wales, Australia; ¹¹St Vincent’s Hospital, Australia; ¹²University of Tasmania, Australia; ¹³Drug and Alcohol Services, Northern Sydney Local Health District, Australia

535 **Does cue exposure treatment improve outcomes in smoking cessation treatment? A controlled trial**  
536 Early mortality after entering a methadone treatment program in Badalona, Spain
I. Rivas¹, A. Sanvisens², E. Faure¹, D. Fuster², T. Muñoz¹, R. Manoli¹, R. Muga². ¹Municipal Center for Substance Abuse Treatment, IMSP, Spain; ²Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain

537 Overlap between food addiction and DSM-5 eating disorders in a treatment-seeking sample
M. C. Rosa¹², J. Collombat², C. M. Denis¹³, J. Alexandre², F. Serre², M. Auriacombe², M. Fatseas¹. ¹Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil; ²Addiction Psychiatry, USR3413, CNRS, Universite Bordeaux, France; ³University of Pennsylvania, United States

538 Higher levels of brain-derived neurotrophic factor associated with inpatient treatment adherence of crack cocaine users

539 Electronic tool for opioid substitution treatment (OST) data collection, processing, and analysis based on the data management platform “SYREX”
A. Shost, Z. Islam, S. Filippovych, V. Kolomiets. ICF “International HIV/AIDS Alliance–Ukraine,” Ukraine

540 HIV/AIDS and opioid use: Current situation in Indonesia
Z. Syarif¹, R. Sarasvita², M. Chawarski¹. ¹Psychiatry Department, University of Indonesia, Indonesia; ²National Narcotics Board (BNN), Indonesia; ³Psychiatry Department, School of Medicine, Yale University, United States

541 Guidelines for establishment and licensing of treatment and rehabilitation centers in Ghana
F. K. Torkornoo. Demand Reduction Division, Narcotics Control Board, Ghana

542 Opioid substitution treatment in Spain: 20 years of experience in harm reduction programs
M. Torrens¹²³, F. Fonseca¹², C. Castillo¹², A. Domingo-Salvany². ¹Institut de Neuropsiquiatria i Addicions–Parc de Salut Mar, Spain; ²Institut Hospital del Mar d’Investigacions Mèdiques, Spain; ³Psychiatry Department, Autonomous University of Barcelona, Spain

543 Patient preference and willingness to pay for stand-alone, integrative, and satellite models of dispensing methadone for the treatment of opioid dependence in Vietnam
B. X. Tran¹², C. A. Latkin². ¹Institute for Preventive Medicine and Public Health, Hanoi Medical University, Vietnam; ²Bloomberg School of Public Health, Johns Hopkins University, United States

544 Effects of fixed or self-titrated dosages of Sativex on cannabis users
J. M. Trigo¹, D. Lagzdins¹, J. Rehm², P. Selby³, I. Gamaleddin¹, B. Fischer²⁴, A. J. Barnes¹, M. Huestis², B. Le Foll¹³. ¹Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Canada; ²Social and Epidemiological Research, CAMH, Canada; ³Ambulatory Care and Structured Treatments, CAMH; ⁴Faculty of Health Sciences, Simon Fraser University, Canada; ⁵National Institute on Drug Abuse, National Institutes of Health, United States

545 Factors associated with illicit methadone injecting in a Canadian setting
D. Tucker¹, M-J. Milloy¹², K. Hayashi¹², R. Lung¹, P. Nguyen¹, T. Kerr¹², E. Wood¹². ¹British Columbia Centre for Excellence in HIV/AIDS, St. Paul’s Hospital, Canada; ²Department of Medicine, University of British Columbia, Canada
Cannabidiol attenuates the increased susceptibility to false memories produced by tetrahydrocannabinol

M. Valle¹, L. C. Martial¹, M. Garrido¹, A. Rodríguez-Fornells², M. Puntes¹, R. M. Antonijoan³, J. Claramunt¹, D. Martínez¹, M. González¹, M. Martínez¹, J. Pérez de los Cobos³, J. Riba¹.
¹Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Spain; ²Universidad de Barcelona, Spain; ³Hospital de la Santa Creu i Sant Pau, Spain

Aripiprazole and risperidone in treatment of methamphetamine-associated psychosis in China: A pilot randomized study

G. Wang¹, Y. Zhang², S. Zhang², H. Chen², Z. Xu², W. Hao¹, M. C. Chawarski³. ¹Mental Health Center, The Second Xiangya Hospital, China; ²Wuhan Mental Health Center, China; ³Department of Psychiatry, School of Medicine, Yale University, United States

Take-home naloxone training: Comparing the effects on knowledge and attitudes between family members and drug users

A. V. Williams, J. Marsden, J. Strang. Institute of Psychiatry, Psychology and Neuroscience, Department of Addictions, King’s College London, United Kingdom

Cognitive impairments and psychological well-being of methamphetamine addicts

N. Zhong, H. Jiang, J. Du, Y. Zhao, C. Li, W. Zhuang, X. Li, W. Wang, M. Zhao. Shanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, China
Tuesday, June 16, 2015

CPDD/INRC Plenary

AZ Biltmore Ballroom
8:00 - 9:00 AM

Drug abuse and addiction research: progress, priorities and challenges
Nora Volkow, Director, National Institute on Drug Abuse

INRC Session 1

Grand Ballroom
9:00 - 10:00 AM

ADDITION TO PRESCRIPTION OPIOIDS

Chair: Fred Nyberg

Prescription opioid abuse and dependence in Scandinavian Countries
Thomas Clausen, University of Osio, Norway, Sweden

Addiction and diversion of prescription opioids in Europe
Gabriele Fischer, Medical University of Vienna, Norway, Sweden

Nonmedical prescription opioid use in North America
Pauline Voon, St. Paul’s Hospital, Vancouver, BC, Canada

Policy Forum

AZ Biltmore Ballroom
9:30 - 11:30 AM

Chairs: William L. Dewey and Martin Y. Iguchi

Introduction:
William L. Dewey, VCU, Richmond, VA

Speaker: Update from Capitol Hill
Ed Long, Van Scoyoc Associates, Washington, DC

Overdose prevention: Community-driven policy change
Fred Wells Brason,II, Project Lazarus, Moravian Falls, NC

Poster Session II

Frank Lloyd Wright Ballroom
11:30 - 1:30 PM

(Lunch)
Odd-numbered posters manned first hour;
Even-numbered, second hour

Set-up time begins Monday 3:00 PM
Must be removed at 2:00 PM Tuesday

GENETICS

1 Functional and behavioral consequences of DRD4 genetic variation in macaques
E. J. Vallender2,4, L. M. Ogawa3,4, L. J. Lynch4, J. L. Schimmel4, G. M. Miller1,4,
1Pharmaceutical Sciences, Northeastern University, Boston, MA, 2Psychiatry and Human
Behavior, University of Mississippi Medical School, Jackson, MS, 3Yale University,
New Haven, CT, 4New England Primate Research Center, Harvard Medical School,
Southborough, MA
2 Clinical characteristics and genotype frequencies of the dopamine transporter gene (DAT1/SLC6A3) 3’UTR variable number of tandem repeats in crack-cocaine users
   A. R. Stolf, G. Akutagawa-Martins, D. Müller, L. Guimarães, F. P. Pechansky, T. Roman, F. Kessler, Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, Department of Genetics, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, Center for Drug and Alcohol Research, UFRGS, Porto Alegre, Brazil

3 Dopaminergic genetic variation moderates effect of nicotine on cigarette reward self-report
   P. T. Harrell, H. Lin, J. Y. Park, D. J. Drobes, D. E. Evans, Moffitt Cancer Center, Tampa, FL, University of South Florida, Tampa, FL

4 A non-parametric method finds genetic etiology of nicotine dependence differs in males and females
   Q. Lu, C. Wei, R. C. Elston, O. Vsevolozhskaya, Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, Department of Biostatistics and Epidemiology, University of North Texas Health Science Center, Fort Worth, TX, Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH

5 Intrinsic clustering of treatment outcome in recovery from opioid use disorder: Results from Starting Treatment with Agonist Replacement Therapies

SEX DIFFERENCES

6 Sex difference in behavioral effects of the THC agonist CP55,940
   H. T. French, A. Klambatsen, C. Chan, S. Jenab, V. Quinones-Jenab, Psychology, Graduate Center of the City University of New York, New York, NY, Psychology, Hunter College CUNY, New York, NY

7 Sex differences in dopamine and serotonin activation of brain pathways in adolescent rats exposed to social partners or amphetamine
   V. G. Weiss, R. S. Hoffer, J. R. Yates, M. T. Bardo, University of Kentucky, Lexington, KY, Northern Kentucky University, Newport, KY

8 Sex differences in reinstatement of cocaine-seeking in rats after acute treatment of progesterone and atomoxetine
   N. Swalve, N. Zlebnik, H. Veglahn, M. E. Carroll, Psychiatry, Univ of Minnesota, Minneapolis, MN, University of Minnesota, Mahtomedi, MN

9 Age and gender effects on subjective drug effect of d-amphetamine
   R. Pang, M. Kirkpatrick, N. Goldenson, C. Guillot, A. Leventhal, University of Southern California, Los Angeles, CA, Department of Preventive Medicine, University of Southern California, Azusa, CA, Preventive Medicine, University of Southern California, Los Angeles, CA

10 Gender differences in associations between neurocognitive impairment and cocaine use among high-risk cocaine-dependent methadone-maintained patients
   R. Shrestha, T. B. Huedo-Medina, M. Copenhaver, Community Medicine & Health Care, University of Connecticut Health Center, Farmington, CT, Allied Health Sciences, University of Connecticut, Storrs, CT
11 Sex differences in intrinsic connectivity during fMRI Stroop in cocaine-dependent and healthy comparison subjects
M. R. Mitchell¹, E. E. DeVito¹, I. Balodis¹, C. Lacadie², D. Scheinost³, R. Constable²,
R. Malison¹, K. M. Carroll¹, M. N. Potenza¹, ¹Psychiatry, Yale University School of
Medicine, New Haven, CT, ²Diagnostic Radiology, Yale University School of Medicine, New
Haven, CT, ³Biomedical Engineering, Yale University School of Medicine, New Haven, CT

12 Gender differences in Stroop performance following guanfacine versus placebo in early abstinent cocaine-dependent men and women
V. Milivojevic¹, N. Jayaram-Lindstrom², R. Sinha¹, H. C. Fox¹, ¹Psychiatry, Yale University
School of Medicine, New Haven, CT, ²Karolinska Institute, Solna, Sweden

13 Impact of yohimbine and cocaine-cues on executive function in cocaine-dependent men and women
M. Moran-Santa Maria¹, K. T. Brady², A. McRae-Clark², J. Prisciandaro², N. Baker³,
¹Psychiatry and Behavioral Sciences, MUSC, Charleston, SC, ²Psychiatry, Medical University
of South Carolina, Charleston, SC, ³Ralph H Johnson VAMC, Charleston, SC, ⁴Department of
Public Health Sciences, Medical University of South Carolina, Charleston, SC

14 Gender differences in methamphetamine use in a Mexico-U.S. border city
O. Loza¹, J. Ferreira-Pinto³, R. Ramos², M. Ramos Rodriguez⁴, ¹Public Health Sciences, UT El
Paso, El Paso, TX, ²Alliance of Border Collaboratives (ABC), El Paso, TX, ³UTEP College of
Health Sciences, El Paso, TX, ⁴Programa Compañeros, A.C., Ciudad Juárez, Mexico

15 The Israeli club drug culture: A qualitative examination of gender differences in substance use and sexual risk behaviors
M. Lawental¹, S. P. Kurtz³, M. E. Buttram², ¹School of Social Work, University of Haifa,
Haifa, Israel, ²Center for Applied Research on Substance Use and Health Disparities, Nova
Southeastern University, Miami, FL, ³ARSH: Center for Research on Substance Use and
Health Disparities, Nova Southeastern University, Miami, FL

16 Risk of sexual abuse among ecstasy users differs by gender and other drug use
S. R. Khan², C. W. Striley², J. Copeland³, S. P. Kurtz¹, L. Cottler², ¹ARSH: Center for Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL, ²Epidemiology, University of Florida, Gainesville, FL, ³NCPIC, University of NSW, Sydney, NSW, Australia

17 Substance use outcomes of girls with ADHD in a 10-year follow-up of a prospective longitudinal study
K. Belendiuk¹, S. Hinshaw¹,², ¹University of California, Berkeley, CA, ²University of California, San Francisco, CA

18 Liability for violence in young women
M. D. Reynolds, S. P. Knopf, L. Kirisci, R. E. Tarter, School of Pharmacy, University of
Pittsburgh, Pittsburgh, PA

19 Prevalence and correlates of spousal sexual violence against married women in India
V. Murugan, Social Work, Washington University St. Louis, Ladue, MO

20 Gender differences among MST survivors on chronic opioid therapy
S. Lin, D. Plott, Mental Healthcare Line, Cincinnati VAMC, Cincinnati, OH

21 Gender differences in mortality among treated opioid-dependent patients
E. Evans², L. Li², J. Min¹, D. Y. Huang², D. Urada², Y. Hser², B. Nosyk¹, ¹BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, ²UCLA Integrated Substance Abuse Programs, Los Angeles, CA
22 Sex differences in alcohol use disorders and risky drinking among chronic non-cancer pain patients receiving opioid therapy  
B. Larance¹, A. Peacock², G. Campbell¹, R. Bruno³, N. Lintzeris³, M. Cohen¹, S. Nielsen¹, W. Hall⁴, R. P. Mattick¹, L. Degenhardt¹, ¹National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, ²School of Psychology, University of Tasmania, Hobart, TAS, Australia, ³Langton Centre, South Eastern Sydney and Illawarra Local Health District, Sydney, NSW, Australia, ⁴University of Queensland, Brisbane, QLD, Australia

23 The gendered risk environment for injection drug use: An event specific analysis of injection risk behavior  
P. Janulis, Department of Epidemiology and Biostatistics, Michigan State University, Lansing, MI

24 Medical and mental health needs of lesbian, gay, and bisexual clients in substance abuse treatment  
A. Flentje¹, N. Livingston², J. Roley³, J. Sorensen¹, ¹University of California, San Francisco, San Francisco, CA, ²University of Montana, Missoula, MT, ³Drexel University, Philadelphia, PA

PHARMACOKINETICS

25 Heroin metabolism in blood and not in brain is critical to its acute effects  
F. Boix Escolan, J. M. Andersen, I. Bogen, A. Gottás, J. G. Mørland, Division for Forensic Sciences, Norwegian Institute of Public Health, Oslo, Norway

26 Do they really inject heroin? A study on the possible changes in opioid content during heroin preparation for intravenous injection  
J. G. Mørland, J. M. Andersen, I. Bogen, R. Karinen, G. Brochman, E. L. Øiestad, V. Vindenes, F. Boix Escolan, Division of Forensic Sciences, Norwegian Institute of Public Health, Oslo, Norway

27 Pharmacokinetics of bupropion sustained release in pregnancy and postpartum at steady state  
V. M. Fokina¹,³, X. Wang¹, E. Rytting¹, M. S. Ahmed¹, C. Oncken², G. Hankins¹, T. Nanovskaya¹, ¹OB&GYN, UTMB, Galveston, TX, ²Medicine, University of Connecticut Health Center, Farmington, CT, ³Pharmacology & Toxicology, UTMB, Galveston, TX

28 Modulation of buprenorphine partial agonism by the opioid antagonist samidorphan: A mechanistic PK/PD model  
R. Turncliff, W. I. Li, Translational Medicine, Alkermes, Inc., Waltham, MA

29 Oral human abuse potential of Oxycodone DETERx: An abuse-deterrent, extended-release formulation in recreational opioid users  

30 Single-center, randomized, double-blind crossover study evaluation of the abuse potential, PK, and safety of crushed and intranasally administered immediate release oxycodone tablets in recreational opioid users  
S. Colucci¹, S. Harris¹, K. Friedman¹, M. Shram², ¹Purdue Pharma L.P., Stamford, CT, ²Altreos Research Partners, Toronto, ON, Canada

31 Impact of CYP2D6 phenotype on response to methamphetamine in healthy volunteers  
A. Oliveto¹, B. Gurley², H. Hendrickson², W. B. Gentry², J. D. Thostenson², M. J. Mancino¹, ¹Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, ²University of Arkansas for Medical Sciences, Little Rock, AR
32 The role of carbonyl reductases in biotransformation of bupropion and 4-methylnitrozamino-1-(3-pyridyl)-1-butanone by human placenta
T. Nanovskaya1, V. M. Fokina1,2, X. Wang1, C. Oncken3, M. S. Ahmed1, G. Hankins1,
1OB&GYN, UTMB, Galveston, TX, 2Pharmacology & Toxicology, UTMB, Galveston, TX,
3Medicine, University of Connecticut Health Center, Farmington, TX

33 Does electronic cigarette liquid nicotine concentration and user experience influence plasma nicotine concentration?
C. Ramoa, T. Spindle, K. Osei, B. Kilgalen, A. Breland, T. Eissenberg, Psychology, VCU, Richmond, VA

34 Physical and self-reported response and the pharmacokinetics of e-cigarettes compared to cigarettes in substance-abusing participants
O. Brooks1, C. Lederhos1, A. Lamp1, D. Howell1, J. White1, J. Padowski2, M. Layton1,
D. Moody3, J. M. Roll1, S. McPherson1, 1Program of Excellence in Addictions Research (PEAR), Washington State University, Spokane, WA, 2Washington State University, Spokane, WA, 3University of Utah, Salt Lake City, UT

35 Nicotine dependence, nicotine metabolism, and the extent of compensation in response to reduced nicotine content cigarettes
K. Ross1, F. Bandiera2, S. Taghavi3, K. Delucchi1, R. Tyndale1, N. Benowitz1, 1Center for Tobacco Control, Research, & Education, University of California, San Francisco, San Francisco, CA, 2University of Texas, Dallas, Dallas, TX, 3University of Toronto, Toronto, ON, Canada

36 Financial incentives promote smoking abstinence among patients with pulmonary disease
A. C. Meyer, J. M. Streck, T. A. Ochalek, B. Hruska, C. C. Teneback, A. E. Dixon,
S. C. Sigmon, University of Vermont, Burlington, VT

37 Migration and time to first tobacco cigarette after waking
W. Xue1, J. C. Anthony2, 1Michigan State University, East Lansing, MI, 2Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

NICOTINE TREATMENT

38 Smoking and cardiac rehabilitation program completion
D. Gaalema1, A. Cutler1, S. T. Higgins1, P. Savage2, P. Ades1,2, 1University of Vermont, Burlington, VT, 2University of Vermont Medical Center, Burlington, VT

39 Cigarette craving is associated with blunted reward processing in nicotine-dependent smokers
A. L. Peechakta1,2, A. E. Whitten1, S. L. Farmer1, D. A. Pizzagalli1, A. Janes1, 1McLean Hospital/ Harvard Medical School, Belmont, MA, 2Psychology, Suffolk University, Boston, MA

40 Does craving intensity influence cue exposure reports? An Ecological Momentary Assessment study in patients with alcohol, tobacco, cannabis and heroin use disorder
F. Serre1, M. Fatseas1, J. Swendsen2, M. Auriacombe1, 1Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, 2CNRS UMR 5284 INCIA Univ. Bordeaux, Bordeaux, France

41 Cigarette smoking trajectories among comorbid cocaine-dependent and attention deficit/hyperactivity-disorder individuals treated with extended-release mixed amphetamine salts
B. Sou1, A. Glass2, D. J. Brooks3, A. Mahony5, J. J. Mariani3, J. Grabowski3, F. R. Levin3, 1The Sophie Davis School of Biomedical Education, New York, NY, 2Biostatistics, New York State Psychiatric Institute, New York, NY, 3New York State Psychiatric Institute, New York, NY, 4Psychiatry, University of Minnesota, Minneapolis, MN, 5New York State Psychiatric Institute, New York, NY
Does cue exposure treatment improve outcomes in smoking cessation treatment? A controlled trial
I. Pericot-Valverde, O. Garcia-Rodriguez, C. López-Núñez, S. Weidberg, R. Secades-Villa, Psychology, University of Oviedo, Oviedo, Spain, University of Oviedo, Oviedo, Spain

Episodic future thinking reduces delay discounting in cigarette smokers
J. S. Stein, T. O. Daniel, L. H. Epstein, W. K. Bickel, Addiction Recovery Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA, Department of Pediatrics, University at Buffalo, Buffalo, NY

Treating smokers in substance treatment with contingent vouchers, nicotine replacement and brief advice adapted for sobriety settings
R. A. Martin, D. Rohsenow, J. W. Tidey, S. Colby, P. Monti, Center for Alcohol and Addiction Studies, Brown University, Providence, RI, Providence Veterans Affairs Medical Center, Providence, RI

Incremental cost-effectiveness of a voucher-based CM protocol added to a CBT for smoking cessation
C. López-Núñez, F. Alonso Pérez, S. E. Weidberg, I. Pericot-Valverde, R. Secades-Villa, Psychology, University of Oviedo, Oviedo, Spain, Psychology, University of Oviedo, Oviedo, Asturias, Spain

Smoking status on day 3 of a quit attempt predicts future smoking outcomes
B. Hruska, A. C. Meyer, S. C. Sigmon, Psychiatry, The University of Vermont, Burlington, VT, Psychiatry, University of Vermont, Burlington, VT

A comparison of the behavioral effects of electronic and tobacco cigarettes following 24-hr tobacco deprivation
A. Harvanko, C. A. Martin, J. S. Fogel, J. Lile, T. H. Kelly, Behavioral Science, University of Kentucky, Lexington, KY, Psychology, University of Kentucky, Lexington, KY, Psychiatry, University of Kentucky, Lexington, KY

WITHDRAWN

Treatment expectations predict quit attempts, reduction in cigarettes per day, and readiness to quit in smokers who were not ready to quit
E. M. Klemperer, J. Hughes, Psychiatry, University of Vermont, Burlington, VT

A tobacco cessation readiness group increases initiation of quitting in residential treatment patients
J. Guydish, V. Gruber, T. Le, B. Tajima, B. Andrews, H. Leo, J. Tsoh, University of California San Francisco, San Francisco, CA, Yale University, New Haven, CT

The role of smoking-specific experiential avoidance in the relation between perceived stress and tobacco use among treatment-seeking smokers
L. Garey, M. J. Zvolensky, N. B. Schmidt, Department of Psychology, University of Houston, Houston, TX, Department of Psychology, Florida State University, Tallahassee, FL

Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts
A. P. Garcia-Romeu, T. Noorani, R. R. Griffiths, M. W. Johnson, Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, Departments of Psychiatry and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
53 Validation of the revised Mystical Experiences Questionnaire in experimental sessions with psilocybin
F. S. Barrett², M. W. Johnson², R. R. Griffiths²,¹, Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

54 The brain mind connection: Effect of trait mindfulness on responses to real-time fMRI feedback in nicotine-dependent smokers
K. Hartwell¹,², M. Canterberry¹, X. Li¹, M. Moran-Santa Maria¹, C. A. Hanlon¹, M. George¹,², K. T. Brady¹,²,¹ Medical University of South Carolina, Charleston, SC, ²Ralph H Johnson VAMC, Charleston, SC

55 Acceptance as a relevant mindfulness facet for cigarette smokers
C. Vinci³, M. R. Peltier¹, C. A. Spears³, A. L. Copeland¹, Louisiana State University, Baton Rouge, LA, ²UT MD Anderson Cancer Center, Houston, TX, ³The Catholic University of America, Washington, D.C., DC

56 Smoking cessation intervention on Facebook: Which content generates the best engagement?
J. Thrul¹, A. B. Klein¹,², D. Ramo¹, UCSF, San Francisco, CA, ²University of California, Berkeley, Berkeley, CA

57 Association between tobacco smoking and death by suicide: A competing risks hazard analysis in a large twin cohort with 35-year follow up
A. Evins¹,², T. Korhonen³,⁴,⁵, T. H. Kinnunen²,⁶, J. Kaprio²,⁵,⁷, Psychiatry, Massachusetts General Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Public Health, University of Helsinki, Helsinki, Finland, ⁴Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland, ⁵National Institute for Health and Welfare, Helsinki, Finland, ⁶Behavioral Science Consulting, Hopkinton, MA, ⁷Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland

PRESCRIPTION OPIOIDS

58 Using behavioral economics to predict opioid use during prescription opioid dependence treatment
M. Worley¹, S. Shoptaw¹, W. K. Bickel², W. Ling³, University of California, Los Angeles, Los Angeles, CA, ²Addiction Recovery and Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA, ³UCLA, Integrated Substance Abuse, Los Angeles, CA

59 Correlates of prescription opioid legitimacy estimations among community pharmacists in Tennessee
N. E. Hagemeier¹, A. Alamian², M. M. Murawski³, R. P. Pack⁴, Pharmacy Practice, East Tennessee State University, Johnson City, TN, ²Biostatistics and Epidemiology, East Tennessee State University, Johnson City, TN, ³Pharmacy Administration, Purdue University, West Lafayette, IN, ⁴Community and Behavioral Health, East Tennessee State University, Johnson City, TN

60 Opioid prescribing practices of members of the National Dental Practice-Based Research Network
J. L. McCauley¹, V. V. Gordan², J. L. Riley², R. B. Fillingim², S. K. Makhija³, K. T. Brady¹, N. Dental PBRN Collaborative Group³, Psychiatry, Medical University of South Carolina, Charleston, SC, ²University of Florida, Gainesville, FL, ³University of Alabama at Birmingham, Birmingham, AL

61 Trends in prescription opioid misuse among young adult multdrug users in Miami, 2006-2014
M. E. Buttram¹, S. P. Kurtz², Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL, ²ARSH: Center for Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL
Potential determinants of unique and co-occurring major depression and nonmedical use of prescription opioids
D. S. Fink1, R. Hu1, M. Cerda1, K. Keyes1, B. D. Marshall2, S. Galea1, S. S. Martins1,
1Epidemiology, Columbia University, New York, NY, 2Epidemiology, Brown University, Providence, RI

Preliminary reliability and validity of an opioid overdose risk behavior scale in a community-based sample of recent veterans
E. R. Pouget, A. S. Bennett, L. Elliott, A. Golub, A. Rosenblum, NDRI, New York City, NY

An online national survey and the Crime Survey for England and Wales: Are the data comparable?
J. L. Green1, P. I. Dargan2, D. M. Wood2, A. C. Besharat1, E. M. Martinez1, R. C. Dart1,
1Rocky Mountain Poison & Drug Center, Denver, CO, 2Guy’s and St. Thomas’ NHS Foundation Trust and King’s Health Partners, London, United Kingdom

Changes in abuse prevalence of prescription opioids and heroin across six years in the ASI-MV network for different patient subgroups
S. F. Butler1, T. A. Cassidy1, S. H. Budman1, 1Inflexxion, Inc, Newton, MA

Evaluation of relative intranasal abuse potential of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users
K. Schoedel1, L. Rabinovich-Guilatt1, M. Gasior1, R. Malamut1, Y. Ma1, L. Webster2, M. Bond3, 1Teva, Frazer, PA, 2PRA Health Sciences, Salt Lake City, UT, 3Altreos Research Partners, Toronto, NU, Canada

Evaluation of the abuse potential of an hydrocodone extended-release bitartrate tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users
M. Bond2, M. Darwish2, Y. Ma1, L. Webster3, 1Teva, Frazer, PA, 2Sci-Med Bridge, Malvern, PA, 3PRA, Salt Lake City, UT

Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study
R. Weiss1,2, J. S. Potter3,1,2, M. L. Griffin1,2, S. Provost1, G. Fitzmaurice1,2,4, K. McDermott1, E. Srisarajivakul1, D. Dodd1, J. A. Dreifuss1,2, K. McHugh1,2, K. M. Carroll1, 1McLean Hospital, Belmont, MA, 2Harvard Medical School, Boston, MA, 3UT Health Science Center, San Antonio, TX, 4Department of Biostatistics, Harvard School of Public Health, Boston, MA, Psychiatry, Yale University School of Medicine, West Haven, CT

Opioid substitution treatment in Spain: 20 years of experience in harm reduction programs
M. Torrens1,2,3, F. Fonseca1,2, C. Castillo1,2, A. Domingo-Salvany2, 1INAD- Parc de Salut Mar, Barcelona, Spain, 2IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain, 3Psychiatry Department, Autonomous University of Barcelona, Barcelona, Spain

Regulatory challenges in evaluating the abuse-deterrent properties of novel opioid products
S. N. Calderon3, 1M, Klein2,1, J. M. Tolliver1,2, 1CDER/CSS, Food and Drug Administration, Silver Spring, MD, 2CDER, FDA, Silver Spring, MD, 3FDA, HHS, Silver Spring, MD

Curbing the rising heroin epidemic in Colombia: Methadone-assisted treatment programs
G. Gonzalez1,2,3, L. Giraldo4, G. DiGirolamo1,5, M. Romero-Gonzalez1,3, 1Division of Addiction Psychiatry, University of Massachusetts, Worcester, MA, 2VA Central Western Massachusetts Healthcare System, Northampton, MA, 3Mayu of New England, New Haven, CT, 4ESE Hospital CARISMA, Medellin, Colombia, 5College of the Holy Cross, Worcester, MA
72 Women’s Intervention to Stop HIV/HCV (WISH)
M. Staton-Tindall, M. Webster, C. Leukefeld, J. R. Havens, C. B. Oser, Sociology, University of Kentucky, Lexington, KY; University of Kentucky, Lexington, LA; Behavioral Science, University of Kentucky, Lexington, KY; Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY; Social Work, University of Kentucky, Lexington, KY

73 A tribal community-wide intervention for addiction
B. Gillette, A. A. Forcehimes, K. Venner, Circle of Life, Three Affiliated Tribes, New Town, ND; Train for Change, Inc., Carson City, NV; Psychiatry, University of New Mexico, Albuquerque, NM

74 Multi-Component Tobacco-Free Workplace Program in community mental health settings: The role of providers’ training in tobacco dependence treatment
V. Correa Fernández, L. R. Reitzel, W. T. Wilson, B. A. Kyburz, T. Stacey, J. Garza, C. Lam, University of Houston, Houston, TX; UT MD Anderson Cancer Center, Houston, TX; Austin Travis County Integral Care, Austin, TX

75 A computerized system for entering and summarizing Timeline Followback information on multiple substances
S. K. McWilliams, C. Thurstone, P. D. Riggs, S. K. Mikulich-Gilbertson, Univ. of Colorado, Aurora, CO

76 Using cellphone technology to monitor and increase dosing adherence
M. Oyama, M. P. Hillhouse, C. Thomas, J. Annun, A. Hasson, L. Mooney, R. Walker, L. Chang, S. Sparenborg, W. Ling, UCLA, Los Angeles, CA; UT Southwestern Medical Center, Dallas, TX; University of Hawaii, Honolulu, HI

77 The Parent’s Modular Toolkit: Development of an online CRAFT program for parents of emerging adults with SUD

78 A new study methodology: ADAPT, The short, staged trial
J. Annun, M. Hillhouse, C. Thomas, L. Mooney, A. Hasson, R. Walker, L. Chang, S. Sparenborg, R. Lindblad, P. VanVeldhuisen, W. Ling, UCLA, Los Angeles, CA; UT Southwestern, Dallas, TX; University of Hawaii, Honolulu, HI; National Institute on Drug Abuse, Bethesda, MD

79 International standards on the treatment of drug use disorders
A. Busse, G. Gerra, I. Koutsenok, E. Saenz, Drug Prevention and Health Branch, UNODC, Vienna, Austria; Prevention, Treatment and Rehabilitation Section (PTRS), United Nations Office on Drugs and Crime (UNODC), Vienna, Austria

80 Current drug scheduling reviews of synthetic cathinones by the U.S. Drug Enforcement Administration

81 Early Career Award in Chemistry of Drug Abuse and Addiction
K. J. Bough, R. Rapaka, D. A. White, J. Rutter, National Institute on Drug Abuse, Rockville, MD
STIMULANTS - HUMANS

82 Learning of fine motor skills is not impaired in individuals with a history of illicit stimulant use
G. Todd, V. Pearson-Dennett, S. C. Flavel, M. Haberfield, H. Edwards, J. White, School of Pharmacy and Medical Sciences and Sansom Institute, University of South Australia, Adelaide, SA, Australia

83 Hand function is altered in individuals with a history of illicit stimulant use
V. Pearson-Dennett, S. C. Flavel, R. A. Wilcox, D. Thewlis, A. Vogel, J. White, G. Todd, 1School of Pharmacy & Medical Sciences, Sansom Institute, University of South Australia, Adelaide, SA, Australia, 2Department of Neurology, Flinders Medical Centre, Adelaide, SA, Australia, 3Speech Neuroscience Unit, University of Melbourne, Melbourne, VIC, Australia, 4School of Health Sciences, Sansom Institute, University of South Australia, Adelaide, SA, Australia

84 The brain structural changes associated with stages of cocaine abstinence
Y. Hser, Q. He, M. Schulte, A. Bechara, 1UCLA, La, CA, 2USC, La, CA

85 Emotional traits predict individual differences in amphetamine-induced positive mood
M. Kirkpatrick, N. Goldenson, C. W. Kahler, H. de Wit, R. Swift, J. McGearry, A. Leventhal, 1University of Southern California, Los Angeles, CA, 2University of Chicago, Chicago, IL, 3Brown University, Providence, RI

86 Neuropsychological effects of placebo stimulants in college students
S. J. Lookatch, T. Moore, E. C. Katz, 1Psychology, University of Tennessee, Knoxville, TN, 2Psychology, Towson University, Towson, MD

87 Personality risk for crack cocaine initiation
W. C. Pedersen, D. G. Fisher, G. L. Reynolds, A. J. Roberts, J. Davis, 1Psychology, California State University, Long Beach, CA, 2Center for Behavioral Research & Services, California State University, Long Beach, CA, 3Sociology, California State University, Long Beach, CA

88 Changes in P300 event-related potentials vary with changes in craving among methamphetamine-dependent patients followed at 3 and 6 months after cessation
H. Jiang, 1Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, 2Shanghai Mental Health Center, Shanghai Jiao Tong University School Of Medicine, Shanghai, China

89 Methylphenidate for methamphetamine use disorders in participants with and without ADHD
A. Ang, M. Hillhouse, J. Jenkins, S. Reed, W. Ling, UCLA, Los Angeles, CA

90 Varenicline for the treatment of methamphetamine dependence
M. Briones, M. Worley, D. DeYoung, A. Swanson, K. G. Heinzerling, S. Shoptaw, 1Department of Family Medicine, UCLA, Los Angeles, CA, 2Stanford University, Stanford, CA

91 The acquisition of coping skills from computerized cognitive behavioral therapy for substance use disorders: It’s all where you start
B. D. Kiluk, E. E. DeVito, M. Buck, C. Nich, K. M. Carroll, Psychiatry, Yale School of Medicine, West Haven, CT

92 Laboratory drug administration does not increase use in the natural ecology immediately following study discharge
93 Alternative endpoints based on health outcomes in stimulant users trials
J. May1, P. VanVeldhuisen1, C. Allen1, R. Lindblad1, L. Hu1, B. Tai1, A. J. Rush2, 3The EMMES Corporation, Rockville, MD, 2Duke University, Durham, NC, 3NIDA CCTN, Bethesda, MD

94 Higher levels of BDNF are associated with inpatient treatment adherence of crack-cocaine users

95 Efficacy and tolerability of doxazosin in psychostimulant-dependent patients
M. J. Mancino1, J. McGaugh1, J. D. Thostenson2, J. Guise1, T. Kosten3, A. Oliveto1, 1Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, 2University of Arkansas for Medical Sciences, Little Rock, AR, 3Psychiatry, Baylor College of Medicine and Michael E DeBakey VA Medical Center, Houston, TX

96 Treatment satisfaction in the CTN Cocaine Use Reduction with Buprenorphine study
C. Thomas, M. Hillhouse, A. Ang, J. Annon, L. Mooney, A. Hasson, W. Ling, UCLA, Los Angeles, CA

97 Opioid use severity and treatment outcomes in cocaine-dependent participants with a history of opioid abuse/dependence
M. P. Hillhouse1, A. Ang1, C. Thomas1, S. Nielsen5, R. Walker4, J. Potter2, G. Brigham3, S. Stout6, M. Weimer7, T. Winhusen8, 1UCLA, Los Angeles, CA, 2UT Health Science Center, San Antonio, TX, 3ADAPT, Roseburg, OR, 4UT Southwestern, Dallas, TX, 5U of New South Wales, Sydney, NSW, Australia, 6Atlanta VA, Atlanta, GA, 7Portland VA, Portland, OR, 8U of Cincinnati, Cincinnati, OH

98 Influence of buspirone maintenance on the pharmacodynamic effects of cocaine and sexual risk taking in cocaine users
B. L. Bolin1, J. A. Lile1,2,3, K. R. Marks2, C. R. Rush1,2,3, W. W. Stoops1,2,3, 1Behavioral Science, University of Kentucky, Lexington, KY, 2Psychology, University of Kentucky, Lexington, KY, 3Psychiatry, University of Kentucky, Lexington, KY

99 Contingency management vs. non-contingent rewards: Intervention response patterns among stimulant-using MSM
J. B. Fletcher1, R. J. Landovitz3, C. J. Reback1,2, 1Friends Research Institute, Inc., Los Angeles, CA, 2Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, 3Center for Clinical AIDS Research & Education, UCLA, Los Angeles, CA

100 Making the most of mindfulness: Which specific mindfulness deficits might be targeted to optimize addiction treatment?
J. Ury, D. Flack, E. Dakwar, NYSPI, New York City, NY

101 Failure to get into drug treatment
L. D’Anna1, D. G. Fisher2, G. L. Reynolds2, D. Hosmer3, K. Hardan-Khalil4, 1Center for Health Equity, California State University, Long Beach, CA, 2Center for Behavioral Research & Services, California State University, Long Beach, CA, 3Department of Mathematics and Statistics, University of Vermont, Stowe, VT, 4School of Nursing, California State University, Long Beach, CA
102 An amphetamine exposure during adolescence alters behavior, dopamine receptors and medial prefrontal cortex function in adulthood
   J. M. Gulley, L. Sherrill, Psychology and Neuroscience, University of Illinois, Urbana-Champaign, Champaign, IL

103 Energy drink compounds differentially affect anxiety, locomotion, depression and cognition in adolescent and adult female rats
   K. Chauhan¹, S. Perez², M. Chrisphonte¹, M. Evelyn¹, M. Guzman¹, D. Woo¹, U. Akpara¹, H. Saleh¹, A. Alexander-Street², K. Salas-Ramirez¹, ¹Physiology, Pharmacology and Neuroscience, The City College of New York, New York, NY, ²Biology, Lehman College, CUNY, Bronx, NY

104 Dysregulation in the cholinergic system after adolescent nicotine is reversed by dietary choline
   E. Holliday, C. Oliver, T. Gould, Psychology, Temple University, Philadelphia, PA

105 A test of the aversive versus the rewarding effects of nicotine in rats neonatally treated with quinpirole
   S. Kirby, E. D. Cummins, D. J. Peterson, L. Kassem, R. W. Brown, Psychology, East Tennessee State University, Johnson City, TN

106 The role of the α7 and α4β2 nicotinic receptors in nicotine sensitization and neural plasticity of adolescent rats neonatally treated with quinpirole
   D. J. Peterson, C. M. Bardo, E. D. Cummins, R. W. Brown, Psychology, East Tennessee State University, Johnson City, TN

107 Genetic and environmental influences on initiation and heaviness of smoking from adolescence to adulthood
   C. B. Bares, K. S. Kendler, H. Maes, Virginia Commonwealth University, Richmond, VA

108 Predictors of early relapse in adolescent crack users after hospital discharge
   H. F. Moura¹, R. L. Rosa¹, F. H. Kessler¹, T. G. Pianca¹, L. S. Guimarães³, P. B. Ferronatto¹, E. Pagnussat¹, F. P. Pechansky², L. von Diemen¹, ¹Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, ²Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, ³CPAD, Porto Alegre, Brazil, ⁴Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil

109 Predictors of e-cigarette use among adolescents
   S. Krishnan-Sarin², G. Kong², D. R. Camenga¹, D. A. Cavallo², P. Simon², C. Connell², R. Wu², M. E. Morean², ¹Pediatrics, Yale School of Medicine, New Haven, CT, ²Department of Psychiatry, Yale University School of Medicine, New Haven, CT

110 The impact of e-cigarette advertisements on e-cigarette initiation among middle and high school students
   K. M. Gutierrez, D. R. Camenga, G. Kong, D. A. Cavallo, P. Simon, R. Wu, C. Connell, S. Krishnan-Sarin, Yale University, New Haven, CT

111 Socioeconomic disparities in electronic cigarette use among adolescents
   P. Simon, D. R. Camenga, G. Kong, D. A. Cavallo, C. Connell, K. M. Gutierrez, S. Krishnan-Sarin, Yale School of Medicine, New Haven, CT

112 Factors contributing to tobacco use and cessation in Hispanic adolescents
   S. E. Gomez Luna¹, D. A. Cavallo², G. Kong², J. Knight³, S. Krishnan-Sarin², ¹School of Medicine, Yale, New Haven, CT, ²Psychiatry, Yale University, New Haven, CT, ³School of Medicine, Havard, Boston, MA
Is cannabis smoking harmful? A mutoscope view discloses patterned maturation of youthful risk perceptions
M. Chandra, S. M. Hughes, J. C. Anthony, Department of Epidemiology & Biostatistics, Michigan State University, East Lansing, MI

Negative affect mediates relations between anxiety sensitivity and substance use problems in adolescents
C. Guillot¹, R. Pang¹, M. Kirkpatrick¹, A. Leventhal², ¹Department of Preventive Medicine, University of Southern California, Azusa, CA, ²Departments of Preventive Medicine and Psychology, University of Southern California, Los Angeles, CA

Relationship between changes in cannabis use and anxiety among adolescents
J. C. Duperrouzel, J. M. Ross, R. Gonzalez, Psychology, Florida International University, Miami, FL

Moderating effects of decision-making on cannabis use and body mass index among adolescents
J. M. Ross, P. Graziano, J. C. Duperrouzel, I. Gonzalez, R. Gonzalez, Psychology, Florida International University, Miami, FL

School context and marijuana use among Maryland high school students
E. Parker¹, R. M. Johnson¹, S. Lindstrom Johnson², C. Bradshaw³⁴, ¹Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, ³Curry School of Education, University of Virginia, Charlottesville, VA, ⁴Johns Hopkins Center for the Prevention of Youth Violence, Baltimore, MD

Cannabis smoking clusters within secondary schools: Results from the United States Monitoring the Future Study 1976-2013
M. A. Parker, J. C. Anthony, Epidemiology & Biostatistics, Michigan State University, East Lansing, MI

Adolescent substance use and specificity of association with educational attainment in young adulthood
E. Silins¹, L. J. Horwood², D. Fergusson², G. Patton³, C. Olsson³, D. Hutchinson¹, L. Degenhardt¹, R. P. Mattick¹, ¹University of NSW, Sydney, NSW, Australia, ²University of Otago, Christchurch, New Zealand, ³University of Melbourne, Parkville, VIC, Australia

Developing a multidimensional measure of marijuana-specific communication with friends
J. A. Kam, Communication, UC Santa Barbara, Santa Barbara, CA

Identifying treatment response subgroups for adolescent cannabis use disorders
S. F. Babbin, C. Stanger, A. J. Budney, Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH

EPIDEMIOLOGY I

Are early-onset users of inhalants at excess risk of developing inhalants dependence soon after onset of inhalant use: Estimates for the United States, 2002-2011
R. Brosig, J. C. Anthony, Michigan State University, Rochester, MI

A rapidly changing recreational drug market: Findings from the Canadian Community Epidemiology Network on Drug Use
M. M. Young, Canadian Centre on Substance Abuse, Ottawa, ON, Canada
124 Novel psychoactive substance use in the European Union
S. P. Novak¹, A. Hakansson², J. Reimer³, J. Martinez-Raga⁴, J. Lorvick³, ¹Behavioral Epidemiology, RTI International, Research Triangle Park, NC, ²Division of Psychiatry, U of Lund, Lund, Sweden, ³RTI International, RTI, San Francisco, CA, ⁴Teaching Unit of Psychiatry and Psychological Medicine, U of Valencia, Valencia, Spain, ⁵Centre for Interdisciplinary Addiction Research, Hamburg Medical, Hamburg, Germany

125 The use of new psychoactive substances amongst a sample of regular psychostimulant users, 2010-2014
R. Sutherland², L. Burns¹, ¹NDARC, UNSW, Sydney, NSW, Australia, ²National Drug & Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia

126 Patterns of performance and image-enhancing drug use among men accessing needle and syringe programs in Sydney, Australia
R. Rowe, I. Berger, Drug and Alcohol Multicultural Education Centre, Sydney, NSW, Australia

127 Combined and independent relationships between current marijuana and cigarette use and cardiometabolic disease risk among United States emerging adults: Results from the National Health and Nutrition Examination Surveys 2007-2012
D. C. Vidot¹, G. Prado¹, K. Arheart¹, W. Hlaing¹, A. Acheampong², S. Messiah¹, ¹University of Miami Miller School of Medicine, Miami, FL, ²University of Florida, Gainesville, FL

128 Marijuana use trajectories during college predict health outcomes nine years post-matriculation
A. M. Arria¹, K. M. Caldeira¹, B. A. Bugbee¹, K. B. Vincent¹, K. E. O’Grady², ¹Univ. of Maryland School of Public Health, College Park, MD, ²Dept. of Psychology, Univ. of Maryland, College Park, MD


130 Are medical marijuana users different than recreational marijuana users?
S. S. Martins², J. Santaella¹, L. R. Pacek³, K. Keyes², M. Cerda², D. S. Hasin², S. Galea², ¹Columbia University, New York, NY, ²Epidemiology, Columbia University, New York City, NY, ³Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD

131 Characteristics and consequences of adults who use cannabis as their first drug
B. J. Fairman, R. M. Johnson, C. M. Furr-Holden, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

132 Associations between age and cannabis use problems among medical cannabis patients
K. Bohnert¹,², M. A. Ilgen¹,², ¹Psychiatry, University of Michigan, Ann Arbor, MI, ²VA Ann Arbor, Ann Arbor, MI

133 Estimated probability of becoming a case of drug dependence in relation to duration of drug-taking experience: A functional approach
O. Vsevolozhskaya², J. C. Anthony¹, ¹Michigan State University, East Lansing, MI, ²Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

134 Cannabis smoking, cardiometabolic health, and cardiovascular disease: United States NHANES, 2005-2010
O. Alshaarawy, J. C. Anthony, Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI
135 Is marijuana use associated with less opioid use among people who inject drugs?  
A. Kral¹, L. Wenger¹, S. P. Novak², K. F. Corsi³, R. Bluthenthal⁴, ¹RTI International, San Francisco, CA, ²Behavioral Epidemiology, RTI International, Research Triangle Park, NC, ³Psychiatry, University of Colorado Denver, Denver, CO, ⁴Preventive Medicine, University of Southern California, Los Angeles, CA

136 Parallel development of longitudinal tobacco smoking and alcohol consumption: The Amsterdam Growth and Health Longitudinal Study  
C. Lederhos, O. Brooks, A. Lamp, C. Barbosa-Leiker, T. Hoekstra, S. Murphy, M. Layton, J. Roll, S. McPherson, Program of Excellence in Addictions Research (PEAR), Washington State University, Spokane, WA

137 Perceived approval of substance use in soldiers vs. civilians  

138 E-cigarettes in Baltimore alcohol outlets: Geographic and demographic correlates of availability  
D. O. Fakunle, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

139 Cigarette smoking and food insecurity in socioeconomically disadvantaged young adults  
J. E. Kim, J. Tsoh, Psychiatry, University of California San Francisco, San Francisco, CA

140 Mental health among smokers in the U.S. from 2008 to 2013: Diverging trends by socioeconomic status  
R. Goodwin¹,², M. Wall³, M. Hu¹, M. J. Zvolensky⁴, D. S. Hasin², ¹Psychology, City University of New York, Queens, NY, ²Epidemiology, Columbia University, New York, NY, ³Biostatistics, Columbia University, New York, NY, ⁴Psychology, University of Houston, Houston, TX

141 Cigarette smoking and risk of substance use and substance use disorder relapse among adults in recovery  
A. H. Weinberger², J. Platt³, S. Galea¹, R. Goodwin¹,², ¹Psychology, City University of New York, Queens, NY, ²Psychiatry, Yale University School of Medicine, New Haven, CT, ³Epidemiology, Columbia University, New York, NY

K. Alcover, J. C. Anthony, Epidemiology & Biostatistics, Michigan State University, East Lansing, MI

143 Crack, powdered cocaine, both or neither: A generalized logit analysis of a community-based sample  
G. L. Reynolds¹,², D. G. Fisher¹, E. Erlyana², ¹Center for Behavioral Research and Services, California State University, Long Beach, Long Beach, CA, ²Health Care Administration, California State University, Long Beach, Long Beach, CA

144 Social rank and cocaine dependence: Estimates for the United States, 2005-2013  
A. M. Mohammed, J. C. Anthony, Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

145 Estimated rapid transition from first stimulant use until onset of stimulant dependence: Larger for methamphetamine users?  
O. J. Santiago Rivera¹, J. C. Anthony², ¹Epidemiology, Michigan State University, Okemos, MI, ²Epidemiology and Biostatistics, Michigan State University, East Lansing, MI
Prevalence and correlates of simultaneous heroin and methamphetamine injection in two parallel cohorts of PWID in San Diego, CA, and Tijuana, BC, Mexico
M. C. Meacham\textsuperscript{1,2}, R. Armenta\textsuperscript{1,2}, R. Garfein\textsuperscript{1}, J. Cuevas-Mota\textsuperscript{1}, P. Gonzalez Moreno-Zuniga\textsuperscript{1}, S. Strathdee\textsuperscript{1}, \textsuperscript{1}University of California San Diego, La Jolla, CA, \textsuperscript{2}San Diego State University, San Diego, CA

Characteristics and predictors of naloxone utilization in a community-based overdose prevention program
P. O. Coffin\textsuperscript{1,2}, C. Rowe\textsuperscript{1}, G. Santos\textsuperscript{1}, E. Vittinghoff\textsuperscript{3}, E. Wheeler\textsuperscript{4}, \textsuperscript{1}Substance Use Research, San Francisco Department of Public Health, San Francisco, CA, \textsuperscript{2}HIV/AIDS, University of California San Francisco, San Francisco, CA, \textsuperscript{3}University of California San Francisco, San Francisco, CA, \textsuperscript{4}Harm Reduction Coalition, Oakland, CA

Symposium VI
AZ Biltmore Ballroom
1:30 - 3:30 PM
MINDFULNESS-BASED APPROACHES: FROM NEUROBIOLOGICAL MECHANISMS TO TREATMENT

Chairs: David Shurtleff and Emmeline Edwards

1:30 Neurobiological mechanisms of mindfulness meditation
Judson Brewer, University of Massachusetts Medical School, New Haven, MA

1:55 Pharmacological facilitation of mindfulness training
Elias Dakwar, New York State Psychiatric Institute, New York, NY

2:20 Applying yoga to smoking cessation interventions
Beth Bock, Miriam Hospital, Providence, RI

2:45 Mindfulness-based relapse prevention: Theoretical and empirical foundations for treatment of addictive behaviors
Sarah Bowen, University of Washington, Portland, OR

3:10 DISCUSSANT:
David Shurtleff, National Institutes of Health, Bethesda, MD

Symposium VII
McArthur Ballroom 1/2
1:30 - 3:30 PM
BEHAVIORAL ECONOMICS OF HEALTH DISPARITIES IN ADDICTION

Chairs: Adam Leventhal and Stephen T. Higgins

1:30 Behavioral economic sources of disparities in addiction
Adam Leventhal, University of Southern California Keck School of Medicine, Los Angeles, CA

1:55 The behavioral economics of tobacco use among people with serious mental illness
Jennifer W. Tidey, Brown University, Providence, RI

2:20 Behavioral economics: Improving outcomes among disadvantaged women and infants
Stephen T. Higgins, University of Vermont, Burlington, VT

2:45 Behavioral economic incentives for drug abstinence in low-income adults at risk for HIV
Kenneth Silverman, Johns Hopkins University School of Medicine, Baltimore, MD
3:10 **DISCUSSANT: Therapeutic opportunities for health disparities: Change and the limits of change**  
Warren K. Bickel, Virginia Tech Carilion Research Institute, Roanoke, VA

**Oral Communications 8**  
**McArthur Ballroom 4**  
**1:30 - 3:30 PM**

**MOMMAS WHO ABUSE: PERINATAL DRUG ABUSE**

Chairs: Sarah H. Heil and Sarah A. Cercone

1:30 *Correspondence between self-reported and biochemical measures of cigarette smoking in pregnant women*  

1:45 *Individual characteristics and social process in influencing maternal smoking behavior: A longitudinal analysis of a national birth cohort*  
W. Liu, E. Mumford, Public Health, NORC at University of Chicago, Bethesda, MD

2:00 *Prenatal tobacco exposure predicts child’s internalizing behavior*  
S. A. Cercone¹, G. G. Homish¹, R. D. Eiden², J. L. Derrick², ¹Community Health & Health Behavior, State University of New York at Buffalo, Buffalo, NY, ²Research Institute on Addictions, Buffalo, NY

2:15 *Second-hand smoke exposure during pregnancy and anxiety disorder in children at age 11-13*  
J. Liu, H. Liu, W. Liu, School of Nursing, University of Pennsylvania, Philadelphia, PA

2:30 *Hospital admissions for alcohol use disorders in pregnancy*  
C. L. Breen¹, F. Xu², L. Burns¹, ¹NDARC, UNSW, Sydney, NSW, Australia, ²UNSW, Simpson Centre for Health Services Research, Sydney, NSW, Australia

2:45 *Prevalence and predictors of antenatal alcohol use prior to awareness of pregnancy*  
C. McCormack¹, D. Hutchinson¹, L. Burns¹, J. Wilson¹, E. Elliott², S. Allsop³, J. Najman⁴, C. Olsson⁵, S. Jacobs⁶, A. Bartu⁷, R. P. Mattick¹, ¹National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, ²Paediatrics and Child Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia, ³National Drug Research Institute, Curtin University of Technology, Perth, WA, Australia, ⁴Queensland Alcohol and Drug Research Education Centre, University of Queensland, Brisbane, QLD, Australia, ⁵Centre for Social and Early Emotional Development, Deakin University, Melbourne, VIC, Australia, ⁶Department of Obstetrics, Royal Prince Alfred Hospital, Sydney, NSW, Australia, ⁷School of Nursing and Midwifery, Curtin University, Perth, WA, Australia

3:00 *Prevalence of heavy fetal alcohol exposure during pregnancy in Canada: A population-based meconium study*  
K. Delano¹², E. Pope²³, B. Kapur², G. Koren¹², ¹Pharmacology and Toxicology, The University of Toronto, Toronto, ON, Canada, ²Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, ON, Canada, ³Health Sciences, McMaster University, Hamilton, ON, Canada

3:15 *Maternal age and trajectories of marijuana use over 17 years*  
N. De Genna¹, L. Goldschmidt², N. Day¹, M. Cornelius¹, ¹Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Western Psychiatric Institute and Clinic (WPIC), University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA
Misty Aspirations: Vaping

1:30 Use patterns, perceptions of relative harm, and gender effects in dual users of electronic and tobacco cigarettes
O. Rass, L. R. Pacek, P. S. Johnson, M. W. Johnson, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

1:45 Use of electronic cigarettes among smokers in addiction treatment
N. R. Gubner1, T. Le2, B. Tajima2, B. Andrews2, E. Passalacqua2, J. Guydish2, 1CTCRE, UCSF, San Francisco, CA, 2IHPS, UCSF, San Francisco, CA

2:00 Predictors of youth use of e-cigarettes for smoking cessation
D. R. Camenga, G. Kong, D. A. Cavallo, C. Connell, K. M. Gutierrez, P. Simon, S. Krishnan-Sarin, Yale School of Medicine, New Haven, CT

2:15 Informing the regulation of e-cigarettes to restrict youth access
G. Kong2, D. A. Cavallo2, M. E. Morean3, D. R. Camenga1, S. Krishnan-Sarin2, 1Pediatrics, Yale School of Medicine, New Haven, CT, 2Psychiatry, Yale University, New Haven, CT, 3Oberlin College, Oberlin, OH

2:30 ECIG-induced suppression of nicotine/tobacco abstinence symptoms
A. A. Lopez, M. Hiler, T. Ratner, K. Pettaway, A. Brelard, T. Eissenberg, Psychology, Virginia Commonwealth University, Richmond, VA

2:45 Efficacy of electronic cigarettes for smoking cessation in veterans
J. Eisenhofer1, T. Makanjuola1, V. Martinez1, D. G. Thompson-Lake1, C. Rodgman2, D. S. DeBrule2, D. P. Graham2, R. De La Garza, II1, 1Baylor College of Medicine, Houston, TX, 2Michael E. DeBakey VA Medical Center, Houston, TX

3:00 Development and validation of a device for the intrapulmonary delivery of Δ²-tetrahydrocannabinol to rats
M. A. Taffe, S. M. Aarde, M. Cole, CNAD, The Scripps Research Institute, La Jolla, CA

3:15 Characterizing vaporizer use among cannabis users
D. C. Lee2, B. S. Crosier1, A. J. Budney2, 1Center for Technology and Behavioral Health, Dartmouth College, West Windsor, VT, 2Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH
Tuesday, June 16, 2015

Symposium VIII

McArthur Ballroom 1/2
3:45 - 4:45 PM

USING TRANSLATIONAL RESEARCH TO DEVELOP INTERVENTIONS FOR STIMULANT USE DISORDERS: NONHUMAN PRIMATE, HUMAN LABORATORY AND CLINICAL TRIAL FINDINGS

Chairs: William W. Stoops and Paul W. Czoty

3:45 Enhancing the predictive validity of laboratory animal drug self-administration procedures by incorporating clinically relevant variables
   Paul W. Czoty, Wake Forest School of Medicine, Winston-Salem, NC

4:10 Utility and predictive validity of human laboratory drug self-administration measures for stimulant treatment development
   William W. Stoops, University of Kentucky, Lexington, KY

4:35 Are new clinical trial designs needed for the successful translation of research into an effective medication for stimulant dependence?
   Keith Heinzerling, University of California-Los Angeles, Los Angeles, CA

Oral Communications 10

McArthur Ballroom 5/6
3:45 - 4:45 PM

MALLEABLE AGE: INFANTS AND CHILDREN

Chairs: Loretta Finnegan and Jillian Hardee

3:45 Surveying lactation professionals regarding breastfeeding and marijuana use
   C. L. Bergeria3,2, S. H. Heil3,1,2, 1Psychiatry, University of Vermont, Burlington, VT,
   2Psychology, University of Vermont, Burlington, VT, 3Vermont Center on Behavior and Health, Burlington, VT

4:00 Gender differences in the development of emotion circuitry in youth at risk for substance abuse: A longitudinal fMRI study
   J. Hardee, L. M. Cope, R. Zucker, M. Heitzeg, Psychiatry, University of Michigan, Ann Arbor, MI

4:15 Drug- and alcohol-exposed pregnancies: Maternal and infant outcomes
   M. Tuten1, S. Moore1, H. Fitzsimons2, M. Velez3, M. S. Chisolm2, L. Jansson3, H. E. Jones4,
   1School of Social Work, UMB, Baltimore, MD, 2Psychiatry and Behavioral Sciences, JHU, Baltimore, MD, 3Pediatrics, JHU, Baltimore, MD, 4OB/GYN, UNC Chapel Hill, Chapel Hill, NC

4:30 Gender differences in associations between childhood sexual abuse and illicit drug use in adulthood
   S. Gao1, J. D. Scheidell2, T. Campion1, K. Vaddiparti1, S. McGorray1, M. R. Khan2, 1Colleges of Public Health & Health Professions and Medicine, University of Florida, Gainesville, FL, 2Population Health, New York University, New York, NY
Oral Communications 11

MANAGING AGONY: OPIOIDS AND PAIN

Chairs: Silvia L. Cruz and Kate McHugh

3:45 Adolescent oxycodone self administration alters subsequent antinociceptive effect of oxycodone in C57Bl/6J mice in adulthood
   J. H. Altschuler, K. Niikura, E. Butelman, M. Kreek, Y. Zhang, Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY

4:00 Morphine and fentanyl chronic effects on lipopolysaccharide response and μ opioid receptor localization in mast cells
   S. L. Cruz, L. Molina, C. Gonzalez-Espinosa, Farmacobiología, Centro de Investigación y de Estudios Avanzados del IPN, Tlalpan, Mexico

4:15 Inflammatory cytokines and pain in patients with opioid use disorders
   J. I. Tsui1, M. C. Lira1, D. M. Cheng1, M. R. Winter1, R. R. Edwards1, J. Mao1, J. Samet1, 1BU School of Medicine, Boston, MA, 2UW School of Medicine, Seattle, WA, 3BU School of Public Health, Boston, MA, 4Brigham and Women’s Hospital, Chestnut Hill, MA, 5Mass General Hospital, Boston, MA

4:30 Mortality and guideline-concordant long-term opioid therapy for pain
   J. R. Gaither1, J. Goulet1,2, W. Becker1,2, S. Crystal1, E. Edelman1, K. Gordon2, R. Kerns1,2, D. Rimland4, M. Skanderson2, A. Justice1,2, D. Fiellin1, 1Yale, New Haven, CT, 2VAHCS, West Haven, CT, 3Rutgers, New Brunswick, NJ, 4Emory, Atlanta, GA

4:45 Predictors for high dose chronic opioid therapy
   D. Plott, S. Miller, MHCL, VHACIN, Cincinnati, OH

5:00 Distress intolerance and prescription opioid abuse in chronic pain patients
   K. McHugh1,3, R. R. Edwards2,3, R. N. Jamison2,3, M. C. Cornelius2, R. Weiss3,1, 1McLean Hospital, Belmont, MA, 2Brigham and Women’s Hospital, Boston, MA, 3Harvard Medical School, Boston, MA

5:15 Pharmaceutical opioid use and dependence among people living with chronic pain: Associations observed within the Pain and Opioids In Treatment cohort
   G. Campbell2, S. Nielsen2, B. Larance2, R. Bruno3, R. Mattick2, W. Hall4, N. Lintzeris1, M. Cohen2, K. Smith2, L. Degenhardt2, 1Langton Centre, Sydney, NSW, Australia, 2National Drug and Alcohol Research Centre, University of NSW, Sydney, NSW, Australia, 3School of Psychology, University of Tasmania, Hobart, TAS, Australia, 4University of Queensland, Brisbane, QLD, Australia

5:30 Examining DSM and ICD definitions of pharmaceutical opioid dependence in people taking opioids for chronic pain: Findings from the Pain and Opioids IN Treatment study
   L. Degenhardt2, R. Bruno4, N. Lintzeris1, W. Hall5, S. Nielsen2, B. Larance2, M. Cohen3, G. Campbell2, 1Langton Centre, Sydney, NSW, Australia, 2National Drug and Alcohol Research Centre, University of NSW, Sydney, NSW, Australia, 3University of New South Wales, Sydney, NSW, Australia, 4School of Medicine, University of Tasmania, Hobart, TAS, Australia, 5Centre for Youth Substance Abuse Research, University of Queensland, Brisbane, QLD, Australia
Oral Communications 12

**MECHANISMS OF ADDICTION**

Chairs: Cassandra D. Gipson and Aron Lichtman

5:00  *The kappa opioid receptor agonist 16-bromosalvinorin A reduces cocaine seeking in rats*
A. Ewald², J. Miller², T. E. Prisinzano¹, B. M. Kivell², ¹Medicinal Chemistry, The University of Kansas, Lawrence, KS, ²Centre for Biodiscovery, Victoria University of Wellington, Wellington, New Zealand

5:15  *Disruption of cortical n-methyl-d-aspartate receptor tone governs impulsive action*
C. Krebs, N. C. Anastasio, C. Wood, Center for Addiction Research, University of Texas Medical Branch, Galveston, TX

5:30  *N-Acetylcysteine inhibits nicotine relapse-associated synaptic plasticity and restores glial glutamate transport in nicotine-withdrawn animals*
C. D. Gipson, S. Spencer, N. Stankeviciute, N. Allen, C. Garcia-Keller, P. W. Kalivas, Neurosciences, Medical University of South Carolina, Charleston, SC

5:45  *Dual blockade of endocannabinoid hydrolyzing enzymes reveal a CB₁ receptor-mediated interoceptive stimulus*
R. Owens¹, P. Beardsley¹, B. Cravatt³, A. Lichtman², ¹VCU, Richmond, VA, ²Virginia Commonwealth University, Richmond, VA, ³The Scripps Research Institute, La Jolla, CA

**Symposium IX**

NEW PERSPECTIVES ON GENETICS AND METABOLOMICS OF NICOTINE DEPENDENCE AND SMOKING CESSATION: IMPLICATIONS FOR NICOTINE DEPENDENCE TREATMENT

Chair: Joni Rutter

5:00  *Genomic contributions to nicotine dependence: A meta-analysis*
Xiangning Chen, Virginia Commonwealth University, Richmond, VA

5:20  *Genetically variable pharmacokinetic influences on nicotine dependence: Implications for smoking cessation*
Meghan Chenoweth, University of Toronto, Toronto, ON, Canada

5:40  *Use of genomic and metabolomic data to increase smoking cessation success*
Li-Shiun Chen, Washington University School of Medicine, St. Louis, MO

**Symposium X**

THE INTERPLAY OF PHARMACOKINETICS AND PHARMACODYNAMICS IN ABUSE POTENTIAL: MODELING MADNESS?

Chairs: Megan Shram and Sharon L. Walsh

5:00  *Pharmacokinetic and dynamic factors in abuse potential: Historical perspectives from research on opioids, stimulants and nicotine*
Jack Henningfield, The Johns Hopkins University School of Medicine, Bethesda, MD
Drug metabolism within the brain alters drug response and abuse liability: Examples from propofol, codeine and nicotine in an animal model
Rachel Tyndale, University of Toronto, Toronto, ON, Canada

Use of PK-PD modeling to evaluate the impact of formulation on a subject’s drug experience: Can we predict abuse potential?
Megan Shram, University of Toronto, Toronto, ON, Canada

Workshop IX

McArthur Ballroom 1/2
7:00 - 9:00 PM

THE INTERTWINING EPIDEMICS OF DRUG USE AND HIV/AIDS:
THE HIV/AIDS WORKGROUP

Chairs: Adam W. Carrico and Don C. Des Jarlais

Gender-specific HIV prevention interventions for women who use alcohol and other drugs: The evolution of the science and future directions
Wendee Wechsberg, Research Triangle Institute, Research Triangle Park, NC

Providing ART to HIV-seropositive persons who use drugs: Progress in New York City, prospects for “ending the epidemic”
Don C. Des Jarlais, Beth Israel Medical Center, New York, NY

Risk and protective factors associated with ARV adherence among aging, indigent, substance abusing people living with HIV
Maria A. Levi-Minzi, Nova Southeastern University, Miami, FL

Injection risk behavior and HIV and HCV prevalence among young opioid injectors in New York City
Pedro Mateu-Gelabert, National Development and Research Institutes, New York, NY

Longitudinal associations between the dissolution of committed partnerships that occurs during incarceration and post-release HIV risk among African-American men released from prison in North Carolina
Maria R. Khan, New York University, New York, NY

Two-year trajectories of HIV sexual risk behaviors among adolescents and emerging adults who use drugs
Erin E. Bonar, University of Michigan, Ann Arbor, MI

Development and factor analysis of a comprehensive behavioral risk assessment for infectious diseases
Evan S. Herrmann, Johns Hopkins University, Baltimore, MD

Theory-based text-messaging to reduce methamphetamine use and sex risks among men who have sex with men
Cathy J. Reback, Friends Research Institute, Los Angeles, CA

Modifying effects of HIV-status on correlates of smoking and vaping among men who have sex with men in San Francisco
Glenn-Milo Santos, University of California, San Francisco, San Francisco, CA

Substance use and delayed HIV testing among young black men who have sex with men
Adam W. Carrico, University of California, San Francisco, San Francisco, CA
Workshop X  
AZ Biltmore Ballroom  
7:00 - 9:00 PM  
MARIJUANA LAWS: THE CHANGING LEGAL LANDSCAPE AND ITS CONSEQUENCES  
Chair: Marsha Lopez  

Medical marijuana laws and U.S. adolescent marijuana use: Results over 20 years  
Deborah S. Hasin, Columbia University, New York, NY  

Adolescent substance use and related risk factors in the context of changes in marijuana-related legislation in Washington and other states  
Katarina Guttmannova, University of Washington, Seattle, WA  

Science in the Federal courthouse: Marijuana rescheduling in a court case in California  
Bertha Madras, Harvard Medical School, Belmont, MA  

Health conditions and patterns of marijuana use among young adult medical marijuana patients in Los Angeles  
Stephen Lankenau, Drexel University School of Public Health, Philadelphia, PA  

Examining length of time between waking and first use of marijuana for the day in adult medical marijuana patients  
Mark Ilgen, University of Michigan, Ann Arbor, MI  

DISCUSSANT: Legalizing and regulating marijuana: Should we be worried?  
Priscilla Hunt, Rand Corporation, Santa Monica, CA

Workshop XI  
McArthur Ballroom 4  
7:00 - 9:00 PM  
21ST ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP  
Chairs: Kelly E. Dunn and Diann Gaalema  

Open to all meeting attendees. For description, see back of book.

Workshop XII  
McArthur Ballroom 5/6  
7:00 - 9:00 PM  
CULTURALLY ADAPTED SUBSTANCE ABUSE TREATMENTS FOR RACIAL/ETHNIC MINORITIES: CURRENT PERSPECTIVES AND FUTURE DIRECTIONS  
Chairs: Kathleen Burlew and Carmen L. Masson

The research and practice of culturally adapting substance abuse treatments for Latino adolescents  
Jason Burrow-Sanchez, University of Utah, Salt Lake City, UT  

Considerations in the treatment of API: Counselor and patient perspectives  
Martin Y. Iguchi, Georgetown University, Washington, DC  

How improving substance use treatment with racial/ethnic minorities can inform treatment for all  
Kamilla Venner, University of New Mexico, Albuquerque, Mexico
Wednesday, June 17, 2015

Grant-Writing Workshop (Pre-Registrants Only)  
AZ Biltmore Ballroom  
8:00 - 12:00 PM

Town Hall Industry  
McArthur Ballroom 4  
8:00 - 10:00 AM

EVALUATION OF SOCIETAL AND ECONOMIC BURDEN OF PRESCRIPTION OPIOID ABUSE

Chairs: Beatriz Rocha and Beatrice Setnik

FDA’s perspective on prescription drug abuse  
Michael Klein, Food and Drug Administration, Silver Spring, MD

Societal impact of Rx opioid abuse from poison center and emergency medicine  
Richard C. Dart, Rocky Mountain Poison and Drug Center - A Division of Denver Health, Denver, CO

An industry perspective on reducing the abuse of opioid medications  
J. David Haddox, Purdue Pharma L.P., Stamford, CT

Abuse of prescription medicines: The primary care perspective  
William McCarberg, American Academy in Pain Medicine, Poway, CA

Big data, crowdsourcing and harm reduction  
Nabarun Dasgupta, University of North Carolina at Chapel Hill, Chapel Hill, NC

2015 Outreach Event  
UMOM New Day Center  
9:00 - 12:00 PM

Organized by Colleen Hanlon

Animals in Research Forum  
McArthur Ballroom 1/2  
10:00 - 12:00 PM

Chairs: Marilyn E. Carroll and Bert Weiss

Animal Forum

Defending scientific research in an age of extremism  
J. David Jentsch, UCLA, Los Angeles, CA

The use of both female and male animals in NIH-funded research  
Cora Lee Wetherington, NIDA, Bethesda, MD
Wednesday, June 17, 2015

Poster Session III
(Lunch) Odd-numbered posters manned first hour; Even-numbered, second hour

Set-up time begins Tuesday 3:00 PM
Must be removed at 2:00 PM Wednesday

Frank Lloyd Wright Ballroom
12:00 - 2:00 PM

CLUB DRUGS

1 Repeated exposure to the 5-HT$_{1B/1A}$ agonist, RU 24969, facilitates the acquisition of MDMA self-administration
   D. Aronsen, N. Bukholt, S. Schenk, Psychology, Victoria University of Wellington, Wellington, New Zealand

2 The differential role of DA and 5-HT in the discriminative stimulus properties of high vs. low doses of ±3,4-methylenedioxymethamphetamine
   J. Webster, S. Schenk, D. Harper, Psychology, Victoria University of Wellington, Wellington, New Zealand

3 Abuse liability evaluation of mephedrone in humans
   M. Farre, C. Pérez-Mañá, J. Mateus, M. Pujadas, F. Fonseca, M. Torrens, R. De la Torre, E. Papaseit, 1Human Pharmacology and Neurosciences, IMIM-UAB, Barcelona, Spain,
      2Institut de Neuropsiquiatria i Addiccions (INAD), Parc de Salut Mar, Barcelona, Spain,
      3Human Pharmacology and Neurosciences, IMIM-UPF, Barcelona, Spain

4 Recent trend of drug-arrested charges and hospital visits in Taiwan: 2009-2013
   J. Hsu, C. Yu, S. Lee, W. Tsay, C. Chen, 1Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan,
      2Institute of Public Health, School of Medicine, National Yang-Ming University, Taiwan, Taipei, Taiwan

5 Decreased thalamocortical connectivity in chronic ketamine users
   Y. Liao, J. Tang, Mental Health Institute, the Second Xiangya Hospital, Central South University, Changsha, China

6 Comparative phenomenology of psilocybin experiences in research and non-research settings
   T. M. Carbonaro, M. Klinedinst, M. W. Johnson, R. R. Griffiths, 1Departments of Psychology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD,
      2Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD

7 Correlates between Brazilian club drug users men who have sex with men, psychiatric vulnerabilities and multiple sexual partners
   L. S. Remy, H. Surratt, S. Kutz, F. P. Pechansky, 1Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL,
      2Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil

8 Prevalence and patterns of the use of novel psychoactive substances, “kiken drugs”, among younger adults at dance parties in Japan
   T. Shimane, K. Wada, Y. Hidaka, M. Funada, 1Drug Dependence Research, NIMH, NCNP, Kodaira, Japan,
      2Takarazuka University School of Nursing, Osaka, Japan
PSYCHIATRIC COMORBIDITY

9  Aripiprazole and risperidone in treatment of methamphetamine associated psychosis in China: A pilot randomized study
G. Wang, Y. Zhang, S. Zhang, H. Chen, Z. Xu, W. Hao, M. C. Chawarski, Mental Health Center, The Second Xiangya Hospital, Changsha, China, 2Psychiatry, Yale University School of Medicine, New Haven, CT, 3Wuhan Mental Health Center, Wuhan, China

10 Psychiatric symptoms and treatment outcomes in cocaine-dependent adults treated with buprenorphine and long-acting naltrexone
L. Mooney, M. P. Hillhouse, C. Thomas, A. Ang, A. Hasson, J. Annon, S. Reed, W. Ling, UCLA, Los Angeles, CA, 2Integrated Substance Abuse Programs, UCLA, Los Angeles, CA

11 Mindfulness-based relapse prevention improves stimulant use among adults with major depression and generalized anxiety disorder
S. Glasner-Edwards, L. Mooney, A. Ang, H. Chokron Garneau, E. E. Hartwell, M. Brecht, R. Rawson, UCLA, Los Angeles, CA, 2Integrated Substance Abuse Programs, UCLA, Los Angeles, CA

12 Mirtazapine pilot trial in comorbid MDD/SUD: Long-term follow-up results

13 The interrelationship of culture and depression in the barrio
Y. Villarreal, T. Luis, P. Bordnick, Family & Community Medicine, University of Texas Medical School, Houston, TX, 2Graduate College of Social Work, University of Houston, Houston, TX

14 Anhedonia, depression, anxiety, and craving for opiates in opiate addicts stabilized on oral naltrexone and long-acting naltrexone implant
E. Krupitsky, E. Zvartau, E. Blokhina, E. Verbitskaya, V. Palatkin, A. Tyurina, T. Yaroslavtseva, N. Bushara, A. Pecoraro, G. E. Woody, St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation, 2First Pavlov State Medical University, St. Petersburg, Russian Federation, 3St. Petersburg Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation, 4Psychiatry, University of Pennsylvania, Philadelphia, PA

15 Incentivizing attendance to prolonged exposure in methadone maintenance
J. M. Peirce, R. L. Schacht, R. K. Brooner, V. L. King, M. S. Kidorf, Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, 2Psychology, University of Maryland, Baltimore County, Baltimore, MD

16 Factors associated with history of drug and psychiatric treatment among active heroin users
J. J. Atchison, J. D. Jones, S. D. Comer, Psychiatry, Columbia University and NYSPI, New York, NY, 2Psychology, City College of New York, New York, NY

17 The impact of co-morbid Borderline Personality Disorder and Substance Use Disorder on HPA axis reactivity to social stressors
R. Browne, E. Fertuck, B. Stanley, The City College of New York (CUNY), Jamaica, NY, 2New York State Psychiatric Institute, New York, NY
18 Gender influence on comorbidity and clinical features of cocaine-dependent patients
C. Roncero1,2, C. Daigre1,2, L. Grau-López1,2,3, E. Ros-Cucurull1,2,3, L. Rodriguez-Cintas1,2,3, C. Barral1,2,3, N. Martinez-Luna1,2,3, J. Pérez-Pazos1,2,3, A. Egido1,2, M. Prat1,2,3, J. Gonzalez4, A. Alfonso5, J. Alvarós1,2, N. Tarifa1,2, M. Casas2,3, 1Outpatient Drug Clinic, ASPB, Barcelona, Spain, 2Psychiatry, Hospital Vall Hebron, Barcelona, Spain, 3Psychiatry, Universidad Autónoma de Barcelona, Barcelona, Spain, 4Psychiatry, Universidad Nacional de asunción, Asunción, Paraguay, 5Psychiatry, Centro de Investigaciones del SNC, Bogota, Colombia

19 Comorbidity and functioning of substance-dependent women with sexual abuse history in the Stage II Women’s Recovery Group therapy trial
D. E. Sugarman1,2, B. Iles2, S. F. Greenfield1,2, 1Harvard Medical School/McLean Hospital, Belmont, MA, 2Division of Alcohol and Drug Abuse; Division of Women’s Mental Health, McLean Hospital, Belmont, MA

20 Shared and distinct neural mechanisms of inhibitory control in individuals with a history of a substance use disorder and depression
N. A. Crane1, L. Gabriel1, K. K. Meyers2, A. L. Weldon1, M. T. Kassel1, R. J. Mermelstein1, J. Zubieta2, S. A. Langenecker1, 1UIC, Chicago, IL, 2UM, Ann Arbor, MI

21 Patterns of behavioral health services provided in a 2012 national sample of U.S. outpatient substance use disorder treatment facilities: Implications for the treatment of co-occurring disorders
P. M. Mauro, C. M. Furr-Holden, R. Mojtabai, Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

22 Applying SBIRT to new settings: Preliminary findings of substance use disorder risk in community mental health settings
S. E. Spear2, M. Karno3, S. Glasner-Edwards3, R. Rawson3, R. Saiz1, B. Domínguez3, 1Community Health Sciences, Boston University and Boston Medical Center, Boston, MA, 2Health Sciences, California State University, Northridge, Northridge, CA, 3Psychiatry, UCLA Integrated Substance Abuse Programs, Los Angeles, CA

23 Social support, cannabis misuse, and post-deployment depression in returning veterans
M. B. Benz1, J. Metrik1,2, B. Borsari1,2, 1Behavioral and Social Sciences, Brown University, Providence, RI, 2Providence VA Medical Center, Providence, RI

24 Black-white disparities in risk for cannabis use and problems in women: The role of early tobacco use, trauma type and psychiatric pathology
K. B. Werner1, V. V. McCutcheon2, C. E. Sartor3, E. C. Nelson2, A. C. Heath2, K. K. Bucholz2, 1Social Work, Washington University (WU), St. Louis, MO, 2Psychiatry, WU School of Medicine, St. Louis, MO, 3Psychiatry, Yale School of Medicine, West Haven, CT

25 The impact of nicotine dose assignment on affect and depression during extended exposure to experimental Spectrum cigarettes: Findings from CENIC Project 1 Study 1
L. R. Pacek3, R. Vandrey2, J. W. Tidey1, D. J. Drobes5, J. Koopmeiners6, A. Umbricht4, D. Hatsukami7, E. Donny8, 1Center for Alcohol & Addictions Studies, Brown University, Providence, RI, 2Johns Hopkins University, Baltimore, MD, 3Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, 4Johns Hopkins University School of Medicine, Baltimore, MD, 5Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, 6Division of Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN, 7Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, 8Department of Psychology, University of Pittsburgh, Pittsburgh, PA
26 Dimensional and categorical phenotypes using Tobacco Use Disorder criteria: Investigating socio-demographic, psychiatric and clinical correlates
J. M. Castaldelli-Maia\(^1,2\), L. H. Andrade\(^1\), A. Andrade\(^1,2\), S. S. Martins\(^3\), \(^1\)Department of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil, \(^2\)Department of Neuroscience, Fundação do ABC Medical School, Santo André, Brazil, \(^3\)Epidemiology, Columbia University, New York City, NY

27 Cigarette smoking and the onset and persistence of panic attacks during mid-adulthood in the United States: 1994-2005
J. Bakhshaie\(^2\), M. J. Zvolensky\(^2\), R. Goodwin\(^1\), \(^1\)Queens College, City University of New York, Flushing, NY, \(^2\)Psychology, University of Houston, Houston, TX

ADOLESCENT II
28 The relationship between risky substance use and friends’ use of nicotine, alcohol, and other drugs in an adolescent sample
S. M. Kelly\(^1\), K. O’Grady\(^2\), J. Gryczynski\(^1\), S. G. Mitchell\(^1\), A. Kirk\(^3\), R. P. Schwartz\(^1\), \(^1\)Friends Research Institute, Baltimore, MD, \(^2\)Univ. of Maryland, College Park, MD, \(^3\)Total Health Care, Baltimore, MD

29 Transition from first substance use to crack-cocaine: Predictors of faster addiction progression, and clinical characteristics in crack-cocaine adolescents users
T. G. Pianca\(^2\), R. L. Rosa\(^3\), A. P. Begnis\(^4\), P. B. Ferronatto\(^5\), M. Jensen\(^4\), F. P. Pechansky\(^1\), L. A. Rohde\(^2\), C. Szobot\(^2\), \(^1\)Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRRGS, Porto Alegre, Brazil, \(^2\)Child & Adolescent Psychiatry Service, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, \(^3\)Hospital Psiquiátrico São Pedro, Porto Alegre, Brazil, \(^4\)ULBRA, Canoas, Brazil, \(^5\)Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

30 Alcohol and tobacco use among Brazilian high school students: The role of psychiatric symptomatology
T. M. Fidalgo\(^2\), Z. M. Sanchez\(^3\), S. Caetano\(^2\), E. Carlini\(^3\), S. S. Martins\(^1\), \(^1\)Epidemiology, Columbia University, New York City, NY, \(^2\)Psychiatry, Federal University of Sao Paulo, Santos, Brazil, \(^3\)Preventive Medicine, Universidade Federal de Sao Paulo, Sao Paulo, Brazil

31 Association of alcohol use with drug use and weapon carrying among Thai adolescents
O. Saiphoklang\(^1\), K. Wongboonsin\(^1\), P. Wongboonsin\(^1\), U. Perngparn\(^3\), L. Cottler\(^2\), \(^1\)College of Population Studies, Chulalongkorn University, Bangkok, Thailand, Patumwan, Thailand, \(^3\)Epidemiology, University of Florida, Gainesville, FL, \(^2\)College of Public Health Sciences, Chulalongkorn University, Patumwan, Thailand

32 Effectiveness of suicide prevention programs with high-risk adolescent alcohol users
S. Fernández-Artamendi\(^2\), S. Al-Halabi\(^2\), P. Burón\(^2\), E. Díaz-Mesa\(^2\), M. Garrido\(^2\), G. Galván\(^2\), J. Ranceño\(^2\), R. Secades-Villa\(^1\), P. García-Portilla\(^2\), P. Sáiz\(^2\), J. Bobes\(^2\), \(^1\)Addictive Behaviors Research Group. Department of Psychology, University of Oviedo, Oviedo, Spain, \(^2\)Department of Psychiatry - University of Oviedo, Biomedical Networking Research Centre for Mental Health (CIBERSAM), Oviedo, Spain

33 A prospective study of alcohol advertisement on alcohol experiences among adolescents in Taiwan
H. Huang\(^1\), K. Chen\(^1\), F. Tseng\(^1\), W. Chen\(^2\), C. Chen\(^1,3\), \(^1\)Institute of Public Health, National Yang-Ming University, Taipei, Taiwan, \(^2\)College of Public Health, National Taiwan University, Taipei, Taiwan, \(^3\)Center for Neuropsychiatric Research, National Health Research Institutes, ZuNan, Taiwan

34 Reducing underage drinking through comprehensive community interventions: The Strategic Prevention Framework
K. D. Anderson-Carpenter, UCLA Integrated Substance Abuse Programs, Los Angeles, CA
35 Underage drinking diversion: Characterizing risk with latent class analysis
N. Mendoza, E. Anthony, D. Row-Sepowitz, Arizona State University, Phoenix, AZ

36 Adolescent substance use: Latent class and transition analysis
J. R. Temple, H. Choi, M. T. Schulte, M. S. Ahmed, T. Nanovskaya, UCLA Integrated Substance Abuse Programs, Los Angeles, CA, Ob/Gyn, UTMB Health, Galveston, TX, OB/GYN Maternal Fetal Medicine, University of Texas Medical Branch, Galveston, TX

37 Daily patterns of substance use and sexual behavior among urban adolescents and emerging adults
E. E. Bonar, M. Walton, E. Austic, F. Blow, B. M. Booth, A. Buu, R. M. Cunningham, Univ Michigan, Ann Arbor, MI, Psychiatry, Univ. Ark Med Sciences, Little Rock, AR, Psychiatry, Building 16, University of Michigan; North Campus Research Complex, Ann Arbor, MI, Indiana University, Bloomington, IN

38 Gender differences in the longitudinal development of normative beliefs for tobacco, alcohol and marijuana use among middle and high school students

39 A gender-stratified analysis of adolescent substance use on violence trajectories
J. Lim, UCLA Integrated Substance Abuse Programs, Los Angeles, CA

40 Role of gender in age of initiation of nonmedical use of prescription drugs among youth 10 to 18 years
S. O. Lasopa, C. W. Striley, L. Cottler, Epidemiology, University of Florida, Gainesville, FL

41 Trajectories of nonmedical use of prescription opioids in adolescents in primary care
L. A. Lin, M. Walton, F. Blow, Univ Michigan, Ann Arbor, MI, Department of Psychiatry, University of Michigan, Ann Arbor, MI

42 Prevalence of nonmedical use of prescription opioids among adolescents in substance use treatment
A. Al-Tayyib, P. Riggs, S. Mikulich-Gilbertson, C. Hopfer, Denver Public Health, CO, University of Colorado School of Medicine, Aurora, CO

43 Working memory predicts outcome for youth opioid addiction treatment
H. T. Vo, M. J. Fishman, G. Barnett, Research, Maryland Treatment Center, Baltimore, MD, Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD

44 Exploring the factor structure of a recovery assessment measure among substance-abusing young people
S. B. Douglas, M. Hernandez, R. Gonzales-Castaneda, C. Yu, Psychology, Azusa Pacific University, CA, Integrated Substance Abuse Programs, Los Angeles, CA

45 Randomized, controlled trial of CRAFT for parents of treatment-resistant adolescents and young adults: Interim results

46 United States national estimates of parenting level and risk of newly incident drug use: 2002-2013
H. H. Yeh, J. C. Anthony, R. Seedall, Epidemiology, Michigan State University, East Lansing, MI, Dept of Family, Consumer, & Human Development, Utah State University, Logan, UT
47 Sequences of substance use initiation among adolescent nonmedical users of prescription opioids and stimulants
   E. A. Austic, S. E. McCabe, Q. Epstein-Ngo, P. T. Veliz, S. A. Stoddard, C. Boyd, University of Michigan, Ann Arbor, MI

48 Do private practitioners provide quality care to adolescents with substance abuse disorders?
   K. Meyers¹, J. Cacciola¹, S. Ward¹, E. Bresani¹, K. C. Kirby¹,², ¹Treatment Research Institute, Philadelphia, PA, ²Psychiatry, University of Pennsylvania, Philadelphia, PA

HIV II / HCV

49 Compulsive sexual behavior, substance abuse, and sexual risk-taking among emerging adult gay and bisexual men in New York City: The P18 Cohort Study
   E. D. Storholmi, D. D. Satre¹, F. Kapadia², P. N. Halkitis², ¹Psychiatry, University of California, San Francisco, San Francisco, CA, ²New York University, New York, NY

50 Risky sexual behavior among OEF/OIF veterans with and without recent substance use
   M. Rosen, A. C. Black, Psychiatry, Yale University, West Haven, CT

51 Conflict, substance use and HIV
   B. T. Kerridge, D. S. Hasin, Epidemiology, Columbia University, Gaithersburg, MD

52 Attacks on PWIDs' dignity: Associations with behaviors

53 The perceived stigma of substance abuse scale: Reliability and validity with substance-using people living with HIV
   K. Stringer¹, J. E. Schumacher², J. M. Turan³, M. Mugavero⁴, M. C. Kempf⁵, E. Baker¹, ¹Sociology, University of Alabama at Birmingham, Hoover, AL, ²Dept of Medicine/Div of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Health Care Organization and Policy, University of Alabama at Birmingham, Birmingham, AL, ⁴School of Medicine/Div. of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, ⁵UAB School of Nursing/ Center for Nursing Research, University of Alabama at Birmingham, Birmingham, AL

54 Substance use disorders treatment history among hospitalized HIV-infected substance users in 11 U.S. cities
   J. A. Frimpong², L. R. Metsch², R. Duan³, D. F. Feaster³, K. Shiu², T. Matheson⁷, E. DeMicco⁷, J. Sorensen¹, R. Walker⁸, M. Drainoni⁴, S. Gaskin⁶, M. Stitzer⁵, E. Farber¹⁰, C. del Rio¹⁰, ¹University of California, San Francisco, San Francisco, CA, ²Columbia University, New York, NY, ³University of Miami, Miami, FL, ⁴Boston University, Boston, MA, ⁵Johns Hopkins University, Baltimore, MD, ⁶National Institute of Drug Abuse, Bethesda, MD, ⁷San Francisco Department of Public Health, San Francisco, CA, ⁸UT Southwestern Medical Center, Dallas, TX, ⁹University of Alabama, Tuscaloosa, AL, ¹⁰Emory University, Atlanta, GA

55 HealthCall: Technology use to reduce non-injection drug use in HIV primary care
   E. Aharonovich², D. S. Hasin¹, M. Stohl³, ¹Epidemiology, Columbia University, New York, NY, ²Psychiatry, Columbia University Medical Center, New York, NY, ³Psychiatry, New York State Psychiatric Institute, New York, NY

56 An mHealth application for increasing HIV and hepatitis knowledge in waitlisted opioid abusers
57 **Acceptability of a mobile-phone-based hepatitis C intervention**  
J. A. Levine¹, S. Cohen¹, P. Harkin², J. Guydish¹, J. Sorensen¹, C. L. Masson¹, ¹University of California, San Francisco, CA, ²GLIDE Health Services, San Francisco, CA

58 **A 3-year follow-up of HCV infection in opioid use disorder patients in treatment**  
C. Duburque², V. Canva³, M. Auriacombe¹, P. Djomboue², B. Hernout³, D. Lucidarme², J. Harbonnier³, ¹Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, ²CH Saint-Philibert, Lomme, Lomme, France, ³CHRU, Lille, Lille, France, ⁴Réseau Hépatite Nord-Pas de Calais, Lille, France, ⁵Centre Boris Vian, Lille, Lille, France

59 **Risks associated with nonmedical prescription opioid use: Transition to heroin use and drug injection, overdose and hepatitis C**  

60 **Hepatitis C and associated risk behaviors in people who inject drugs**  
K. Butler, L. Burns, National Drug and Alcohol Research Centre, UNSW Australia, Sydney, NSW, Australia

61 **Opioid use trajectories, injection drug use and HCV risk among young adults from the former Soviet Union in NYC**  
H. Guarino¹, L. A. Marsch³, S. Deren², S. L. Straussner⁴, A. Teper¹, ¹National Development & Research Institutes, New York, NY, ²College of Nursing, New York University, New York, NY, ³Psychiatry, Dartmouth College, Hanover, NH, ⁴Silver School of Social Work, New York University, New York, NY

62 **Diagnosis of hepatitis C virus infection after entry to opioid substitution therapy**  
S. Larney³, J. Grebely³, M. Falster⁴, A. Swart⁶, J. Amin⁴, L. Degenhardt², L. Burns¹, C. Vajdic⁶, ¹NDARC, UNSW, Sydney, NSW, Australia, ²National Drug and Alcohol Research Centre, University of New South Wales, Randwick, NSW, Australia, ³The Kirby Institute, University of New South Wales, Sydney, NSW, Australia, ⁴Centre for Health Research, University of Western Sydney, Sydney, NSW, Australia, ⁵Prince of Wales Clinical School, University of NSW, Sydney, NSW, Australia

**OPIOID TREATMENT**

63 **The cost-effectiveness of opioid agonist treatment in California’s publicly funded drug treatment facilities**  
E. Krebs¹, L. Li², J. Min¹, E. Evans², R. Rawson², Y. Hser², B. Nosyk¹, ¹BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, ²UCLA Integrated Substance Abuse Programs, Los Angeles, CA

64 **Challenges to opioid treatment programs after Hurricane Sandy: Impact, preparedness, and recovery**  
H. Matusow¹, E. Benoit², A. Rosenblum¹, ¹Institute for Treatment and Services Research, National Development and Research Institutes, Inc., New York, NY, ²Institute for Special Populations Research, NDRI, New York, NY

65 **Counselors’ views of providing patient-centered methadone treatment in a clinical trial**  
S. G. Mitchell¹, L. Monico¹, E. Lertch¹, J. Gryczynski¹, S. M. Kelly¹, K. E. O’Grady², J. H. Jaffe¹, R. P. Schwartz¹, ¹Friends Research Institute, Baltimore, MD, ²University of Maryland, College Park, MD
66 Health service use in a randomized clinical trial comparing three methods of emergency department interventions for opioid dependence
S. Busch, K. Hawk, D. Fiellin, P. O’Connor, M. Chawarski, P. Owens, M. Pantalon, S. Bernstein, G. D’Onofrio, Yale University, New Haven, CT

67 A randomized clinical trial of emergency department initiated treatment for opioid dependence: Two- and six-month outcomes
G. D’Onofrio, P. O’Connor, M. Pantalon, M. Chawarski, S. Busch, P. Owens, S. Bernstein, D. Fiellin, Yale University, New Haven, CT

68 Early mortality after entering a methadone treatment program in Badalona, Spain
I. Rivas1, A. Sanvisens2, E. Faure1, D. Fuster2, M. Trinidad1, M. Rubio1, R. Muga2, 1Municipal Center for Substance Abuse Treatment, Badalona, Spain, 2Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain, Badalona, Spain

69 Predictors of induction onto XR-NTX in patients with opioid use disorder
P. Mannelli, K. Peindl, L. Wu, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC

70 Intranasal buprenorphine alone and in combination with naloxone: Reinforcing efficacy and abuse liability in physically dependent opioid abusers
S. L. Walsh2, P. A. Nuzzo2, C. Elayi1,2, M. R. Lofwall2, 1University of Kentucky, Lexington, KY, 2Department of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, 3Internal Medicine, University of Kentucky, Lexington, KY

71 Associations between buprenorphine treatment trajectories and clinical outcomes in a large Medicaid program
W. Lo-Ciganic1,3, W. F. Gellad1,3, A. J. Gordon1,3, G. Cochran3, J. M. Donohue3, 1University of Arizona, Tucson, AZ, 2VA Pittsburgh Healthcare System, Pittsburgh, PA, 3University of Pittsburgh, Pittsburgh, PA

72 Determining menstrual phase in substance use research: A review with recommendations
A. M. Allen1, A. McRae-Clark2, M. E. Saladin1, K. M. Gray2, C. Wetherington4, S. A. McKee6, S. Allen5, 1Health Sciences and Research, Med. Univ. of SC, Charleston, SC, 2Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 3Family Medicine & Community Health, University of Minnesota, Minneapolis, MN, 4NIDA, Bethesda, MD, 5University of Minnesota, Minneapolis, MN, 6Psychiatry, Yale, New Haven, CT

73 Interim buprenorphine treatment: Leveraging technology to bridge waitlist delays
S. C. Sigmon1, A. C. Meyer1, B. Hruska1, T. Ochalek1, S. H. Heil1, S. T. Higgins1, R. P. Schwartz2, 1Psychiatry, University of Vermont, Burlington, VT, 2Friends Research Institute, Baltimore, MD

74 Impaired cognitive control in longer-term abstinent buprenorphine-assisted treatment opioid-dependent patients
G. DiGirolamo1,2, G. Gonzalez1, C. Hynes2, D. Smelson1, M. Romero-Gonzalez1, 1Division of Addiction Psychiatry, University of Massachusetts, Worcester, MA, 2Psychology, College of the Holy Cross, Worcester, MA

75 Drug-free period from non-opioids before start of the treatment with methadone or buprenorphine for heroin-dependence improves efficacy
O. M. Hoffmann1, T. Ljungberg2, F. Frisell1, 1Addiction Center, Psychiatric Clinic Eskilstuna, Stockholm, Sweden, 2Center for Clinical Research, Psychiatric Clinic, Nyköping, Sweden
Physician integration in formerly “drug-free” outpatient programs providing buprenorphine
L. Monico1, S. G. Mitchell1, J. Gryczynski1, R. P. Schwartz1, Y. Olsen2, K. E. O’Grady3,
J. H. Jaffe1, 1Friends Research Institute, Baltimore, MD, 2IBR Reach, Baltimore, MD,
3University of Maryland, College Park, MD

Testing the VACS Index as a measure of health outcomes associated with abstinence among
patients receiving opioid agonist treatment
D. A. Fiellin1, K. McGinnis2, J. Tate1, A. Justice1, 1Yale University, New Haven, CT,
2Univ. of Pittsburgh, Pittsburgh, PA

Health state transitions among prescribed opiate patients accessing pharmacological treatment
for opioid dependence in California, 2006 - 2010
L. Li1, E. Evans1, J. Min2, L. Liu3, D. Y. Huang1, D. Urada1, E. Wood2,5, Y. Hser1, B. Nosyk2,4,
1UCLA Integrated Substance Abuse Programs, Los Angeles, CA, 2BC Centre for Excellence
in HIV/AIDS, Vancouver, BC, Canada, 3Northwestern University Feinberg School of
Medicine, Chicago, IL, 4Simon Fraser University, Faculty of Health Sciences, Vancouver, BC,
Canada, 5Division of AIDS, Faculty of Medicine, University of British Columbia,
Vancouver, BC, Canada

Estimation of life expectancy and the expected years of life loss among heroin users in the era of
opiate substitution treatment in Taiwan
K. Chang1,2, C. Chen3, J. Wang2, T. Lu2, 1General Psychiatry, Jianan Psychiatric Center,
Ministry of Health & Welfare, Tainan, Taiwan, Tainan, Taiwan, 2Department of Public
Health, National Cheng Kung University, Tainan, Taiwan, Tainan, Taiwan, 3Institute of Public
Health & Department of Public Health, National Yang-Ming University, Taipei, Taiwan

Does drug of choice matter in mHealth delivery? Comparison of methamphetamine- and heroin-
dependent patients
M. T. Schulte1, Y. Hser2, 1UCLA Integrated Substance Abuse Programs, Los Angeles, CA,
2Department of Psychiatry & Behavioral Sciences, UCLA, Los Angeles, CA

Evaluating the effectiveness of telehealth-delivered opioid agonist therapy across Ontario,
Canada
J. K. Eibl1, J. Daiter2, M. Varenbut2, D. Pellegrini1, D. C. Marsh1, 1Northern Ontario School of
Medicine, Sudbury, ON, Canada, 2University of Toronto, Toronto, ON, Canada

Pilot evaluation of the “Tailored telephone intervention delivered by peers to prevent recurring
opioid overdoses”
T. Winhusen, J. Theobald, D. Lewis, C. M. Wilder, M. Lyons, University of Cincinnati,
Cincinnati, OH

Constrained choices: The care-decision-making experience for pregnant opioid-dependent
women
H. G. Howard, Social Work, Women & Infants Hospital, Lincoln, RI

Postpartum contraceptive behavior of opioid-maintained pregnant women
H. S. Melbostad1,2, S. H. Heil1,3,2, 1Vermont Center on Behavior and Health, University of
Vermont, Burlington, VT, 3Psychological Sciences, University of Vermont, Burlington, VT,
A SMART design: Response to reinforcement-based treatment intensity among pregnant, drug-dependent women
H. Fitzsimons1, M. Tuten2, K. O’Grady3, M. S. Chisolm1, H. E. Jones4, 1Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, 2School of Social Work, University of Maryland Baltimore, Baltimore, MD, 3Psychology, University of Maryland, College Park, MD, 4OB/GYN, UNC Chapel Hill, Chapel Hill, NC

Correspondence between self-reported and biochemical measures of smoking in opioid-dependent pregnant women
C. A. Arger, S. T. Higgins, S. H. Heil, Vermont Center on Behavior and Health, Burlington, VT

Effects of prenatal cocaine and nicotine on maternal white matter integrity in early postpartum
M. Leming, M. Styner, K. M. Grewen, Psychiatry, UNC, Chapel Hill, NC

Characteristics of smoking pregnant women in Guadalajara, Mexico
O. Campollo1, F. Hernandez-Mora2, E. Angulo-C3, A. Guzman2, A. Munguia1, M. Garcia1, J. K. Cunningham4, 1Center of Studies on Alcohol and Addictions, University of Guadalajara, Guadalajara, Mexico, 2Obstetrics and Gynecology, AHCG, Guadalajara, Mexico, 3Neonatology, AHCG, Gdl., Mexico, 4Family and Community Medicine, University of Arizona, Tucson, AZ

Pregnancy, tobacco use, and access to health care
Q. Brown1, K. Keyes1, D. S. Hasin1, O. Ravenell2, D. S. Fink1, S. S. Martins1, 1Epidemiology, Columbia University, New York, NY, 2Kraemer Women’s Care, Columbia, SC

Smoking and mental health from first prenatal visit to postpartum
V. H. Coleman-Cowger1,2, B. Koszowski1, K. Mark2, M. Terplan3, 1Health & Analytics, Battelle, Baltimore, MD, 2Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland Baltimore, Maryland, 3Behavioral Health System Baltimore, Baltimore, MD

Perinatal attentional retraining intervention for smoking - A pilot study
D. W. Foster1, A. J. Waters2, A. Forray1, 1Psychiatry, Yale School of Medicine, New Haven, CT, 2Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, MD

Psychiatric symptoms among pregnant and newly postpartum women receiving financial incentives for smoking cessation
I. A. Zvorsky1, A. A. Lopez1, T. J. White1, J. M. Skelly2, S. T. Higgins1, 1Psychiatry, University of Vermont, Burlington, VT, 2Biostatistics, University of Vermont, Burlington, VT, 3Psychology, Virginia Commonwealth University, Richmond, VA

A comparison of meconium screening outcomes as an indicator of the impact of state-level relaxation of marijuana policy
J. T. Jones, A. Baldwin, I. Shu, Lab, United States Drug Testing Laboratories, Des Plaines, IL

Patient pre-treatment expectations and substance use treatment outcomes
K. Serafini2, S. Decker2,3, B. D. Kiluk1, L. Anez2, M. Paris2, T. Frankforter2, K. M. Carroll2, 1Psychiatry, Yale School of Medicine, West Haven, CT, 2Department of Psychiatry, Yale University School of Medicine, New Haven, CT, 3West Haven VA, West Haven, CT
95 A longitudinal mediational study of the stability of alexithymia among alcohol treatment seekers
F. A. Thorberg\textsuperscript{1,3}, R. M. Young\textsuperscript{4}, K. Sullivan\textsuperscript{4}, M. Lyvers\textsuperscript{2}, J. Connor\textsuperscript{5}, E. P. Noble\textsuperscript{7},
E. London\textsuperscript{7}, R. Tyssen\textsuperscript{3}, G. Feeney\textsuperscript{6}, \textsuperscript{1}Natnl Centre Dual Diagnosis, Inlandet Hosp Trust,
Hamar, Norway, \textsuperscript{2}Bond University, Gold Coast, QLD, Australia, \textsuperscript{3}University of Oslo, Oslo, Norway,
\textsuperscript{4}Queensland University of Technology, Brisbane, QLD, Australia, \textsuperscript{5}University of Queensland, Brisbane, QLD, Australia, \textsuperscript{6}Princess Alexandra Hospital, Brisbane, QLD, Australia, \textsuperscript{7}University of California Los Angeles, Los Angeles, CA

96 Alcohol screening and brief intervention among opioid agonist patients in a primary care and
opioid treatment program
J. Klimas\textsuperscript{1}, J. Muench\textsuperscript{1}, K. Wiest\textsuperscript{1}, R. Croff\textsuperscript{1}, T. R. Rieckmann\textsuperscript{2}, D. McCarty\textsuperscript{3}, \textsuperscript{1}BC Centre for
Excellence in HIV/AIDS, Addiction & Urban Health Research Initiative, Vancouver, BC, Canada, \textsuperscript{2}Public Health, OHSU, Portland, OR, \textsuperscript{3}CB 669 PHPM, Oregon Health & Science
Univ, Portland, OR, \textsuperscript{4}Public Health & Preventive Medicine, Oregon Health & Science
University, Portland, OR, \textsuperscript{5}Coda, Portland, OR

97 Heterogeneity of alcohol use treatment services: A latent class analysis
R. J. Evans-Polce, M. S. Schuler, The Methodology Center and Prevention Research Center,
Pennsylvania State University, State College, PA

98 Markers of inflammation and mortality in a cohort of alcohol-dependent patients
D. Fuster\textsuperscript{1}, A. Sanvisens\textsuperscript{1}, F. Bolao\textsuperscript{2}, P. Zuluaga\textsuperscript{1}, I. Rivas\textsuperscript{3}, J. Tor\textsuperscript{1}, R. Muga\textsuperscript{1}, \textsuperscript{1}Internal
Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, \textsuperscript{2}Internal Medicine,
Hospital Bellvitge, L'Hospitalet de Llobregat, Spain, \textsuperscript{3}IMSP Badalona, Municipal Centre for
Substance Abuse Treatment (Centro Delta), Badalona, Spain

99 Exposure to ethanol in Brazilian gasoline station attendants
R. P. Limberger\textsuperscript{4}, B. T. Borille\textsuperscript{4}, T. R. Fiorentin\textsuperscript{4}, B. C. Coppe\textsuperscript{4}, E. Comiran\textsuperscript{4}, A. B. Jacques\textsuperscript{4},
T. R. Sousa\textsuperscript{2}, G. Pasa\textsuperscript{1}, F. H. Kessler\textsuperscript{3}, F. P. Pechansky\textsuperscript{3}, S. M. Castro\textsuperscript{4}, \textsuperscript{1}Center for Drug
and Alcohol Research - Federal University of Rio Grande do Sul - Hospital de Clinicas de
Porto Alegre, Porto Alegre, Brazil, \textsuperscript{2}Center for Drug and Alcohol Research, CPAD - Federal
University of Rio Grande do Sul - UFRGS, Porto Alegre, Brazil, \textsuperscript{3}Psychiatry, Center for Drug
and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, \textsuperscript{4}Pharmacy, Federal University of
Rio Grande do Sul, Porto Alegre, Brazil

100 Online feasibility study about HIV-negative male couples substance use with weekly ecological
momentary diary assessments
J. W. Mitchell\textsuperscript{1}, F. Davis\textsuperscript{1}, Y. Pan\textsuperscript{2}, D. J. Feaster\textsuperscript{1}, \textsuperscript{1}Public Health Sciences, University
of Miami Miller School of Medicine, Miami, FL, \textsuperscript{2}University of Miami Miller School of
Medicine, Miami, FL

101 Personality and gambling characteristics of problem gamblers with and without alcohol
dependence
J. J. Lister\textsuperscript{1}, A. Milosevic\textsuperscript{2}, D. M. Ledgerwood\textsuperscript{1}, \textsuperscript{1}Psychiatry, Wayne State School of Medicine,
Detroit, MI, \textsuperscript{2}Psychology, University of Windsor, Windsor, ON, Canada

102 The moderating role of negative urgency in the relation between distress intolerance and
alcohol drinking motives
M. Yang\textsuperscript{1}, T. M. Leyro\textsuperscript{2}, S. Moshier\textsuperscript{3}, K. Szuhany\textsuperscript{3}, M. W. Otto\textsuperscript{3}, \textsuperscript{1}Department of Psychology, Rutgers University, Highland Park, NJ, \textsuperscript{2}Department of Psychology, Rutgers University,
Piscataway, NJ, \textsuperscript{3}Department of Psychological and Brain Sciences, Boston University,
Boston, MA
103 Exploring substance group differences on the simultaneous alcohol and tobacco expectancy questionnaire in a young adult community
   R. S. Trim\textsuperscript{1,2}, N. Doran\textsuperscript{1,2}, C. Barnet\textsuperscript{1}, \textsuperscript{1}Psychiatry, UC-San Diego, San Diego, CA, \textsuperscript{2}VA San Diego Healthcare System, San Diego, CA

104 Prevalence, correlates, and substance use and psychiatric predictors of regularly drinking alcohol before sex among adults in the United States
   N. R. Eaton\textsuperscript{3}, R. G. Thompson\textsuperscript{2}, M. Hu\textsuperscript{1}, D. S. Hasin\textsuperscript{1}, \textsuperscript{1}Epidemiology, Columbia University, New York, NY, \textsuperscript{2}Psychiatry, Columbia University, New York, NY, \textsuperscript{3}Psychology, Stony Brook University, Stony Brook, NY, \textsuperscript{4}Columbia University, New York, NY

105 Geographic distance to nationwide professional treatment for alcohol use disorder in Mexico
   C. Rafful\textsuperscript{3}, R. Orozco\textsuperscript{1}, S. Strathdee\textsuperscript{2}, M. E. Medina-Mora\textsuperscript{4}, \textsuperscript{1}National Institute of Psychiatry, Mexico City, Mexico, \textsuperscript{2}Univ of California San Diego, San Diego, CA, \textsuperscript{3}Global Public Health, University of California San Diego, San Diego State University, San Diego, CA, \textsuperscript{4}National Institute of Psychiatry, Mexico City, Mexico

POLYDRUG ABUSE

106 Comparison of DWI prevalences among fatal, non-fatal and roadside samples of Brazilian drivers
   F. P. Pechansky\textsuperscript{1}, L. Von Diemen\textsuperscript{1}, A. O. Sordi\textsuperscript{2}, \textsuperscript{1}Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, \textsuperscript{2}Department of Psychiatry, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil

107 Different patterns of drug use among crack and powder cocaine users in Brazil
   M. P. Pachado\textsuperscript{1}, D. S. Souza\textsuperscript{3}, J. N. Scherer\textsuperscript{4}, S. Halpern\textsuperscript{1}, L. Von Diemen\textsuperscript{2}, F. P. Pechansky\textsuperscript{2}, F. Kessler\textsuperscript{2}, \textsuperscript{1}Psychiatric Dept, Center for Drug and Alcohol Research, Porto Alegre, Brazil, \textsuperscript{2}Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, \textsuperscript{3}Psychiatry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, \textsuperscript{4}Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

108 Inhibitory processing in relation to age of first substance use and age of first regular substance use
   A. L. Paz, J. Conniff, B. Gonzalez, M. Rosselli, Florida Atlantic University, Miami, FL

109 Evaluation of cognitive functioning of individuals with co-occurring opiate and amphetamine-type stimulants use disorders in Malaysia
   W. Chooi\textsuperscript{2}, N. M. Zaharim\textsuperscript{2}, A. Desrosiers\textsuperscript{1}, I. Ahmad\textsuperscript{2}, M. M. Yasin\textsuperscript{2}, S. Z. Syed Jaapar\textsuperscript{2}, R. S. Schottenfeld\textsuperscript{1}, V. B. Kasinather\textsuperscript{2}, M. C. Chawarski\textsuperscript{1}, \textsuperscript{1}Psychiatry, Yale University School of Medicine, New Haven, CT, \textsuperscript{2}Universiti Sains Malaysia, Penang, Malaysia

110 Pilot study of atomoxetine for BUP/NX-maintained patients with co-occurring opioid and ATS use disorder
   R. S. Schottenfeld\textsuperscript{1}, M. C. Chawarski\textsuperscript{1}, M. Sofuoglu\textsuperscript{1}, W. Chooi\textsuperscript{2}, N. M. Zaharim\textsuperscript{2}, M. M. Yasin\textsuperscript{2}, I. Ahmad\textsuperscript{2}, S. Jaapar\textsuperscript{2}, V. B. Kasinather\textsuperscript{2}, \textsuperscript{1}Psychiatry, Yale University, New Haven & West Haven, CT, \textsuperscript{2}Universiti Sains Malaysia, Penang & Kota Bharu, Malaysia

111 Alexithymia level and response to computer-based training in cognitive behavioral therapy among cocaine-dependent methadone-maintained individuals
   K. P. Morie\textsuperscript{1}, C. Nich\textsuperscript{2}, K. Hunkele\textsuperscript{2}, M. N. Potenza\textsuperscript{2}, K. M. Carroll\textsuperscript{2}, \textsuperscript{1}Diagnostic Radiology, Yale University, New Haven, CT, \textsuperscript{2}Psychiatry, Yale University School of Medicine, West Haven, CT
Efficacy of computer and therapist brief interventions for drug users
F. Blow¹, A. S. Bohnert¹, R. Ignacio³, K. Barry³, M. A. Ilgen³, B. M. Booth², R. Cunningham¹,
M. Walton¹, ¹University of Michigan, Ann Arbor, MI, ²Psychiatry, Univ. Ark Med Sciences,
Little Rock, AR, ³Psychiatry, University of Michigan, Ann Arbor, MI

Web-based treatment for substance use disorders: Differential effects by primary substance
G. Cochran¹, M. L. Stitzer², A. Campbell¹, M. Hu⁴, R. Vandrey⁴, E. V. Nunes⁴, ¹Social Work, University of Pittsburgh, Pittsburgh, PA, ²Psychiatry, Johns Hopkins, Baltimore, MD, ³Substance Abuse Division, New York State Psychiatric Institute, New York, NY, ⁴Psychiatry, Columbia University, New York, NY, ⁵Johns Hopkins University, Baltimore, MD

Characterizing nicotine withdrawal in opioid-maintained smokers
J. M. Streck², A. C. Meyer¹, J. Bunn³, S. C. Sigmon¹, ¹Psychiatry, University of Vermont, Burlington, VT, ²Psychology, University of Vermont, Burlington, VT, ³Biostatistics, University of Vermont, Burlington, VT

The longitudinal influence of multiple depressant use on nonfatal overdose among young people who inject drugs
E. Riley², J. A. Hahn², J. L. Evans², A. Briceno², P. J. Davidson¹, P. J. Lum², K. Page³,
¹Medicine, University of California, San Diego, La Jolla, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Epidemiology, University of New Mexico, Albuquerque, NM

Self-reported drug use patterns for drug users presenting in emergency department
G. Sharma¹, M. Bogenschutz², ¹The EMMES Corporation, Rockville, MD, ²University of NM, Albuquerque, NM

What is the impact of "professional subjects" on medication efficacy trials?
D. McCann, NIDA/NIH, Bethesda, MD

Problems of treatment demands related to substance dependency
V. Kirzhanova, E. Koshkina, K. Vyshynskiy, Federal Medical Research Centre for Psychiatry and Addictions, Moscow, Russian Federation

Cautious use of race in analyses to predict retention in substance abuse treatment
A. Duncan¹, R. Ahmed², ¹IMPAQ International, Washington, DC, ²University of Manitoba, Winnipeg, MB, Canada

How do gender and race/ethnicity influence perceived barriers to help-seeking for substance use problems?
C. E. Grella¹, A. Otitiano Verissimo², ¹Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, ²California State University, San Bernardino, San Bernardino, CA

Does urban size and region predict outpatient substance abuse treatment completion?
G. Stahler, J. Mennis, Geography & Urban Studies, Temple University, Philadelphia, PA

Comprehensive women-centered treatment for substance use disorders in Georgia: Initial examination of sex risk
H. E. Jones², I. Kirtadze³, D. Otiashvili³, W. Zule⁴, W. Wechsberg⁴, E. Krupitsky¹, ¹KG Consulting, St. Petersburg, Russian Federation, ²OB/GYN, UNC Chapel Hill, Chapel Hill, NC, ³Addiction Research Center, Union Alternative Georgia, Tbilisi, Georgia, ⁴RTI International, Rtp, NC

Effects of non-pharmacological treatment of substance use in Medicare elderly with prostate cancer
S. Chhatre¹, D. Metzger¹, R. Jayadevappa², ¹Psychiatry, University of Pennsylvania, Philadelphia, PA, ²Medicine, University of Pennsylvania, Philadelphia, PA
124 *Coping strategies as a mediator of Internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial*
A. Levesque, A. Campbell, M. Pavlicova, M. Hu, E. V. Nunes, Mount Sinai Roosevelt Hospital, New York, NY, New York State Psychiatric Institute, New York, NY, Department of Psychiatry, Columbia University Medical Center, New York, NY, Department of Biostatistic, Mailman School of Public Health, New York, NY, Columbia University, New York, NY

125 *Development of a prospective memory training program for substance use treatment*
M. M. Sweeney, O. Rass, P. S. Johnson, M. W. Johnson, Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD

126 *A behavioral economic demand model modification to improve versatility*

127 *Fidelity monitoring model for an MI-based brief intervention*
A. A. Forcehimes, M. Bogenschutz, G. Sharma, K. Wilson, T. Moyers, NIDA Data & Statistics Center, The EMMES Corporation, Rockville, MD, CASAA, University of New Mexico, Albuquerque, NM, Psychiatry, University of New Mexico, Albuquerque, NM

128 *Expanded brief intervention in primary care results in reduced self-reported substance use at six-month follow-up: Preliminary results*
R. B. Medvin, A. C. Brooks, C. M. Carpenedo, J. Lauby, D. Metzger, E. Byrne, K. Favor, K. C. Kirby, Treatment Research Institute, Philadelphia, PA, Public Health Management Corporation, Philadelphia, PA, University of Pennsylvania, Philadelphia, PA, Lincoln University, Lincoln University, PA

129 *Evidence-based multimedia 12-Step facilitation toolkit durably improves counselor adherence in group counseling with minimal training*

130 *Health-related issues among people who inject drugs in Australia*
J. Stafford, L. Burns, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia

131 *Does screening and brief intervention for drug use in primary care increase receipt of substance use disorder treatment?*
T. W. Kim, J. Bernstein, D. M. Cheng, J. Samet, C. Lloyd-Travaglini, T. Palfai, J. German, R. Saitz, Schools of Medicine and Public Health, Boston University, Boston, MA, Department of Psychology, Boston University, Boston, MA, Boston Medical Center, Boston, MA

132 *Incentives in public addiction treatment systems: Context and effects on access, retention, selection and outcomes*
S. Reif, M. Stewart, C. M. Horgan, B. Mohr, M. Torres, M. T. Davis, D. Hodgkin, G. Ritter, A. Nguyen, Brandeis University, Waltham, MA
LITERATURE REVIEW

133 Screening, brief interventions and referral to treatment for substance use disorders in South African health services: Opportunities and challenges
B. Myers1,2, K. Sorsdahl1, 1Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Tygerberg, South Africa, 2Psychiatry, University of Cape Town, Cape Town, South Africa

134 Contingency management in the treatment of substance use disorders: Trends in the literature
D. R. Davis2,1, A. N. Kurti1, S. T. Higgins1,2, 1Psychiatry, University of Vermont, Burlington, VT, 2Psychology, University of Vermont, Burlington, VT

135 Prescription monitoring programs: Best practice and Canadian program review
B. Sproule, 1Centre for Addiction and Mental Health, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada

136 Current challenges in implementing prescription monitoring programs
S. Sarkar2, B. C. Ginsburg1, M. Pugh2, E. Finley2, D. McGeary2, V. Bebarta2, A. Garcia2, J. S. Potter1, 1Psychiatry and Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 2Psychiatry, UT Health Science Center, San Antonio, TX

137 Assessing aberrant behaviors related to prescription drugs in the patient population: Recent studies, methodologies and findings
B. Setnik3, C. Kornegay4, M. Sokolowska2, C. L. Roland1, P. Geoffroy3, 1Pfizer Inc, Cary, NC, 2Grunenthal, Bedminster, NJ, 3INC Research, Toronto, ON, Canada, 4CDER/OSE/OPE, FDA, Silver Spring, MD

138 More than meets the eye: What visual cortex reactivity to cues may tell us about neural processing in addiction
L. T. Dowdle, T. Naselaris, B. Froeliger, C. A. Hanlon, Medical University of South Carolina, Charleston, SC

139 Reinforcing effects of very low nicotine content cigarettes: A review
T. J. White1,2, R. Redner1,2, S. T. Higgins1,2, 1Vermont Center on Behavior & Health, University of Vermont, Burlington, VT, 2Psychiatry, University of Vermont, Burlington, VT

140 Buprenorphine-assisted treatment of opioid-dependent adolescents: State of the science
J. Borodovsky1, L. A. Marsch1, S. K. Moore2, 1Dartmouth College, Lebanon, NH, 2Capital Health Medical Center, Hopewell, NJ

141 Cocaine use and sexual risk among individuals with a severe mental illness: A narrative review
T. M. Bishop1, S. A. Maisto2, L. Ashrafioun1, 1VA VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY, 2Psychology, Syracuse University, Syracuse, NY

142 N-acetylcysteine for cocaine addiction: A systematic review
M. N. Echevarria, T. M. Fidalgo, T. A. Reis, D. X. Silveira, V. S. Soares, G. R. Capatti, Psychiatry, Federal University of São Paulo, São Paulo, Brazil

143 Poppers: A systematic review
B. Banducci Rahe2,3, T. M. Fidalgo1,2, D. Xavier da Silveira1,2, 1Psychiatry, Federal University of Sao Paulo, Santos, Brazil, 2Proud-Unifesp, Sao Paulo, Brazil, 3Psiquiatria, Faculdade Santa Marcelina, São Paulo, Brazil
Symposium XI
CPDD/INRC Joint Symposium
NOVEL STRATEGIES FOR REDUCING OPIOID ABUSE
Chairs: Sandra Comer and Paul Pentel

2:00 Prospects for serotonin therapeutics in addictive disorders
Kathryn A. Cunningham, University of Texas Medical Branch, Galveston, TX

2:30 Development of vaccines for opioid abuse
Marco Pravetoni, University of Minnesota, Minneapolis, MN

3:00 Assessing the ability of glial inhibitors to alter the abuse liability of opioids using laboratory models in humans
Jermaine D. Jones, Columbia University, New York, NY

3:30 Epidemiology on the impact of opioid abuse-deterrent medications on opioid abuse in the community
Ted Cicero, Washington University, St. Louis, MO

Symposium XII
ENVIRONMENTAL AND SOCIAL INFLUENCES ON DRUG-TAKING:
THE GOOD, THE BAD AND THE UGLY
Chairs: Minda Lynch and Michael T. Bardo

2:00 Differential effects of enrichment on stimulant reward in males and females
Sari Izenwasser, University of Miami Miller School of Medicine, Miami, FL

2:25 Anti-craving effects of environmental enrichment: Generalization to different drugs of abuse
Marcello Solinas, University of Poitiers, Poitiers Cedex, France

2:50 The influence of social learning on drug self-administration
Mark A. Smith, Davidson College, Davidson, NC

3:15 Dyadic social interaction as an alternative reward to cocaine
Gerald Zernig, Medical University of Innsbruck, Innsbruck, ACT, Australia

3:40 DISCUSSANT: The translational puzzle: Fitting the pieces
Michael T. Bardo, University of Kentucky, Lexington, KY

Symposium XIII
CANNABIS USE IN YOUTH: NEUROCOGNITIVE EFFECTS, GENETIC MODERATORS, AND EPIGENETIC FINDINGS
Chair: Krista Lisdahl

2:00 Half baked? Exploring the impact of early onset marijuana use on brain structure and function
Staci A. Gruber, McLean Hospital - CCNC, Belmont, MA

2:25 Endocannabinoid genetics moderate the impact of regular cannabis use on cognition and brain structure in adolescents and emerging adults
Krista Lisdahl, UW-Milwaukee, Milwaukee, WI
Wednesday, June 17, 2015

2:50 Genetic modulators of marijuana's effects on brain morphometry  
Francesca Filbey, University of Texas at Dallas, Dallas, TX

3:15 Methylation patterns in adolescent cannabis use symptoms: A preliminary investigation  
Sarah Feldstein Ewing, University of New Mexico, Albuquerque, NM

3:40 DISCUSSION: Cannabis science: Information needed to inform policy  
Krista Lisdahl, UW-Milwaukee, Milwaukee, WI

---

Oral Communications 13  
McArthur Ballroom 5/6  
2:00 - 4:00 PM

**MULTIPLE ADVERSITIES: COMORBIDITY**

Chairs: Kristen D. Seay and Steven L. Batki

2:00 A comparison of male and female caregivers: Caregiver depression as a mediator in the pathway from caregiver problematic drug use to child internalizing behaviors  
K. D. Seay, College of Social Work, The University of South Carolina, Columbia, SC

2:15 Retention in a methadone maintenance treatment: Impact of comorbidity  
F. Fonseca, C. Castillo, D. Martinez-Sanvisens, P. Rossi, A. Roquer, M. Farre, M. Torrens,  
Human Pharmacology and Neurosciences, IMIM-UAB, Barcelona, Spain,  
Institut de Neuropsiquiatria i Addiccions (INAD), Parc de Salut Mar, Barcelona, Spain,  
IMIM (Institut Hospital del Mar d’Investigacions Mèdiques), Barcelona, Spain, Psychiatry Department, Autonomous University of Barcelona, Barcelona, Spain

2:30 Association between morningness/eveningness, addiction severity and psychiatric disorders among individuals with addictions  
C. Kervran, R. Debrabant, J. Taillard, P. Philip, M. Auriacombe, M. Fatseas,  
Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, Sanpsy CNRS USR 3413, Sleep Research, Bordeaux, France

2:45 Association between drug use and suicidal ideation and attempt among at-risk primary care patients  
L. Ashrafioun, W. R. Pigeon, T. M. Bishop, S. Leong, D. W. Oslin,  
Philadelphia VA, Philadelphia, PA, VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY

3:00 A comparison of attempted suicide rates by methylphenidate exposure in adult and adolescent populations  
E. M. McRae, M. C. Le Lait, N. West, R. C. Dart, RMPDC, Denver, CO

3:15 Borderline personality disorder diagnosis, diagnostic criteria, and criterion count as predictors of regularly drinking alcohol before sex among adults in the United States  
R. G. Thompson, N. R. Eaton, M. Hu, D. S. Hasin,  
Columbia University, New York, NY, Psychiatry, Columbia University, New York, NY, Psychology, Stony Brook University, Stony Brook, NY, Columbia University, New York, NY

3:30 ADHD and substance use disorders: Subtype and gender differences  
H. Hurmic, R. Debrabant, C. Kervran, F. Serre, M. Auriacombe, M. Fatseas, Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France

3:45 Smoking and non-alcohol substance use in veterans with PTSD and alcohol use disorder  
S. L. Batki, D. Pennington, B. Lasher, E. Herbst, E. Schrodek, S. Yohannes,  
J. McDonald, B. Schmeling, T. Wong, UCSF, San Francisco, CA, SFVAMC, San Francisco, CA
**Wednesday, June 17, 2015**

**Late-Breaking Research**  
AZ Biltmore Ballroom  
4:15 - 5:15 PM

**Business Meeting**  
(MEMBERS ONLY)  
AZ Biltmore Ballroom  
5:15 - 6:00 PM

**DINNER AND DANCING**  
BADGES MUST BE WORN FOR ADMISSION  
McArthur Ballroom 1/2  
7:30 - 10:30 PM
Poster Session IV
(Breakfast)
Odd-numbered posters manned first hour;
Even-numbered, second hour

Set-up time begins Wednesday 3:00 PM
Must be removed at 12:00 Noon Thursday

BENZODIAZEPINES

1 Gender effects on zolpidem efficacy and safety  
   T. Roehrs\textsuperscript{1,2}, T. Roth\textsuperscript{1,2}, \textsuperscript{1}Sleep Disorders Center, Henry Ford Health System, Detroit, MI,  
   \textsuperscript{2}Dept of Psychiatry, Wayne State University, School of Medicine, Detroit, MI  

2 WITHDRAWN  

3 Reinstatement of drug-seeking behavior in rats trained to self-administer intravenous injections of midazolam  
   B. W. Gunter\textsuperscript{1}, D. Platt\textsuperscript{1}, D. Rueedi-bettschen\textsuperscript{1}, K. Freeman\textsuperscript{1}, J. Rowlett\textsuperscript{1,2}, \textsuperscript{1}Psychiatry and Human Behavior, Univ. Mississippi Medical Center, Jackson, MS, \textsuperscript{2}Tulane National Primate Research Center, Covington, LA

4 Problematic pregabalin and gabapentin use: Results from the Canada Vigilance Adverse Reaction Online Database  
   M. Zhang\textsuperscript{1,2}, B. Sproule\textsuperscript{1,2}, \textsuperscript{1}Centre for Addiction and Mental Health, Toronto, ON, Canada,  
   \textsuperscript{2}University of Toronto, Toronto, ON, Canada

5 Evidence for sedative effects of benzodiazepines involving unexpected GABA\textsubscript{A} receptor subtypes  
   J. Rowlett\textsuperscript{2,1,3}, A. N. Duke\textsuperscript{4,1}, D. Platt\textsuperscript{2,1}, O. A. Namjoshi\textsuperscript{5}, M. Poe\textsuperscript{6}, P. Tiruveedhula\textsuperscript{6}, J. Cook\textsuperscript{6},  
   \textsuperscript{1}NEPRC, Harvard Med Sch, Southborough, MA, \textsuperscript{2}University of Mississippi Medical Center, Jackson, MS, \textsuperscript{3}TNPRC, Tulane Univ, Covington, LA, \textsuperscript{4}Wake Forest Medical Center, Winston-Salem, NC, \textsuperscript{5}Discovery Sciences, RTI International, Research Triangle Park, NC, \textsuperscript{6}University of Wisconsin-Milwaukee, Milwaukee, WI

6 Oral midazolam consumption using a two-bottle choice procedure in C57BL/6J mice  
   M. E. Follett\textsuperscript{1}, J. Rowlett\textsuperscript{1,2}, \textsuperscript{1}University of Mississippi Medical Center, Jackson, MS, \textsuperscript{2}Tulane National Primate Research Center, Covington, LA

7 Cardiovascular toxicity of single and repeated inhalation of “Kolla” – A locally abused Egyptian glue  
   A. A. Elkoussi, Pharmacology, Assiut College of Medicine, Assiut, Egypt

ABUSE LIABILITY

8 Designing a human abuse potential study for a drug with a novel mechanism of action  
   K. Bonson, M. Klein, Controlled Substance Staff, Food and Drug Administration, Silver Spring, MD

9 Abuse potential of oral phendimetrazine in cocaine-dependent individuals  
   W. W. Stoops\textsuperscript{1,2,3}, B. L. Bolin\textsuperscript{1}, J. P. Sites\textsuperscript{4}, C. R. Rush\textsuperscript{1,2,3}, \textsuperscript{1}Behavioral Science, University of Kentucky, Lexington, KY, \textsuperscript{2}Psychology, University of Kentucky, Lexington, KY, \textsuperscript{3}Psychiatry, University of Kentucky, Lexington, KY, \textsuperscript{4}College of Medicine, University of Kentucky, Lexington, KY
10 Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users
K. S. Koblan1, S. S. Hopkins1, K. Sarma1, N. Senmartin1, N. Levy-Cooperman2, K. Schoedel2, A. Loebel1, 1Sunovion Pharmaceuticals, Inc, Marlborough, MA, 2Altreos Research Partners, Toronto, ON, Canada

11 An exploratory human abuse potential assessment of centanafadine, a novel triple reuptake inhibitor
M. Shram1,2, K. Schoedel1, N. Chen1, D. Kelsh2, C. O’Brien2, B. Robertson2, T. Hsu2, 1Altreos Research Partners, Inc., Toronto, ON, Canada, 2Neurovance, Inc., Cambridge, MA, 3Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada, 4Alstat, Toronto, ON, Canada, 5Vince and Associates Clinical Research, Overland Park, KS

12 New epidemiological evidence on coca leaf chewing and a dependence syndrome in 2008
V. Cruz1,2, J. C. Anthony1,3, 1Epidemiology, Michigan State University, East Lansing, MI, 2Peruvian National Institute of Mental Health, Lima, Peru, 3School of Public Health, Cayetano Heredia University, Lima, Peru

13 Changes in the pain analgesic and heroin epidemiology
J. C. Maxwell, Addiction Research Institute, University of Texas at Austin, Austin, TX

14 Abuse liability of controlled-release oxycodone formulations
B. Rafat1,2, A. Smith1, K. Farid Araki1, A. Furlan2, B. Sproule1,2, 1Centre for Addiction and Mental Health, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3University Health Network, Toronto, ON, Canada

15 Individual difference in opioid response
K. E. Dunn3, B. Brands1,4, D. Marsh5,6, G. Bigelow2, 1Health Canada, Toronto, ON, Canada, 2Psychiatry & Behavioral Sciences, Johns Hopkins Medical School, Baltimore, MD, 3Johns Hopkins School of Medicine, Baltimore, MD, 4University of Toronto, Toronto, ON, Canada, 5Northern Ontario School of Medicine, Sudbury, ON, Canada, 6Laurentian University, Sudbury, ON, Canada

16 Subjective and objective evidence of low abuse potential of the peripherally acting kappa opioid, CR845, compared with pentazocine
J. W. Stauffer1, F. Menzaghi1, L. R. Webster2, R. H. Spencer1, N. E. Abrouk3, M. Lewis1, D. Chalmers1, 1Cara Therapeutics, Shelton, CT, 2PRA, Salt Lake City, UT, 3Innovexe, Mountain View, CA

17 Prevalence of opioid misuse in cancer survivors in palliative medicine clinic at a tertiary cancer center
N. Moryl, A. Wiesenthal, T. Nikolova, Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

18 Opioid therapy for chronic non-cancer pain: Does typology of risk predict aberrant behaviour?
A. Peacock1, L. Degenhardt3, N. Lintzeris2, B. Laranee1, G. Campbell1, S. Nielsen3, M. Cohen3, R. Bruno1, 1UTAS, Hobart, TAS, Australia, 2Langton Centre, Sydney, NSW, Australia, 3UNSW, Sydney, NSW, Australia

19 The abuse liability of buprenorphine is blocked by samidorphan, a novel opioid modulator, in rats tested in the intracranial self-stimulation paradigm
M. S. Todtenkopf, K. O’Neill, D. Deaver, Life Sciences, Alkermes, Inc., Cambridge, MA

20 Locomotor depression and THC-like discriminative stimulus effects of three novel synthetic cannabinoids: ADBICA, THJ-2201, and ADB-PINACA
S. Dolan, M. J. Forster, M. B. Gatch, Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX
Cytotoxicity of synthetic cannabinoid on primary neuronal cells of the forebrain
M. Funada, K. Tomiyama, K. Wada, Drug Dependence Research, NIMH, NCNP, Kodaira, Japan

Cannabidiol and tetrahydrocannabinol interactions on antinociception in male and female rats
S. Britch, Psychology, Washington State University, Pullman, WA

Effects of norbinaltorphimine pretreatment on THC-induced place and taste avoidance in Sprague-Dawley rats
S. M. Flax1, A. G. Wakeford1, K. Rice2,3, A. Riley1, 1Psychology, American University, Washington, DC, 2Chemical Biology and Research Branch, National Institute on Drug Abuse, Bethesda, MD, 3National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD

Multidimensional assessment of cue-elicited increases in incentive salience for marijuana
J. Metrik1, E. Aston1, C. W. Kahler1, D. Rohsenow1, J. McGeary1, V. Knopik1, J. MacKillop2, 1Brown University, Providence, RI, 2McMaster University, Hamilton, ON, Canada

Magnitude and duration of cue-induced craving for marijuana in volunteers with cannabis use disorder
L. H. Lundahl2, M. Greenwald1, 1Psychiatry, Wayne State University, Detroit, MI, 2Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, MI

Effects of repeated cue exposure on cannabis craving
J. S. Fogel1, T. H. Kelly2,1, A. M. Harvanko2, J. Lile1, 1Behavioral Science, University of Kentucky, Lexington, KY, 2Psychology, University of Kentucky, Lexington, KY

Eye tracking measures of attentional bias to individually calibrated marijuana cues
J. H. Yoon, A. Vujanovic, M. Weaver, R. Suchting, C. Green, J. Schmitz, S. D. Lane, Psychiatry and Behavioral Sciences, University of Texas Health Science Center - Houston, Houston, TX

Cannabis use, schizotypy, and attentional inhibition
L. Albertella1, M. Le Pelley2, J. Copeland1, 1National Cannabis Prevention and Information Centre, UNSW Medicine, Sydney, NSW, Australia, 2Psychology, UNSW, Sydney, NSW, Australia

ADHD and the risk of initiation of marijuana use among a national sample of youth 10 to 18 years of age
C. Okafor, S. O. Lasopa, C. W. Striely, R. Cook, L. Cottler, Epidemiology, University of Florida, Gainesville, FL

Methods for associating trajectories of comorbidities: ADHD and substance use
S. K. Mikulich-Gilbertson, B. D. Wagner, P. D. Riggs, S. K. McWilliams, G. O. Zerbe, Univ. of Colorado, Aurora, CO

Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence
D. Notzon3, J. J. Mariani2, M. Pavlicova1, A. Glass5, A. Mahony3, D. J. Brooks4, J. Grabowski1, F. R. Levin2, 1Martina Pavlicova, Columbia University, New York, NY, 2Psychiatry/Division on Substance Abuse, Columbia University/New York State Psychiatric Institute, New York, NY, 3Division on Substance Abuse, NY State Psychiatric Institute, New York, NY, 4Substance Abuse, NYSPI, New York, NY, 5Biostatistics, New York State Psychiatric Institute, New York, NY, 6Psychiatry, University of Minnesota, Minneapolis, MN
32 Cannabidiol attenuates the increased susceptibility to false memories produced by tetrahydrocannabinol
M. Valle2, L. C. Martial2, M. Garrido2, A. Rodríguez-Fornells3, M. Puntes4, R. M. Antonijoan1, J. Claramunt4, D. Martínez4, M. González4, M. Martínez4, J. Pérez de los Cobos1, J. Riba1, 1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Pharmacokinetic and pharmacodynamic modeling and simulation, Institut de Recerca HSCSP, Barcelona, Spain, 3IDIBELL, Hospital de Llobregat, Spain, 4Institut de Recerca HSCSP, Barcelona, Spain

33 Examination of the behavioral effects of oral cannabidiol alone and in combination with smoked marijuana
S. Babalonis1, M. R. Lofwall1, P. A. Nuzzo1, C. Elayi2, R. J. Malcolm3, M. Haney4, S. L. Walsh1, 1Behavioral Science and Center on Drug and Alcohol Research, Univ of Kentucky, Lexington, KY, 2Internal Medicine, Univ of Kentucky, Lexington, KY, 3Psychiatry and Behavioral Sciences, Medical Univ of South Carolina, Charleston, SC, 4Psychiatry, Columbia University, New York, NY

34 The point of a joint: A multivariate classification of marijuana use motives
A. Ketcherside, F. Filbey, Behavior and Brain Sciences, University of Texas at Dallas, Dallas, TX

35 Acute effects of cannabis on young drivers’ performance of driving-related skills
J. Burston2,1, R. Mann1,2, B. Le Foll1,2, G. Stoduto1, C. Wickens1,2, J. Pan1,1, M. A. Huestis3, B. Brands3,1, 1Centre for Addiction and Mental Health, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3IRP, Chemistry and Drug Metabolism, National Institute on Drug Abuse, Baltimore, MD, 4Health Canada, Ottawa, ON, Canada

36 Preliminary report on the residual effects of cannabis on young drivers’ performance of driving-related skills
J. Pan2,1, R. Mann1, B. Brands3,1,2, G. Stoduto1, C. Wickens1, J. Burston2,1, M. A. Huestis3, B. Le Foll1,2, 1Centre for Addiction and Mental Health, Toronto, ON, Canada, 2Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada, 3IRP, Chemistry and Drug Metabolism, National Institute on Drug Abuse, Baltimore, MD

37 Physiologic effects of dronabinol during opioid withdrawal in humans
P. A. Nuzzo1, M. R. Lofwall1, S. Elayi2, K. Gill1, S. Babalonis1, S. L. Walsh1, 1Behavioral Science, Center on Drug and Alcohol Research, Univ of Kentucky, Lexington, KY, 2Internal Medicine, Univ of Kentucky, Lexington, KY

38 Effects of fixed or self-titrated dosages of Sativex on cannabis users
J. M. Trigo1, D. Lagzdins1, J. Rehm2, P. Selby3, I. Gamaleddin1, B. Fischer2,4, A. Barnes5, M. Huestis5, B. Le Foll1, 1Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada, 2Social and Epidemiological Research, Centre for Addiction and Mental Health, Toronto, ON, Canada, 3Ambulatory Care and Structured Treatments, Centre for Addiction and Mental Health, Toronto, ON, Canada, 4Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada, 5National Institute on Drug Abuse, Baltimore, MD

39 A randomized delayed implementation trial of computerized brief intervention for drug misuse
R. P. Schwartz1, J. Gryczynski1, S. G. Mitchell1, K. O’Grady3, S. Ondersma2, 1Friends Research Institute, Baltimore, MD, 2Wayne State, Detroit, MI, 3University of Maryland, College Park, MD

40 Do alcohol-focused interventions reduce marijuana use in mandated college students?
A. Yurasek2, A. Fernandez2, M. Miller2, J. Metrik1, B. Borsari2, 1Behavioral and Social Sciences, Brown University, Providence, RI, 2Public Health, Brown University, Providence, RI
A very brief intervention for cannabis users in an emergency department setting  
L. Webb, N. Clement, E. Matalon, T. Joel, J. Copeland, National Cannabis Prevention and Information Centre, UNSW Medicine, Sydney, NSW, Australia

Development of a brief cannabis use disorder screening tool: The CUDIT Short-Form  
M. O. Bonn-Miller2,3,4, A. Heinz5, E. Smith5, R. Bruno1, S. Adamson6, 1School of Psychology, University of Tasmania, Hobart, TAS, Australia, 2Center of Excellence in Substance Abuse Treatment and Education, VA Palo Alto Health Care System, Menlo Park, CA, 3National Center for PTSD, VA Palo Alto Health Care System, Menlo Park, CA, 4Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, 5Department of Educational Psychology, University of Illinois at Chicago, Chicago, IL, 6National Addiction Centre, University of Otago, Christchurch, New Zealand

Challenges encountered while recruiting frequent marijuana smokers for an outpatient laboratory study  
V. R. Votaw, S. Babalonis, M. R. Lofwall, P. A. Nuzzo, S. L. Walsh, Behavioral Science and Center on Drug and Alcohol Research, Univ. of Kentucky, Lexington, KY

IMAGING

Neuroimaging and cognitive abnormalities in anabolic androgenic steroid abusers  
M. Kaufman, E. Jensen, A. Janes, J. Hudson, G. Kanayama, A. Kerrigan, H. Pope, McLean Hospital, Belmont, MA

Impact of adolescent marijuana use on emotion processing: An fMRI study  
L. M. Cope, J. Hardee, M. E. Martz, R. Zucker, M. Heitzeg, University of Michigan, Ann Arbor, MI

Correlation between PFC gyrification and white matter integrity in young cannabis users  
S. G. Shollenbarger2, J. S. Price1, K. E. Maple2, K. M. Lisdahl2, 1McLean Hospital - Harvard Medical School, Belmont, MA, 2Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI

Cortical thinning in adolescent females with substance and conduct problems  
P. Boulos1, M. Dalwani1, J. Tanabe1, S. K. Mikulich-Gilbertson1, M. T. Banich2, T. J. Crowley1, J. Sakai1, 1University of Colorado, Aurora, CO, 2University of Colorado Boulder, Boulder, CO

Sleep quality does not predict frontolimbic white matter integrity in young marijuana users  
K. E. Maple, S. G. Shollenbarger, E. R. Gilbart, K. M. Lisdahl, Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI

Neural activation to social influence in young adult cannabis users  
J. Gilman1,2, M. Curran1, V. Calderon1, A. Evins1,2, 1Massachusetts General Hospital, Boston, MA, 2Harvard Medical School, Boston, MA

Neural correlates of attentional bias for cannabis cues: Influence of sex  
T. Franklin1, R. R. Wetherill1, K. Jagannathan1, N. Hager1, J. Suh1, A. Childress1, 1Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Cannabis users show increased susceptibility to false memories  
J. Riba1, F. Sampredo2, A. Rodríguez-Puigadas2, S. Martínez-Horta1, J. Kulisevsky1, J. Pérez-de-los-Cobos1, A. Rodríguez-Fornells1, M. Valle1, 1Hospital Sant Pau, Barcelona, Spain, 2University of Barcelona, Barcelona, Spain

Regional grey matter volume and externalizing score: Not yet related in middle childhood  
J. Sakai1, M. Dalwani1, M. A. McMahon1, S. K. Mikulich-Gilbertson1, J. Tanabe1, S. K. McWilliams1, K. Raymond1, M. T. Banich2, T. J. Crowley1, 1University of Colorado, Aurora, CO, 2University of Colorado Boulder, Boulder, CO
Positive association between cingulate brain volume and sensation seeking in young adults
T. H. Kelly¹, M. J. Wesley¹, C. E. Emurian¹, C. A. Martin¹, J. E. Joseph², J. A. Lile¹,
¹University of Kentucky, Lexington, KY, ²Medical University of South Carolina,
Charleston, SC

Inhibitory control: A brain connectivity study comparing cocaine-dependent subjects and controls
L. Ma¹, J. L. Steinberg¹, K. A. Cunningham², S. D. Lane³, J. M. Bjork¹, P. A. Narayana³,
T. Kosten¹, A. Bechara², F. Moeller¹, ¹Virginia Commonwealth University Institute for Drug
and Alcohol Studies, Richmond, VA, ²University of Texas Medical Branch, Galveston, TX, ³University of Texas Health Science Center, Houston, TX, ⁴Baylor College of Medicine,
Houston, TX, ⁵University of Southern California, Los Angeles, CA

Influence of dorsolateral prefrontal cortex and ventral striatum on risk avoidance in addiction:
A mediation analysis
D. Yamamoto¹, C. Woo², T. Wager², J. Tanabe¹, ¹Radiology, University of Colorado Denver,
Aurora, CO, ²Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO

Aberrant brain function as at-risk children make risky decisions
T. J. Crowley¹, M. Dalwani¹, S. Mikulich-Gilbertson¹, J. Sakai¹, S. Young¹, K. Raymond¹,
S. K. McWilliams¹, M. T. Banich¹,², ¹Univ. of Colorado Denver, Auror, CO, ²Univ. of
Colorado Boulder, Boulder, CO

A higher hill to climb! Older cocaine-addicted patients viewing 500 msec cocaine cues have
reduced activation of modulatory circuits and increased activation of motivational circuits
Z. A. Monge¹, K. Jagannathan¹, J. Suh¹,², R. Ehrman¹,², Z. Wang¹, T. Franklin¹,
R. R. Wetherill², K. A. Young³, M. J. Gawrysiak¹,², D. Langleben¹,², C. P. O’Brien¹,²,
A. Childress¹, ¹Psychiatry, University of Pennsylvania, Philadelphia, PA, ²VA VISN 4
MIRECC, Philadelphia, PA

“Dangerous liaisons”: Heightened intra-limbic connectivity during subliminal cocaine cues is a
relapse-vulnerable endophenotype
A. Childress¹,², K. Jagannathan¹, J. Suh¹,², Z. A. Monge¹, K. A. Young¹, Z. Wang¹,
T. Franklin¹, D. Langleben¹,², Z. Li³, K. M. Kampman¹,², R. R. Wetherill², R. Ehrman¹,²,
M. Gawrysiak¹,², R. Szucs-Reed¹, C. P. O’Brien¹, ¹Psychiatry, UPENN Perelman Sch. Med.,
Philadelphia, PA, ²VA Med Ctr., Philadelphia, PA

Differential brain response to successful and failed response inhibition: Cocaine-dependent vs.
healthy subjects
J. Suh¹,², K. Jagannathan¹, R. Ehrman¹,², M. Goldman¹, Z. A. Monge¹, E. Berkowitz-
Sturgis², T. Franklin¹, K. Marquez¹, R. Szucs-Reed¹, C. P. O’Brien¹, A. Childress¹, ¹Univ. of
Pennsylvania, Philadelphia, PA, ²MIRECC, PVAMC, Philadelphia, PA

Reduced ACC response to presentation of negative feedback differentiates stimulant abusers
from non-abusers and predicts abstinence at 12 months
M. S. Shane¹, E. D. Claus², ¹University of Ontario Institute of Technology, Oshawa, ON,
Canada, ²The Mind Research Network, Albuquerque, NM

Classification of drug and placebo with functional magnetic resonance imaging
M. J. Wesley¹, J. A. Lile¹, C. E. Emurian¹, C. A. Martin¹, J. E. Joseph², T. H. Kelly¹,
¹University of Kentucky, Lexington, KY, ²Medical University of South Carolina,
Charleston, SC

Decreased brain creatine kinase activity in methamphetamine abusers: Preliminary results
Y. Sung¹, X. Shi¹, D. Kondo¹,², T. Hellem¹, C. Riley¹, E. Jeong¹, K. Lundberg¹, D. Yurgelun-
Todd¹,²,³, P. Renshaw¹,²,³, ¹University of Utah, Salt Lake City, UT, ²VISN 19 MIRECC, Salt
Lake City, UT, ³USTAR, Salt Lake City, UT
63 Social processing in aging cocaine smokers
G. Bedi¹, Z. D. Cooper¹, N. Van Dam², M. Haney¹, ¹Psychiatry, Columbia University and NY State Psychiatric Institute, New York, NY, ²Nathan Kline Institute, Orangeburg, NY

64 Different patterns of neural activity among cocaine-dependent individuals with and without current methadone treatment: Relationship to treatment outcomes
S. W. Yip¹, K. M. Carroll², M. N. Potenza¹, ¹Psychiatry, Yale University, New Haven, CT, ²Psychiatry, Yale University School of Medicine, West Haven, CT

65 Opioid antagonist treatment modulates the brain responses to baby schema in opioid-dependent patients
A. Wang¹, S. B. Lowen³, S. J. Blady¹, E. D. Dowd¹, A. Bouril¹, A. Childress², C. P. O’Brien², D. Langleben², ¹University of Pennsylvania, Philadelphia, PA, ²Psychiatry, University of Pennsylvania, Philadelphia, PA, ³Harvard University, Cambridge, MA

66 Brain default mode network functional connectivity in polysubstance-using emerging adults during opioid dependence treatment
J. S. Price², M. L. Copersino², G. Vitaliano³, S. E. Lukas⁴, R. Weiss¹, A. Janes², ¹Harvard Medical School, Belmont, MA, ²McLean Hospital - Harvard Medical School, Belmont, MA, ³Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA

67 Effect of hemispheric dominant versus non-dominant insular damage on smoking behaviors
A. Abdolahi¹2, G. Williams³, C. Benesch², H. Wang², E. Spitzer³, B. Scott³, R. Block², E. van Wijngaarden², ¹Philips Research, Briarcliff Manor, NY, ²University of Rochester, Rochester, NY, ³Rochester General Health System, Rochester, NY

68 Functional connectivity in an insula-based network is associated with smoking cessation outcomes
M. Addicott¹, M. Sweitzer¹, B. Froeliger³, E. Westman², J. Rose¹, J. McClernon¹, ¹Psychiatry and Behavioral Sciences, Duke University, Durham, NC, ²Duke University Medical Center, Durham NC, NC, ³Medical University of South Carolina, Charleston, SC

69 A novel data-driven resting state connectivity analysis reveals distinct networks associated with delay discounting between controls and smokers
M. Um, S. Li, B. Salmeron, National Institute on Drug Abuse, Baltimore, MD

ETHNIC DIFFERENCES

71 The drug use patterns of Latino day laborers in Baltimore
N. Negi¹, A. Valdez², A. Cepeda², ¹Social Work, University of Maryland, Baltimore, MD, ²School of Social Work, University of Southern California, Los Angeles, CA

72 Polysubstance use profiles among people who inject drugs in Los Angeles and San Francisco
D. Chu², A. Kral¹, J. Huh², R. Bluthenthal¹, ¹RTI International, San Francisco, CA, ²Preventive Medicine, University of Southern California, Los Angeles, CA

73 Born in the USA: Estimated annual incidence rates for use of cannabis in the 21st century United States
C. Lopez-Quintero, R. Brosig, J. C. Anthony, Michigan State University, Rochester, MI

74 The truth about marijuana is all rolled up in a blunt: Prevalence and predictors of blunt use among young African-American adults
L. Montgomery¹, O. Oluwoye², ¹Counseling/Substance Abuse Counseling, University of Cincinnati, Cincinnati, OH, ²Health Promotion and Education, University of Cincinnati, Cincinnati, OH
Thursday, June 18, 2015

75 Prescription drug abuse, heroin, & IV drug use among incarcerated Black men
D. Stevens-Watkins³, J. Knighton³, M. Staton-Tindall², E. Winston⁴, C. G. Leukefeld¹,
¹Behavioral Science, Univ of Kentucky, Lexington, KY, ²College of Social Work,
University of Kentucky, Lexington, KY, ³Counseling Psychology, University of Kentucky,
Lexington, KY, ⁴CDAR, University of Kentucky, Lexington, KY

76 Association of gender and genetic ancestry with frequency of methamphetamine use among
methamphetamine-dependent Hispanic and Non-Hispanic Whites
K. Heinzerling¹, L. Demirdjian¹, M. Briones¹, A. Swanson², Y. Wu¹, S. Shoptaw¹, ¹UCLA, Los
Angeles, CA, ²Stanford University, Stanford, CA

77 Incident alcohol use among adult Arab refugees and immigrants
C. L. Arfken¹, B. Arnetz¹, C. Broadbridge², M. Lumley¹, J. Arnetz¹, N. Pole³, H. Jamil¹,
¹Wayne State University, Detroit, MI, ²Kentucky Wesleyan College, Owensboro, KY, ³Smith
College, Northampton, MA

EPIDEMIOLOGY II

78 The epidemic that never happened: Zohydro ER and the impact of media coverage

79 Incident non-medical use of prescription opioids is associated with heroin initiation among U.S.
veterans: A prospective cohort study
G. Banerjee⁴, E. J. Edelman¹, D. T. Barry¹, W. Becker³, M. Cerda⁵, S. Crystal⁶, J. R. Gaither¹,
A. J. Gordon², K. S. Gordon⁷, R. Kerns⁷, S. Martins⁵, D. A. Fiellin¹, B. D. Marshall⁸, ¹Yale,
New Haven, CT, ²VA Pittsburgh, Pittsburgh, PA, ³CT VA, West Haven, CT, ⁴Brown,
Providence, RI, ⁵Columbia, New York, NY, ⁶Rutgers, New Brunswick, NJ, ⁷CT VA, New
Haven, CT

80 Non-oral abuse of immediate-release hydrocodone
A. DeVeaugh-Geiss, H. Chilcoat, N. Sessler, P. Coplan, Purdue Pharma, Stamford, CT

81 Changes in diagnosed addiction rates in patients prescribed opioids after introduction of
oxycontin with abuse-deterrent properties
P. Coplan¹,², A. Kadakia³, ¹Epidemiology, Purdue Pharma, Stamford, CT, ²Purdue,
Stamford, CT, ³Univ. of Pennsylvania, Philadelphia, PA

82 Changes in age-specific rates of doctor-shopping for opioids following introduction of
reformulated OxyContin® tablets
H. Chilcoat, P. Coplan, N. Sessler, V. Harikrishnan, Risk Management and Epidemiology,
Purdue Pharma, Stamford, CT

83 How long is too long? The continued misuse of non-abuse deterrent Oxycontin after removal
from the market in a cohort of rural Appalachian opioid abusers
J. R. Havens², M. R. Lofwall³, S. L. Walsh¹, ¹Behavioral Science, Univ. of Kentucky,
Lexington, KY, ²Center on Drug and Alcohol Research, University of Kentucky,
Lexington, KY, ³University of Kentucky College of Medicine, Lexington, KY

84 Diverted buprenorphine use among Appalachian people who use drugs
R. V. Smith, M. R. Lofwall, S. L. Walsh, J. R. Havens, Behavioral Science, Univ. of
Kentucky, Lexington, KY

85 Examining the relationship between social context and prescription opioid initiation routes
among young adults entering detoxification
M. A. Levi-Minzi, H. Surratt, C. L. O’Grady, S. P. Kurtz, ARSH: Center for Research on
Substance Use and Health Disparities, Nova Southeastern University, Miami, FL
86 Polysubstance combinations involving prescription opioids and rationales for combining among people who use Internet drug discussion forums
   T. Green1, M. Doe-Simkins2, M. Barratt3, T. A. Cassidy1, S. F. Butler1, 1Inflexxion, Inc.,
   Newton, MA, 2Prescribetoprevent.org, Chicago, IL, 3Curtin University, Perth, WA, Australia

87 Trajectories of nonmedical prescription medication use among youth
   C. Boyd1, J. A. Cranford1, S. E. McCabe1, 1University of Michigan, Ann Arbor, MI

88 Substance use among sexual minority collegiate athletes: A national study
   P. T. Veliz, C. J. Boyd, Q. Epstein-Ngo, S. E. McCabe, Institute for Research on Women &
   Gender, University of Michigan, Ann Arbor, MI

89 Ultrahigh chronic opioid therapy subjects: A population description
   U. Bhatt2, D. Plott1, 1Mental Healthcare Line, Cincinnati VAMC, Cincinnati, OH, 2OSUWMC,
   Columbus, OH

90 The geospatial and temporal correlation of oxycodone and heroin deaths in Florida counties,
   2011 to 2013
   C. Delcher1, J. Hall1, D. Lee2, M. Maldonado-Molina1, 1Health Outcomes and Policy,
   University of Florida, Gainesville, FL, 2Departments of Pathology, Immunology and
   Laboratory Medicine, University of Florida, Gainesville, FL

91 National trends in hospitalizations for opioid pill- and heroin-related overdose, 2005-2012
   D. Ciccarone1, G. J. Unick2, 1Family and Community Medicine, UCSF, San Francisco, CA,
   2School of Social Work, University of Maryland, Baltimore, MD

92 The changing nature of opioid-related mortality in Australia
   A. Roxburgh1, L. Burns1, W. Hall21, L. Degenhardt1,3, 1National Drug and Alcohol Research
   Centre, University of New South Wales, Sydney, NSW, Australia, 2Centre for Youth
   Substance Abuse Research, University of Queensland, Brisbane, QLD, Australia, 3School of
   Population and Global Health, University of Melbourne, Melbourne, VIC, Australia

93 Changing patterns of treatment seeking for pharmaceutical opioids in Australia (2002-2011)
   S. Nielsen21, A. Roxburgh2, R. Bruno32, N. Lintzeris1, A. Jefferson5, L. Degenhardt2, 1Drug
   and Alcohol, SESLHD, Sydney, NSW, Australia, 2National Drug and Alcohol Research
   Centre, University of New South Wales, Sydney, NSW, Australia, 3School of Psychology,
   University of Tasmania, Hobart, TAS, Australia, 4AIHW, Canberra, ACT, Australia

94 Childhood traumatic experience and illicit drug use in adolescence, emerging adulthood, and
   adulthood
   J. D. Scheidell1, S. McGorray2, K. Vaddiparti2, L. Cottler2, M. R. Khan1, 1Population Health,
   New York University, New York, NY, 2Colleges of Public Health & Health Professions and
   Medicine, University of Florida, Gainesville, FL

95 Trend in substance use admissions among older adults
   R. Jayadevappa1, S. Chhatre2, D. Metzger2, 1Medicine, University of Pennsylvania,
   Philadelphia, PA, 2Psychiatry, University of Pennsylvania, Philadelphia, PA

96 U.S. estimates of hospitalization by substance use profile
   J. Gryczynski1, R. P. Schwartz1, J. H. Jaffe1, K. O’Grady2, S. G. Mitchell1, 1Friends Research
   Institute, Baltimore, MD, 2Psychology, University of Maryland, College Park, MD

97 One for the road: The role of substance misuse on outcomes from traumatic brain injury
   L. A. Keyser-Marcus2, L. Thacker3, A. Starkweather3, D. Ramesh1, F. Moeller4, 1Pharm
   Tox, VCU, Richmond, VA, 2Psychiatry, VCU, Richmond, VA, 3School of Nursing, VCU,
   Richmond, VA, 4VCU IDAS, Richmond, VA
98 Characteristics of gamblers choosing self-exclusion from casinos: A prospective study in a French overseas territory
N. Lhommeau², J. Alexandre¹, D. Mete², M. Fatseas¹, M. Auriacombe¹, ¹Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, ²CHU Reunion, Saint Denis, France

99 Trait, state, and place: The role of personality and environment in drug use
K. A. Phillips¹, D. Louie², M. A. Furnari¹, W. J. Kowalczyk¹, D. Epstein¹, K. L. Preston¹, ¹NIDA, Baltimore, MD, ²UCSF, San Francisco, CA

100 Stable housing, stable substance use? Evaluation of two ‘housing first’ programs for homeless individuals
E. Whittaker, L. Burns, National Drug and Alcohol Research Centre, UNSW, Sydney, NSW, Australia

101 No place to call home: What homelessness means for people who use drugs
L. Burns, E. Whittaker, National Drug and Alcohol Research Centre, UNSW, Sydney, NSW, Australia

102 Increased risk of substance use and health-related problems among male homeless veterans
E. M. Dunne¹, A. Diggins¹, L. Burrell¹, N. E. Whitehead¹, W. W. Latimer², ¹Clinical and Health Psychology, University of Florida, Gainesville, FL, ²Lehman College, Bronx, NY

103 Predictors of agreement between hair analysis and self-report of drug use
P. VanVeldhuisen¹, G. Sharma¹, M. Bogenschutz², ¹The EMMES Corporation, Rockville, MD, ²University of NM, Albuquerque, NM

104 Does type of drug lead to quicker onset of injection?
R. Bluthenthal², D. Chu², L. Wenger¹, T. Valente², A. Kral¹, ¹RTI International, San Francisco, CA, ²Preventive Medicine, University of Southern California, Los Angeles, CA

105 Ineligible for most protocols: What differentiates drug users?
C. W. Striley, L. Cottler, Epidemiology, University of Florida, Gainesville, FL

106 Informed consent practices among NIH-funded researchers
C. Ryan, B. Seymour, M. Stephens, R. Comly, C. Sierka, T. G. Musselman, K. L. Dugosh, D. Festinger, Section on Law and Ethics, Treatment Research Institute, Philadelphia, PA

RISK

107 Substance use among highly sexually active gay and bisexual men: Examining sexual compulsivity, hypersexuality, and substance use
R. L. Moody¹,², J. T. Parsons¹,², A. Ventuneac¹, H. J. Rendina¹, C. Grov¹, ¹Center for HIV Educational Studies & Training (CHEST), Hunter College, CUNY, New York, NY, ²Graduate Center, CUNY, New York, NY

108 Women can force men to have sex? Forced sex tactic and substance use among sexually victimized men
M. Cook, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA

109 Contraceptive use and risky sexual behavior varies with frequency of cocaine, crack cocaine, or methamphetamine use
D. J. Hand, S. H. Heil, Vermont Center on Behavior and Health, University of Vermont, Burlington, VT
110 Trichomonas vaginalis infection and drug abuse risk for women
   D. G. Fisher¹, G. L. Reynolds¹, P. Xandre², ¹Center for Behavioral Research & Services,
   California State University, Long Beach, Long Beach, CA, ²Nursing, California State
   University, Long Beach, Long Beach, CA

111 Predicting sexually transmitted infections in sexually transmitted disease clinics in U.S.: A
   machine-learning approach
   D. J. Feaster¹, Y. Pan¹, M. Nelson¹, J. Sorensen², L. R. Metsch³, ¹Public Health Sciences,
   University of Miami Miller School of Medicine, Miami, FL, ²University of California, San
   Francisco, San Francisco, CA, ³Columbia University, New York, NY

112 A new repeated measures approach of sexual and substance use risk behaviors among patients
   in transmitted disease clinics
   Y. Pan¹, L. R. Metsch², J. Sorensen³, D. J. Feaster¹, ¹Public Health Sciences, University
   of Miami Miller School of Medicine, Miami, FL, ²Columbia University, New York, NY,
   ³University of California, San Francisco, San Francisco, CA

113 Binge drinkers have greater vulnerability to engage in risky behaviors in traffic and drug use
   G. Pasa¹, T. R. Sousa¹, J. Lunnen², F. P. Pechansky¹, ¹Psychiatry, Center for Drug and Alcohol
   Studies at HCPA/UFRGS, Porto Alegre, Brazil, ²Johns Hopkins Bloomberg School of Public
   Health, Baltimore, MD

114 A qualitative investigation comparing sexual effects of alcohol and marijuana among adults
   J. J. Palamar¹,², P. Acosta¹, V. Falb¹, D. C. Ompad³, ¹Department of Population Health,
   New York University Langone Medical Center, Astoria, NY, ²Center for Drug Use and HIV
   Research, New York University College of Nursing, New York, NY, ³Global Institute of
   Public Health, New York University, New York, NY

115 Non-medical prescription opioid use and commercial sex work among adults in residential
   substance use treatment
   A. K. Matusiewicz¹,²,³, A. S. Bohnert¹,²,³, E. E. Bonar², M. Ilgen¹,²,³, ¹VA Center for Clinical
   Management Research, Ann Arbor, MI, ²Psychiatry, University of Michigan Medical School,
   Ann Arbor, MI, ³VA Ann Arbor Healthcare System, Ann Arbor, MI

116 High rate of ED presentations in a cohort of people who inject drugs: 2008-2013
   D. Nambiar¹,², M. Stoove¹,², P. Dietze¹,², ¹Centre for Population Health, Burnet Institute,
   Melbourne, VIC, Australia, ²Epidemiology and Preventive Medicine, Monash University,
   Melbourne, VIC, Australia

117 Drug use and injection practices in Tajikistan: Qualitative study in Kulob and Khorog
   D. Otiashvili¹, A. Latypov², U. Ibragimov³, I. Kirtadze¹, W. Zule⁴, ¹Addiction Research
   Center, Alternative Georgia, Tbilisi, Georgia, ²Management Sciences for Health, Leadership,
   Management and Governance, Kiev, Ukraine, ³Laney Graduate School, Emory University,
   Atlanta, GA, ⁴RTI International, Research Triangle Park, NC

BEHAVIOR

118 Staff acceptability of contingency management to promote longer breastfeeding duration at WIC
   Y. Washio¹, M. Humphreys², D. Zeigler³, ¹Treatment Research Institute, Philadelphia, PA,
   ²Temple University, Philadelphia, PA

119 Do consumers substitute between cannabis and opium? Evidence from British India
   S. Chandra, Asian Studies Center, Michigan State University, Okemos, MI

120 An in-depth analysis of cocaine-induced negative subjective effects in humans
   La Garza, II, Psychiatry, Baylor College of Medicine, Houston, TX
121 Cocaine images and alcohol administration impair inhibitory control
E. Pike\textsuperscript{1,2}, K. R. Marks\textsuperscript{1,2}, W. W. Stoops\textsuperscript{1,2,3}, C. R. Rush\textsuperscript{1,2,3}, \textsuperscript{1}Psychology, Univ. of KY, Lexington, KY, \textsuperscript{2}Behav Sci, Univ. of KY, Lexington, KY, \textsuperscript{3}Psychiatry, Univ. of KY, Lexington, KY

122 The relationship between methamphetamine self-administration and subject-rated effects
J. C. Strickland\textsuperscript{2}, W. W. Stoops\textsuperscript{1,2,3}, C. R. Rush\textsuperscript{1,2,3}, \textsuperscript{1}Behavioral Science, Univ of KY, Lexington, KY, \textsuperscript{2}Psychology, Univ of KY, Lexington, KY, \textsuperscript{3}Psychiatry, Univ of KY, Lexington, KY

123 Coordinated and homologous intravenous cocaine self-administration procedures in monkeys and humans: A translational approach to medications development
J. A. Lile\textsuperscript{2}, S. S. Negus\textsuperscript{1}, W. W. Stoops\textsuperscript{2}, A. Johnson\textsuperscript{1}, N. Kate\textsuperscript{1}, M. Banks\textsuperscript{1}, C. R. Rush\textsuperscript{2}, L. Hays\textsuperscript{2}, P. Glaser\textsuperscript{2}, \textsuperscript{1}Virginia Commonwealth University, Richmond, VA, \textsuperscript{2}University of Kentucky, Lexington, KY

124 Scientific writing seminar to help early-stage investigators publish research
J. Sorensen, C. L. Masson, A. Flentje, M. Shopshire, J. Guydish, Department of Psychiatry, University of California, San Francisco, San Francisco, CA

THEORETICAL - COMMENTARY

125 Considerations on designs of intranasal studies for abuse-deterrent products
L. Chen\textsuperscript{1}, S. N. Calderon\textsuperscript{1}, S. H. Hertz\textsuperscript{1}, \textsuperscript{1}FDA/CDER, Silver Spring, MD

126 Design considerations for integrating video into tablet-based mHealth interventions addressing HIV and substance use
I. D. Aronson\textsuperscript{2}, D. Perlman\textsuperscript{1}, \textsuperscript{1}Beth Israel Medical Center, New York, NY, \textsuperscript{2}NDRI, Inc., New York, NY

127 Use of telemedicine to treat hepatitis C at a medication-assisted opioid treatment program
L. S. Brown\textsuperscript{1}, A. Talal\textsuperscript{2}, M. Zeremski\textsuperscript{1}, R. Zavala\textsuperscript{1}, B. Smith\textsuperscript{4}, A. Martinez\textsuperscript{2}, M. Lin\textsuperscript{1}, R. Dimova\textsuperscript{2}, J. Zibbell\textsuperscript{1}, S. Kritz\textsuperscript{1}, \textsuperscript{1}START Treatment & Recovery Centers, Brooklyn, NY, \textsuperscript{2}SUNY Buffalo School of Medical and Biological Sciences, Buffalo, NY, \textsuperscript{3}Weill Cornell Medical College, New York, NY, \textsuperscript{4}Centers for Disease Control and Prevention, Atlanta, GA

128 Redefining the recreational drug user population in human abuse potential studies
T. Hopyan\textsuperscript{1}, P. Geoffroy\textsuperscript{1}, Y. Hirata\textsuperscript{1}, M. Sokolowska\textsuperscript{2}, A. Jorga\textsuperscript{3}, B. Setnik\textsuperscript{1}, \textsuperscript{1}INC Research, Toronto, ON, Canada, \textsuperscript{2}Grunenthal, Bedminster, NJ, \textsuperscript{3}Pfizer, New York, NY

129 FDA guidance assessment of abuse potential of drugs
C. P. Moody\textsuperscript{1}, M. Klein\textsuperscript{2}, \textsuperscript{1}CDER/Controlled Substance Staff (CSS), US Food and Drug Administration (FDA), Silver Spring, MD, \textsuperscript{2}Controlled Substance Staff, Food & Drug Administration, Silver Spring, MD

130 Abuse Quotient: An essential measure of opioid analgesic Human Abuse Potential (HAP)
L. R. Webster, M. D. Smith, EDS, PRA Health Sciences, Salt Lake City, UT

131 Assessing potential abuse and misuse of testosterone and other anabolic steroids among middle-aged and older men prescribed steroids
J. Randall-Thompson, A. Lerner, J. Hunt, M. Klein, Controlled Substance Staff (CSS), Food and Drug Administration (FDA), Silver Spring, MD

132 Beyond pharmacotherapy: Emerging data that non-invasive brain stimulation may be an efficacious strategy for decreasing drug craving in substance-dependent individuals
C. A. Hanlon, L. T. Dowdle, W. DeVries, Medical University of South Carolina, Charleston, SC
133 Internalizing and externalizing disorders as risk factors for the increase of cannabis use and
the onset and stability of cannabis use disorders: A systematic review of cohort studies from the
general population
   M. Neumann1, S. Behrendt1, A. Perkonigg2, G. Buehringer1, 1Institute of Clinical Psychology
   and Psychotherapy, Dresden, Germany, 2University of Zurich, Zurich, Switzerland

134 The use of a parallel latent growth model in understanding smoking as a comorbid disorder
   M. Mamey2, S. McPherson1,3, 1Program of Excellence in Addictions Research (PEAR),
   Washington State University, Spokane, WA, 2Psychology, Washington State University,
   Pullman, WA, 3College of Nursing, Washington State University, Spokane, WA

135 Weaving evidenced-informed, culture-based interventions into treatment in Native American
   and Alaska Native communities
   A. Skinstad1, R. Walker2, J. Gringer Richards1, S. A. Bear1, 1Community and Behavioral
   Health, University of Iowa, Iowa City, IA, 2Psychiatry, Oregon Health and Science University
   and the One Sky Center, Portland, OR

136 Evaluation of electronic nicotine delivery systems: Regulatory precedents from the FDA 2013
draft guidance for abuse-deterrent opioids
   J. Henningfield1, E. J. Cone1, A. R. Buchhalter1, R. V. Fant1, J. G. Gitchell1, J. M. Pinney1,
   1PinneyAssociates, Inc., Bethesda, MD

137 Patient selection for extended-release naltrexone among criminal justice-involved persons with
   opioid use disorder
   P. D. Friedmann1,2, J. D. Lee3, E. V. Nunes5, T. W. Kinlock6, C. P. O’Brien2, 1Medicine,
   Rhode Island Hospital, Providence, RI, 2U Penn, Phila, PA, 3Research Service, Providence VA
   Medical Center, Providence, RI, 4Population Health, New York University, New York, NY,
   5Psychiatry, Columbia University, New York, NY, 6Friends Research Institute, Baltimore, MD

Symposium XIV
INRC/CPDD Joint Symposium
AZ Biltmore Ballroom
10:00 - 12:00 PM

Cannabinoid Mechanisms and Interventions

Chair: Todd Vanderah

10:00 Therapeutic interventions through the modulation of CB1/CB2 cannabinoid receptor function
   Alexandros Makriyannis, Northeastern University, Boston, MA

10:30 Inhibition of the 2-AG biosynthetic enzyme diacetylgllycerol lipase beta: Antinociception through
   a cannabinoid receptor independent pathway
   Aron Lichtman, Virginia Commonwealth University, Richmond, VA

11:00 Synergistic actions of opioid/cannabinoid agents for discrete pain etiologies
   Todd Vanderah, University of Arizona-Tucson, Tucson, AZ

11:30 The therapeutic promise of nonpsychoactive cannabinoid analgesics
   Andrea G. Hohmann, Indiana University, Indianapolis, IN
Oral Communication 14

MEDICATIONS FOR ABUSE—LATEST FINDINGS: TREATMENTS FOR STIMULANT ABUSE

Chairs: Sally L. Huskinson and Stephanie M. Groman

10:00 Impact of an exercise intervention on methamphetamine use outcomes post residential treatment care
R. Rawson1, J. Chudzynski1, R. Gonzales-Castaneda2, A. Ang1, D. Dickerson1, L. Mooney1, J. Penate1, B. Salem1, B. Dolezal3, C. Cooper3, 1Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, 2Psychology, Azusa Pacific University, Azusa, CA, 3Exercise Physiology Research Laboratory, UCLA, Los Angeles, CA

10:15 The cocaine use reduction with buprenorphine study: Cocaine use findings
L. Walter1, M. Hillhouse1, A. Saxon2, L. Mooney1, C. Thomas1, A. Ang1, A. Hasson1, J. Annon1, C. Study Group3, 1UCLA, Los Angeles, CA, 2VA Puget Sound Health Care System, Seattle, WA, 3CTN, Bethesda, MD

10:30 Unpredictable availability as a determinant of cocaine choice
S. L. Huskinson1, J. Rowlett1,3, N. Petry2, K. Freeman1, 1University of Mississippi Medical Center, Jackson, MS, 2University of Connecticut Health Center, Farmington, CT, 3Tulane National Primate Research Center, Covington, LA

10:45 Reversal learning is predictive of and affected by cocaine self-administration: Dissecting decision-making processes with computational models
S. M. Groman1, N. Smith1, L. Chen1, D. Lee2, J. Taylor1, 1Psychiatry, Yale University, New Haven, CT, 2Neurobiology, Yale University, New Haven, CT

11:00 Cocaine impairs serial feature negative learning: Implications for cocaine abuse
A. L. Riley1, D. Kearns1, S. Hargrave1, T. Davidson1, 1Psychology, American University, Washington, DC

11:15 Mechanisms and reversal of adolescent cocaine-induced habits
L. DePoy1,2,3, S. Gourley1,2,3, 1Department of Pediatrics, Emory School of Medicine, Atlanta, GA, 2Yerkes National Primate Research Center, Atlanta, GA, 3Graduate Program in Neuroscience, Emory University, Atlanta, GA

11:30 PPARγ agonism attenuates cocaine-seeking behavior via ERK
K. Dineley2,1, W. Miller1, R. G. Fox1, S. J. Stutz1, 1Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, 2Neurology, University of Texas Medical Branch, Galveston, TX

11:45 A novel neuropeptide regulator of behavioral sensitization to cocaine
J. M. Kasper1,2, D. L. McCue1,3, C. Benzon2, Z. Ding3, S. Carlton3, J. D. Hommel1,2, 1Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, 2Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, 3Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX
Oral Communications 15

**MEDICATIONS ANTIRETROVIRAL LEVELS AND FUNCTIONALITY: HIV/AIDS**

Chairs: Richard Saitz and David S. Festinger

10:00  *The microbiota-gut-brain axis as a potential therapeutic approach for HIV-1+ cocaine abuse*
S. B. Harrod, S. J. Bertrand, C. F. Mactutus, D. Booze, Psychology, University of South Carolina, Columbia, SC

10:15  *Exposure to HIV-1 Tat protein potentiates the rewarding effects of morphine and reinstates extinguished conditioned place preference*
J. P. McLaughlin², M. L. Ganno², J. J. Paris², Y. Zhang¹, M. J. Kreek¹, ¹The Laboratory of the Biology of the Addictive Diseases, The Rockefeller University, New York, NY, ²Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL

10:30  *The North-South divide: Substance use risk, care engagement, and viral suppression among hospitalized HIV-infected patients in 11 U.S. cities*
M. Philbin¹, D. Feaster², L. Goode², Y. Pan³, M. Das², R. Pati², G. Lucas², H. Coley², A. Nijhawan², J. Jacobson², R. Mandler², E. Daar², D. McMahon², ¹Columbia University, New York, NY, ²NIDA Clinical Trials Network, Bethesda, MD, ³University of Miami, Miami, FL

10:45  *Childhood parental incarceration and HIV-related drug and sex risk over the young adult life course*
M. R. Khan¹, S. McGorray², J. D. Scheidell¹, K. Vaddiparti¹, L. M. Brotman¹, ¹Population Health, New York University, New York, NY, ²Colleges of Public Health & Health Professions and Medicine, University of Florida, Gainesville, FL

11:00  *The effects of opioid substitution treatment and highly active antiretroviral therapy on the cause-specific risk of mortality among opioid-dependent individuals with HIV/AIDS*
B. Nosyk¹, ², ³, J. Min¹, E. Evans², L. Li³, L. Liu³, V. D. Lima¹, E. Wood¹, J. Montaner¹, ¹BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, ²UCLA, Los Angeles, CA, ³UCLA Integrated Substance Abuse Programs, Los Angeles, CA, ⁴Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada, ⁵Northwestern University, Chicago, IL

11:15  *Is opioid use associated with T cell dysfunction?*
K. Armah³, E. J. Edelman¹, D. M. Cheng², M. Doyle¹, S. Coleman², C. Bridgen², N. Gnatienko², D. Lioznov³, E. Blokhina³, B. Emu¹, M. Freiberg³, E. Krupitsky³, J. Samet², ¹Yale, New Haven, CT, ²Boston University, Boston, MA, ³First Pavlov State Medical University of St.Petersburg, St. Petersburg, Russian Federation, ⁴UVM, Colchester, VT, ⁵Vanderbilt, Nashville, TN

11:30  *Substance dependence criteria, not substance use, associated with HIV virologic control*
S. Nolan¹, A. Walley², T. Heeren², G. Pattis², A. S. Ventura², M. Sullivan³, J. Samet², R. Saitz², ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Boston University, Boston, MA

11:45  *Delivering HIV prevention services to drug court clients*
D. Festinger, K. L. Dugosh, Section on Law and Ethics, Treatment Research Institute, Philadelphia, PA
Symposium XV

McArthur Ballroom 4
10:00 - 11:00 AM

A TRIO OF TRANSLATIONAL PROJECTS: BIOMARKERS, BIOIMMUNOLOGY, AND BEHAVIOR IN RODENTS AND HUMANS


10:00 Identification of novel lipid biomarkers of cocaine use in humans
Brian Cummings, University of Georgia, Athens, GA

10:20 A novel mechanism of levamisole-induced autoimmunity in cocaine use
Peter Grayson, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

10:40 Buprenorphine plus clonidine increases time to lapse and reduces heroin craving at low-to-moderate stress levels
Kenzie L. Preston, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD

Symposium XVI

McArthur Ballroom 4
11:15 - 12:15 PM

NEW STRATEGIES TO IDENTIFY THE GENETICS OF ADDICTION-RELATED BEHAVIORS IN MICE

Chair: J. David Jentsch

11:15 Impulsivity and cocaine reinforcement: Identifying genetic relationships in inbred mice
J. David Jentsch, University of California at Los Angeles, Los Angeles, CA

11:35 Initial sensitivity to cocaine in genetically diverse inbred mouse strains
Lisa Tarantino, University of North Carolina, Chapel Hill, NC

11:55 Behavioral predictors of drug self-administration in diversity outbred mice
Elissa J. Chesler, The Jackson Laboratory, Bar Habor, ME

BRUNCH WITH CHAMPIONS
Aztec
12:15 - 1:15 PM

Oral Communications 16
McArthur Ballroom 1/2
1:30 - 2:30 PM

LATE-NIGHT FUNKADELICS: CLUB DRUGS

Chairs: Ryan A. Gregg and Michael S. Placzek

1:30 Effects of the GLT-1 activator ceftriaxone on the rewarding and locomotor activating effects of ‘bath salt’ compound 3,4-methylenedioxypyrovalerone in rats
R. A. Gregg¹, C. S. Tallarida¹, S. Rawls¹, ¹Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
1:45 Self-administration of second-generation synthetic cathinones in rats
J. Naylor1, E. Townsend1, K. Freeman1, J. Rowlett2, B. E. Blough3, S. L. Huskinson1,
1Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS, 2University of Mississippi Medical Center, Jackson, MS, 3Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, NC

2:00 Immediate and persistent effects of salvinorin A on the kappa opioid receptor in rodents, monitored in vivo with PET
M. S. Placzek2,1, G. C. Van de Bittner1, H. Wey1, S. E. Lukas2, J. M. Hooker1, 1Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA

2:15 Body temperature and cardiovascular effects of some synthetic cannabinoids found in “spice” products
C. W. Schindler1, Z. Justinova1, E. B. Thorndike1, S. R. Goldberg1, M. H. Baumann2,
1Preclinical Pharmacology, NIH/NIDA Intramural Research, Baltimore, MD, 2Designer Drug Research, NIH/NIDA Intramural Research, Baltimore, MD

Oral Communications 17
McArthur Ballroom 4
1:30 - 2:30 PM

MALADAPTIVE ALCOHOL LIBATIONS AND FIREFLARE:
ALCOHOL ABUSE

Chair: Elizabeth J. Santa Ana

1:30 Early parental supply of alcohol and alcohol consumption in mid-adolescence: A longitudinal study
R. P. Mattick1, M. Wadolowski1, A. Aiken1, J. Najman1, K. Kypri4, T. Slade1, D. Hutchinson1, R. Bruno2, N. McBride3, 1National Drug & Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, 2School of Psychology, University of Tasmania, Hobart, TAS, Australia, 3School of Public Health, University of Queensland, Brisbane, QLD, Australia, 4Centre for Clinical Epidemiology & Biostatistics, School of Medicine & Public Health, University of Newcastle, Newcastle, NSW, Australia, 5National Drug Research Institute, Curtin University, Perth, WA, Australia

1:45 Delay discounting and alcohol abuse among early adolescents
C. Lopez-Nuñez, S. Weidberg, V. Martinez-Loredo, I. Pericot-Valverde, R. Secades-Villa, J. Fernández-Hermida, Department of Psychology, University of Oviedo, Oviedo, Spain

2:00 6-month follow-up of baclofen treatment in patients with alcohol use disorder and other psychiatric comorbidities
B. Gelot1, M. Fatseas1, F. Serre1, C. M. Denis2,1 J. Dubernet3, S. Sarram3, M. Auriacombe1, 1Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, 2University of Pennsylvania, Philadelphia, PA, 3Addiction Psychiatry, CH Ch Perrens/CHU Bordeaux, Bordeaux, France

2:15 Impact of telehealth in-home-messaging devices on alcohol use in dually diagnosed veterans
E. J. Santa Ana1, S. Martino2, M. Gebregziabher1, 1Charleston VAMC and Medical University of South Carolina, Charleston, SC, 2Yale University School of Medicine, West Haven, CT
Oral Communications 18

MUST ACT, LITTLE FORETHOUGHT: IMPULSIVITY

Chair: Ayca Coskunpinar

1:30 The effects of mirtazapine on pramipexole-induced riskiness in a rat model of Parkinson’s disease
N. A. Holtz², S. E. Tedford², A. Persons¹, C. Napier¹, Rush University Medical Center, Chicago, IL, ²Pharmacology, Rush University Medical Center, Chicago, IL

1:45 The protective effect of enrichment on drug abuse vulnerability may reflect a decrease in mood-based impulsivity using a rat model of negative urgency
D. B. Vazquez-Sanroman¹², M. T. Bardo¹², Psychology, University of Kentucky, Lexington, KY, ²Center for Drug Abuse Research Translation, Lexington, KY

2:00 Nicotine shows a therapeutic effect on impulsivity through a different mechanism from that of paroxetine
H. Miyata¹, N. Murota², K. Sawa³, N. Hironaka⁴, K. Nakayama¹, Psychiatry, Jikei University School of Medicine, Tokyo, Japan, ²Pharmacology, Ina-Research, Tokyo, Japan, ³Graduate School of Humanity, Senshu University, Kawasaki, Japan, ⁴Pharmacology, Mitsubishi Chemical Medience Corp, Udo, Japan

2:15 Sex differences in effects of trait impulsivity on vulnerability to substance dependence
A. Coskunpinar³, J. Vassileva², E. Martin¹, Psychiatry, Rush University Medical Center, Chicago, IL, ²Virginia Commonwealth University, Richmond, VA, ³Behavioral Sciences, Rush University Medical Center, Chicago, IL

SWEEPSTAKES DRAWING

McArthur Ballroom 4
2:45 - 3:15 PM
YOU MUST BE SEATED IN ONE OF THE SESSIONS STARTING AT 1:30 PM IN ORDER TO HAVE YOUR BADGE COLLECTED FOR THE DRAWING

HAVE A SAFE TRIP HOME!

SEE YOU IN LA QUINTA, CA, JUNE, 11-16, 2016
<table>
<thead>
<tr>
<th>Author Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aarde, S. M.</td>
<td>68</td>
</tr>
<tr>
<td>Abdolahi, A.</td>
<td>99</td>
</tr>
<tr>
<td>Abrouk, N. E.</td>
<td>94</td>
</tr>
<tr>
<td>Abts, K.</td>
<td>19</td>
</tr>
<tr>
<td>Acharaya, S.</td>
<td>22</td>
</tr>
<tr>
<td>Acheampong, A.</td>
<td>20, 64</td>
</tr>
<tr>
<td>Acosta, P.</td>
<td>103</td>
</tr>
<tr>
<td>Adamson, S.</td>
<td>97</td>
</tr>
<tr>
<td>Addicott, M.</td>
<td>99</td>
</tr>
<tr>
<td>Ades, P.</td>
<td>55</td>
</tr>
<tr>
<td>Adler, Martin W.</td>
<td>1</td>
</tr>
<tr>
<td>Agage, D.</td>
<td>18</td>
</tr>
<tr>
<td>Aguilar-Moya, R.</td>
<td>19</td>
</tr>
<tr>
<td>Ahamad, K.</td>
<td>17</td>
</tr>
<tr>
<td>Aharonovich, E.</td>
<td>19, 80</td>
</tr>
<tr>
<td>Ahmad, I.</td>
<td>86</td>
</tr>
<tr>
<td>Ahmed, M. S.</td>
<td>54, 55, 79</td>
</tr>
<tr>
<td>Ahmed, R.</td>
<td>87</td>
</tr>
<tr>
<td>Ahmed, S.</td>
<td>11</td>
</tr>
<tr>
<td>Ahn, W. 2, 14</td>
<td></td>
</tr>
<tr>
<td>Ahuama-Jonas, C.</td>
<td>20</td>
</tr>
<tr>
<td>Aiello, A.</td>
<td>3</td>
</tr>
<tr>
<td>Aiken, A. 109</td>
<td></td>
</tr>
<tr>
<td>Akpara, U.</td>
<td>62</td>
</tr>
<tr>
<td>Akutagava-Martins, G.</td>
<td>52</td>
</tr>
<tr>
<td>Al-Halabí, S.</td>
<td>78</td>
</tr>
<tr>
<td>Al-Tayyib, A.</td>
<td>79</td>
</tr>
<tr>
<td>Alamian, A.</td>
<td>57</td>
</tr>
<tr>
<td>Alaniz, V. M.</td>
<td>23</td>
</tr>
<tr>
<td>Albertella, L.</td>
<td>19, 95</td>
</tr>
<tr>
<td>Alcover, K.</td>
<td>65</td>
</tr>
<tr>
<td>Alden, H. 22</td>
<td></td>
</tr>
<tr>
<td>Aldrich, J.</td>
<td>15</td>
</tr>
<tr>
<td>Aleixandre-Agulló, R.</td>
<td>20</td>
</tr>
<tr>
<td>Aleixandre-Benavent, R.</td>
<td>19, 20</td>
</tr>
<tr>
<td>Alexander-Street, A.</td>
<td>62</td>
</tr>
<tr>
<td>Alexandre, J.</td>
<td>10, 102</td>
</tr>
<tr>
<td>Alfonso, A.</td>
<td>77</td>
</tr>
<tr>
<td>Alford, D. 15, 22</td>
<td></td>
</tr>
<tr>
<td>Allen, A. M.</td>
<td>82</td>
</tr>
<tr>
<td>Allen, C. 61</td>
<td></td>
</tr>
<tr>
<td>Allen, N. 71</td>
<td></td>
</tr>
<tr>
<td>Allen, S. 82</td>
<td></td>
</tr>
<tr>
<td>Allende-labastida, J.</td>
<td>13</td>
</tr>
<tr>
<td>Allsop, S. 67</td>
<td></td>
</tr>
<tr>
<td>Alonso Pérez, F.</td>
<td>56</td>
</tr>
<tr>
<td>Alshaarawy, O.</td>
<td>64</td>
</tr>
<tr>
<td>Altomare, D.</td>
<td>27</td>
</tr>
<tr>
<td>Altschuler, J. H.</td>
<td>70</td>
</tr>
<tr>
<td>Alvarós, J. 77</td>
<td></td>
</tr>
<tr>
<td>Alving, C. 25</td>
<td></td>
</tr>
<tr>
<td>Amador, C. 3</td>
<td></td>
</tr>
<tr>
<td>Amaro, H. 20</td>
<td></td>
</tr>
<tr>
<td>Amin, J. 81</td>
<td></td>
</tr>
<tr>
<td>Ananthan, S. 13</td>
<td></td>
</tr>
<tr>
<td>Anastasio, N. C.</td>
<td>9, 10, 11, 12, 14, 28, 71</td>
</tr>
<tr>
<td>Andersen, J. M.</td>
<td>11, 54</td>
</tr>
<tr>
<td>Andersen, R. 21, 22</td>
<td></td>
</tr>
<tr>
<td>Anderson-Carpenter, K. D.</td>
<td>78</td>
</tr>
<tr>
<td>Andrade, A. 78</td>
<td></td>
</tr>
<tr>
<td>Andrade, L. H. 78</td>
<td></td>
</tr>
<tr>
<td>Andrews, B. 56, 68</td>
<td></td>
</tr>
<tr>
<td>Anez, L. 84</td>
<td></td>
</tr>
<tr>
<td>Ang, A. 19, 60, 61, 76, 106</td>
<td></td>
</tr>
<tr>
<td>Angulo-C, E. 84</td>
<td></td>
</tr>
<tr>
<td>Annon, J. 59, 61, 76, 106</td>
<td></td>
</tr>
<tr>
<td>Anthony, E. 79</td>
<td></td>
</tr>
<tr>
<td>Anthony, James C. 4, 55, 63, 64, 65, 79, 94, 99</td>
<td></td>
</tr>
<tr>
<td>Antoine, D. G. 10, 18</td>
<td></td>
</tr>
<tr>
<td>Antoline, J. 25</td>
<td></td>
</tr>
<tr>
<td>Antonijooan, R. M. 96</td>
<td></td>
</tr>
<tr>
<td>Aphyyanaphongs, Y. 18</td>
<td></td>
</tr>
<tr>
<td>Arfken, C. L. 17, 100</td>
<td></td>
</tr>
<tr>
<td>Arger, C. A. 84</td>
<td></td>
</tr>
<tr>
<td>Arheart, K. 64</td>
<td></td>
</tr>
<tr>
<td>Armah, K. 107</td>
<td></td>
</tr>
<tr>
<td>Armenta, R. 66</td>
<td></td>
</tr>
<tr>
<td>Arnetz, B. 100</td>
<td></td>
</tr>
<tr>
<td>Arnetz, J. 100</td>
<td></td>
</tr>
<tr>
<td>Aronsen, D. 75</td>
<td></td>
</tr>
<tr>
<td>Aronson, I. D. 104</td>
<td></td>
</tr>
<tr>
<td>Arredondo, J. 23</td>
<td></td>
</tr>
<tr>
<td>Arria, A. M. 64</td>
<td></td>
</tr>
<tr>
<td>Arroyo, M. 21, 22</td>
<td></td>
</tr>
<tr>
<td>Ashrifioun, L. 89, 91</td>
<td></td>
</tr>
<tr>
<td>Aston, E. 14, 95</td>
<td></td>
</tr>
<tr>
<td>Atchison, J. J. 76</td>
<td></td>
</tr>
<tr>
<td>Auriacombe, M. 10, 16, 55, 81, 91, 102, 109</td>
<td></td>
</tr>
<tr>
<td>Aystic, E. A. 20, 79, 80</td>
<td></td>
</tr>
<tr>
<td>Ayers, K. L. 3</td>
<td></td>
</tr>
<tr>
<td>Babaloni, S. 3, 96, 97</td>
<td></td>
</tr>
<tr>
<td>Babin, S. F. 63</td>
<td></td>
</tr>
<tr>
<td>Bachman, J. 26</td>
<td></td>
</tr>
<tr>
<td>Back, Sudie E. 3, 7</td>
<td></td>
</tr>
<tr>
<td>Bagwell, B. 19</td>
<td></td>
</tr>
<tr>
<td>Baker, E. 80</td>
<td></td>
</tr>
<tr>
<td>Baker, N. 53</td>
<td></td>
</tr>
<tr>
<td>Bakhshaie, J. 78</td>
<td></td>
</tr>
<tr>
<td>Baldwin, A. 84</td>
<td></td>
</tr>
<tr>
<td>Bale, A. S. 59</td>
<td></td>
</tr>
<tr>
<td>Balodis, I. 53</td>
<td></td>
</tr>
<tr>
<td>Bandiera, F. 55</td>
<td></td>
</tr>
<tr>
<td>Banducci Rahe, B. 89</td>
<td></td>
</tr>
<tr>
<td>Banerjee, G. 100</td>
<td></td>
</tr>
<tr>
<td>Banerjee, S. 8</td>
<td></td>
</tr>
<tr>
<td>Banich, M. T. 97, 98</td>
<td></td>
</tr>
<tr>
<td>Banks, M. 104</td>
<td></td>
</tr>
<tr>
<td>Banta-Green, Caleb J. 2</td>
<td></td>
</tr>
<tr>
<td>Barbosa-Leiker, Celestina 5 65</td>
<td></td>
</tr>
<tr>
<td>Bardo, C. M. 62</td>
<td></td>
</tr>
<tr>
<td>Bardo, Michael T. 2, 13, 52, 90, 110</td>
<td></td>
</tr>
<tr>
<td>Bares, Cristina B. 5, 62</td>
<td></td>
</tr>
<tr>
<td>Barnes, A. 96</td>
<td></td>
</tr>
<tr>
<td>Barnet, C. 86</td>
<td></td>
</tr>
<tr>
<td>Barnett, G. 79</td>
<td></td>
</tr>
<tr>
<td>Barnhouser, C. 10</td>
<td></td>
</tr>
<tr>
<td>Barr, J. L. 28</td>
<td></td>
</tr>
<tr>
<td>Barral, C. 77</td>
<td></td>
</tr>
<tr>
<td>Barratt, M. 101</td>
<td></td>
</tr>
<tr>
<td>Barrett, F. S. 57</td>
<td></td>
</tr>
<tr>
<td>Barry, D. T. 100</td>
<td></td>
</tr>
<tr>
<td>Barry, K. 87</td>
<td></td>
</tr>
<tr>
<td>Bart, G. 15, 16</td>
<td></td>
</tr>
<tr>
<td>Bartu, A. 67</td>
<td></td>
</tr>
<tr>
<td>Baskin, B. M. 26</td>
<td></td>
</tr>
<tr>
<td>Batchelder, A. 17, 24</td>
<td></td>
</tr>
<tr>
<td>Batki, Steven L. 91</td>
<td></td>
</tr>
<tr>
<td>Baumann, M. H. 13, 27, 109</td>
<td></td>
</tr>
<tr>
<td>Bear, S. A. 105</td>
<td></td>
</tr>
<tr>
<td>Beardsley, P. 71</td>
<td></td>
</tr>
<tr>
<td>Bebarta, V. 89</td>
<td></td>
</tr>
<tr>
<td>Bechara, A. 14, 60, 98</td>
<td></td>
</tr>
<tr>
<td>Beck, Z. 25</td>
<td></td>
</tr>
</tbody>
</table>
AUTHOR INDEX

Becker, W. 16, 70, 100
Beckmann, J. S. 2, 10
Bedell, P. 20
Bedi, G. 99
Begnis, A. P. 78
Behrendt, S. 105
Bedell, P. 20
Bennett, A. S. 22, 58
Benishek, L. 88
Bennett, A. S. 22
Benowitz, N. 55
Benz, M. B. 77
Benowitz, N. 55
Benzon, C. 106
Bereket, S. 18
Berger, I. 64
Bergeria, C. L. 69
Bergman, J. 2, 12
Berkowitz-Sturgis, E. 98
Bernstein, E. 26
Bernstein, I. M. 67
Bernstein, J. 22
Bernstein, S. 82
Berritini, W. 52
Bertrand, S. J. 107
Besharat, A. C. 58
Bettes, J. 14
Beylotte, F. 3
Bhatt, U. 101
Bickel, Warren K. 3, 13, 14, 56, 57, 67, 88
Bielavitz, S. 16
Bierer, S. 23
Bigelow, G. 10, 94
Billing, S. 25
Binswanger, I. A. 22
Bishop, T. M. 89, 91
Bixler, E. 15
Bjork, J. M. 14, 98
Black, A. C. 80
Blady, S. J. 99
Block, R. 99
Blokhina, E. 17, 18, 76, 107
Blough, B. E. 12, 109
Blow, F. 20, 21, 79, 87
Bluthenthal, R. 3, 65, 99, 102
Bobashev, Georgiy 4, 11
Bobes, J. 78
Bock, Beth 66
Bogen, I. 54
Bogenschutz, M. 87, 88, 102
Bohnert, A. S. 21, 87, 103
Bohnert, K. 64
Boix Escolan, F. 11, 54
Bolao, F. 85
Bolin, B. L. 61, 93
Bonab, A. A. 13
Bonadonna, J. 27
Bonar, Erin E. 21, 72, 79, 103
Bond, M. 58
Bone, C. 22
Bonn-Miller, M. O. 97
Bonson, K. 93
Booker, J. 4
Boos, T. L. 59
Booth, B. M. 79, 87
Booth, R. E. 3, 23
Booze, D. 107
Bordnick, P. 76
Borille, B. T. 85
Borodovsky, J. 89
Borsari, B. 77, 96
Bough, K. J. 59
Boukli, N. 16
Boulos, P. 97
Bouril, A. 99
Bowen, Sarah 66
Boyd, C. J. 80, 101
Boyer, E. W. 19
Bradshaw, C. 63
Brady, Kathleen T. 8, 28, 53, 57
Brands, B. 94, 96
Brandt, L. 24
Brason, II, Fred Wells 8, 51
Brech, M. 76
Breen, C. L. 67
Bresnan, A. 55, 68
Bresnani, E. 59, 79, 80
Brewer, Judson 66
Briceno, A. 87
Bridden, C. 17, 18, 107
Brigham, G. 61
Briones, M. 60, 100
Britch, S. 95
Britton, P. 22
Broadbridge, C. 100
Brochman, G. 54
Brooks, A. C. 20, 88
Brooks, Audrey 29
Brooks, D. J. 55, 95
Brooks, O. 55, 65
Brooner, R. K. 76
Brosig, R. 63, 99
Brotman, L. M. 107
Brown, L. S. 18, 104
Brown, Q. 24, 84
Brown, R. W. 62
Browne, F. 21
Browne, R. 76
Bruno, R. 14, 54, 70, 94, 97, 101, 109
Bryant, K. 16
Bubar, M. J. 12
Buchert-Bartelson, B. 8
Buchhalter, A. R. 18, 105
Bucholz, K. K. 77
Buck, M. 60
Budman, S. H. 58, 100
Budney, Alan J. 19, 30, 63, 68
Buehringer, G. 105
Bueno-Cañigral, F. 19, 20
Bugbee, B. A. 64
Bukhari, M. O. 27
Bukholt, N. 75
Bunce, S. 15
Bunn, J. 87
Burlew, K. 20
Burlew, Kathleen 73
Burnett, J. 4
Burns, L. 64, 67, 81, 88, 101, 102
Burón, P. 78
Burrell, L. 16, 102
Burrow-Sanchez, J. 73
Burston, J. 96
Busch, S. 82
Bushara, N. 17, 76
Busse, A. 59
AUTHOR INDEX

Butelman, E. 70
Butler, K. 81
Butler, S. F. 58, 64, 100, 101
Buttram, M. E. 53, 57
Buu, A. 20, 79
Bybee, D. 21
Byrne, E. 88

Cacciola, J. 80
Caetano, S. 78
Caldeira, K. M. 64
Calderon, S. N. 58, 104
Calderon, V. 97
Callaghan, R. C. 23, 24
Camenga, D. R. 62, 68
Campbell, Aimee 29, 87, 88
Campbell, Cynthia 4
Campbell, G. 14, 54, 70, 94
Campion, T. 69
Campollo, O. 84
Cannizzaro, D. 19
Cano, M. 23
Canterberry, M. 57
Canva, V. 81
Capaldi, D. 27
Capaldi, Deborah 7
Capatti, G. R. 89
Carbonaro, T. M. 75
Carise, D. 88
Carlezon, W. 12
Carliner, H. 3
Carlini, E. 78
Carlson, R. 19, 21
Carlton, S. 106
Carney, T. 21
Carpenedo, C. M. 20, 79, 88
Carpenter, M. J. 18
Carrico, Adam W. 17, 72
Carroll, K. M. 53, 58, 60, 84, 86, 99
Carroll, M. E. 8, 14, 52
Carroll, Marilyn E. 74
Carter, P. M. 20
Casas, M. 77
Case, T. 59
Cassidy, T. A. 58, 64, 100, 101
Cassidy, T. A. 58, 64, 100, 101
Castaldelli-Maia, J. M. 78
Castillo, C. 58, 91
Castro, S. M. 85
Castro, Y. 23
Cavallo, D. A. 62, 68
Cepeda, A. 99
Cercone, Sarah A. 65, 67
Cerda, M. 23, 58, 64, 100
Cerulli, C. 20
Chaison, C. 18
Chalmers, D. 94
Chalmers, S. 21
Chambers, J. E. 20, 88
Chan, C. 52
Chandler, Redonna K. 2
Chandra, M. 63
Chandra, S. 103
Chang, C. 25
Chang, K. 83
Chang, L. 59
Chauhan, K. 62
Chavez, K. 19
Chawarsi, M. C. 76, 82, 86
Cheetham, S. 12
Chen, C. 23, 75, 78, 83
Chen, H. 76
Chen, K. 78
Chen, L. 104, 106
Chen, Li-Shiun 71
Chen, N. 94
Chen, W. 78
Chen, Xiangning 71
Chen, Y. 11
Cheng, D. M. 15, 17, 18, 22, 70, 88, 107
Chenoweth, Meghan 71
Chermack, S. 20, 21
Chesler, Elissa J. 108
Chhatre, S. 87, 101
Chilcoat, Howard 7, 100
Childress, Anna Rose 6, 97, 98, 99
Chisolm, M. S. 69, 84
Choi, H. 79
Chokron Garneau, H. 76
Choo, E. 19
Chooi, W. 86
Chow, J. 1.0
Chrisphonte, M. 62
Chu, D. 99, 102
Chudzynski, J. 106
Chung, T. 76
Ciccarone, D. 101
Cicero, Ted 90
Claramunt, J. 96
Clark, H. Westley 28
Claus, E. D. 98
Clasen, Thomas 51
Clement, N. 97
Clingan, S. 14
Cochran, G. 82, 87
Coe, M. A. 15
Coffin, Phillip O. 2, 66
Cohen, A. 9
Cohen, M. 14, 54, 70, 94
Cohen, S. 81
Cohn, J. A. 17
Colby, S. 9, 56
Cole, M. 68
Coleman-Cowger, V. H. 84
Coleman, S. 107
Coley, H. 107
Collins, M. 8
Collombat, J. 10
Colucci, S. 54
Comer, Sandra D. 11, 21, 26, 76, 90
Comiran, E. 85
Comly, R. 102
Compton, Wilson 8
Cone, E. J. 18, 105
Connell, C. 62, 68
Conner, K. R. 91
Conniff, J. 86
Connor, J. 85
Constable, R. 53
Cook, C. 16
Cook, J. 93
Cook, M. 102
Cook, R. 16, 95
Cooper, C. 106
Cooper, Ziva D. 1, 99
Cope, L. M. 69, 97

113
AUTHOR INDEX

Copeland, A. L. 57
Copeland, Jan 4, 19, 22, 53, 95, 97
Copenhaver, M. 52
Copersino, M. L. 99
Coplan, Paul 7, 100
Coppe, B. C. 85
Cornelius, J. R. 76
Cornelius, M. 67
Cornelius, M. C. 70
Correa Fernández, V. 59
Corsi, K. F. 3, 23, 65
Coskunpinar, Ayca 110
Cotter, A. 27
Cottler, L. 20, 21, 53, 78, 79, 95, 101, 102
Cowan, Ronald 27, 28
Cox, N. 22
Coyle, J. 12
Craft, Rebecca 1
Crane, Nataania A. 2, 27, 77
Cranford, J. A. 101
Cravatt, B. 71
Creek, K. E. 27
Crist, R. 52
Croff, R. 85
Crofton, E. J. 12
Crooks, P. A. 13
Crosby, R. 17
Crosier, B. S. 19, 68
Crothers, K. 16
Crowley, T. J. 97, 98
Cruz, Silvia L. 70
Cruz, V. 94
Crystal, S. 70, 100
Cubano, L. 16
Cuevas-Mota, J. 66
Culver, J. P. 13
Culverhouse, A. 9
Cummings, Brian 108
Cummings, K. 65
Cummins, E. D. 62
Cunningham, J. K. 24, 84
Cunningham, Kathryn A. 9, 10, 11, 12, 13, 14, 28, 90, 98
Cunningham, R. M. 20, 21, 79, 87
Curnyn, C. 17
Curran, M. 97
Cutler, A. 55
Czachowski, C. L. 9
Czoty, Paul W. 8, 69
D’Anna, L. 61
D’Onofrio, G. 82
Daar, E. 107
Daigre, C. 77
Daiter, J. 83
Dakwar, Elias 61, 66
Daley, D. 76
Dalwani, M. 97, 98
Daniel, T. O. 56
Daniulaityte, R. 19, 21
Darfler, K. 15, 16
Dargan, P. I. 58
Dart, Richard C. 8, 58, 74, 91
Darwish, M. 58
Das, M. 107
Dasgupta, Nabarun 7, 74
Daulouede, J. 10, 16
Davidson, P. J. 24, 87
Davidson, S. 19
Davidson, T. 106
Davis, D. R. 89
Davis, F. 85
Davis, J. 60
Davis, J. M. 3, 23
Davis, M. T. 88
Daws, R. 65
Day, N. 67
de Dios, M. 23
De Genna, Natacha 6, 67
De La Garza, II, R. 9, 27, 68, 103
De la Torre, R. 75
de Wit, H. 60
Dean, R. 15
Deaver, D. 94
Debrabant, R. 10, 91
DeBrule, D. S. 68
Decker, A. M. 13
Decker, S. 84
Dedert, Eric 7
Degenhardt, L. 14, 54, 63, 70, 81, 94, 101
del Rio, C. 80, 107
Delano, K. 67
Delcher, C. 101
DelDonno, S. 27
Delker, E. 19
Della Vedova, C. 15
Delucchi, K. 55
DeMicco, E. 80
Demirdjian, L. 100
Denis, C. M. 10, 16, 109
Dennis, L. 16
Dennis, Michael L. 29
Dental PBRN Collaborative
Group, N. 57
DePoy, L. 106
Deren, S. 81
Derrick, J. L. 67
Des Jarlais, Don C. 72
Desrosiers, A. 86
DeVeaux-Geiss, A. 100
DeVito, E. E. 53, 60
DeVries, W. 104
Dewey, William L. 51
DeYoung, D. 60
Diaz-Mesa, E. 78
Dickerson, D. 106
Dickson, M. F. 18, 20
Dietrich, M. 28
Dietze, P. 103
Diggins, A. 102
DiGirolamo, G. 58, 82
DiLeone, R. J. 12
Dillon-Carter, O. 27
Dimova, R. 104
Dineley, K. 13, 106
Ding, Z. 106
Dixon, A. E. 55
Djomboue, P. 81
Dobrer, S. 17
Dodd, D. 58
Doe-Simkins, M. 101
Dolan, S. 94
Dolezal, B. 106
Domingo-Salvany, A. 58
Dominguez, B. 77
Donahue, R. 12
AUTHOR INDEX

Donny, E. 8, 77
Donohue, J. M. 82
Doran, A. 25
Doran, N. 86
Douaihy, A. 76
Doughen, B. 8
Douglas, S. B. 19, 79
Dowd, E. D. 99
Dowdle, L. T. 89, 104
Doyle, M. 107
Drainoni, Mari-Lynn 6, 26, 80
Dreifuss, J. A. 58
Drobes, D. J. 52, 77
Dry, M. 15
Du, H. C. 12
Duan, R. 80
Dubernet, J. 109
Duburque, C. 81
Dugosh, K. L. 20, 79, 88, 102, 107
Duke, A. N. 93
Duncan, A. 87
Dunn-Sims, E. 25
Dunn, E. 3
Dunn, Kelly E. 73, 94
Dunn, T. 13
Dunne, E. M. 102
Duperrouzel, J. C. 63
Dwoskin, L. P. 9, 13, 26
Eans, S. O. 15
Eaton, N. R. 86, 91
Echevarria, M. N. 89
Eddens, K. 17
Edelman, E. 70
Edelman, E. J. 16, 18, 100, 107
Edwards, Emmeline 66
Edwards, H. 60
Edwards, R. R. 15, 70
Egido, A. 77
Ehrman, R. 98
Eibl, J. K. 83
Eiden, R. D. 67
Eisenhofer, J. 68
Eissenberg, T. 55, 68
Elayi, C. 3, 82, 96
Elayi, S. 96
Elkoussi, A. A. 93
Elliott, E. 67
Elliott, L. 22, 58
Ellison, J. 26
Elston, R. C. 52
Emu, B. 107
Emurian, C. E. 98
Epstein-Ngo, Q. 20, 80, 101
Epstein, D. 3, 18, 26, 102
Epstein, L. H. 56
Erlyana, E. 65
Evans-Polce, R. J. 85
Evans, D. E. 52
Evans, Elizabeth 5, 53, 81, 83, 107
Evans, J. L. 87
Evelyn, M. 62
Evins, A. 57, 97
Ewald, A. 71
Ewin, S. 9
Fairman, B. J. 64
Fakunle, D. O. 20, 65
Falb, V. 103
Faller, S. 24
Falster, M. 81
Fan, X. 12
Fang, L. 59
Fang, S. 23
Fant, R. V. 105
Farber, E. 80
Farid Araki, K. 94
Farmer, S. L. 14, 55
Farre, M. 75, 91
Fatseas, M. 10, 55, 91, 102, 109
Faure, E. 82
Favor, K. 88
Feaster, D. F. 80, 107
Feaster, D. J. 85, 103
Feeney, G. 85
Feinstein, M. 11
Feldman, J. 26
Feldstein Ewing, Sarah 91
Fergusson, D. 63
Fernández-Artamendi, S. 78
Fernández-Hermida, J. 109
Fernandez, A. 96
Ferreira e Ferreira, E. 10
Ferreira-Pinto, J. 53
Ferronatto, P. B. 62, 78
Fertuck, E. 76
Festinger, David S. 20, 59, 102, 107
Fidalgo, T. M. 78, 89
Fiellin, D. A. 16, 70, 82, 83, 100
Filbey, F. 96
Filbey, Francesca 91
Fillingim, R. B. 57
Fink, D. S. 58, 84
Finley, E. 89
Finnegan, Loretta 1, 69
Fiorentin, T. R. 85
Fischer, B. 96
Fischer, Gabriele 24, 51
Fischman, A. J. 13
Fisher, D. G. 14, 60, 61, 65, 103
Fishman, M. J. 79
Fitzmaurice, G. 58
Fitzsimons, H. 69, 84
Flack, D. 61
Flavel, S. C. 60
Flax, S. M. 11, 95
Fleming, A. B. 54
Flentje, A. 54, 104
Fletcher, J. B. 19, 61
Flores, David V. 3, 4
Fogel, J. S. 56, 95
Fokina, V. M. 54, 55
Follett, M. E. 93
Fong, C. 26
Fonseca, F. 58, 75, 91
Forcehimes, A. A. 59, 88
Forman, L. 17
Forray, A. 84
Forster, G. L. 28
Forster, M. J. 94
Foster, D. W. 84
Fox, H. C. 53
Fox, R. G. 9, 11, 12, 28, 106
Franck, C. T. 13, 14, 88
Frankforter, T. 84
Franklin, T. 97, 98
Freeman, K. 11, 93, 106, 109
AUTHOR INDEX

Freiberg, M. 107
French, H. T. 52
Friedman, E. 8
Friedman, K. 54
Friedman, S. R. 80, 81
Friedmann, P. D. 26, 105
Frimpong, J. A. 80
Frisell, F. 82
Froeliger, B. 89, 99
Fronk, G. 25
Funada, M. 75, 95
Furlan, A. 94
Furnari, M. A. 3, 26, 102
Furr-Holden, C. M. 64, 77
Fuster, D. 82, 85
Gaalema, Diann 55, 73
Gabriel, L. 27, 77
Gaines, T. 23
Gaither, J. R. 6, 16, 70, 100
Galea, S. 3, 58, 64, 65
Galván, G. 78
Galvez, R. 26
Gamaleddin, I. 96
Ganno, M. L. 15, 107
Gao, J. 13
Gao, S. 69
Garcia-Keller, C. 71
García-Portilla, P. 78
Garcia-Rodriguez, O. 56
Garcia-Romeu, A. P. 56
Garcia, A. 89
Garcia, M. 84
Garcia, R. 27
Gardner, E. 22
Garey, L. 56
Garfein, R. 66
Garg, P. 64
Garina, D. 24
Garnick, D. W. 23
Garrido, M. 78, 96
Garza, J. 59
Gasier, M. 58
Gaskin, S. 80
Gatch, M. B. 94
Gatley, J. 23

Gauthier, J. M. 12
Gawrysiak, M. J. 98
Gebregziabher, M. 109
Gelberg, L. 21, 22
Gellad, W. F. 82
Gelot, B. 109
Gentry, W. B. 54
Geoffroy, P. 89, 104
George, M. 57
Gereghty, S. 21
German, J. 88
German, N. A. 13
Gerra, G. 59
Ghitza, U. 26
Ghozland, S. 59
Gibert, C. 16
Gibson, K. 9
Gifford, A. 17
Gilbart, E. R. 97
Gilbertson, S. 11, 12
Gill, K. E. 3, 96
Gillette, B. 59
Gilman, J. 97
Gilmour, B. P. 13
Ginsburg, B. C. 89
Gipson, Cassandra D. 71
Giraldo, L. 58
Gitchell, J. G. 105
Glanz, J. 22
Glaser, P. 104
Glaser-Edwards, Suzette 30, 76, 77
Glass, A. 55, 95
Gnatienko, N. 17, 18, 107
Goddard, K. 22
Goldberg, S. R. 109
Goldenson, N. 52, 60
Goldman, M. 98
Goldschmidt, L. 67
Goldsmith, J. 52
Golroo, F. 19
Golub, A. 22, 58
Gomez Luna, S. E. 62
Gomez, A. M. 27
Gonzales-Castaneda, R. 19, 79, 106
Gonzalez Moreno-Zuniga, P. 66
Gonzalez-Espinosa, C. 70
Gonzalez, B. 86
Gonzalez, G. 58, 82
Gonzalez, I. 63
Gonzalez, J. 17, 77
González, M. 96
Gonzalez, R. 16, 63
Gooden, L. 107
Goodwin, R. 65, 78
Gordan, V. V. 57
Gordon, A. J. 16, 82, 100
Gordon, K. 70
Gordon, K. S. 16, 100
Gordon, M. S. 26
Gore-Langton, J. K. 11
Gosden, J. 15
Gottás, A. 54
Gould, T. 27, 62
Goulet, J. 70
Gourley, S. 106
Gowins, J. 27
Grabinski, M. 21
Grabowski, J. 55, 95
Graham, D. P. 68
Grana Mayne, R. 19
Grasing, K. 27
Grasso, S. 12, 59
Grau-López, L. 77
Gray, K. M. 18, 82
Grayson, Peter 108
Graziano, P. 63
Grebely, J. 81
Green, C. 13, 95
Green, Carla 7
Green, J. L. 58
Green, T. 12, 64, 101
Green, T. A. 12
Green, Traci C. 2
Greenfield, Shelly F. 29, 77
Greenwald, M. K. 13, 14, 16, 17, 21, 95
Gregg, Ryan A. 108
Grell, C. E. 87
Grewen, K. M. 84
Griffin, M. L. 58
AUTHOR INDEX

Hsu, T. 94
Hu, L. 61
Hu, M. 65, 86, 87, 88, 91
Hu, R. 58
Huang, D. Y. 53, 83
Huang, H. 78
Huang, L. 16
Hudson, J. 97
Huedo-Medina, T. B. 52
Huestis, M. A. 96
Hughes, J. 56
Hughes, S. M. 63
Huh, J. 99
Huhn, A. S. 15
Humphreys, M. 103
Hunkele, K. 86
Hunt, J. 104
Hunt, Priscilla 73
Hurd, Yasmin L. 25
Hunnicutt, H. 91
Huskinson, Sally L. 106, 109
Hutchinson, D. 63, 67, 109
Hynes, C. 82
Ibragimov, U. 103
Idrisov, B. 18
Ignacio, R. 87
Iguchi, Martin Y. 51, 73
Iles, B. 77
Ilgen, Mark A. 64, 73, 87, 103
Iwanicki, J. L. 6, 8
Izenwasser, Sari 90
Jaapar, S. 86
Jacobs, S. 67
Jacobson, A. 25
Jacobson, J. 107
Jacques, A. B. 85
Jaffe, J. H. 81, 83, 101
Jagannathan, K. 97, 98
Jagsch, R. 24
Jalah, R. 25
Jamil, H. 100
Jamison, R. N. 70
Janes, A. 55, 97, 99
Janganati, V. 13
Janssen, L. 69
Janulis, P. 54
Jayadevappa, R. 87, 101
Jayaram-Lindstrom, N. 53
Jefferson, A. 101
Jenab, S. 52
Jenkins, J. 60
Jensen, E. 97
Jensen, M. 78
Jentsch, J. David 74, 108
Jeon, S. 26
Jeong, E. 98
Jessell, L. 81
Jiang, H. 60
Jing, L. 9
Jobes, M. L. 3, 18, 26
Joel, T. 97
Johnson, A. 104
Johnson, E. 15
Johnson, J. A. 21
Johnson, Matthew W. 6, 28, 56, 57, 68, 75, 88
Johnson, P. S. 68, 88
Johnson, R. M. 63, 64
Johnston, L. A. 26
Jones, H. E. 17, 69, 84, 87
Jones, J. T. 84
Jones, Jermaine D. 21, 26, 76, 90
Jones, Y. 80
Jordan, C. J. 26
Jordan, Chloe J. 26
Jorga, A. 104
Joseph, J. E. 98
Justice, A. 16, 70, 83
Justinova, Z. 109
Jutras-Aswad, Didier 25
Kadakia, A. 100
Kahler, C. W. 14, 60, 95
Kalivas, P. W. 71
Kam, J. A. 63
Kampman, K. M. 3, 98
Kanayama, G. 97
Kang, S. 26
Kangiser, M. 9
Kantak, K. M. 12, 26
Kapadia, F. 80
Kaphalia, B. 13
Kaprio, J. 57
Kapur, B. 67
Karinen, R. 54
Karno, M. 77
Kasinather, V. B. 86
Kasper, J. M. 106
Kassell, M. T. 77
Kassem, L. 62
Kaye, N. 104
Katz, E. C. 23, 60
Kaufman, M. 97
Kay-Lambkin, Frances 30
Kayser, A. 14
Kearns, D. 106
Kelly, S. M. 78, 81
Kelly, T. H. 56, 95, 98
Kelly, U. 21
Kelsh, D. 94
Kempf, M. C. 80
Kendler, K. S. 62
Kennedy, A. 18
Kerns, R. 70, 100
Kerr, D. C. 27
Kerr, T. 17, 24
Kerridge, B. T. 80
Kerrigan, A. 97
Kershaw, S. 15
Kervran, C. 91
Kessler, F. H. P. 10, 24, 52, 61, 62, 85, 86
Ketcherside, A. 96
Keyes, K. M. 3, 24, 58, 64, 84
Keyser-Marcus, L. A. 14, 101
Khan, Maria R. 69, 72, 101, 107
Khan, S. R. 53
Kidorf, M. S. 76
Kilgalen, B. 55
Killeen, Therese 8, 29
Kiluk, B. D. 60, 84
Kim, G. 19
Kim, J. 28
Kim, J. E. 65
Kim, J. H. 23
Kim, J. K. 12
Kim, S. J. 18
Kim, T. W. 88
King, H. E. 11
King, V. L. 76
Kinlock, T. W. 26, 105
Kinnunen, T. H. 57
Kirby, K. C. 20, 59, 79, 80, 88
Kirby, S. 62
Kiriazova, T. K. 17
Kirisci, L. 53
Kirk, A. 78
Kirkpatrick, M. 52, 60, 63
Kirtadze, I. 17, 87, 103
Klambatsen, A. 52
Klein, A. B. 57
Klein, Michael 74
Klempener, E. M. 56
Klimas, J. 85
Kline, D. 21
Klinedinst, M. 75
Knight, J. 62
Knighton, J. 100
Knopf, S. P. 53
Knopik, V. 95
Knudsen, H. K. 20, 24
Koblan, K. S. 94
Koenen, K. C. 3
Koester, S. 22
Koffarnus, M. N. 13, 14, 88
Kohut, S. 12
Kollins, S. H. 23
Kondo, D. 98
Kong, G. 62, 68
Koon, K. 3
Koopmeiners, J. 77
Kopecky, E. A. 54
Koppelman, E. 26
Korch, R. 20
Koren, G. 67
Korhonen, T. 57
Kornegay, C. 89
Korte, J. E. 8
Korthuis, P. T. 16
Koshkina, E. 87
Kosten, T. 9, 14, 27, 61, 98
Koszowski, B. 84
Koutsenok, I. 59
Kowalczyk, W. J. 3, 26, 102
Kral, A. 3, 65, 99, 102
Krebs, C. 71
Krebs, E. 81
Kreek, M. J. 27, 70, 107
Krishnan-Sarin, S. 62, 68
Kritz, S. 18, 104
Kromrey, Sarah A. 8
Krupitsky, E. 17, 18, 76, 87, 107
Kulisevsky, J. 97
Kulkarni, R. 12
Kumar, S. 18
Kurzziel, G. 23
Kurti, A. N. 89
Kurtz, S. P. 53, 57, 100
Kutlu, M. G. 27
Kutz, S. 75
Kyburz, B. A. 59
Kypri, K. 109
Lacadie, C. 53
LaConte, S. 14
Lacy, R. 11, 25
Laezza, F. 12
Lagzdins, D. 96
Lam, C. 59
Lamp, A. 55, 65
Landino, S. 12
Landovitz, R. J. 61
Lane, S. D. 13, 14, 95, 98
Langenecker, S. A. 27, 77
Langleben, D. 98, 99
Lanier, Ryan K. 9
Lankenhau, Stephen 73
Larance, B. 14, 54, 70, 94
Larney, S. 81
Larson, M. 18
Lasher, B. 91
Lasopa, S. O. 79, 95
Latimer, W. W. 102
Latypov, A. 103
Lauby, J. 20, 88
Laudet, A. B. 88
Lawental, M. 53
Le Foll, B. 96
Le Lait, M. C. 8, 91
Le Pelley, M. 95
Le Truong, G. 16
Le, G. M. 15, 16
Le, K. 21
Le, T. 24, 56, 68
Lederhos, C. 55, 65
Ledgerwood, D. M. 17, 85
Lee, D. 101, 106
Lee, D. C. 19, 68
Lee, J. D. 18, 26, 105
Lee, S. 75
Leming, M. 84
Lemons III, A. 60
Leo, H. 56
Leong, S. 91
Lerner, A. 104
Lertch, E. 81
Leslie, K. 27
Leukefeld, C. G. 18, 20, 59, 100
Leventhal, Adam 52, 60, 63, 66
Levesque, A. 88
Levi-Minzti, Maria A. 72, 100
Levin, F. R. 55, 95
Levina, J. A. 81
Levy-Cooperman, N. 94
Lewis, D. 83
Lewis, M. 94
Leyro, T. M. 85
Lhommeau, N. 102
Li, D. 12
Li, F. 25
Li, J. 9, 13
Li, L. 53, 81, 83, 107
Li, P. 12
Li, S. 12, 99
Li, W. I. 54
Li, X. 57
Li, Z. 98
Liao, Y. 75
Lichtman, Aron 71, 105
Liebschutz, J. M. 15
AUTHOR INDEX

Lien, Y. 23
Lile, Joshua A. 1, 56, 60, 61, 95, 98, 104
Lim, J. 79
Lima, V. D. 107
Limberger, R. P. 85
Lin, H. 52
Lin, L. A. 79
Lin, M. 18, 104
Lin, S. 53
Lindblad, R. 59, 61
Lindstrom Johnson, S. 63
Ling, W. 3, 52, 57, 59, 60, 61, 76
Lintzeris, N. 14, 54, 70, 94, 101
Lioznov, D. 18, 107
Lira, M. C. 15, 70
Lisdahl, Krista M. 90, 91, 97
Lisowski, R. 16
Lister, J. J. 13, 14, 85
Liu, H. 67
Liu, J. 67
Liu, L. 24, 83, 107
Liu, W. 67
Liu, Y. 12
Livingston, N. 54
Ljungberg, T. 82
Lloyd-Travaglini, C. 88
Lo-Ciganic, W. 82
Loebel, A. 94
Lofwall, Michelle R. 2, 3, 15, 24, 82, 96, 97, 100
London, E. 85
Long, Ed 51
Lookatch, S. J. 23, 60
Lopez-Nunez, C. 56, 109
Lopez-Quintero, C. 99
Lopez, A. A. 68, 84
Lopez, Marsha 73
Lopez, S. 16
Lorkiewicz, S. A. 16
Lorvick, J. 64
Louie, B. 18
Louie, D. 102
Lowen, S. B. 99
Loza, O. 53
Lu, Q. 52
Lu, T. 83
Luba, R. 21
Lucas, G. 107
Lucidarme, D. 81
Luis, T. 76
Lukas, S. E. 14, 99, 109
Lum, P. J. 87
Lumley, M. 100
Lundahl, L. H. 13, 14, 16, 17, 95
Lundberg, K. 98
Lung, R. 24
Lunnen, J. 103
Lunze, K. 17, 18
Luo, S. 52
Lynch, K. G. 3
Lynch, L. J. 51
Lynch, Minda 90
Lyons, M. 83
Lyvers, M. 85
M. Yasin, M. 86
Ma, L. 14, 98
Ma, Y. 58
MacKillop, J. 14, 95
Macmillan, D. 21
Mactutus, C. F. 107
Madera, G. 21
Madras, Bertha K. 1, 6, 13, 73
Maes, H. 62
Mahoney, E. 20
Mahoney, J. J. 9, 103
Mahony, A. 55, 95
Mai Thi Hoai, S. 16
Maisto, S. A. 89
Majumder, I. 15
Makanjuola, T. 68
Makhiya, S. K. 57
Maki, P. 16
Makriyannis, Alexandros 105
Malamut, R. 58
Malcolm, R. J. 96
Maldonado-Molina, M. 101
Malek, A. 8
Malison, R. 53
Mamey, M. 105
Mancino, M. J. 54, 61
Mandel, J. B. 15
Mandler, R. 80, 107
Mann, R. 96
Mannelli, P. 82
Manubay, J. M. 21, 26
Mao, J. 70
Maple, K. E. 97
Mariani, J. J. 55, 95
Mark, K. 84
Marks, K. R. 60, 61, 104
Marques, K. 98
Marsh, L. A. 18, 21, 81, 89
Marsh, D. C. 83, 94
Marshall, B. D. 16, 58, 100
Martial, L. C. 96
Martin, C. A. 56, 98
Martin, E. 16, 27, 110
Martin, R. A. 9, 56
Martinez-Horta, S. 97
Martinez-Loredo, V. 109
Martinez-Luna, N. 77
Martinez-Raga, J. 64
Martinez-Sanvisens, D. 91
Martinez, A. 104
Martinez, D. 96
Martinez, E. M. 58
Martinez, M. 96
Martinez, V. 68
Martino, S. 109
Marts, S. S. 3, 19, 21, 23, 58, 64, 78, 84, 100
Martz, M. E. 97
Marusich, Julie A. 1
Mashhoon, Y. 14
Masson, Carmen L. 73, 81, 104
Matalon, E. 97
Mateu-Gelabert, Pedro 72, 81
Mateus, J. 75
Matheson, T. 80
Mattick, R. P. 54, 63, 67, 70, 109
Matusiewicz, A. K. 103
Matusow, H. 26, 81
Matyas, G. R. 25
Mauro, P. M. 77
Maxwell, J. C. 94
May, J. 61
<table>
<thead>
<tr>
<th>Author</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>McAllister, C. E.</td>
<td>9</td>
</tr>
<tr>
<td>McBride, N.</td>
<td>109</td>
</tr>
<tr>
<td>McCabe, S. E.</td>
<td>80, 101</td>
</tr>
<tr>
<td>McCann, D.</td>
<td>87</td>
</tr>
<tr>
<td>McCarberg, William</td>
<td>74</td>
</tr>
<tr>
<td>Mccarty, D.</td>
<td>23, 85</td>
</tr>
<tr>
<td>McClernon, J.</td>
<td>23, 99</td>
</tr>
<tr>
<td>McClure, E. A.</td>
<td>18</td>
</tr>
<tr>
<td>McConnell, J.</td>
<td>23</td>
</tr>
<tr>
<td>McCuakeley, J. L.</td>
<td>57</td>
</tr>
<tr>
<td>McClernon, J.</td>
<td>23, 99</td>
</tr>
<tr>
<td>Mcclerc, E. A.</td>
<td>18</td>
</tr>
<tr>
<td>Mcclerc, E.</td>
<td>23</td>
</tr>
<tr>
<td>McCue, D. L.</td>
<td>106</td>
</tr>
<tr>
<td>McCutcheon, V. V.</td>
<td>77</td>
</tr>
<tr>
<td>McDermott, K.</td>
<td>58</td>
</tr>
<tr>
<td>McDonald, J.</td>
<td>91</td>
</tr>
<tr>
<td>McDonell, M. G.</td>
<td>25</td>
</tr>
<tr>
<td>Mcgaugh, J.</td>
<td>61</td>
</tr>
<tr>
<td>Mceedey, D.</td>
<td>89</td>
</tr>
<tr>
<td>Mcearney, J.</td>
<td>60, 95</td>
</tr>
<tr>
<td>Mcearney, K.</td>
<td>83</td>
</tr>
<tr>
<td>Mcgooray, S.</td>
<td>69, 101, 107</td>
</tr>
<tr>
<td>Meacham, Kate</td>
<td>58, 70</td>
</tr>
<tr>
<td>McKeown, A.</td>
<td>19</td>
</tr>
<tr>
<td>McLaughlin, J. P.</td>
<td>15, 107</td>
</tr>
<tr>
<td>Mcmahon, D.</td>
<td>107</td>
</tr>
<tr>
<td>Mcmahon, M. A.</td>
<td>97</td>
</tr>
<tr>
<td>McNaughton, E. C.</td>
<td>100</td>
</tr>
<tr>
<td>Mcpherson, Sterling</td>
<td>5, 25, 55, 65, 105</td>
</tr>
<tr>
<td>Mcrae-clark, A.</td>
<td>53, 82</td>
</tr>
<tr>
<td>Mcrae, E. M.</td>
<td>91</td>
</tr>
<tr>
<td>Mcwilliams, S. K.</td>
<td>59, 95, 97, 98</td>
</tr>
<tr>
<td>Meacham, M. C.</td>
<td>66</td>
</tr>
<tr>
<td>Mead, A. N.</td>
<td>25</td>
</tr>
<tr>
<td>Medina-Mora, M. E.</td>
<td>86</td>
</tr>
<tr>
<td>Medvin, R. B.</td>
<td>88</td>
</tr>
<tr>
<td>Melbostad, H. S.</td>
<td>83</td>
</tr>
<tr>
<td>Melero-fuentes, D.</td>
<td>19, 20</td>
</tr>
<tr>
<td>Melli, S.</td>
<td>22</td>
</tr>
<tr>
<td>Mello, M.</td>
<td>19</td>
</tr>
<tr>
<td>Meltzer, P. C.</td>
<td>13</td>
</tr>
<tr>
<td>Mendoza, N.</td>
<td>79</td>
</tr>
<tr>
<td>Mendoza, S.</td>
<td>23</td>
</tr>
<tr>
<td>Mennis, J.</td>
<td>87</td>
</tr>
<tr>
<td>Menzaghi, F.</td>
<td>94</td>
</tr>
<tr>
<td>Mericle, A.</td>
<td>20</td>
</tr>
<tr>
<td>Mermelstein, R. J.</td>
<td>27, 77</td>
</tr>
<tr>
<td>Merrick, E. L.</td>
<td>23</td>
</tr>
<tr>
<td>Messiah, S.</td>
<td>64</td>
</tr>
<tr>
<td>Mete, D.</td>
<td>102</td>
</tr>
<tr>
<td>Metrick, J. 14, 77, 95, 96</td>
<td></td>
</tr>
<tr>
<td>Metsch, L.</td>
<td>107</td>
</tr>
<tr>
<td>Metsch, L. R. 80, 103</td>
<td></td>
</tr>
<tr>
<td>Metz, V. 21, 26</td>
<td></td>
</tr>
<tr>
<td>Metzger, D. 16, 20, 87, 88, 101</td>
<td></td>
</tr>
<tr>
<td>Meyer, A. C. 55, 56, 80, 82, 87</td>
<td></td>
</tr>
<tr>
<td>Meyer, R. E. 15</td>
<td></td>
</tr>
<tr>
<td>Meyers, J. L. 3</td>
<td></td>
</tr>
<tr>
<td>Meyers, K. K. 77, 79, 80</td>
<td></td>
</tr>
<tr>
<td>Meyers, R. J. 59</td>
<td></td>
</tr>
<tr>
<td>Mickey, B. 27</td>
<td></td>
</tr>
<tr>
<td>Miech, R. 26</td>
<td></td>
</tr>
<tr>
<td>Miech, Richard 6, 26</td>
<td></td>
</tr>
<tr>
<td>Mikulich-gilbertson, Susan K.</td>
<td>5, 59, 79, 95, 97, 98</td>
</tr>
<tr>
<td>Milivojevic, V. 53</td>
<td></td>
</tr>
<tr>
<td>Miller, G. M. 51</td>
<td></td>
</tr>
<tr>
<td>Miller, J. 71</td>
<td></td>
</tr>
<tr>
<td>Miller, M. 96</td>
<td></td>
</tr>
<tr>
<td>Miller, S. 70</td>
<td></td>
</tr>
<tr>
<td>Miller, T. G. 59</td>
<td></td>
</tr>
<tr>
<td>Miller, W. 106</td>
<td></td>
</tr>
<tr>
<td>Milloy, M. 24</td>
<td></td>
</tr>
<tr>
<td>Milosevic, A. 85</td>
<td></td>
</tr>
<tr>
<td>Min, J. 53, 81, 83, 107</td>
<td></td>
</tr>
<tr>
<td>Mitchell, J. 14</td>
<td></td>
</tr>
<tr>
<td>Mitchell, J. T. 23</td>
<td></td>
</tr>
<tr>
<td>Mitchell, J. W. 85</td>
<td></td>
</tr>
<tr>
<td>Mitchell, M. R. 53</td>
<td></td>
</tr>
<tr>
<td>Mitchell, P. 26</td>
<td></td>
</tr>
<tr>
<td>Mitchell, S. G. 78, 81, 83, 96, 101</td>
<td></td>
</tr>
<tr>
<td>Miyata, H. 110</td>
<td></td>
</tr>
<tr>
<td>Mizrachi, E. 15</td>
<td></td>
</tr>
<tr>
<td>Moeller, F. G. 2, 11, 14, 98, 101</td>
<td></td>
</tr>
<tr>
<td>Moger, S. 21, 26</td>
<td></td>
</tr>
<tr>
<td>Mohammed, A. M. 65</td>
<td></td>
</tr>
<tr>
<td>Mohmr, B. 88</td>
<td></td>
</tr>
<tr>
<td>Mojtabai, R. 77</td>
<td></td>
</tr>
<tr>
<td>Molina, L. 70</td>
<td></td>
</tr>
<tr>
<td>Monge, Z. A. 98</td>
<td></td>
</tr>
<tr>
<td>Monico, L. 81, 83</td>
<td></td>
</tr>
<tr>
<td>Montaner, J. 17, 107</td>
<td></td>
</tr>
<tr>
<td>Montgomery, L. 99</td>
<td></td>
</tr>
<tr>
<td>Monti, P. M. 9, 56</td>
<td></td>
</tr>
<tr>
<td>Moody, C. P. 104</td>
<td></td>
</tr>
<tr>
<td>Moody, D. 55</td>
<td></td>
</tr>
<tr>
<td>Moody, L. 3</td>
<td></td>
</tr>
<tr>
<td>Moody, R. L. 102</td>
<td></td>
</tr>
<tr>
<td>Mooney, L. 3, 59, 61, 76, 106</td>
<td></td>
</tr>
<tr>
<td>Moore, S. 69</td>
<td></td>
</tr>
<tr>
<td>Moore, S. K. 21, 89</td>
<td></td>
</tr>
<tr>
<td>Moore, T. 23, 60</td>
<td></td>
</tr>
<tr>
<td>Moran-santa maria, M. 53, 57</td>
<td></td>
</tr>
<tr>
<td>Morani, A. 9</td>
<td></td>
</tr>
<tr>
<td>Morean, M. E. 62, 68</td>
<td></td>
</tr>
<tr>
<td>Morie, K. P. 86</td>
<td></td>
</tr>
<tr>
<td>Mørland, J. G. 54</td>
<td></td>
</tr>
<tr>
<td>Morse, D. 20</td>
<td></td>
</tr>
<tr>
<td>Moryl, N. 94</td>
<td></td>
</tr>
<tr>
<td>Moser, L. 24</td>
<td></td>
</tr>
<tr>
<td>Moshier, S. 85</td>
<td></td>
</tr>
<tr>
<td>Moukha-Chafiq, O. 13</td>
<td></td>
</tr>
<tr>
<td>Moura, H. F. 62</td>
<td></td>
</tr>
<tr>
<td>Moyers, T. 88</td>
<td></td>
</tr>
<tr>
<td>Mueller, S. 22</td>
<td></td>
</tr>
<tr>
<td>Muench, J. 85</td>
<td></td>
</tr>
<tr>
<td>Muga, R. 82, 85</td>
<td></td>
</tr>
<tr>
<td>Mugaverro, M. 80</td>
<td></td>
</tr>
<tr>
<td>Müller, D. 52</td>
<td></td>
</tr>
<tr>
<td>Mumford, E. 67</td>
<td></td>
</tr>
<tr>
<td>Munguia, A. 84</td>
<td></td>
</tr>
<tr>
<td>Murawska, M. M. 57</td>
<td></td>
</tr>
<tr>
<td>Murota, N. 110</td>
<td></td>
</tr>
<tr>
<td>Murphy, S. M. 25, 65</td>
<td></td>
</tr>
<tr>
<td>Murphy, Sean M. 5</td>
<td></td>
</tr>
<tr>
<td>Murugan, V. 53</td>
<td></td>
</tr>
<tr>
<td>Musselman, T. G. 102</td>
<td></td>
</tr>
<tr>
<td>Myers, B. 21, 89</td>
<td></td>
</tr>
<tr>
<td>Nader, M. A. 8</td>
<td></td>
</tr>
<tr>
<td>Nagel, C. 27</td>
<td></td>
</tr>
<tr>
<td>Nahhas, R. W. 19, 21</td>
<td></td>
</tr>
<tr>
<td>Najman, J. 67, 109</td>
<td></td>
</tr>
<tr>
<td>Nakamura, A. 15</td>
<td></td>
</tr>
<tr>
<td>Nakayama, K. 110</td>
<td></td>
</tr>
<tr>
<td>Nambiar, D. 103</td>
<td></td>
</tr>
</tbody>
</table>
AUTHOR INDEX

Namjoshi, O. A. 93
Nanovskaya, T. 54, 55, 79
Napier, C. 12, 110
Narayana, P. A. 13, 14, 98
Narvaez, K. 16
Naselaris, T. 89
Natera, G. 21, 22
Naylor, J. 109
Neelakantan, H. 12, 14
Negi, N. 99
Negus, S. S. 104
Neisewander, J. L. 27
Newton, T. F. 9, 27, 103
Nguyen, A. 88
Nguyen, H. 15, 16
Nguyen, P. 17, 24
Nguyen, S. 16
Nich, C. 60, 86
Nickell, J. 13
Nielsen, D. A. 27
Nielsen, E. M. 27
Nielsen, S. 14, 54, 61, 70, 94, 101
Niikura, K. 70
Nijhawan, A. 107
Nikolova, T. 94
Noble, E. P. 85
Nolan, S. 107
Noorani, T. 56
Nosyk, B. 53, 81, 83, 107
Notzon, D. 95
Novak, S. P. 64, 65
Nucero, P. A. 27
Nunes, E. V. 23, 26, 52, 87, 88, 105
Nuzum, C. 19
Nuzzo, P. A. 3, 15, 82, 96, 97
Nyberg, Fred 51
O’Brien, C. P. 16, 26, 94, 98, 99, 105
O’Connor, M. 54

O’Connor, P. 82
O’Grady, C. L. 100
O’Grady, K. E. 17, 64, 78, 81, 83, 84, 96, 101
O’Malley, P. 26
O’Neill, K. 94
Oberleitner, L. 4
Ochalek, T. A. 55, 80, 82
Oesterle, Sabrina 30
Ogawa, L. M. 51
Ojiesta, E. L. 54
Ojeda, L. 23
Okafor, C. 16, 95
Olive, M. F. 27
Oliver, C. 62
Oliveto, A. 54, 61
Olsen, Y. 83
Olsson, C. 63, 67
Oludoye, O. 99
Ompad, D. C. 103
Oncken, C. 54, 55
Ondersma, S. 96
Ornell, F. 61
Orozco, R. 86
Osei, K. 55
Oser, C. B. 17, 18, 20, 59
Oslin, D. W. 91
Otiaishvili, D. 17, 87, 103
Otiniano Verissimo, A. 87
Otto, M. W. 85
Owens, P. 82
Owens, R. 71
Oyama, M. 59

Pacek, L. R. 64, 68, 77
Pachado, M. P. 24, 86
Pack, R. P. 57
Padowski, J. 55
Page, K. 87
Pagnussat, E. 62
Palamar, J. 1. 103
Palatkin, V. 76
Palfai, T. 22, 88
Palma, A. 17
Pan, J. 96
Pan, Y. 85, 103, 107

Pang, R. 52, 63
Pantalon, M. 82
Papaseit, E. 75
Paris, J. J. 107
Paris, M. 84
Park, J. Y. 52
Parker, E. 63
Parker, M. A. 63
Parra-Cardona, Ruben 4, 21
Parsons, J. T. 102
Partilla, J. S. 13, 27
Pasa, G. 85, 103
Passalacqua, E. 24, 68
Pathak, V. 13
Pati, R. 107
Patrick, M. 26
Patton, G. 63
Patts, G. 18, 107
Pavlicova, M. 88, 95
Payne, F. 21
Paz, A. L. 86
Peacock, A. 14, 54, 94
Pears, K. C. 27
Pearson-Dennett, V. 60
Peasley, L. 4
Pechansky, F. P. 10, 24, 52, 61, 62, 75, 78, 85, 86, 103
Pecoraro, A. 76
Pedersen, W. C. 60
Peechatka, A. L. 55
Peindl, K. 82
Peirce, J. M. 76
Pellegrini, D. 83
Peltier, M. R. 57
Penate, J. 106
Pennington, D. 91
Pentel, Paul 90
Pentkowski, N. 27
Pérez de los Cobos, J. 19, 20, 96, 97
Pérez-Mañà, C. 75
Pérez-Pazos, J. 77
Perez, S. 62
Pericot-Valverde, I. 56, 109
Perkonigg, A. 105
Perlman, D. 104
AUTHOR INDEX

Perngparn, U. 78
Perrey, D. A. 13
Perry, B. 17
Persons, A. 12, 110
Peterson, D. J. 62
Petras, H. 79
Petry, N. 106
Pettaway, K. 68
Pettinati, H. M. 3
Pfaff, M. N. 9
Philbin, M. 107
Philip, P. 91
Phillips, Karran A. 3, 18, 26, 102, 108
Pianca, T. G. 62, 78
Pigeon, W. R. 91
Pike, E. 104
Pinder, L. 12
Pinney, J. M. 105
Pizzagalli, D. A. 55
Placzek, Michael S. 15, 108, 109
Platt, D. 93
Platt, J. 65
Plebani, J. G. 3
Plot, D. 53, 70, 101
Poe, M. 93
Polak, K. M. 22
Polcin, D. L. 20
Pole, N. 100
Polk, A. R. 59
Pomfrey, R. 11
Pomm, D. 22
Pope, E. 67
Pope, H. 97
Popova, L. 19
Porath-Waller, A. 21
Potenza, M. N. 53, 86, 99
Potter, J. S. 58, 61, 89
Pouget, E. R. 22, 58, 80
Prado, G. 64
Prat, M. 77
Pravetoni, Marco 90
Preston, Kenzie L. 3, 18, 26, 102, 108
Price, A. E. 14
Price, J. S. 97, 99

Prielau, C. 59
Prisciandaro, J. 53
Prisinzano, T. E. 9, 71
Proudfoot, J. 24
Provost, S. 58
Pugh, M. 89
Puhl, M. 12
Pujadas, M. 75
Pullen, E. 17, 20
Puntes, M. 96
Quinn, A. 23
Quinn, E. 17, 18
Quinones-Jenab, V. 52
Quisenberry, A. 13
Rabinovich-Guilatt, L. 58
Rafat, B. 94
Rafful, C. 86
Raghu, G. 16
Rahm, S. P. 27
Raj, A. 17, 18
Ramesh, D. 14, 101
Ramirez, S. H. 12
Ramo, Danielle 19, 30, 57
Ramao, C. 55
Ramos Rodriguez, M. 53
Ramos, R. 53
Rancaño, J. 78
Randall-Thompson, J. 104
Ranganathan, Mohini 25
Rapaka, R. 59
Rass, Olga 68, 88
Rasmussen, B. A. 28
Ratner, T. 68
Ravenell, O. 84
Rawls, S. 12, 28, 108
Rawson, R. 15, 16, 76, 77, 81, 106
Ray, L. A. 8
Raymond, K. 97, 98
Read, E. 65
Reback, Cathy J. 19, 61, 72
Reddy, A. 22
Redner, R. 89
Reed, S. 60, 76
Rehm, J. 96
Reid, H. H. 14
Reif, S. 23, 88
Reimer, J. 64
Reis, L. R. 10
Reis, T. A. 89
Reitzel, L. R. 59
Remy, L. S. 75
Rendina, H. J. 102
Renfro, S. 23
Renshaw, P. 98
Reynolds, G. L. 14, 60, 61, 65, 103
Reynolds, M. D. 53
Riba, J. 96, 97
Rice, K. 11, 25, 95
Rich, M. T. 11
Rico, M. 21, 22
Rieckmann, Traci R. 5, 15, 16, 23, 85
Ries, R. 25
Riggs, P. D. 59, 79, 95
Riley, A. L. 11, 95, 106
Riley, C. 98
Riley, E. 87
Riley, J. L. 57
Rimland, D. 70
Rios, E. 16
Ritter, G. 88
Ritter, K. 23
Rivas, I. 82, 85
Rivera, M. 16
Roberts, A. J. 60
Robertson, B. 94
Robeson, P. 21
Rocha, Beatriz 74
Rodgman, C. 68
Rodriguez-Barradas, M. 16
Rodriguez-Cintas, L. 77
Rodriguez-Fornells, A. 96, 97
Rodriguez-Pujadas, A. 97
Rodriguez, M. 16
Roehrs, T. 93
Rohde, L. A. 78
Rohenkow, D. 9, 56, 95
Rohde, L. A. 89
Rolen, C. L. 89
Roley, J. 54
Roll, J. M. 25, 55, 65
AUTHOR INDEX

Roman, T. 52
Romero-Gonzalez, M. 58, 82
Roncancio, A. 23
Roncero, C. 77
Rooke, S. 19
Roquer, A. 91
Ros-Cucurull, E. 77
Rosa, Carmen 29
Rosa, M. C. 10
Rosa, R. L. 62, 78
Rosado, A. 25
Rose, J. 99
Rosen, B. R. 15
Rosen, M. 80
Rosenblum, Andrew 22, 25, 26, 58, 81
Ross, J. M. 63
Ross, K. 55
Rosselli, M. 86
Rossi, P. 91
Roth, T. 93
Rothman, R. B. 13, 27
Rotrosen, J. 23
Row-Sepowitz, D. 79
Rowe, C. 66
Rowe, R. 64
Rowlett, J. 93, 106, 109
Rowley, H. L. 12
Roxburgh, A. 101
Rubio, M. 82
Rueedi-bettschen, D. 93
Runyon, S. P. 13
Rush, A. J. 61
Rush, C. R. 19, 60, 61, 93, 104
Rutter, Joni 59, 71
Ryan, C. 102
Rytting, E. 54

Saenz, E. 59
Saini, S. K. 13
Saiphoklang, O. 78
Saitz, Richard 16, 22, 77, 88, 107
Sáiz, P. 78
Sakai, J. 97, 98
Saladin, M. E. 82
Salas-Ramirez, K. 8, 62
Saleh, H. 62
Salem, B. 106
Salmeron, B. 99
Saltino, D. 65
Samet, J. H. 15, 16, 17, 18, 22, 70, 88, 107
Sampedro, F. 97
Sanches, M. 23
Sanchez, Z. M. 78
Sandoval, M. R. 80
Santa Ana, Elizabeth J. 7, 109
Santaella, J. 23, 64
Santiago Rivera, O. J. 65
Santos, Glenn-Milo 66, 72
Sanvisens, A. 82, 85
Sarkar, S. 89
Sarma, K. 94
Sarram, S. 109
Sartor, C. E. 77
Satre, D. D. 80
Savage, P. 55
Sawa, K. 110
Saxon, A. 52, 106
Schacht, R. L. 76
Scheidell, J. D. 69, 101, 107
Scheinost, D. 53
Schenk, S. 27, 75
Scherer, J. N. 24, 61, 86
Schimmel, J. L. 51
Schindler, C. W. 109
Schmeling, B. 91
Schmidt, N. B. 56
Schmitz, Joy 3, 7, 13, 95
Schoedel, K. 58, 94
Schoenbaum, E. 17
Scholl, J. L. 28
Schottenfeld, R. S. 86
Schroedeker, E. 91
Schroeder, J. R. 10
Schuch, S. 61
Schulenberg, J. 26
Schuler, M. S. 85
Schulte, M. T. 60, 79, 83
Schumacher, J. E. 80
Schwartz, D. 16
Schwartz, R. P. 78, 81, 82, 83, 96,
101
Scott, B. 99
Seale, P. 21
Sears, R. M. 12
Seay, Kristen D. 91
Secades-Villa, R. 56, 78, 109
Seedall, R. 79
Seider, N. 11
Selby, P. 96
Semino, S. 21
Senadheera, S. 15
Senmartin, N. 94
Serafini, K. 84
Sera, B. 59
Serre, F. 10, 55, 91, 109
Sessler, N. 100
Setnik, Beatrice 74, 89, 104
Severtson, S. G. 8
Seymour, B. 102
Shane, M. S. 98
Sharma, G. 87, 88, 102
Shellenberger, S. 21
Sherrill, L. 62
Sheth, A. P. 19
Shi, X. 98
Shimane, T. 75
Shin, S. 4
Shiu, K. 80
Shmulewitz, D. 24
Shollenbarger, S. G. 97
Shopshire, M. 104
Shoptaw, S. 57, 60, 100
Shram, Megan 54, 71, 72, 94
Shrestha, R. 52
Shu, I. 84
Shurtleff, David 66
Sierka, C. 102
Sigmon, S. C. 55, 56, 80, 82, 87
Silins, E. 63
Silveira, D. X. 89
Silverman, Kenneth 66
Simon, P. 62, 68
Sinha, R. 53
Sites, J. P. 93
Skanderson, M. 16, 70
Skelly, J. M. 67, 84
AUTHOR INDEX

Skinstad, A. 105
Slade, T. 109
Sloboda, Z. 79
Smelson, D. 82
Smethells, J. R. 14
Smith, A. 94
Smith, B. 104
Smith, Douglas C. 29
Smith, E. 97
Smith, K. 70
Smith, K. Z. 4
Smith, M. A. 11, 25
Smith, Mark A. 25, 90
Smith, N. 106
Smith, Philip H. 3, 4
Smith, R. V. 100
Smith, S. 15
Snider, S. E. 14
Soares, V. S. 89
Sofuoglu, M. 86
Sokolowska, M. 89, 104
Solinas, Marcello 90
Solomon, L. J. 67
Sonne, S. 8
Sordi, A. O. 61, 86
Sorensen, J. 54, 80, 81, 103, 104
Sorsdahl, K. 89
Soto, C. 12
Sou, B. 55
Sousa, T. R. 85, 103
Souza, D. S. 24, 86
Spealman, Roger D. 2, 12
Spear, S. E. 77
Spears, C. A. 57
Spencer, R. H. 94
Spencer, S. 71
Spindle, T. 55
Spitzer, E. 99
Sproule, B. 89, 93, 94
Srebnik, D. 25
Srisarajivakul, E. 58
Stacey, T. 59
Stafford, J. 88
Stahler, G. 87
Stairs, D. J. 9
Stanger, C. 63
Stankeviciute, N. 71
Stanley, B. 76
Starkweather, A. 101
Staton-Tindall, M. 18, 20, 59, 100
Stauffer, J. W. 94
Stein, J. S. 56, 88
Steinberg, J. L. 14, 98
Stephens, M. 102
Sterling, Stacy 29
Stevens-Watkins, D. 100
Stewart, M. 23, 88
Stitzer, M. L. 80, 87
Stodard, S. A. 80
Stoduto, G. 96
Stohl, M. 24, 80
Stolf, A. R. 52
Stoltman, J. J. 13
Stoops, William W. 19, 60, 61, 69, 93, 104
Stoove, M. 103
Storholm, E. D. 80
Stout, S. 61
Strain, Eric C. 1, 10, 18
Strasser, A. 8
Strathee, S. 66, 86
Straussner, S. L. 81
Streck, J. M. 55, 80, 87
Strickland, J. C. 11, 19, 104
Striley, C. W. 20, 53, 79, 95, 102
Stringer, K. 80
Strong, D. 19
Study Group, C. 106
Stutz, S. J. 10, 11, 12, 28, 106
Stynier, M. 84
Suchting, R. 13, 95
Sugarman, D. E. 77
Suh, J. 97, 98
Suleta, K. 23
Sullivan, K. 85
Sullivan, M. 16, 107
Sullivan, M. A. 21, 26
Sun, W. 27
Sung, Fung-Chang 5
Sung, Y. 98
Sung, Yung-Fong 1
Surratt, H. 75, 100
Sutherland, R. 64
Svikis, Dace 7, 22
Swalve, N. 52
Swanson, A. 60, 100
Swart, A. 81
Sweeney, M. M. 88
Sweitzer, M. 23, 99
Swendsen, J. 55
Swift, R. 60
Swinford-Jackson, Sarah E. 12, 27, 28
Syckes, C. 81
Syed Jaapar, S. Z. 86
Szobot, C. 78
Szuucs-Reed, R. 98
Szuhan, K. 85
Taffe, Michael A. 68
Taghavi, S. 55
Tai, B. 61
Taillard, J. 91
Tajima, B. 24, 56, 68
Talal, A. 104
Tallarida, C. S. 28, 108
Tanabe, J. 97, 98
Tancer, M. E. 17
Tang, J. 75
Tanner-Smith, Emily 29
Tannu, N. S. 13
Tarantino, Lisa 108
Tarifa, N. 77
Tarter, R. E. 53
Tate, J. 16, 83
Taylor, D. M. 26
Taylor, J. 106
Tedford, S. E. 12, 110
Tella, S. R. 59
Temple, J. R. 79
Teneback, C. C. 55
Teper, A. 81
Terplan, M. 84
Thacker, L. 101
Theobald, J. 83
Thewlis, D. 60
AUTHOR INDEX

Thomas, B. F. 13
Thomas, C. 3, 59, 61, 76, 106
Thomas, L. 21
Thompson-Lake, D. G. 9, 68, 103
Thompson, R. G. 86, 91
Thorberg, F. A. 85
Thorn, D. 13
Thorndike, E. B. 109
Thostenson, J. D. 54, 61
Thorberg, F. A. 85
Thorn, D. 13
Thorndike, E. B. 109
Thostenson, J. D. 54, 61
Tidey, Jennifer W. 1, 8, 9, 56, 66, 77
Tindol, A. 21
Tiruveedhula, P. 93
Todd, G. 60
Todtenkopf, M. S. 15, 94
Tofighi, B. 18
Tolliver, J. M. 58
Tomiyama, K. 95
Tompkins, D. A. 10
Tor, J. 85
Torregrossa, M. M. 11
Torrens, M. 58, 75, 91
Torres, M. 88
Torres, O. 25
Tousova, O. 17
Townsend, D. 11
Townsend, E. 109
Tran, H. 15, 16
Trecki, J. 59
Treiber, F. A. 18
Tremblay, B. 16
Trias, V. 16
Trigo, J. M. 96
Trim, R. S. 86
Trinidad, M. 82
Tsai, W. 75
Tseng, F. 78
Tsoh, J. 56, 65
Tsui, J. I. 15, 70
Tucker, D. 24
Tunno, A. 23
Turan, J. M. 80
Turncliff, R. 54
Tuten, M. 69, 84
Tyzburski, M. 18
Tyndale, Rachel 55, 72
Tyssen, R. 85
Tyurina, A. 18, 76
Uddin, M. 3
Um, M. 99
Umbricht, A. 10, 77
Unger, A. 24
Unick, G. J. 101
Unterwald, E. 27, 28
Urada, D. 53, 83
Urbe, K. 8
Ury, J. 61
Vaddiparti, K. 69, 101, 107
Vahidi, M. 22
Vajdic, C. 81
Valderrama-Zurián, J. 19, 20
Valdez, A. 99
Valente, T. 102
Valle, M. 96, 97
Vallender, E. J. 51
Van Dam, N. 99
Van de Bittner, G. C. 109
van Wijngaarden, E. 99
Vanderah, Todd 105
Vandrey, R. 8, 77, 87
VanVeldhuisen, P. 59, 61, 102
Varena, R. K. 54
Varenbut, M. 83
Varga, M. 9
Varma, D. S. 21
Vasilev, G. 2
Vassileva, J. 2, 16, 110
Vaughan, B. 26
Vaughan, E. 23
Vazquez-Sanroman, D. B. 110
Veglahn, H. 52
Velez, M. 69
Veliz, P. T. 80, 101
Venault, J. 27
Venner, Kamilla 59, 73
Ventuneac, A. 102
Ventura, A. S. 16, 107
Wada, K. 75, 95
Wadolowski, M. 109
Wager, T. 98
Wager, T. T. 25
Wagner, B. D. 95
Wagner, F. P. 19
Wagner, K. D. 24
Wakeford, A. G. 95
Walker, M. 59
Walker, R. 59, 61, 80, 105
Wall, M. 65
Walley, Alexander Y. 2, 16, 17, 18, 26, 107
Walsh, Sharon L. 3, 15, 71, 82, 96, 97, 100
Walter, L. 106
Walton, M. A. 20, 21, 79, 87
Wang, A. 99
Wang, D. W. 18
Wang, G. 76
Wang, H. 99
Wang, J. 83
Wang, L. 13
Wang, X. 54, 55
Wang, Z. 98
Verbitskaya, E. 76
Verrico, C. D. 9
Vidot, Denise C. 5, 64
Villarreal, Y. 76
Vincent, J. 3
Vincent, K. B. 64
Vinci, C. 57
Vindenes, V. 54
Vitaliano, G. 99
Vittinghoff, E. 66
Vo, H. T. 79
Vogel, A. 60
Vogelman, J. 21
Volkow, Nora 51
von Diemen, L. 24, 61, 62, 86
Voon, Pauline 51
Votaw, V. R. 97
Vsevolozhskaya, O. 52, 64
Vujanovic, Anka 3, 7, 95
Vyshynskiy, K. 87
Wada, K. 75, 95
Wadolowski, M. 109
Wager, T. 98
Wager, T. T. 25
Wagner, B. D. 95
Wagner, F. P. 19
Wagner, K. D. 24
Wakeford, A. G. 95
Walker, M. 59
Walker, R. 59, 61, 80, 105
Wall, M. 65
Walley, Alexander Y. 2, 16, 17, 18, 26, 107
Walsh, Sharon L. 3, 15, 71, 82, 96, 97, 100
Walter, L. 106
Walton, M. A. 20, 21, 79, 87
Wang, A. 99
Wang, D. W. 18
Wang, G. 76
Wang, H. 99
Wang, J. 83
Wang, L. 13
Wang, X. 54, 55
Wang, Z. 98
AUTHOR INDEX

Ward, M. 15
Ward, S. 80
Washio, Y. 103
Waters, A. J. 84
Watson, C. 11
Weaver, M. 95
Webb, L. 19, 97
Webster, J. 75
Webster, L. R. 58, 94, 104
Webster, M. 18, 20, 59
Wechsberg, P. 21
Wechsberg, Wendee 72
Weber, D. 23
Weiss, Bert 74
Weiss, Friedbert 25
Welch, J. 19
Weldon, A. L. 77
Wenger, L. 65, 102
Werb, D. 23
Werner, K. B. 77
Wesesky, M. A. 76
Wesley, M. J. 98
West, N. 91
Westman, E. 99
Wetherill, R. R. 97, 98
Wetherington, Cora Lee 1, 74, 82
Wetzell, B. B. 11
Wey, H. 15, 109
Wheeler, E. 24, 66
White, D. A. 59
White, J. 15, 55, 60
White, Thomas J. 5, 84, 89
Whitehead, N. E. 16, 102
Whittaker, E. 102
Whitton, A. E. 55
Wickens, C. A. 96
Wiesenthal, A. 94
Wiest, K. 85
Wijeratne, S. 19
Wilcox, R. A. 60
Wild, C. 9
Wilder, C. M. 83
Wildman, D. 3
Wiley, Jenny 1, 2
Willenbring, D. 59
Williams, G. 99
Williams, K. 3
Williamson, P. 15
Wills, T. 4
Wilson, A. 13
Wilson, J. 67
Wilson, J. L. 20
Wilson, K. 88
Wilson, V. 16
Wilson, W. T. 59
Windisch, K. A. 9
Winhusen, T. 61, 83
Winston, E. 100
Winter, M. R. 15, 16, 22, 70
Winters, Ken 21, 29
Wong, L. L. 59
Wong, T. 91
Wongboonsin, K. 78
Wongboonsin, P. 78
Woo, C. 98
Woo, D. 62
Wood, C. 71
Wood, D. M. 58
Wood, D. S. 76
Wood, E. 17, 24, 83, 107
Woodcock, E. A. 13
Woody, G. E. 76
Worley, M. 57, 60
Wright, C. 9
Wu, L. 82
Wu, M. 26
Wu, P. 13
Wu, R. 62
Wu, Y. 100
Wulach, L. A. 17
Xandre, P. 103
Xavier da Silveira, D. 89
Xu, F. 67
Xu, H. 27
Xu, R. 24
Xu, Z. 76
Xue, W. 55
Yacenda, J. 22
Yamamoto, D. 98
Yang, F. 27
Yang, M. 85
Yaroslavtseva, T. 17, 76
Yasin, M. M. 86
Yates, J. R. 52
Yip, S. W. 99
Yohannes, S. 91
Yoon, J. H. 95
Young, K. A. 98
Young, M. M. 63
Young, R. M. 85
Young, S. 98
Yu, C. 75, 79
Yurasek, A. 96
Yurgelun-Todd, D. 98
Zaharim, N. M. 86
Zald, D. 28
Zaslav, D. 79
Zavala, R. 18, 104
Zeigler, D. 103
Zentgraf, K. 79
Zerbe, G. O. 95
Zeremski, M. 104
Zernig, Gerald 90
Zhang, G. 9
Zhang, M. 93
Zhang, S. 76
Zhang, Y. 9, 12, 13, 27, 70, 76, 107
Zhao, S. 19
Zheng, G. 13
Zhou, J. 9
Zhou, M. 12
Zhou, Z. 16
Zhu, J. 27
Zibbell, J. 104
Zimmerman, M. 20
Zlebnik, N. 52
Zlotnick, C. 19
Zubieta, J. 27, 77
Zucker, R. 69, 97
Zule, W. 17, 87, 103
Zuluaga, P. 85
Zvartau, E. 76
Zvolensky, M. J. 56, 65, 78
Zvorsky, I. A. 84